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The aims of this programme of research are to investigate the subjective description of 
ischaemic pain and to investigate the effects of TENS on lower limb ischaemic pain and 
walking performance in patients with Intermittent Claudication (IC).  
 
Methods:  
Four studies were conducted: two in the laboratory and two clinical trials. Laboratory- The 
first study investigated the reliability of a method of inducing lower limb ischaemic pain in 
healthy volunteers, the modified Submaximal Effort Tourniquet Test (mSETT). The second 
investigated the effects of High Frequency TENS (HF-TENS) and Placebo TENS (P-TENS) on 
lower limb ischaemic pain induced using the mSETT in healthy volunteers. Clinical- The first 
clinical study investigated the effects of HF-TENS and Low Frequency TENS (LF-TENS) on 
measures of pain and treadmill walking performance in patients with Peripheral Arterial 
Disease (PAD) and IC. The second examined patients’ experiences of using TENS at home for 
PAD and IC.  
 
Results:  
The mSETT was found to have good test-retest reliability and induce pain similar in quality 
to that experienced by patients with IC. The pain experience induced with the mSETT was 
reduced by both HF- and P-TENS compared to baseline. HF-TENS however was more 
effective compared to P-TENS in this regard, prolonging time to pain threshold and 
tolerance whilst reducing the levels of pain reported throughout. In patients with PAD and 
IC, HF and LF-TENS interventions were found to increase maximum walking distance on a 
treadmill compared to P-TENS. HF-TENS was also found to increase pain-free walking 
distance. The experience of using TENS in daily life was characterised by feelings of both 
benefit and disappointment. This was interpreted through the following themes: (i) 
‘masking, but not taking the pain away’ and (ii) ‘walking further, but not far enough’.  
 
Conclusions:  
The mSETT is a reliable method of inducing lower limb, ischaemic pain in healthy volunteers 
and could be useful for the purposes of pre-clinical analgesic trials and investigation of the 
ischaemic pain experience. HF-TENS was found to reduce mSETT pain indicating hypoalgesic 
effects of TENS in experimentally induced, lower limb ischaemic pain. HF and LF-TENS have 
potential as interventions that increase walking performance for patients with IC. If using 
TENS at home for IC, expectations of treatment effect need to be managed to avoid 
disappointment and feelings of frustration.  
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To allow more seamless reading of the thesis, some fundamental terms have been 
abbreviated. Below is a comprehensive list of these abbreviations in alphabetical order 
along with explanation of their meaning for reference.  
 
Abbreviation: Meaning: 
21-NRS 21 point Numerical Rating Scale 
ACD Absolute Claudication Distance  
B-TENS Burst Transcutaneous Electrical Nerve Stimulation  
BMI Body Mass Index  
BP Blood Pressure  
BP (sys)  Systolic Blood Pressure  
End mA TENS Intensity at the end of the test  
FCD Functional Claudication Distance  
FPQ Fear of Pain Questionnaire  
HF-TENS High Frequency Transcutaneous Electrical Nerve Stimulation  
HI High Intensity  
HR Heart Rate  
IC Intermittent Claudication 
ICC Intraclass Correlation Coefficient  
ICD Initial Claudication Distance 
IPAQ International Physical Activity Questionnaire  
LF-TENS Low Frequency Transcutaneous Electrical Nerve Stimulation 
LI Low Intensity  
MMSE Mini Mental State Examination  
MPQ McGill Pain Questionnaire 
mSETT Modified Submaximal Effort Tourniquet Test 
MSK Musculoskeletal  
MSQ Mental Status Questionnaire  
MWD Maximal Walking Distance  
NRS Numerical Rating Scale 
P-TENS Placebo Transcutaneous Electrical Nerve Stimulation  
PAD Peripheral Arterial Disease 
PCS Pain Catastrophising Scale  
PFWD Pain Free Walking Distance 
PGIC Patient Global Impression of Change Scale  
PRI Pain Rating Index  
PSEQ Pain Self-Efficacy Questionnaire  
QoL Quality of Life 
RCT Randomised Controlled Trial  
RPRI Reactive Pain Rating Index  





SF-MPQ-2 Short Form McGill Pain Questionnaire 2 
SpO2  Saturations of Oxygen  
SPRI Sensory Pain Rating Index  
Start mA TENS Intensity at the start of the test  
TENS Transcutaneous Electrical Nerve Stimulation 
TSK Tampa Scale of Kinesiophobia  
VAS Visual Analogue Scale 
VASCUQoL Vascular Quality of Life Questionnaire  
WIQ Walking Impairment Questionnaire  
ΔACD Change in Absolute Claudication Distance  
ΔFCD Change in Functional Claudication Distance  
ΔICD Change in Initial Claudication Distance 





CHAPTER 1: INTRODUCTION 
1.1: AIM OF CHAPTER 1:  
The aim of Chapter 1 is to summarise the components that informed the development of 
the current project. The research questions, aims of the thesis and the outline of how each 
component of the research programme achieves these aims will be identified.  
 
1.2: INTRODUCTION TO THE THESIS:  
Peripheral arterial disease (PAD) is a common manifestation of systemic atherosclerosis. The 
cardinal symptom of PAD is intermittent claudication (IC), generally described as pain, 
fatigue and cramping in the lower limb(s) on exertion. PAD and especially IC causes 
significant disability, decreased physical function and a decrease in overall quality of life. 
Exercise therapy is at the core of the management of PAD and helps to reduce the chance of 
the disease progressing and patients suffering heat attack or stroke. Adherence to regular 
exercise is a problem for patients with IC. The most commonly reported symptom of IC is 
pain and pain is also the factor that, according to patients, limits their activity and 
participation (Wann-Hansson et al 2008). Current management of IC is mainly 
pharmaceutical and focussed on increasing perfusion in the lower limbs and slowing the 
progression of the disease.  
 
This management is successful at increasing walking distance although it does not address 
the experience of pain. A cheap, non-pharmacological hypoalgesic intervention may be a 
useful adjunctive treatment that could help reduce the experience of pain. If successful this 
treatment could augment the efficacy of the current management of IC, lead to greater 
adherence to exercise therapy and ultimately help reduce the chance of progression to 
more serious manifestations of cardiovascular disease.  
 
To effectively address the pain associated with IC and test possible novel interventions an 
in-depth understanding of the subjective quality of the pain experience is required. 
Currently, there is a dearth of literature investigating the pain experience and none 
regarding the efficacy of hypoalgesic interventions for IC pain. This study aims to address 
  
20 
these two aspects, exploring the pain experience of IC and investigating the effects of a 
common, non-pharmacological intervention on measures of pain and walking distance.  
 
1.2.1: The Clinical Problem:  
There are an estimated 27 million people in North America and Europe living with PAD 
(Belch et al 2003; Hankey et al 2006). IC is a painful condition defined as pain usually in the 
calf of one or both legs, which occurs on walking, and is relieved by rest (Stewart et al 2002; 
Bendermacher et al 2006; Meru et al 2006).  
 
IC is commonly but not exclusively the result of the atherosclerotic and arteriosclerotic 
process where the arteries become narrower and harder leading to inadequate blood 
supply in peripheral tissues and creation of an ischaemic environment. During exercise the 
decreased blood supply cannot meet the increased oxygen demand of the muscles, which 
then operate anaerobically. This anaerobic metabolism produces lactic acid and other 
metabolites that act on nerve endings causing pain (Meru et al 2006). 
 
Patients experiencing the pain of IC are characterised by reduced levels of daily physical 
activity, which is associated with diminished performance of personal, social and 
occupational activities of daily life. Many individuals become housebound or dependent on 
others (Falcone et al 2003; Aquarius et al 2006). A significant problem is that up to 45% of 
patients do not comply with medical advice to take regular exercise and to walk ‘through’ IC 
pain (Leng et al 2000; Roche et al 2005). The reasons for this non-compliance are commonly 
stated as too painful, lack of supervision or definite advice, and unsatisfying results 
(Bartelink et al 2004; Kruidenier et al 2009c). Since both of these activities relieve IC and 
help minimise further deterioration, for example into chronic heart disease and stroke 
(Izquierdo-Porrera et al 2000; Wannamathee and Shaper 2001), the lack of detailed 
understanding of IC and its effects on general exercise and function is a major problem.  
 
IC represents a chronic pain problem. Chronic pain can be defined as daily pain reoccurring 
for more than 6 months, usually beyond the time for normal organic healing and is 
associated with negative psychosocial effects (Vlaeyen et al 1995; Crombez et al 1999). 
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Clinicians are acutely aware of the link between the chronic nature of IC and deterioration in 
function and quality of life in patients with PAD (Falcone et al 2003). Nevertheless, unlike 
other major chronic pain syndromes such as cancer pain, arthritis and post-surgical pain 
(Graham et al 1980; Roche and Heim 1997; Roche et al 2003; Bruce et al 2004; Ngamkham 
et al 2012), the subjective nature of IC (i.e. the disease-specific quality and intensity of the 
pain), has not been explored.  
 
1.2.2: Subjective Description of IC Pain:  
In recent decades pain researchers have shown the value of obtaining patients’ subjective 
descriptions of chronic pain syndromes by using the multidimensional McGill Pain 
Questionnaire (MPQ) (Melzack 1975). The MPQ details the subjective description of pain in 
sensory-discriminative, affective-motivational and cognitive-evaluative dimensions, which 
reflect the complexity of pain perception in the brain (Treede et al 1999; Mayer et al 2005). 
These dimensions are assessed via 78 pain adjectives separated into 20 subclasses and 
ranked within these subclasses in order of intensity. Despite its descriptive, subjective 
nature the MPQ can also produce a single quantitative score of pain intensity, termed the 
Pain Rating Index (PRI). The MPQ has now become a frequently used tool in the assessment, 
diagnosis and management of complex, chronic pain syndromes (Melzack 1987; Wright et al 
2001) but has not been used to describe IC pain in suitably large populations.  
 
One pilot study used the MPQ retrospectively to investigate IC pain during walking (Roche et 
al 2005). High PRI scores were reported along with participants’ high percentage use of 
specific sensory and affective-evaluative descriptors from the MPQ (Roche et al 2005). The 
conclusions were limited however due to the small sample size and retrospective nature of 
the study. Further study examining IC pain when present and in a larger sample are required 
to validate these descriptions of IC pain and serve as a clinical profile of IC. This initial 
indication, that IC pain is severe in intensity, enforces the importance of having a more 
multidimensional investigation into IC and the importance of testing and effectively 





1.2.3: Current Management of IC:  
Current treatment of IC pain is mainly pharmaceutical and aims to delay the onset of pain by 
altering physiological factors in the limbs such as reducing blood viscosity and increasing 
vessel diameter thus delaying the creation of the ischaemic environment. Although this type 
of treatment can be successful pharmaceutical interventions are expensive, potentially 
problematic in relation to accurate dosing and can cause side effects. In addition, to gain the 
full benefits from exercise therapy the person needs to walk ‘through’ pain, (i.e. endure the 
ischaemic environment in their limb(s)). This helps to encourage the formation of collateral 
vessels and improve muscular and walking efficiency (Laurenzano et al 2009; Beckitt et al 
2012). As pharmaceutical treatment delays the onset of pain, rather than affecting the pain 
itself, patients are less likely to walk ‘through’ an ischaemic environment and gain the full 
benefit of exercise therapy.   
 
1.2.4: Possible Adjunct to Current Treatment of IC:  
Transcutaneous Electrical Nerve Stimulation (TENS) is acknowledged as a safe, portable and 
inexpensive method of providing non-invasive pain relief (Johnson 2001; Vance et al 2012). 
TENS is a form of mild electrical stimulation and has consistently shown greater analgesic 
effects than placebo TENS, chiefly in musculoskeletal pain problems (Law and Cheing 2004) 
but also in postoperative (Hamza et al 1999) and neuropathic pain (Somers and Somers 
1999). It is a non-invasive modality packaged in a small, portable unit that is easy to apply 
via small electrodes placed on the skin. It can be kept in a pocket or clipped to a trouser belt 
and is used widely and daily by patients with chronic pain to reduce their pain, improve their 
daily functioning and in some cases return to work (Johnson et al 1991; Sluka and Walsh 
2003). However, it is not known to what extent TENS (and more specifically the different 
stimulation patterns of TENS that can be applied) may modify the barriers mentioned above 
in patients with PAD. Studies conducted to date suggest that the fast-acting, reflexive 
mechanism of High Frequency TENS (HF-TENS) may act most effectively at the mild (pain 
threshold) level of the pain experience. Low Frequency TENS (LF-TENS) however may act 
most effectively at the stronger (pain tolerance) level of the pain experience due to 




Possibly due to the focus on medical management and the limited investigation of IC pain, 
TENS has not been tested as an effective method of pain relief of IC. Also the potential for 
High Frequency (HF) verses Low Frequency (LF) patterns of TENS to affect different portions 
of the IC pain experience has not been examined. The potential for HF/LF-TENS to modify IC 
pain when it is mild (which normally occurs in PAD patients after walking a short distance), 
while it builds up (during continued walking), and when it becomes intolerable, is the basis 
for this proposal to test these two types of TENS stimulus pattern on IC.  
 
1.2.5: Laboratory Investigations of Pain:  
Clinical pain syndromes are complex in nature with both sensory-discriminative and 
affective-evaluative components occurring simultaneously (Woolf 1979). These factors 
make patients with clinical pain syndromes less than ideal subjects for initial investigations 
into the efficacy of potential analgesics (Staahl and Drewes 2004). Clinically, patients often 
have confounding co-morbidities and are likely to be taking some form of medication 
(Staahl and Drewes 2004). Patients may also interpret other effects of the intervention as a 
relief of pain. For example, a reduction in disease-related anxiety or depression may be 
misinterpreted as a reduction in pain.  
 
Experimental pain models are advantageous in pre-clinical investigation of an intervention 
as they allow some quantitative control over the input that subjects receive (Woolf 1979). 
The investigator can control the experimentally induced pain, i.e. the location, nature, 
intensity, frequency and duration and provide quantitative measures of the psychophysical, 
behavioural or neurophysiological responses (Graven-Nielsen et al 2001; Staahl and Drewes 
2004). Therefore prior to examining the effects of TENS on clinical IC pain it would be 
advantageous to examine its efficacy on an experimental model of ischaemic pain.  
 
1.2.6: Laboratory Ischaemic Pain:  
The Submaximal Effort Tourniquet Test (SETT) is an experimental method of inducing 
ischaemic pain in the upper limb of healthy volunteers. The effects of TENS have been 
investigated on experimental ischaemic pain in the upper limb (Woolf 1979; Roche et al 
1984; Walsh et al 1995a; Chen and Johnson 2011). TENS has been shown to significantly 
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increase time taken to report pain threshold, time taken to report pain tolerance and overall 
pain endurance in the upper limb (Woolf 1979; Roche et al 1984; Chen and Johnson 2011). 
 
IC pain however occurs in the lower limb and when standing. Despite these promising 
results of TENS in the upper limb it is not known whether TENS will produce the same 
results in the lower limb.  
 
Establishing a valid and reliable method of inducing lower limb ischaemic pain could be 
useful. If developed this method could be used for investigation of the qualities of ischaemic 
pain. In addition, it could provide a platform to investigate how those qualities of pain 
respond to interventions. It is anticipated, for example, that laboratory-induced ischaemic 
pain may have similar sensory-discriminative qualities to IC but have fewer affective-
motivational and cognitive-evaluative components. Such a non-chronic profile of the 
sensory-discriminative components of ischaemic pain could be a useful way to examine how 
TENS affects the common sensory experience of IC pain.  
 
A series of pilot studies have adapted the upper limb SETT to the lower limb and applied it in 
both supine and/or standing postures with laboratory participants (Roche et al 2007). These 
studies have developed a method for inducing ischaemic pain in the lower limb of healthy 
volunteers in standing. This modified SETT (mSETT) has also been used to test the effects of 
TENS on lower limb ischaemic pain with analgesic trends observed. However, these did not 
reach significance because of limitations in sample sizes and study methodologies (Roche et 
al 2007). Further investigation of the effects of TENS on lower limb experimental ischaemic 
pain is required prior to examining its effects in patients with IC.  
 
1.2.7: Summary:  
In summary, the clinical problem of IC is well established. An aspect that has so far been 
neglected is the pain experience of IC. The recording and evaluation of the subjective 
descriptions of IC pain could be an effective means of improving the understanding and 
management of patients with IC. The MPQ provides a method by which the subjective 




Although never tested for IC pain, TENS is a possible useful intervention. Due to the 
complex, chronic nature of clinical IC pain, an investigation of the effects of TENS on lower 
limb experimental ischaemic pain is warranted prior to clinical investigation. This 
examination would allow exploration of the qualities of experimental ischaemic pain and 
the effect of TENS on these qualities. Any hypoalgesic effects observed in lower limb 
experimental ischaemic pain could be used to inform the study of TENS for IC pain in a 
clinical population.  
 
1.3: RESEARCH QUESTIONS ADDRESSED IN THIS THESIS:  
There are the two research questions addressed in this thesis:  
 What qualities characterise the subjective description of IC pain?  
 What are the effects of TENS on measures of pain and walking performance in 
patients with IC?  
 
1.4: AIMS AND OBJECTIVES:  
From these two questions the aims of this project are formulated. One aim is to investigate 
the subjective description of the multidimensional qualities of ischaemic pain. The second 
aim is to investigate the hypoalgesic effects of TENS on lower limb ischaemic pain and 
walking performance in patients with IC.  
 
These aims can be addressed through four clear objectives that are linked to four distinct 
studies:  
 
Objective 1: to develop and validate the mSETT in the lower limb of healthy volunteers. 
This objective aims to establish the mSETT as a reliable method of inducing ischaemic pain in 
the lower limb of healthy volunteers. This will contribute to both aims of the project by 
establishing a method that allows investigation of the subjective descriptive qualities of 
lower limb ischaemic pain and examination of the effects of TENS on these qualities.  
 Study 1: An examination of the test re-test reliability of the ability of the mSETT to 
induce consistent levels of pain was conducted (Chapter 7). A laboratory study is 
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proposed that examines the pain induced by the mSETT in healthy volunteers. The 
ability of the mSETT to induce comparable levels of pain on separate occasions will 
be examined in a preliminary validation study.  
 
Objective 2: to investigate the effects of TENS on the pain induced by the mSETT. This 
objective contributes evidence regarding the effects of TENS on lower limb ischaemic pain 
and more specifically which aspects of the pain experience are affected by TENS 
intervention. Again this objective will contribute to both aims as MPQ descriptions of 
ischaemic pain will be recorded and the effects of TENS on lower limb ischaemic pain 
investigated.  
 Study 2: An investigation into the hypoalgesic effects of HF-TENS on mSETT induced 
pain in healthy volunteers (Chapter 8). Following the validation study another 
laboratory study is proposed that investigates the effects of HF-TENS and Placebo 
TENS (P-TENS) on reports of mSETT-induced pain intensity and quality as measured 
by the MPQ.  
 
Objective 3: to investigate the effects of TENS on pain and walking performance in 
patients with IC. This objective is central to the attempt of this thesis to address the 
identified clinical problem of IC. Both aims will be addressed by investigating the effects of 
TENS on IC pain and walking performance and recording of the descriptions of clinical 
ischaemic pain with the MPQ.  
 Study 3: An investigation into the hypoalgesic effects of HF and LF-TENS on measures 
of pain and walking performance in patients with IC (Chapter 9). A clinical Medical 
Research Council (MRC) phase IIa,  ‘proof of concept’ study is proposed that 
investigates the effects of TENS on walking performance in patients with PAD and IC. 
This study will also examine the psychosocial aspects of IC pain and relationships to 
walking performance.   
 
Objective 4: to record and compare the subjective descriptions of the pain experience 
associated with IC and mSETT induced pain. This objective will specifically address the first 
aim of the project: to investigate the subjective description of ischaemic pain. By comparing 
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descriptions of pain between the clinical IC population and healthy volunteers experiencing 
the mSETT, the subjective descriptions of lower limb ischaemic pain can be explored.  
 Study 4: A post hoc examination of the pain descriptions as recorded by the MPQ in 
patients with IC and healthy volunteers experiencing mSETT induced pain (Chapter 
10). The specific subjective nature and quality of IC pain will be compared to that 
induced by the mSETT.  
 
The original contribution of this project is threefold. The preliminary validation of the mSETT 
procedure is unique as a method of inducing ischaemic pain in the lower limb of healthy 
volunteers. The detailed, subjective description of lower limb ischaemic pain in the 
laboratory and clinical settings is also unique and the investigation of TENS as an adjunctive 
intervention for IC pain is novel. The findings of this project could be used to make 
recommendations for future management of lower limb ischaemic pain and the evaluation 
of TENS as an adjunctive treatment for PAD and IC.  
 
1.5: STRUCTURE OF THESIS:  
The flow diagram in Figure 1.1 details the structure of this thesis and the progress and 
interaction of the research programme presented in this thesis. The general contents of 





Figure 1.1: Flow diagram of thesis structure. The additional study not discussed in section 
1.4 above will be introduced and discussed in Chapter 11. This is due to its nature as a 




1.6: SUMMARY OF THESIS CONTENT:  
 
1.6.1: Chapter 2: Peripheral Arterial Disease (PAD) and Intermittent 
Claudication (IC)  
This chapter provides the background to PAD and IC and summarises what is known about 
the disease. Special focus will be afforded to the experience of IC and its impact on function, 
QoL, psychosocial health and the role of pain as being central to the disease process and 
responsible for many of the functional limitations associated with IC. The current 
management of IC pain will be discussed in this chapter. The advantages and disadvantages 
of the current approaches will be explored along with possible options for future 
management of IC.  
 
1.6.2: Chapter 3: Pain 
The aim of this chapter is to provide a summary of the current understanding of pain and 
relate this to the study of IC. The basic definitions and concepts will be discussed followed 
by a more in-depth exploration of the measurement and description of pain and the 
associated psychosocial factors. Finally IC pain will be discussed in this context.  
 
1.6.3: Chapter 4: Transcutaneous Electrical Nerve Stimulation (TENS)  
This chapter will briefly explore possible non-invasive, adjunctive methods of pain 
management in IC. It will justify the use of Transcutaneous Electrical Nerve Stimulation 
(TENS) as the selected option, examine its mechanisms of action and discuss the evidence 
for its pain-relieving effects.  
 
1.6.4: Chapter 5: Laboratory-Induced Pain 
This chapter will explore issues in pain research. The benefits of experimental pain models 
will be discussed with a focus on laboratory-induced ischaemic pain. The reported effects of 
TENS on this laboratory-induced ischaemic pain will be examined along with the rationale 
for development of a laboratory-induced ischaemic pain method in the lower limb of a 




1.6.5: Chapter 6: Literature Review Summary and Rationale  
This chapter will summarise the aims of this thesis as informed by the literature review and 
outline how each component of the research programme plans to address these aims.  
 
1.6.6: Chapter 7: Experiment One - Test-Retest Reliability of the modified SETT 
A pilot study conducted to examine the test-retest reliability of the mSETT will be described 
in this chapter. The results observed and contribution to the thesis will be explored.  
 
1.6.7: Chapter 8: Experiment Two - The Effects of TENS on mSETT-Induced Pain  
The aim of this chapter is to describe the investigation of mSETT-induced, lower limb 
ischaemic pain and the effects of HF-TENS on measures of pain compared to P-TENS.  
 
1.6.8: Chapter 9: Experiment Three - The Effects of TENS on Pain and Walking 
Performance in Patients with PAD and IC  
The aim of chapter nine is to describe the investigation of the effects of TENS on pain and 
walking performance in patients with PAD and IC. The effects of HF- and LF-TENS were 
investigated using a standardised treadmill test. Measures of pain and walking performance 
were used to examine the effects of TENS compared to P-TENS.   
 
1.6.9: Chapter 10: Comparison of Experimental and Clinical Ischaemic Pain  
An analysis of MPQ descriptions of experimentally induced and clinical ischaemic pain will 
be presented in this chapter. The similarities and differences in subjective descriptions of 
pain will be discussed.  
 
1.6.10: Chapter 11: A Pilot Investigation into Patients’ Experiences of Using 
TENS for Daily Life with PAD and IC   
Chapter eleven describes a preliminary follow-up study of a small selection of patients with 
PAD and IC. This qualitative study was conducted as a preliminary investigation of the 
experience of using TENS at home for daily life with PAD and IC. This additional study was 




1.6.11: Chapter 12: General Discussions and Conclusions  
The findings of the research programme will be discussed in relation to the research 
questions and aims. Conclusions regarding the results of the studies will be discussed based 
on the data presented. The clinical implications, limitations and recommendations of this 





CHAPTER 2: PERIPHERAL ARTERIAL DISEASE (PAD) AND 
INTERMITTENT CLAUDICATION (IC) 
2.1: AIM OF CHAPTER 2:  
The aim of this chapter is to outline the clinical problem of Peripheral Arterial Disease (PAD) 
and Intermittent Claudication (IC). The aetiology, epidemiology, prognosis and current 
management of PAD and IC will be discussed, highlighting the current state of the published 
literature surrounding the topic (see sections 2.2 and 2.3). Special attention will be paid to 
the perceived gaps in understanding and limitations in management of IC (section 2.4). The 
relationships between these factors and the aims of the thesis will be explored indicating 
the possible contributions of the current project to the clinical evidence base.  
 
2.2: PERIPHERAL ARTERIAL DISEASE:  
Peripheral Arterial Disease (PAD) has been described as:  
“a diverse group of disorders that lead to progressive stenosis or occlusion, or 
aneurysmal dilation, of the aorta and its non-coronary branch arteries, including the 
carotid, upper extremity, visceral, and lower extremity arterial branches. Peripheral 
arterial disease is the preferred clinical term that should be used to denote stenotic, 
occlusive, and aneurysmal diseases of the aorta and its branch arteries, exclusive of 
the coronary arteries”  
(Hirsch et al 2005, p466) 
 
PAD is operationally defined as an obstruction of blood flow into an arterial tree excluding 
the intracranial or coronary circulations and is most commonly a result of the 
atherosclerotic process in multiple vascular beds (Garcia 2006; Hankey et al 2006; Gornik 
and Creager 2006; Norgren et al 2007). The reported disease prevalence of PAD ranges from 
3-30% (Criqui et al 1985; Hiatt et al 1995; Hirsch et al 2001; Murabito et al 2002; Belch et al 
2003; Selvin and Erlinger 2004; Olin et al 2010) and there are approximately 2.7 million 
people in the UK and 27 million people in North America and Europe living with PAD (Belch 
et al 2003; Hankey et al 2006).  
 
The most common cause of death in patients with PAD is Coronary Artery Disease (CAD) 
(40-60% of deaths) (Norgren et al 2007). Additionally, Cerebral Vascular Disease (CVD) 
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accounts for 10-20% of deaths and other vascular events, approximately 10%. Only 20-30% 
of patients with PAD die of non-cardiovascular causes (Norgren et al 2007).  
 
Myocardial Infarction (MI) and Cerebrovascular Accident (CVA) are the main contributors to 
the high mortality rate, alone contributing to approximately 25-30% of all mortality in the 
PAD population within 5 years of diagnosis (Gornik and Creager 2006; Hankey et al 2006; 
Norgren et al 2007).  
 
PAD is a clinical manifestation of cardiovascular disease. PAD has an age, and sex-adjusted 
risk ratio of 3.34 for all cause mortality (Garcia 2006; Heald et al 2006; Roger et al 2011). 
Cardiovascular disease affects approximately 80 million people in the USA and 2.5 million in 
the UK (BHF 2008; Roger et al 2011). It is the most common cause of mortality, responsible 
for approximately 200,000 deaths in the UK each year and an annual healthcare cost of 14.4 
billion pounds (BHF 2008). In the USA, the annual figure is estimated to be 503.2 billion 
dollars in direct and indirect costs (Olin et al 2010).  
 
2.3: INTERMITTENT CLAUDICATION  
PAD is mostly asymptomatic in the early stages although as the disease progresses, the 
continuing atherogenesis may manifest as Intermittent Claudication (IC) (Garcia 2006; Olin 
et al 2010). IC is the cardinal symptom of PAD and is frequently, operationally defined as 
pain in the lower limb(s) that manifests during walking, and is relieved by rest (Stewart et al 
2002; Bendermacher et al 2006). The prevalence of IC has been reported as 3% in people 
aged 40 years, rising to 6% in those aged 60 years (Norgren et al 2007). Approximately 60% 
of patients with PAD report leg symptoms with 30% reporting typical IC (Murabito et al 
2002; Olin et al 2010).  
 
IC describes the collection of symptoms that occurs whilst walking and is the result of 
decreased perfusion in the periphery (Olin et al 2010). These symptoms can include pain, 
muscle cramps, muscle weakness, paraesthesia and altered gait pattern. This collection of 
symptoms can be relatively stable over time although they are associated with significant 
levels of functional disability, psychological distress and increased risk of morbidity and 
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mortality independent of PAD (Treat-Jacobson et al 2002; Falcone et al 2003; Olin et al 
2010). ‘IC pain’ refers specifically to the pain experienced during IC (Rüger et al 2008).  
 
2.3.1: IC Pain:  
The mechanisms associated with IC pain are not fully understood (Graven-Nielsen and 
Arendt-Nielsen 2008; Gardner et al 2010). It is accepted that IC pain is a result of tissue 
ischaemia but how this leads to the perception of pain is still debated. Previous authors 
have proposed that ischaemic pain is a result of the following different mechanisms: a build 
up of a chemical mechanism, termed ‘Factor P’ (Lewis 1932); a build up of lactate in the 
muscle tissues (Saltin et al 1981); an increased concentration of potassium (Harpuder and 
Stein 1943); general tissue acidosis (Allsop et al 1990) and an increased concentration of 
interstitial adenosine (Costa et al 1999). None of these theories have been conclusively 
demonstrated and the most recent research suggests that pain originates from the vascular 
system with contribution from the exercising muscle (Graven-Nielsen and Arendt-Nielsen 
2008).   
 
The PAD literature commonly reports that IC pain is the result of the atherosclerotic process 
and arises from dual mechanisms: ‘ischaemic mismatch’ and peripheral neuropathy (Rieger 
and Schefler 1999; Lang et al 2006). Ischaemic mismatch develops due to inadequate blood 
supply, and thus oxygenation, of peripheral tissues during walking (Garcia 2006; Meru et al 
2006; Gardner et al 2010). During walking the muscles of the lower limb operate 
anaerobically owing to the limited blood supply. It is thought to be the by-products of this 
anaerobic metabolism (lactic acid and other metabolites) that sensitise and stimulate 
chemo-sensitive nociceptors (chemoreceptors), causing the perception of leg pain (Rieger 
and Scheffler 1999; Meru et al 2006; Graven-Nielsen and Arendt-Nielsen 2008). The 
neuropathic component of IC pain is thought to be a result of prolonged reduction in 
perfusion to the neural tissues distal to the atherosclerotic lesion (Rieger and Scheffler 
1999; Lang et al 2006). This reduced perfusion of neural tissues has been shown to lead to 
peripheral neuropathy, axonal degeneration and central sensitisation, accentuating the 




Clinicians are acutely aware of the link between IC and deterioration in function and quality 
of life in patients with PAD (Falcone et al 2003). Nevertheless, unlike other major chronic 
pain syndromes such as cancer pain and arthritis (Roche and Heim 1997; Roche et al 2003), 
the subjective nature of IC (i.e. the disease-specific quality and intensity of the pain), has not 
been fully explored.  
 
Rüger et al (2008) used the Short Form of the MPQ (SF-MPQ) (Melzack 1987) to assess pain 
in patients with PAD and IC. They recruited 102 participants with confirmed diagnosis of 
PAD and IC pain during exercise or at rest. A VAS and the SF-MPQ were used to measure the 
multidimensional nature of the pain. Of the participants, 61 had IC (pain on exertion) and 41 
had Critical Limb Ischaemia (CLI) (further progressed disease characterised by pain at rest). 
Intensity of IC pain was reported as 6.8 ± 0.3 (VAS 0-10; mean ± SD) and mean Total Pain 
Rating Index (TPRI) score was 9.4 (±0.9) (TPRI 0-45) demonstrating a high pain intensity as 
measured by the VAS but a contrastingly low TPRI score. The SF-MPQ data demonstrated a 
high percentage usage of specific sensory descriptors: ‘stabbing’, ‘cramping’ and ‘aching’. 
However, the descriptor that was used by the greatest number of participants was the 
affective-evaluative descriptor: ‘tiring-exhausting’. These findings indicate that patients with 
IC or CLI experience a substantial intensity of pain and this experience consists of common, 
specific sensory and affective components.  
 
The main limitation of this study is due to the SF-MPQ being used rather than the full 
version. This could explain the lower TPRI scores as the SF-MPQ excludes adjectives that 
might best describe IC pain (tugging/ wrenching (Sensory); wretched/ blinding (Affective) 
and annoying/ unbearable (Evaluative)).  
 
Another limitation to this study is that it is retrospective and relied on the participants’ 
ability to accurately recall and rate the pain they experience. This could have resulted in 
inaccuracies in the pain descriptions reported with some aspects being exaggerated and 




One pilot study used the full MPQ to investigate IC pain during walking (Roche et al 2005). 
Thirty-one participants were recruited who had PAD and IC. A Visual Analogue Scale (VAS) 
and the MPQ were used to measure IC pain retrospectively. The mean VAS (±SD) was 5.31 
(±1.64) and PRI score was 25.29 (±10.42) demonstrating a high intensity of pain. High 
percentage use of specific sensory and affective-evaluative descriptors from the MPQ was 
also reported (Roche et al 2005). The conclusions regarding the nature of IC pain are limited 
however, due to the small sample size and retrospective nature of the study.  
 
Further study is required that uses the full MPQ and examines IC pain immediately after 
exercise to validate these descriptions of the IC pain experience and serve as a qualitative 
profile of IC. The results from these studies of patients with IC indicate that the pain 
experienced is severe in intensity and unique in quality. This supports the hypothesis that 
the pain of IC has a significant effect on the limited walking ability and decreased quality of 
life in patients with PAD. If this hypothesis were true, this would also suggest a need for 
further investigation and testing of interventions for IC pain.  
 
Regardless of the generating mechanisms, IC pain is experienced as severe muscle pain 
whilst walking and results in significant reduction in Quality of Life (QoL) (Chetter et al 1997; 
King et al 2012). Physiological variables such as Ankle Brachial Pressure Index (ABPI) have 
not been found to sufficiently predict walking tolerance or behaviour (Kruidenier et al 
2009a). Psychosocial aspects such as walking intentions and perceived behavioural control 
however have been found to account for a large proportion of variance in walking (Galea 
and Bray 2007).  
 
2.3.2: Psychosocial Aspects of IC:  
‘Psychosocial’ can be defined as ‘relating to the interrelation of social factors and individual 
thought and behaviour’ (Oxford Dictionaries 2010). The psychosocial aspects of a condition 
refer to those additional to the measurable physiological status of a person’s condition, they 
are the associated psychological and social factors, regardless of direction of relationship 
e.g. somatic distress, pain amplification, depression, fear, anxiety, catastrophising (Carragee 




Patients experiencing IC are characterised by reduced levels of daily physical activity, which 
is associated with diminished performance of personal, social and occupational activities of 
daily life and many individuals become housebound or dependent on others (Falcone et al 
2003; Aquarius et al 2006). Impaired physical functioning in patients with PAD and IC has 
been found to lead to an inability to continue full-time employment, feelings of social 
isolation and inadequacy, and believing they had become a burden to family (Treat-
Jacobson et al 2002). 
 
Despite the link between PAD and IC and decreased QoL and the inability of physiological 
variables to predict walking, there are a limited number of studies that examine the 
psychosocial nature of IC pain.  
 
A pilot study (Roche et al 2005) examined the relationships between walking and cognitive-
behavioural factors in patients with PAD and IC. Statistically significant correlations were 
reported between Perceived Disability (Roland Disability Questionnaire) and cognitive-
behavioural measures including: pain self-efficacy; fear of pain/re-injury; frustration; 
helplessness; pain intensity (Visual Analogue Scale) and quality (MPQ). This study, although 
limited in sample size (n=31), indicated the uniqueness in quality and severity of IC pain.  It 
also found significant relationships between the associated psychosocial factors measured 
and functional performance (Roche et al 2005).  
 
Smolderen et al (2008) examined depressive symptoms in patients with PAD. Participants 
with PAD and IC (n=166) were recruited from a vascular outpatient clinic and followed up at 
6, 12 and 18 months. Participants’ baseline characteristics, resting Ankle Brachial Pressure 
Index (ABPI) (measure of lower limb arterial stenosis), Pain-Free Walking Distance (PFWD) 
and Maximal Walking Distance (MWD) on a standardised treadmill test were recorded at 
baseline along with their score on the Center for Epidemiological Studies Depression Scale 
(CES-D). At each time point after baseline, the CES-D was completed but no other measures 
were repeated. At baseline, 16% of participants were classified as having ‘depressive 
symptoms’. This group of participants were found to have significantly decreased PFWD and 
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MWD compared to the rest of the sample (Smolderen et al 2008). At each follow-up time 
point these levels of depression remained constant and they were found to be related to 
other aspects of the disease including: having no partner, smoking, hyperlipidaemia, 
hypertension, decreased walking distance, increased intake of psychotropic medication and 
report of back symptoms (Smolderen et al 2008). The analysis only indicated likelihood odds 
rather than any direct causal relationships. However, the significant and complex 
associations are suggestive of a complex, chronic disease process with significant 
psychosocial aspects. The strengths of this study include a large sample size that consisted 
exclusively of patients with IC and there was no drop out ensuring that the results are a true 
representation of the sample. However, the measure of depression used (CES-D) is a 
somewhat blunt instrument although useful in this design when the aim was to classify 
participants into groups dependent on their depressive symptoms. A more detailed 
questionnaire, set of questionnaires or qualitative methodology, could give more 
information regarding the different aspects of their depressive symptoms and possibly 
identify specific targets for intervention.  
 
Garnefski et al (2009) examined depressive symptoms in more detail in a sample of 88 
patients with PAD and IC. In a questionnaire-based study they examined the different 
coping strategies (goal re-engagement or goal disengagement) adopted by these patients in 
relation to depressive symptoms, catastrophising, physical limitations, age, gender and 
positive refocusing. Depressive symptoms were found to be associated with increased 
catastrophising and physical limitations and decreased goal re-engagement and positive 
refocusing. This suggests that focusing on the disease in a catastrophic manner is a 
maladaptive coping strategy and is associated with more symptoms of depression. Coping 
by re-engaging in alternative, meaningful goals is an adaptive strategy and associated with 
less depressive symptoms (Garnefski et al 2009). This study was limited due to the exclusive 
use of questionnaires as a method of data collection, which could be susceptible to reporter 
bias. Many of these variables are however hard to measure without using self-report 
questionnaires. Future studies could perhaps employ qualitative methods, e.g. interviews, 
to gain a richer understanding of the patient experience. Also, the response rate was only 




These two studies demonstrate an association between psychosocial factors and PAD and IC 
although they are not without limitations. Both heavily relied on self-report measures to 
provide a general overview of the population. To comprehensively address the question of 
direction of relationships, further qualitative studies are required to identify the disease-
specific psychosocial constructs that need to be measured and secondly, additional 
longitudinal studies are required to test the relationships between these constructs.   
  
All of the studies discussed recommend further detailed and expansive investigation of the 
psychosocial factors of PAD and IC and emphasise the need for a detailed understanding of 
the pain experience (Roche et al 2005; Smolderen et al 2008; Garnefski et al 2009). IC is a 
chronic condition and as such is associated with psychosocial effects (Galea and Bray 2007). 
A detailed understanding of the IC pain experience and associated psychosocial factors 
could be beneficial in the development of management strategies that aim to reduce the 
burden of PAD and IC.  
 
2.4: MANAGEMENT OF PAD AND IC:  
Currently there is no cure for atherosclerosis and therefore, PAD or IC. The primary 
recommended focus of treatment is atherosclerosis risk factor modification and 
management (SIGN 2006; Norgren et al 2007).  
 
Atherosclerosis is a systemic disease, typically affecting multiple vascular beds concurrently. 
As such, the risk factors for PAD are similar to those of other atherosclerotic diseases, such 
as coronary artery disease (Smith et al 2004). Age, family history of cardiovascular disease, 
dyslipidaemia, smoking, diabetes mellitus, hypertension and metabolic syndrome are the 
main risk factors for developing atherosclerosis and thus PAD (Smith et al 2004; Garcia 
2006; Norgren et al 2007). Diabetes and smoking are thought to be the strongest risk factors 
of PAD. Smoking is the most important modifiable risk factor, increasing the risk of 
developing PAD threefold (Smith et al 2004). Race (non-Hispanic black), gender (male), 
inflammatory markers, hyperviscosity and hypercoagulable states, hyperhomocysteinemia 
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and chronic renal insufficiency also have positive associations with increased risk of 
developing PAD (Norgren et al 2007).  
 
Patients with PAD have multiple atherosclerosis risk factors and extensive atherosclerotic 
disease, which puts them at increased risk of cardiovascular events (Gornik and Creager 
2006; Norgren et al 2007; Olin et al 2010). As many patients with PAD are asymptomatic 
(approximately 40%), they are not identified and thus their atherosclerotic risk factors are 
not adequately identified and managed (Hirsch et al 2005; Norgren et al 2007). As discussed, 
a diagnosis of PAD increases the odds of all-cause mortality, and especially cardiovascular 
disease mortality. Therefore, aggressive risk factor modification is indicated when diagnosed 
(Hirsch et al 2005; Norgren et al 2007).  
 
There are numerous recommendations and clear guidance for atherosclerotic risk factor 
modification in PAD and CVD. Table 2.1 summarises the current medical management of 
PAD risk factors and the supporting research.  
 
Invasive options, including endovascular and surgical management are available but are 
normally reserved for severe cases where there is need to salvage a threatened limb 
(Almahameed and Bhatt 2006). Invasive therapy may also be considered in patients with 
vocation or lifestyle-limiting IC pain that have shown poor response to exercise and 
pharmacotherapy (Almahameed and Bhatt 2006).  
 
Exercise Therapy is recommended as a first line treatment for PAD and IC (Hirsch et al 2005). 
Specifically, supervised exercise training for at least 30-45 minutes, 3 times a week for a 
period of 12 weeks (Hirsch et al 2005; Layden et al 2012). Physical activity/exercise is also 
recommended for the management of cardiovascular disease as increased physical activity 




Table 2.1: Current medical management of PAD risk factors.  
Risk factor  Intervention  Method/Comment Evidence for Efficacy 





Jorenby et al (1999)  
Anthonisen et al (2005) 
Increased BMI Weight Reduction Counselling  
Diet modification  
Exercise Therapy  
Yusuf et al (2005) 
Hyperlipidaemia  Pharmacotherapy  Diet modification  
Statins  
Exercise Therapy  
HPSCG (2002) 
Hypertension  Pharmacotherapy  Thiazides 
ACE inhibitors  
Beta-Blockers  
Exercise Therapy  
Yusuf et al (2000) 
ESH/ESC (2003) 





Dormandy et al (2005) 
Homocysteine  Avoid folate 
supplementation 
Do Not take Folate 
Supplements 
Bonaa et al (2006) 
Lonn et al (2006) 
Inflammatory 
Markers 











2.4.1: Exercise Therapy:  
Exercise therapy interventions have been shown to have a significant positive effect on 
increasing self-report physical activity, measured cardio-respiratory fitness, exercise time 
and functional ability in patients with PAD and IC (Gardner and Poehlman 1995; Leng et al 
2000; Regensteiner and Treat-Jacobson 2001; Gardner et al 2001; Stewart et al 2002; 
Bulmer and Coombes 2004; Hillsdon et al 2005; Carman and Fernandez 2006; Gardner and 
Afaq 2008). The mechanisms behind exercise therapy and the improvement in walking 
distance in patients with IC remains unclear (Carman and Fernandez 2006). It is thought that 
there are a number of contributing factors, including the following: improved collateral 
circulation; an improvement in rheological characteristics of the blood; increased cellular 
oxygen uptake from the blood; improvements in walking efficiency; improvements in 
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endothelial function, metabolic adaptations in skeletal muscle and improvement in 
psychosocial factors (Leng et al 2000; Stewart et al 2002; Carman and Fernandez 2006; 
Milani and Lavie 2007) (see Figure 2.2).  
 
There are a number of studies that have investigated exercise therapy for IC patients. Of 
these studies there is a wide variation in results obtained. The Cochrane Review by Leng et 
al (2000) found that all of the included studies demonstrated significant improvements in 
walking distance with an average improvement of approximately 150% although the range 
of improvement was wide: 74-230%. Bulmer and Coombes (2004) also observed similar 
wide ranges of improvements in their meta-analysis. A median improvement of 83% was 
noted in absolute walking ability with a range of 23-210% (Bulmer and Coombes 2004). A 
Cochrane Review by Bendermacher et al (2006) which compared the effect of supervised 
versus non-supervised exercise therapy observed a 35-39% increase in maximal walking 
distance in eight separate trials. The broad ranges reported in these reviews are likely due 
to differences in the components of the exercise programmes used, such as training 
intensity, level of supervision, duration of the programme and heterogeneity in the study 
populations.  
 
The two Cochrane Reviews concluded that the most effective course was a 6 month 
programme of thrice weekly supervised exercise classes lasting more than, or equal to 30 
minutes, incorporating intermittent walking to near-maximal pain (Leng et al 2000; 
Bendermacher et al 2006). Bulmer and Coombes (2004) agree except they suggest that 
training to pain-free thresholds is as beneficial as training to higher intensity (i.e. to maximal 
pain). The authors however, provide only one study supporting this claim, and acknowledge 
the difficulty of systemically assessing the effect of training intensity on IC pain (Bulmer and 






Figure 2.1: The cycle of disability and the benefits of exercise training in pat ients 
with PAD and IC. Reproduced with permission from Milani and Lavie (2007).  
 
A problem for clinicians is that despite the wealth and quality of evidence demonstrating 
the effectiveness of exercise in the treatment of IC a number of patients do not adhere to 
exercise regimes or follow the advice to take regular independent exercise (Hamburg and 
Balady 2011). Despite this, there are a limited number of studies investigating adherence to 
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exercise therapy in patients with PAD and IC and even fewer that examine the psychosocial 
factors associated with motivation and adherence to exercise.  
 
2.4.2: Pharmacological Therapy: 
Patients with PAD and IC should all receive pharmaceutical and lifestyle treatment for their 
cardiovascular risk factors (Norgren et al 2007). A number of pharmaceutical interventions 
have been shown to be successful in increasing walking distance in patients with IC including 
cilostazol, pentoxifylline, naftidrofuryl, carnitine, propionyl-L-carnitine and lipid lowering 
drugs (Norgren et al 2007). The mechanisms of action of each of these interventions, the 
supporting evidence and any reported side effects will now be discussed.   
 
2.4.2.1: Cilostazol:  
Cilostazol is a phosphodiesterase III inhibitor with vasodilator, metabolic and antiplatelet 
activity (Norgren et al 2007). Cilostazol is a direct arterial vasodilator which also inhibits 
platelet aggregation and has antithrombotic, antimitogenic and cardiogenic properties (NICE 
2009; O’Donnell et al 2009). Cilostazol mechanisms of action are still under debate but it is 
accepted that it improves blood flow to the peripheral tissues in patients with IC, improving 
the oxygenation of the muscles and thus reducing IC pain (O’Donnell et al 2009). Cilostazol 
has the best overall evidence for treatment benefit in patients with IC. In a meta-analysis of 
six randomised, controlled trials (RCT) it has been shown to have a net benefit over placebo 
of 50-70 metres in peak treadmill walking performance (Regensteiner et al 2002). It was also 
shown to significantly improve QoL as measured by the Walking Impairment Questionnaire 
(WIQ) and SF-36. These are significant and useful treatment effects in patients with PAD and 
IC. However, the side effects of the drug include headache, diarrhoea and heart palpitations. 
In addition, it does not reduce the rates of cardiovascular events and cardiovascular 
morbidity compared to placebo (Pratt 2001) and cannot be given to patients with 
congestive heart failure due to its mechanisms of action.  
 
2.4.2.2: Pentoxifylline:  
Pentoxifylline lowers fibrinogen levels, improves red cell and white cell deformability and 
thus lowers blood viscosity (Norgren et al 2007; Jacoby and Mohler 2004). This lower 
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viscosity improves the perfusion of tissues distal to the atherosclerotic vessels, which in turn 
allows increased aerobic metabolism and thus prolongs the time to onset of IC pain. The 
evidence supporting the use of Pentoxifylline is somewhat inconsistent. Meta-analyses have 
not demonstrated unequivocal results although Pentoxifylline is a registered and prescribed 
medication for IC pain in the UK and Europe (Hood et al 1996; Moher et al 2000). Both 
studies concluded modest improvements in treadmill walking performance and functional 
status compared to placebo although the clinical benefits are questionable (Hood et al 1996; 
Moher et al 2000; Norgren et al 2007). Reported adverse reactions include dizziness, 
headache, dyspepsia, nausea and vomiting. It is contraindicated in patients with recent 
cerebral or retinal haemorrhage (Jacoby and Mohler 2004).  
 
2.4.2.3: Naftidrofuryl:  
Naftidrofuryl is a 5-hydroxytryptamine type 2 antagonist which may improve muscle 
metabolism, and reduce erythrocyte and platelet aggregation (Norgren et al 2007). Similar 
to Cilostazol, Naftidrofuryl reduces IC pain by increasing blood flow to the tissues, but it is 
also proposed to improve aerobic metabolism in the muscles thus prolonging the time 
before the build up of products of anaerobic metabolism and thus IC pain. The efficacy of 
Naftidrofuryl has been reported in one meta-analysis in 1994 (Lehert et al 1994) and more 
recently, by Kieffer et al (2001) and Spengel et al (2002). It has been shown to increase 
treadmill walking distance by 26% and produce improvements in QoL measures compared 
to placebo. The reported side effects of Naftidrofuryl are minor with the most common 
being mild gastrointestinal disorders with some reports of headache, dizziness, insomnia 
and hepatitis (Jacoby and Mohler 2004; Norgren et al 2007).  
 
2.4.2.4: Carnitine and Propionyl-L-Carnitine:  
Carnitine and Propionyl-L-Carnitine work by interacting with skeletal muscle oxidative 
metabolism, reducing the impact of IC on walking performance in a similar way to 
Naftidrofuryl (Norgren et al 2007). Two multicentre trials have investigated the effects of 
Propionyl-L-Carnitine on treadmill walking distance (Brevetti et al 1999; Hiatt et al 2001). It 
was reported to increase initial and maximal treadmill walking distance and improve 
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reported QoL, compared with placebo. Reported side effects are diarrhoea, increased 
appetite, body odour and rash.  
 
2.4.2.5: Lipid lowering drugs (Statins):  
Statins lower the lipid content of the blood by reducing the production of lipids in the liver. 
Statins are thought to work in PAD and IC by improving endothelial and metabolic 
abnormalities secondary to atherosclerosis (Norgren et al 2007). Currently, the evidence for 
the use of Statins in PAD and IC is limited but the initial results are promising. Two studies 
have reported improved treadmill walking distance after 3 months, 6 months and 1 year 
(Mohler et al 2003; Mondillo et al 2003). The side effects again are rare and include 
headaches, abdominal pains, ‘pins and needles’, bloating, diarrhoea and nausea.   
 
2.4.3: Limitations with the Current Management of PAD and IC:  
Currently, non-surgical management of PAD and IC consists of management of risk factors 
with exercise therapy and pharmacological interventions. Both of these management 
strategies have been shown to be successful at increasing walking distance and decreasing 
the rate of further complications (Leng et al 2000; Norgren et al 2007). These management 
strategies however, are not without their limitations. As mentioned in section 2.4.1, 
adherence to exercise therapy has been identified as a problem. Also, pharmacological 
interventions are expensive, can cause side effects and damage to the internal organs 
(Squires et al 2011). These issues will be discussed in turn with specific reference to the 
central research aim of this thesis: the possible effects of TENS for patients with PAD and IC.  
 
2.4.3.1: Adherence to Exercise Therapy:  
Exercise therapy has numerous benefits for patients with PAD and IC. However, patient 
adherence has been identified as an issue (Hamburg and Balady 2011). There are a limited 
number of studies that have investigated long-term exercise habits in IC patients. Bartelink 
et al (2004) retrospectively examined walking exercise habits in patients with PAD and IC. 
They recruited 216 participants from local GP practices who had been diagnosed with 
atherosclerosis or PAD in the last 6 years and had the term ‘claudication’ present in their 
file. The study found that 52% of participants reported that they walked for the purpose of 
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exercise (n=113). Of those that reported walking for the purpose of exercise, only 44% 
(n=49) walked to the recommended intensity (i.e. through the pain), and just 25% (n= 28) 
walked to the optimum frequency (more than, or equal to 3 times a day). However, these 
results should be interpreted with caution as only 70% of the 216 respondents reported that 
they had been given advice about the need for exercise and the advice given was generally 
not very specific (Bartelink et al 2004). Also, the authors state the optimum frequency of 
exercise as more than, or equal to 3 times a day which contrasts with the current 
recommendations in the literature of exercising 3 times a week (Leng et al 2000; Bulmer and 
Coombes 2004; Bendermacher et al 2006; Hamburg and Balady 2011).  
 
Kruidenier et al (2009c) recruited a consecutive sample of IC patients referred for 
community-based supervised exercise therapy (n=272) in an effort to examine the 
effectiveness of this type of exercise program. The program consisted of 2-3 times a week, 
30 minute sessions for the first three months although the frequency of the sessions was 
reduced to 1 session every 2 weeks and 1 session every 8 weeks at 6 month and 12 month 
follow-up respectively (Kruidenier et al 2009c). At the one year follow-up, 52% (n=143) of 
the original participants had discontinued the program, giving a 48% compliance rate. This is 
a large dropout rate although it is comparable to that observed in a hospital setting (10-
50%) (Regensteiner et al 1996; Kakkos et al 2005; Collins et al 2005; Kruidenier et al 2009c).  
 
Bartelink et al (2004) and Kruidenier et al (2009c) reported the explanations given by the 
participants for poor exercise therapy adherence. Explanations for not starting exercising 
were either: co-morbidity; low pain tolerance; too painful or lack of supervision (Bartelink et 
al 2004). Participants in the study by Kruidenier et al (2009c) provided similar explanations 
(reported as reason and (% of dropouts)): satisfaction with the acquired walking distance 
(13%); unsatisfying results (18%); not motivated (15%); non-vascular comorbid disease 
(34%); and other reasons (not detailed in the study) (20%) (Kruidenier et al 2009c). Roche et 
al (2005) reported similar findings with 52% of participants interviewed citing IC pain as the 
reason they discontinued walking. These findings suggest a complex disease process and 
multifaceted psychosocial factors affecting motivation for exercise therapy. Nevertheless, a 
common theme amongst the studies was the influence of pain (Bartelink et al 2004; Roche 
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et al 2005; Kruidenier et al 2009c). The only study of the three that further examined the 
nature of the pain experienced was that of Roche et al (2005). They employed the McGill 
Pain Questionnaire (MPQ) to elicit subjective description of the quality and intensity along 
with separate psychosocial questionnaires. Preliminary analysis suggested that the pain 
experience of IC was severe, unique and associated with specific psychosocial factors (Roche 
et al 2005). A detailed examination of the IC pain experience, and its effects on walking 
performance is therefore indicated. This detailed knowledge of the pain experience is 
essential firstly, to begin to understand the impact of the disease and how IC pain 
experience could relate to exercise adherence and secondly, to begin investigation of 
possible adjunctive management strategies.  
 
2.4.3.2: Side Effects, Cost-Effectiveness and Mechanisms of Action of 
Pharmacological Therapy: 
The pharmaceutical interventions for PAD and IC all have reported side effects. These range 
from headaches and dizziness to heart palpitations and diarrhoea. Some of the medications 
mentioned are also contraindicated in conditions common to the IC patient population due 
to increased mortality rates. In addition, there is a chance of drug interactions due to poly-
pharmacy. These interactions can have significant risks for the patient, potentially causing 
permanent damage to their internal organs (Pratt 2001). In addition, the cost effectiveness 
of pharmacological intervention has been questioned when compared to exercise therapy 
(Lee et al 2007).  
 
Squires et al (2011) conducted a systematic review and economic evaluation of IC 
medications compared to non-vasoactive medications in patients with PAD and IC. Twenty-
six randomised controlled trials (RCTs) met the inclusion criteria and meta-analysis was 
performed for measures of walking distance. Cilostazol and naftidrofuryl oxalate were found 
to increase maximum walking distance from baseline compared to placebo. Side effects 
reported for all medications included headaches and gastrointestinal difficulties. There was 
no difference in serious adverse events (cardiovascular events and mortality) between IC 
medications and placebo although follow-up was limited in the included studies (maximum 
24 weeks). For cost-effectiveness, naftidrofuryl oxalate was found to be best with a cost per 
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‘Quality-Adjusted Life-Year’ (QALY) gained of approximately £6070 compared with no 
treatment (Squires et al 2011).  
 
Lee et al (2007) examined the cost-effectiveness of supervised exercise therapy (3 sessions a 
week for 12 weeks) compared to conservative medical therapy (antiplatelet therapy, 
smoking cessation advice and support, and management of hypertension, 
hypercholesterolaemia and diabetes) on measures of walking performance and health-
related quality of life. This three-month exercise programme was associated with a gain of 
0.027 QALYs per year above conservative medical therapy. This results in a cost per QALY of 
£1780, considerably less than reported with pharmaceutical management (Lee et al 2007).  
 
In addition, current pharmacological treatment of IC aims to delay the onset of IC pain by 
altering physiological factors in the limbs, thus delaying the creation of the resulting 
ischaemic environment (Regensteiner et al 2002; Norgren et al 2007). Studies on patients 
with IC have found that when patients with IC walk ‘through’ pain, i.e. endure the ischaemic 
environment in their limb(s), this helps to encourage the formation of collateral vessels 
(arteriogenesis), increase cellular oxygen uptake from the blood, improve endothelial 
function and metabolic adaptations in skeletal muscle (Leng et al 2000; Stewart et al 2002). 
As pharmacological treatments work by delaying the onset of ischaemia, patients with IC 
may not be as encouraged to walk ‘through’ an ischaemic environment. Therefore, they 
may not gain the full benefits of arteriogenesis and any alterations in the physiology of the 
peripheral tissues that are associated with enduring ischaemia. Conversely, exercise therapy 
that encourages patients to regularly walk to maximal pain tolerance will utilise these 
compensatory physiological mechanisms and possibly produce a longer-lasting treatment 
effect (Treesak et al 2004; Lee et al 2007).  
 
2.4.4: Summary of the Management of PAD and IC:  
Management of PAD and IC centres on the slowing of the progression of atherosclerosis and 
thus is focussed on the modification of cardiovascular risk factors (SIGN 2006; Norgren et al 
2007). Core aspects of this approach to management are exercise and pharmacological 
therapy. The evidence for the benefit of these interventions is considerable, although they 
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are not without limitations. Patient adherence to exercise therapy has been found to be an 
issue and pharmacological interventions can cause side effects and are costly. These issues 
inform both aims of the current research programme. A greater understanding of the IC 
pain experience could help to examine the reasons for the reduced adherence to exercise 
therapy. Also, if TENS intervention is found to have a hypoalgesic effect on IC pain, it may 
prove to be a safe, low-cost, non-pharmacological adjunctive treatment which could 
augment the current pharmacological management of IC and improve the adherence to 
exercise therapy.  
 
2.5: CURRENT HEALTHCARE PROVISION FOR THOSE WITH PAD AND IC IN THE UK:  
Recent commentary within the vascular literature has highlighted a lack of adherence with 
optimal management of PAD and IC (Belch et al 2003; 2007). Guidelines exist that detail the 
optimal management for patients with PAD and IC (SIGN 2006; Norgeren et al 2007). 
Nevertheless patients with PAD and IC in the UK are currently under-diagnosed and under-
treated (Belch et al 2007).  
 
Khan et al (2007) investigated the current provision of medical management for patients 
with PAD and IC in 23 different sites across the UK. This well-designed, prospective cohort 
study recruited 473 participants with PAD and IC attending specialised vascular outpatient 
clinics. Data collected included demographic and disease measures of function along with 
information about current management. The sample was representative of a PAD and IC 
population with common comorbidities of hypertension (54%), diabetes (20%) and coronary 
artery disease (29%) (Khan et al 2007). Management focussed on risk factor modification 
but this was found to be sub-optimal. Antiplatelet therapy, lipid-lowering agents and ACE-
inhibitors are recommended in the guidelines (Table 2.1) although 30% of the sample were 
not prescribed an antiplatelet, 50% were not prescribed a statin and 75% did not receive 
ACE-inhibitors or other medication for hypertension (Khan et al 2007). These results indicate 
poor management of blood pressure and cholesterol. The researchers noted that of the 40% 
of the sample that continued to smoke, only 50% had tried to stop within 6 months prior to 
enrolment in the study. Of these participants only half had been offered nicotine 
replacement therapy or smoking cessation counselling indicating poor adherence with the 
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guidelines on smoking cessation for patients with PAD (Anthonisen et al 2005; Khan et al 
2007). D’Souza et al (2008) also highlighted the sub-standard level of medical management 
of patients with PAD in the UK. When compared to patients with coronary heart disease 
who share the same risk factors and similar outcomes, patients with PAD were less likely to 
receive advice and support with smoking cessation, less likely to be prescribed anti-platelet 
or lipid-lowering medications and for those with diabetes, blood sugar management was 
inadequate (D’Souza et al 2008).  
 
Similar evidence of sub-optimal management of PAD and IC in the UK was also found in 
relation to supervised exercise (another guideline recommendation). Makris et al (2012) 
aimed to investigate the provision of supervised exercise therapy for patients with PAD and 
IC worldwide. Electronic questionnaires were sent to vascular surgeons and 378 were 
completed representing 43 countries. The majority or responses were from Europe (95%) 
and of these, 34% were from the UK. The vascular surgeons surveyed reported a lack of 
access to supervised access to supervised exercise programs with only 30% of the overall 
sample having the ability to refer to a program. Within the UK alone, 36% reported access to 
supervised exercise programs. This compared poorly to the 100% of surgeons in the 
Netherlands and 67% in France that were able to refer their patients to a supervised 
exercise program (Makris et al 2012). In a separate, but similar questionnaire study that 
focussed solely on the UK, Shalhoub et al (2009) found that only 24% of the vascular 
surgeons that responded had access to a supervised exercise program.  
 
Overall, current evidence suggests that the management of PAD and IC in the UK focuses on 
modification of cardiovascular risk factors and exercise therapy. This is in line with the 
current guidelines however, when compared to the management of medical conditions with 
a similar risk profile or when compared to other European countries, management of PAD 
and IC is inferior and supervised exercise therapy is an under-utilised tool despite high 





2.6: CONCLUSION:  
PAD is a cardiovascular disease characterised by widespread atherosclerosis. The cardinal 
symptom of PAD is IC. IC is the symptomatic manifestation of the atherosclerotic limitation 
of blood flow to the legs, causing pain, fatigue and/or cramping on muscle exertion. PAD 
and IC are currently managed through a number of strategies, primarily risk factor 
modification and exercise therapy. A number of barriers to the success of exercise therapy 
have been identified and the pain due to IC has been highlighted as a potential key factor.  
 
Current treatment of IC is focussed on modifying cardiovascular risk factors and is mainly 
pharmaceutical. These management strategies are effective and have been found to result 
in an increase in walking distance and QoL. Nevertheless, any additional, adjunctive 
intervention that increases physical activity or engagement with exercise therapy with fewer 





2.7: CHAPTER 2 SUMMARY: 
The aim of this chapter was to outline the clinical problem of PAD and IC. This chapter has 
highlighted that PAD is common, debilitating and merely a manifestation of more general 
atherosclerosis. IC has been identified as the cardinal symptom of PAD and represents a 
collection of symptoms that develop in the lower limbs when walking. The central 
component of IC is pain. The experience of IC is related to considerable physical limitations 
and a decrease in quality of life. Nevertheless, the specific qualities of IC pain have not been 
fully examined. These factors contribute to the first aim of this thesis: to investigate the 
subjective description of the multidimensional qualities of ischaemic pain.  
 
This chapter also discussed the current management of PAD and IC. Management is 
focussed on cardiovascular risk factor modification with the aim of slowing the progression 
of atherosclerosis whilst increasing function and quality of life. The management strategies 
employed in patients with PAD and IC are exercise therapy and pharmacological 
management. Issues have been identified however with adherence to exercise therapy and 
pharmaceutical treatment has been shown to be associated with side effects. Both aims of 
the thesis look to address these limitations in the management of IC. By investigating the 
subjective descriptions of IC pain, the reasons for the reduced compliance with exercise 
therapy may be explored. Also, by investigating the hypoalgesic effects of TENS on lower 
limb ischaemic pain, TENS could be identified as a possible safe, non-pharmacological and 
low-cost adjunctive intervention for IC pain. If successful in reducing the experience of IC 
pain and increasing walking performance, TENS may help to increase adherence to exercise 
therapy and augment the beneficial effects of current medical management of IC.  
 
The next two chapters examine the two concepts related to the aims of the thesis: pain and 
TENS. Chapter 3 will discuss the multidimensional nature of pain, how it can be measured 
and the common psychosocial aspects of pain. Chapter 4 will explore the theory and 
evidence for the use of TENS as a hypoalgesic intervention. This discussion within these 
chapters aims to summarise the current understanding of each topic and explore how this 




CHAPTER 3: PAIN  
3.1: AIM OF CHAPTER 3:  
The aim of this chapter is to explore and discuss the current understanding of pain. 
Definitions and concepts will be discussed (sections 3.2 to 3.4) followed by a more in-depth 
exploration of the measurement and description of pain and associated psychosocial factors 
(sections 3.5 and 3.6). Throughout this chapter, the knowledge and evidence highlighted will 
be discussed in relation to the clinical problem of IC.  
 
3.2: DEFINITIONS OF PAIN:  
Pain is a complex experience, unique to the individual (Coghill et al 2003; Vetter 2007). It 
can occur with tissue damage or in the absence of damage and its impact goes beyond 
perception (Becker et al 1997). There are two distinct aspects of the pain experience, 
nociception and the perception of pain. Nociception is the physiological process associated 
with perception of pain and can be defined as:  
“the neural process of encoding noxious stimuli”  
(Merskey and Bogduk 1994 p215) 
 
Pain is a psychophysiological process related to the perception of an experience. The 
International Association for the Study of Pain (IASP) defines pain as:  
“an unpleasant sensory and emotional experience associated with actual or potential 
tissue damage, or described in terms of such damage”  
(Merskey and Bogduk 1994 p210) 
 
Pain therefore includes, and is dependent on, psychological constructs such as expectations, 
past experiences, anxiety, suggestion and attention (Villemure and Bushnell 2002; Wiech et 
al 2008).  
 
3.3: THEORIES OF PAIN:  
Over the past 10 centuries, the understanding of pain has developed through a number of 
theories. One of the earliest theories was ‘Specificity Theory’, proposed by Avicenna in the 
11th century and René Descartes in the 17th century. They proposed that there were specific 
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nerve endings that processed each different sensation e.g. touch, temperature and pain 
(Brooks and Tracey 2005; Tashani and Johnson 2010).   
 
In 1955, Sinclair and Weddell proposed the ‘Peripheral Pattern Theory’ (Sinclair 1995). They 
proposed that all nerve fibre endings are similar and that pain is produced by the intensity 
of stimulation e.g. slight stimulation represents touch and intense stimulation represents 
pain.  
 
Ten years later, Melzack and Wall published their theory named ‘Gate Control Theory’ in the 
journal Science (Melzack and Wall 1965). This was a major step forward in the 
understanding of pain and specifically the modulation and facilitation of nociception in the 
spinal cord. The theory was based on much of the previous work. However it also 
incorporated the psychosocial aspects of pain perception.  
 
Melzack and Casey published an addition to the ‘Gate Control Theory’ that proposed three 
specific dimensions of pain (Melzack and Casey 1968). They described sensory-
discriminative, motivational-affective and cognitive-evaluative dimensions of the pain 
experience (Melzack and Casey 1968). There were however still limitations and conflict 
between the theories. For example, none was thought to thoroughly explain congenital 
insensitivity to pain or phantom limb pain (Melzack 1999). 
 
In an effort to address the limitations of these previous theories, Melzack proposed a 
further theory, the ‘Neuromatrix Theory’ (Melzack 1999; 2001). This theory originated from 
the study of phantom limb phenomena and indications of central ‘pattern generation’ of 
pain (Melzack and Loeser 1978). Four general conclusions were presented (Melzack 1999; 
2001):  
1. The perceived ‘body’ is served by certain neural processes in the brain  
2. The origins of the experience of pain lie in the neural networks of the brain  
3. The body is perceived as a unity and ‘self’, distinct from other people  




These conclusions led to the development of the theory of a body-self ‘Neuromatrix’. The 
‘Neuromatrix’ is proposed as a genetically built-in matrix of neurons for the whole body that 
produces characteristic nerve-impulse patterns that represent the body and all that is 
perceived. This matrix is initially determined genetically but is later sculpted by sensory 
inputs and is constructed from a widespread network of neurones that link the thalamus, 
cortex and limbic systems (Melzack 1999; 2001).  
 
In terms of pain perception, the ‘Neuromatrix Theory’ suggests that pain arises from the 
output from the central matrix, termed a ‘neurosignature’. The ‘neurosignature’ is the result 
of pattern recognition where genetic and sensory influences are mixed together with 
sensory inputs and cognitive events and the ‘difference’ from normal is recognised as pain 
(Melzack and Loeser 1978; Melzack 1999; 2001).   
 
An understanding and appreciation of these theories of pain is important in achieving the 
aims of this thesis. To be able to fully examine the subjective descriptions of ischaemic pain 
and investigate the effects of TENS, these theories will be useful as a framework through 
which the different aspects of the pain experience can be explored. Nevertheless, in 
practice, these theories of pain offer too much detail to be useful in a clinical situation. 
Therefore, simpler concepts have evolved that are utilised for interpreting pain experience. 
In general, it is agreed that pain can be described in terms of four broad components: 
Nociception, Perception of pain, Suffering and Pain behaviours (Loeser and Melzack 1999; 
Melzack and Katz 2012). Nociception, as described above relates to the detection of tissue 
damage by specialised nerve endings (nociceptors). The perception of pain is often triggered 
by nociception but can occur in the absence of such input. Suffering is the negative response 
to pain or the associated fear, anxiety or stress. Pain behaviours are the outward display of 
the internal experience of pain and suffering (Loeser and Melzack 1999; Asghari and 
Nicholas 2001). These factors are essential and will be considered when interpreting 





3.4: CLASSIFICATION OF PAIN: 
In addition to this simplified method for interpreting pain, general classifications of pain 
have developed. Pain is commonly described relating to its temporal nature i.e. acute or 
chronic. Acute pain describes pain that is limited by time and usually has a defined cause 
(Merskey and Bogduk 1994; Walsh et al 2009). It can be sudden in onset and may be mild, 
moderate or severe, but usually disappears when healing has taken place. It can serve as a 
protective function for the body, which alerts an individual to potential damage and can 
encourage rest of the affected part in order to promote healing (Melzack and Katz 2012).  
 
Chronic pain can be defined as: ‘daily pain reoccurring for more than 6 months, usually 
beyond the time for normal organic healing and is associated with negative psychosocial 
effects’ (Vlaeyen et al 1995; Crombez et al 1999). Chronic pain may begin as acute pain but 
tends to last over an extended period of time, is linked to chronic pathological processes 
and can cause suffering in multiple systems (Merskey and Bogduk 1994). Unlike acute pain, 
its cause may be unknown or if known cannot be eliminated. This intractable pain has no 
biological value and can affect a person psychologically, emotionally and spiritually, as well 
as physically (Autton 1986; Villemure and Bushnell 2002; Wiech et al 2008).   
 
The concept that chronic pain should be viewed as a disease in its own right has been 
gathering momentum over the past decade (Niv and Devor 2004; Siddall and Cousins 2004; 
Tracey and Bushnell 2009). This has resulted from the creation of a critical mass around the 
biopsychosocial model of health and the recognition that pain, and especially chronic pain, 
is a ‘state’ (persistent pain over time) rather than a ‘symptom of something’ (Croft et al 
2010).  
 
IC can be classified as a chronic pain syndrome and as such will be associated with individual 
psychological and psychosocial factors that have developed over time. This is an important 
concept to appreciate and may impact on the examination of laboratory and clinical 
ischaemic pain. It could be theorised that, compared to laboratory ischaemic pain, clinical 
ischaemic pain will be affected to a greater degree by psychosocial factors. Ultimately, what 
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is important in achieving the aims of this thesis is that all of these multidimensional factors 
of the pain experience are recorded and measured.  
 
3.5: MEASUREMENT OF PAIN:  
This section will discuss some of the methods that can be used to measure these aspects of 
pain. As discussed, pain is a personal, subjective experience that is influenced by cultural 
learning, the meaning of the situation, direction of attention and other psychological 
variables (Melzack and Wall 1996). When attempting to measure the experience of pain, 
two main types of measure have emerged as key components to any assessment. The Visual 
Analogue Scale (VAS) and Numerical Rating Scales (NRS) have emerged as single ratings of 
pain that encompass the other dimensions in a format that is easy to use and comprehend. 
The McGill Pain Questionnaire (MPQ) also measures pain intensity although due to the 
method of selecting adjectives that describe the person’s pain, it can also be used as a 
measure of pain quality or the ‘language of pain’ (Katz and Melzack 1999).   
 
Unlike many major chronic pain syndromes such as cancer pain, arthritis and post-surgical 
pain (Graham et al 1980; Roche and Heim 1997; Roche et al 2003; Bruce et al 2004; 
Ngamkham et al 2012), the qualitative nature of IC pain has not been explored. To achieve 
the aim of this project and examine the subjective description of IC pain, it is important that 
the intensity and quality of pain is measured and analysed.  
 
3.5.1: The Visual Analogue Scale (VAS) and Numerical Rating Scale (NRS):  
A VAS is a 100mm horizontal, or vertical line with two boundaries and anchors representing 
“no pain” and “worst pain imaginable”. Responders are asked to make a mark somewhere 
along the line that represents their symptoms. Most commonly they are asked to rate their 
“current pain” or “pain in the last 24 hours” (Hawker et al 2011). The score is determined by 
using a ruler to measure the distance (mm) between the “no pain” anchor and the 
responder’s mark on the line.  
 
The VAS is used to measure pain in diverse adult populations and has been found to be 
sensitive to change (Jenkinson et al 1995; Williamson and Hoggart 2005) and closely 
  
59 
correlate with verbal and numerical ratings of pain (DeLoach et al 1998, Briggs and Closs 
1999; Bijur et al 2003).  
 
A NRS is similar to the VAS in that it is a one-dimensional measure that employs anchors of 
“no pain” and “worst pain imaginable”. Responders are asked to verbally “rate their pain on 
a scale between 0 and 10, where 0 represents no pain and 10 represents the worst pain 
imaginable”. The NRS most commonly consists of 11 levels (0-10) however; there are 
versions with 21 (0-20) or 101 (0-100) levels also.  
 
Similar to the VAS, the NRS has been shown to be sensitive to change and relates to other 
measures of pain (Bolton and Wilkinson 1998; Williamson and Hoggart 2005). Jensen et al 
(1994) compared seven different measures of pain intensity, including 101-, 21- and 11-
point NRS, in an effort to determine how many levels are required in a pain intensity scale 
to reliably measure pain with optimum sensitivity. The authors found that all measures were 
highly correlated in 124 mixed chronic pain patients and that little sensitivity was lost when 
using 11 or 21 levels compared to 101. They also found that when using the 101-point NRS, 
patients often selected numbers that were multiples of 5 or 10 and thus were using as if it 
were a 21-point scale (Jensen et al 1994).  
 
Overall, both the VAS and the NRS have been shown to be sensitive and reliable measures 
of pain intensity. The NRS has an added benefit due to its ease of use. It can be 
administered verbally and in writing and is simpler to score (Hawker et al 2011).  
 
3.5.2: The McGill Pain Questionnaire (MPQ):  
Melzack and Casey (1968) suggested that there are three dimensions of pain experience: 
sensory-discriminative, motivational-affective and cognitive-evaluative. Following the 
development of this theory and the subsequent examination of the language used to 
describe pain the McGill Pain Questionnaire (MPQ) was conceived (Melzack and Torgerson 




Based on this theoretical principle Melzack and Torgerson (1971) conducted a two-part 
study on the specifying qualities of pain. They asked physicians and university graduates to 
classify 102 words, obtained from the clinical literature, into small groups that describe the 
different aspects of the experience of pain. On the basis of this data, the words were 
categorised into three major classes (sensory, affective and evaluative) and 16 subclasses. 
The classes were based on a) words that describe the sensory qualities of pain; b) words 
that describe the affective qualities of pain in terms of tension, fear and punishment; and c) 
evaluative words that describe the subjective, overall intensity of the total pain experience 
(Melzack and Torgerson 1971; Melzack and Katz 2012). In the second part of the study, they 
attempted to determine the intensity of the words included in each subclass. Again, they 
asked physicians, graduates but patients as well to assign an intensity value to each word, 
from “least pain” to “worst pain”. Although the values on the intensity scale chosen in each 
group were different, they all agreed on the position of the words relative to each other. 
Using the data from these studies, Melzack constructed the MPQ as an experimental tool 
for use in studies on pain management (Melzack 1975).  
 
The MPQ consists of 78 pain adjectives separated into 20 subclasses describing different 
aspects of the pain experience, and ranked within these subclasses in order of intensity (see 
Table 3.1). Responders are asked to choose one adjective from each subclass that describes 
their pain or, if none of the adjectives in a subclass adequately describes their pain, they are 
instructed to leave it blank. These subclasses are divided into four major groups: sensory 
(subgroups 1-10), affective (11-15), evaluative (16) and miscellaneous (17-20), referring to 
the sensory-discriminative, affective-motivational and cognitive-evaluative dimensions 
previously described.   
 
Despite its descriptive, qualitative nature, the MPQ can also produce a single quantitative 
score of pain intensity, which is termed the Pain Rating Index (PRI). This is calculated by 
summing the score for each subclass. Melzack et al (1985) further developed this 





Table 3.1: 20 Subgroups of the MPQ and the ranked pain descriptors (Melzack 1975)  
1- Temporal  2- Spatial  3- Punctuate Pressure  4- Incisive 
Pressure  
1. Flickering  
2. Quivering  
3. Pulsing  
4. Throbbing  
5. Beating  
6. Pounding  
1. Jumping  
2. Flashing  
3. Shooting  
1. Pricking  
2. Boring  
3. Drilling  
4. Stabbing  
5. Lancinating  
1. Sharp  
2. Cutting  
3. Lacerating  
5- Constrictive 
Pressure  
6- Traction Pressure  7- Thermal  
 
8- Brightness  
 
1. Pinching  
2. Pressing  
3. Gnawing  
4. Cramping  
5. Crushing  
1. Tugging  
2. Pulling  
3. Wrenching  
1. Hot  
2. Burning  
3. Scalding  
4. Searing  
1. Tingling  
5. Itchy  
6. Smarting  
7. Stinging  




11- Tension  
 
12- Autonomic  
1. Dull  
2. Sore  
3. Hurting  
4. Aching  
5. Heavy  
1. Tender  
2. Taut 
3. Rasping  
4. Splitting  
1. Tiring  
2. Exhausting  
1. Sickening  
2. Suffocating  
13- Fear  
 




16- Evaluative  
 
1. Fearful  
2. Frightening  
3. Terrifying  
1. Punishing  
2. Gruelling  
3. Cruel  
4. Vicious  
5. Killing  
1. Wretched  
2. Blinding  
1. Annoying  
2. Troublesome  
3. Miserable  
4. Intense  
5. Unbearable  
17- Miscellaneous  18- Miscellaneous  19- Miscellaneous  20- Miscellaneous  
1. Spreading  
2. Radiating  
3. Penetrating  
4. Piercing  
1. Tight  
2. Numb  
3. Drawing  
4. Squeezing  
5. Tearing  
1. Cool  
2. Cold  
3. Freezing  
1. Nagging  
2. Nauseating  
3. Agonising  
4. Dreadful  





3.5.2.1: Psychometric Properties:  
Since its development, the MPQ has been shown to be a valid and reliable measure of acute 
and chronic clinical pain and laboratory-induced pain (Melzack 1983; Wilkie et al 1990).  
 
Reliability:  
The MPQ has been shown to reliably measure quality and intensity of pain over time 
(Graham et al 1980; Love et al 1989; Roche et al 2003; Broderick et al 2008). Graham et al 
(1980) investigated the reliability of the MPQ in a group of 36 community-dwelling patients 
with cancer pain. All participants completed the MPQ describing their current pain, once a 
week for 5 weeks. Participants selected similar adjectives and PRI scores were comparable 
at each time point (Graham et al 1980). Broderick et al (2008) found that the 3 items from 
the MPQ were found to have good test-retest reliability over 1 day recall (r = 0.81) but this 
became poorer when the recall was over 7 days (r = 0.59) in a sample of patients with 
rheumatology pain. Generally, the MPQ has been shown to have good test-retest reliability 
in a variety of populations (r > 0.70) (Melzack et al 1975; Graham et al 1980; Love et al 1989; 
Roche et al 2003; Broderick et al 2008).  
 
Validity:  
The MPQ has content validity. Respondents regularly utilise all 20 subclasses of adjectives 
and those with the same pain syndrome select similar clusters of words to describe their 
pain experience, regardless of disease severity (Dubuisson and Melzack 1976; Burckhardt 
1984).   
 
Turk et al (1985) examined the factor structure of the MPQ in a varied sample of 168 
patients with chronic pain and concluded that the PRI lacked discriminant validity. The 
authors examined the three-factor structure (sensory, affective and evaluative) of the PRI 
and found that all three were highly inter-correlated and therefore not distinct. The 
recommendations were therefore to use the total PRI score as this will reflect changes in 
any of the subcategories or examine the patterns of adjective selection in the individual 
subclasses. These conclusions are supported and expanded by Holroyd et al (1992) who 
reported that despite a four-factor model of the PRI (2 sensory, 1 affective and 1 evaluative) 
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best explaining covariance, the high inter-correlation between the factors cast doubt on the 
discriminant validity of the PRI subcategories.  
 
Criterion and construct validity of the MPQ has also been established. The number of words 
chosen has been found to correlate significantly with VAS scores in arthritis and post-
operative pain (Papageorgiou and Badley 1989; Katz et al 1994), and with measures of 
health-related quality of life in osteoarthritis (Gandhi et al 2010).  
 
Use of the MPQ has been questioned due to the level of literacy and comprehension 
required to complete it correctly. The descriptors included in the MPQ were selected by 
scientists and arose from words patients used to describe pain 40 years ago and therefore 
may not possess the same meaning, or at least common usage today (e.g. lancinating, 
rasping). Also, the adjectives used do not necessarily encompass all terms in current usage 
to describe pain (Skevington 1995; Hawker et al 2011).  
 
Sensitivity:  
The MPQ has been found to be sensitive to change in clinical and laboratory pain 
populations. In post-surgical pain, the PRI of the MPQ was found to be less sensitive to 
change in pain intensity than a VAS or a verbal rating scale however; this was over a very 
short time period (4 hours) (Jenkinson et al 1995). In laboratory pain, the MPQ has been 
shown to detect differences between type and intensity of pain, both with PRI scores and 
patterns of words chosen (Klepac et al 1981; Chen and Treede 1985).  
 
3.5.2.2: Describing Pain Syndromes with the MPQ:  
In addition to being a multidimensional measure of pain intensity, the MPQ has been used 
to examine the characteristics of common pain conditions. Dubuisson and Melzack (1976) 
utilised the MPQ to examine the description of eight pain syndromes. By using multi-group 
discriminant analysis they were able to identify specific adjectives that commonly describe 
each pain experience. Table 3.2 details the adjectives chosen by more than a third of 
participants in six of these pain syndromes. Commonalities of description have been found 
in patients with phantom limb pain, labour pain, cancer pain, toothache pain and arthritis 
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pain (Graham et al 1980; Melzack et al 1981; Grushka and Sessle 1984; Katz and Melzack 
1991; Katz 1992; Roche and Heim 1997; Roche et al 2003).  
 
The MPQ has now become a frequently used tool in the assessment, diagnosis and 
management of complex, chronic pain syndromes (Melzack 1987; Wright et al 2001) but has 
not been used to describe IC pain.  
 
The PRI scores for different pain syndromes have also been examined. In order of severity, 
PRI scores were: causalgia = 42; labour pain = 29-38; back pain = 27; cancer pain = 26 
phantom limb pain = 25; post herpetic neuralgia = 22; toothache = 19; fracture = 19; arthritis 
= 18; and tissue damage including cuts, bruises and sprains = 16-21 (Melzack 1984). PRI is 
however a crude measure of overall pain intensity. These statistics do provide an indication 
of the number of pain syndromes that have been investigated using the MPQ. The specific 
qualities of IC pain have not yet been explored. Employing the MPQ in a sample of patients 
with PAD and IC would allow an investigation into the common and distinctive 
characteristics of the pain experience. The results of such a study would help to inform 
further investigation of management strategies aimed at targeting specific aspects of the 





Table 3.2: MPQ adjectives chosen by more than 33% of participants for menstrual, 
arthritic, labour, dental, back and cancer pain (adapted from Dubuisson and 
Melzack 1976).  
Syndrome Number Sensory Affective  Evaluative  





Arthritic Pain 16 Gnawing  
Aching 
Exhausting  Annoying  










Dental Pain 10 Throbbing  
Boring  
Sharp  
Sickening  Annoying  
















Exhausting  Unbearable  
 
3.5.3: The Short-Form MPQ (SF-MPQ):  
Due to the need for a quicker method of measuring the qualities of pain, a ‘short-form’ of 
the MPQ has been developed (Melzack 1987). The Short Form MPQ (SF-MPQ) was felt to be 
important for research where brief assessments of multidimensional pain intensity were 
required e.g. in the evaluation of pharmaceuticals. The shortened version contains 15 
adjectives representing 11 sensory and 4 affective categories. These adjectives were chosen 
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as the most popular descriptors utilised to describe a range of pain conditions (Melzack 
1987; Fernandez and Towery 1997).  
 
The SF-MPQ was found to correlate highly with the MPQ and is sensitive to change (Melzack 
1987; Dudgeon et al 1993; Grafton et al 2005). It has also been shown to have test-retest 
reliability over 5 days in patients with arthritic joint pain (ICC = 0.88-0.96) (Grafton et al 
2005). However, dissimilar to the full version, the SF-MPQ has been shown to have only a 
two-factor structure (sensory and affective) (Wright et al 2001).  
 
Overall it is judged to be easier to use and takes less time to administer than the full MPQ. 
These properties make it useful when investigating change from baseline in order to 
evaluate the effect of an intervention (Grafton et al 2005). However, when investigating the 
subjective qualities of a pain experience, the SF-MPQ is limited in its ability to explore the 
nuances of the full experience (van Wijk and Hoogstraten 2002). This is primarily because it 
does not include words commonly used to describe pain and also does not measure 
evaluative components (Dudgeon et al 2005).  
 
Due to these limitations, the SF-MPQ is not ideal when investigating the multidimensional 
nature and subjective description of a pain experience such as IC. The full version of the 
MPQ is more suited as it includes a greater range of pain descriptors that encompass more 
components of the pain experience. As the aim of the current study is to examine the 
subjective description of the IC pain experience, the full version of the MPQ is therefore 
more appropriate to employ compared to the SF-MPQ.  
 
3.5.4: Summary:  
Overall, the MPQ is recommended for the assessment of clinical and laboratory pain. It is 
most useful when examining the descriptive qualities of a pain experience and should be 
used in conjunction with a VAS or other simpler measure for evaluation of a change in pain 
intensity over time. As this thesis aims to record the subjective descriptions of IC pain and 
examine the effect of TENS on this pain experience, the MPQ and a NRS are both required. 
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The MPQ will function to measure the descriptive qualities of the pain and the use of a NRS 
will allow examination of the effects of TENS over time.  
 
As discussed in section 3.4, chronic pain syndromes are associated with negative 
psychosocial effects (Crombez et al 1999). An exploration of a chronic pain experience 
would not be complete therefore without investigation of these psychosocial aspects. As 
identified in Chapter 1, IC has been shown to be associated with negative psychosocial 
factors, chiefly depression. It is therefore important to have an understanding of the origin 
and nature of these factors when examining IC pain.  
 
3.6: PSYCHOSOCIAL ASPECTS OF PAIN:  
Pain, and especially chronic pain represents a stressful situation that extends beyond merely 
enduring the sensation. Thus living with chronic pain can impact many aspects of the 
sufferer’s life and cause significant emotional effects (Turk and Monarch 2002). Most 
commonly, the primary focus of someone in pain is the elimination of the experience. In 
chronic pain, when this is not always possible the failure in achieving relief can lead to 
negative emotions (Main and Watson 1999). In addition, the sufferer does not experience 
this in isolation. The complex interactions with significant others, healthcare professionals 
and their respective environments can both positively and negatively impact these emotions 
and thus the pain experience (Turk and Monarch 2002). These emotions, cognitions and 
social interactions have been investigated in numerous chronic pain conditions and are 
collectively termed ‘psychosocial aspects’ of pain (Keefe et al 2004).  
 
It is still debated whether it is psychosocial aspects of pain that sensitise patients to the 
development of chronic pain or whether they are a consequence of the pain experience 
(Large 1996). Nevertheless, it has been shown that they contribute significantly to 
functional disability, independent of physiological measures and pain severity in a wide 
range of chronic pain syndromes (Main and Watson 1999; Karoly and Rueblman 2007). It is 
important therefore to acknowledge and appreciate the psychological and social aspects of 




Psychosocial aspects of pain are multiple and multifaceted. There are however, a few key 
aspects that have been the focus of a considerable amount of research and have been 
found to impact on clinical pain. These factors will now be briefly reviewed and the current 
status of evidence summarised.  
 
3.6.1: Pain Catastrophising:  
Pain Catastrophising can be defined as “an exaggerated negative orientation toward actual 
or anticipated pain experiences” (Gatchel et al 2007, p602). Pain catastrophising can be 
measured using a subscale of the Coping Strategies Questionnaire (CSQ) (Rosentiel and 
Keefe 1983) or the more focussed Pain Catastrophising Questionnaire (PCS) (Sullivan et al 
1995). Factor analysis of the PCS has identified three second-order factors: rumination, 
magnification and helplessness (Sullivan et al 1995; Granot and Ferber 2005). These factors 
clearly indicate the components of pain catastrophising: thinking about, or ruminating on 
the pain, magnifying the threat value of pain and feeling helpless in the context of pain.  
 
Research has identified pain catastrophising as one of the most important predictors of 
pain, accounting for between 7 and 39% of variance in the rating of pain intensity (Sullivan 
et al 2001; Geisser et al 1994; Sullivan et al 2006). Catastrophising has also been shown to 
be associated with a number of other health-related outcomes, independent of pain 
intensity. These include higher levels of healthcare usage (Gil et al 1992); longer hospital 
stays (Gil et al 1993); higher levels of disability (Martin et al 1996); increased use of 
medication (Jacobson and Butler 1996); increased motor pain behaviours (Keefe et al 1997); 
slower progress with rehabilitation (Kendell et al 2001); perception of pain intensity and 
disability when experiencing experimentally induced pain (Parr et al 2012).  
 
3.6.2: Pain-Related Fear:  
Pain-related fear is closely associated with pain catastrophising (Gatchel et al 2007). Fear of 
pain is associated with beliefs that pain represents damage or significant harm to the body 
and beliefs that activities that cause pain should be avoided (Waddell et al 1993; Vlaeyen et 




Patients with high levels of pain-related fear have been shown to report higher levels of pain 
(McCracken 1997; Crombez et al 1999), score highly on self-report measures of disability 
and depression (McCracken et al 1992) and lower on measures of pain-related coping 
(McCracken and Gross 1993). An increase in reported fear of pain has also been shown to 
relate to changes in observed behaviour: avoidance of tasks (Swinkels-Meewisse et al 2003) 
and a decrease in speed of performance of tasks (Vlaeyen et al 1995).  
 
3.6.3: Perceived Control and Pain Self-Efficacy:  
Perceived control related to pain refers to “the belief that one can exert influence on the 
duration, frequency, intensity or unpleasantness of pain” (Gatchel et al 2007, p603). Self-
efficacy has been conceptualised as an intrinsic motivational factor in learning (Bandura et 
al 2001; Eccles and Wigfield 2002). Perceived self-efficacy can be defined as “people’s 
beliefs about their capabilities to produce designated levels of performance that exercise 
influence over events that affect their lives” (Bandura 1994).   
 
It is conceptualised that it is these beliefs that modify the meaning of the stimulus of pain 
and thus directly affect the appraisal of the threat of pain. High scores on self-report 
measures of pain self-efficacy have been shown to be related to lower levels of pain, lower 
levels of psychological distress and improved outcomes (Lorig et al 1989; Parker et al 1993; 
Buckelew et al 1994; Keefe et al 1997; Brekke et al 2003).  
 
3.6.4: Helplessness and Depression:  
Based on the theory of the learned helplessness model of depression (Abramson et al 1978), 
Helplessness refers to a focus on generalised, uncontrollable, long-term outcomes of 
chronic pain. It signifies an assumed ‘style’ where negative events such as chronic pain and 
its consequences are perceived as unpredictable and unavoidable.  
 
Depression affects approximately 40-50% of patients with chronic pain (Romano and Turner 
1985; Fishbain et al 1997; Dersh et al 2006). Although symptoms of depression are closely 
related to chronic pain, it is still argued whether depression is an antecedent or 





Recent and growing research has shown that psychosocial factors have both positive and 
negative effects on pain and disability in patients with chronic pain. There is strong evidence 
that supports the theories that pain catastrophising and pain-related fear are both related 
to ‘poor adjustment’ to pain. There is also strong evidence that increased level of pain self-
efficacy are related to improved adjustment in the face of pain. What is still not known 
however, is the direction of these relationships i.e. is the experience of chronic pain an 
antecedent or consequence of the psychosocial factors?  
 
For the purposes of the current project, it is important that when exploring the qualities of 
lower limb ischaemic pain and investigating the effects of TENS that these factors are 
considered and taken into account when interpreting the results observed.  
 
3.7: CONCLUSION:  
At present there is a wealth of literature examining the physiological causes and nature of 
PAD. Conversely, there is a dearth of literature examining the tangible manifestation of the 
most debilitating symptom of the disease: the pain of IC. A detailed understanding of the 
specific, multidimensional quality and intensity of the pain experienced and the associated 
psychosocial factors could be a step towards understanding, and ultimately managing, IC 
pain.  
 
The MPQ is an ideal measurement tool with which to investigate pain description in patients 
with IC. Use of the MPQ will allow eliciting of a quantitative measure of intensity (PRI) whilst 
also recording the qualitative nature of the pain experienced i.e. the vocabulary chosen to 
describe the pain. This type of understanding of IC pain could help to enhance the 





3.8: CHAPTER 3 SUMMARY: 
The aim of this chapter was to explore and discuss the current understanding of pain. This 
aim was achieved by discussing the definitions and theories of pain and how these have 
changed over time. The current understanding of pain is as a complex, multidimensional 
experience: the result and cause of multiple, complex interactions between physiological 
and psychological factors. The classification of pain as either acute or chronic was also 
discussed and related to the clinical problem addressed by the current project: chronic IC 
pain. Measurement of pain is focussed primarily on simple, single-rating scales that provide 
an overall indication of pain intensity although these scales are not able to provide detail 
regarding the specific qualities of pain. The MPQ uses the subjective description of pain to 
form a measure of intensity but that also allows some exploration of the specific qualities of 
the pain experience. Finally, the current understanding of the psychosocial aspects 
associated with pain was briefly discussed. Four different psychosocial constructs were 
identified that have been shown to be associated with pain. These aspects contribute 
positively and negatively to the experience of pain, adjustment to pain and pain-related 
disability.  
 
The discussions within this Chapter inform both aims of the thesis.  The theories and 
classification of pain help to frame the exploration of lower limb ischaemic pain within the 
current evidence base. The discussions relating to the measurement of pain help to 
establish the method with which to measure and explore the ischaemic pain experience and 
also how to evaluate the effects of TENS on this pain. Finally, psychosocial aspects of pain 
have been shown to be important in other chronic pain syndromes and will be important to 
measure when describing the ischaemic pain experience and examining the effects of TENS 




CHAPTER 4: TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION 
(TENS) 
4.1: AIM OF CHAPTER 4:  
The first two substantial chapters of this thesis have explored the perceived clinical 
problems associated with IC (Chapter 2) and this has been framed within the current 
understanding of pain (Chapter 3). This chapter aims to introduce the concept of TENS as a 
possible useful adjunctive intervention for IC pain.  
 
The basic mechanisms of TENS will first be discussed (section 4.4) then the evidence for the 
use of TENS as a method of pain relief will be explored (sections 4.5 and 4.6). This discussion 
will inform the central aim of the thesis: to investigate the hypoalgesic effects of TENS for 
lower limb ischaemic pain. The contents of this chapter will influence the methods and 
interpretation of the results from the study of TENS for ischaemic pain.  
 
4.2: NON-PHARMACEUTICAL INTERVENTIONS FOR IC:  
As discussed, current management of IC is mainly pharmaceutical and somewhat 
ineffective, specifically for IC pain. A non-pharmaceutical, low-cost and easily applied 
intervention that allows patients to walk longer before the onset of pain and/or to walk 
longer while experiencing pain could be a useful adjunctive method of treatment. This could 
result in patients improving their exercise performance and engagement with exercise 
therapy. TENS is a potential modality for investigation.  
 
4.2.1: TENS:  
TENS is a form of electrical stimulation that provides symptomatic pain relief that is used 
extensively within the health-care setting. It is a non-invasive modality; packaged in a small, 
portable unit that is easy to apply via small electrodes placed on the skin. It can be kept in a 
pocket or clipped to a trouser belt and is used widely and daily by patients with chronic pain 
to reduce their pain, improve their daily functioning and in some cases return to work 




4.3: HISTORY OF TENS:  
TENS is defined as the application of electrical stimulation to the skin for purposes of pain 
control (American Physical Therapy Association 2001). The development of TENS as a 
hypoalgesic modality followed the publication of the Pain Gate Theory (Melzack and Wall 
1965). Wall and Sweet (1967), in a study of spinal cord stimulation, demonstrated that high 
frequency electrical stimulation at an intensity which activated Aβ afferent nerve fibres 
reduced neuropathic pain in a sample of chronic pain patients.  
 
Since its inception, different stimulation parameters of TENS have been tested and 
employed clinically. This investigation of TENS has resulted in the efficacy of different 
stimulation parameters being tested and different neurophysiological mechanisms of action 
proposed (Claydon et al 2011).  
 
4.4: TENS MECHANISMS OF ACTION:  
TENS acts by delivering pulsed electrical currents across the intact surface of the skin via 
electrodes (Johnson 2002). The theoretical foundation for this type of electroanalgesia 
builds on the mechanisms described in the ‘Pain Gate Theory’ (Melzack and Wall 1965). This 
theory proposed that there was a metaphorical ‘gate’ in the dorsal horn of the spinal cord, 
which could regulate the amount of incoming nociceptive information from the periphery 
via small diameter afferent nerve fibres. They proposed that this ‘gate’ could be effectively 
closed by a variety of other stimuli, such as: touch, pressure and electrical stimulation, 
which are carried by large diameter afferent fibres. This theory has been discussed and 
examined over the last four decades resulting in the development of a neurophysiological 
evidence base (Eriksson et a 1979; Eriksson et al 1985; Tulgar et al 1991; Garrison and 
Foreman 1994; Sluka and Walsh 2003; Radhakrishnan and Sluka 2005; Chen and Johnson 
2010a; 2010b; 2011).  
 
Due to technological advances, current TENS machines provide a range of possible ways that 
TENS can be delivered, with the different settings having different mechanisms of action 
(Johnson 2002; Walsh et al 2009). Two main stimulation patterns of TENS have been 
identified that work through distinct neurophysiological pathways of analgesia:  
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1. Conventional, or High-Frequency TENS (HF-TENS)  
2. Acupuncture-Like, or Low-Frequency TENS (LF-TENS)  
 
The mechanisms of action of each of these types of TENS stimulation will now be discussed 
in detail and related to the current problem of IC.  
 
4.4.1: High-Frequency TENS (HF-TENS):  
HF-TENS is high frequency electrical stimulation delivered at low, non-noxious intensities. 
The typical stimulation parameters for HF-TENS are a frequency between 10 and 200Hz and 
a pulse width of 100-200μs (Johnson 2002). The intensity of the current is adjusted to 
provide a strong, but comfortable paraesthesia. This mode of TENS is sometimes termed 
‘high frequency, low intensity TENS’ and is the most commonly used form of TENS in the 
clinical setting (Johnson 2002).  
 
HF-TENS is proposed to act at the spinal segmental level by selectively activating large 
diameter mechanoreceptors (Aβ-fibres), without concurrent activation of nociceptive Aδ- 
and C-fibres or muscle efferents (Johnson 2002; Sluka and Walsh 2003). Selective activation 
of Aβ-fibres inhibits nociceptive nerve transmission, through excitation of inhibitory inter-
neurones, at the segmental level in the spinal dorsal horn, thus inhibiting Aδ- and C-fibre 
stimuli transmission up the spinal cord.  
 
One of the most important reported therapeutic characteristics of HF-TENS, which relates to 
this mechanism of action, is the rapid onset and offset of the induced analgesia (DeSantana 
et al 2008). Analgesia is commonly reported immediately after the stimulation has begun 
and it is lost less than 30 minutes after the machine is switched off. Thus, analgesia is 
present during HF-TENS stimulation but is lost shortly after the stimulation is ceased 
(Johnson 2002; Defrin et al 2005).  
 
4.4.2: Low-Frequency TENS (LF-TENS): 
The typical stimulation parameters for LF-TENS are a frequency between 2 and 10Hz and 
pulse duration of 200-300μs (Johnson 2002). The electrodes are placed over a motor point 
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and the intensity of the current is adjusted to generate phasic muscle contractions. This 
mode of TENS is sometimes referred to as ‘low frequency, high intensity TENS’. Due to the 
method of inducing analgesia, LF-TENS is uncomfortable and therefore often not well 
tolerated by patients in the clinical setting.  
 
LF-TENS is low frequency stimulation (2-10Hz) delivered at high intensities, explained as: 
intensity that induces forceful but non-painful phasic muscle contractions at myotomes 
related to the origin of the pain (Eriksson and Sjolund 1976; Woolf and Thompson 1994; 
Johnson 2002). LF-TENS is proposed to act through extrasegmental mechanisms, promoting 
the release of endorphins (endogenous opioids) and inducing extrasegmental, generalised 
analgesia (Sluka and Walsh 2003). LF-TENS is theorised to selectively activate small diameter 
fibres (Aδ or group III) arising from muscles (ergoreceptors) by the induction of phasic 
muscle contractions (Eriksson and Sjolund 1976). Ultimately, LF-TENS produces anti-
nociception by activating descending neural pathways that inhibit nociceptive propagation 
through the spinal cord (endogenous opiates binding to opiate receptors on the spinal cord) 
and higher brain centres (Sjolund et al 1977; Barlas and Lundeberg 2006). Laboratory and 
clinical studies have shown that LF-TENS, unlike HF-TENS, produces delayed, but long-lasting 
analgesic action (Johnson et al 1991; Woolf and Thompson 1994; Walsh 1997). The delayed 
onset of analgesia is thought to be a result of the extrasegmental mechanism of action, as it 
takes longer to activate the descending neural pathways. Post-stimulation analgesia has also 
been reported and this is also thought to be a result of this systemic mechanism of action 
and the endogenous opiates providing a latent analgesic effect (Johnson et al 1991; Francis 
et al 2011). Therefore, LF-TENS appears not to induce analgesia immediately but takes a few 
minutes to provide effective pain relief. However, this pain relief continues for some time 
after stimulation has stopped.   
 
4.5: EVIDENCE FOR THE NEUROPHYSIOLOGICAL MECHANISMS OF TENS 
Numerous studies have examined the neurophysiological mechanisms of TENS in both 
animal and human studies of experimental and clinical pain. Gradually, an understanding of 




4.5.1: Animal Pain Models:  
A detailed study by Garrison and Forman (1994) examined the effects of HF-TENS on 
spontaneous and noxiously evoked dorsal horn cell activity in an anaesthetised cat. They 
reported that HF-TENS application resulted in decreased spontaneous, and noxiously 
evoked cellular activity at the corresponding spinal level. The authors were unable to draw 
any conclusions relating to the role of supraspinal mechanisms, as the spinal cords used in 
their model were not intact.   
 
Sluka et al (2005) also presented evidence of segmental inhibition with HF-TENS. In a rat 
model of inflammatory pain, they found that HF-TENS significantly reduced the 
concentration of neurotransmitters in the spinal cord associated with the transmission of 
pain (glutamate and asparate). This action was extinguished by blockage of delta-opioid (δ-
opioid) receptors in the spinal cord and thus it was hypothesised that HF-TENS works by 
activating δ-opioid receptors, reducing the release of neurotransmitters into the spinal cord 
(Sluka et al 2005).  
 
The original hypothesis for the action of LF-TENS was the activation of Aδ fibres and the 
resulting supraspinal release of endogenous endorphins and generalised hypoalgesia. This 
contrasted with the proposed mechanisms of HF-TENS to work through activation of Aβ 
fibres and hypoalgesia purely through the gating mechanism in the spinal cord. A well-
designed study by Radhakrishnan and Sluka (2005) however, has questioned these proposed 
mechanisms. In a rat model of hyperalgesia induced by local inflammation, the researchers 
showed that, by selective anaesthesia of cutaneous and deep tissue afferent fibres, both HF- 
and LF-TENS stimulate large diameter, deep tissue Aβ fibres. It was only when the intensity 
of TENS stimulation was increased to twice the motor threshold that there was evidence of 
activation of Aδ fibres. These results suggest that both types of TENS work through spinal 
inhibition of nociception, rather than through two distinct mechanisms.  
 
Nevertheless, the same researchers also found evidence of supraspinal mechanisms and 
descending inhibition of nociception originating in the rostral ventral medulla (RVM). 
Stimulation of Aβ fibres was found to result in activation of supraspinal mechanisms, and as 
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both types of TENS were found to stimulate these fibres, this suggests that both HF and LF-
TENS activate both mechanisms of hypoalgesia and thus share mechanisms of action 
(Radhakrishnan and Sluka 2005). These findings have been supported by further study on a 
rat model of inflammatory pain, which found that both types of TENS activate the RVM and 
the midbrain (venterolateral periaqueductal grey) initiating opioid-mediated hypoalgesia 
(DeSantana et al 2009).  
 
In the spinal cord, examinations of rat knee joint inflammatory pain and the selective use of 
opioid receptor antagonists have identified the specific opioid receptors through which the 
different types of TENS produce their action (Sluka et al 1999). The effects of HF-TENS were 
reduced with selective blockage of δ-opioid receptors and the effects of LF-TENS reduced 
with blockage of μ-opioid receptors (Sluka et al 1999). This finding has also been repeated in 
the rostral ventral medulla (RVM) indicating quite definite mechanisms of action for HF and 
LF-TENS (Kalra et al 2001).  
 
Apart from acting on the opioid receptors in the spinal cord, LF-TENS has also been found to 
cause an increase in serotonin concentration (Sluka et al 2006). Again, using a model of 
inflammatory pain in the rat, LF but not HF-TENS stimulation resulted in an increase in 
serotonin concentration compared to sham TENS (Sluka et al 2006). Related to this finding, 
hypoalgesia with LF but not HF-TENS was reduced with blockage of serotonin receptors (5-
HT2 and 5-HT3) in the spinal cord (Radhakrishnan et al 2003). This reinforces the finding of 
Sluka et al (2006) and indicates clear differences in mechanisms of action between the two 
types of TENS in the spinal cord of rats. In addition to the differences in opioid receptors and 
the stimulation in release of serotonin in the spinal cord, HF-TENS has been found to 
increase the concentration of the neurotransmitter, gamma-Aminobutyric acid (GABA) in 
the spinal cord of rats (Maeda et al 2007). This increase in concentration was shown to 
occur with and without induced pain and only with HF-TENS simulation.  
 
4.5.2: Human Pain Models: 
The mechanisms of hyperalgesia with TENS have also been investigated in human 
experimental pain models. Chesterton et al (2003) examined the effect of frequency, 
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intensity and stimulation site on pressure pain threshold. The authors examined six different 
parameter combinations of both LF- and HF-TENS on time taken to report pain threshold 
during treatment, and for 30 minutes post-treatment. The application of HF-TENS at high 
intensity, segmentally (at the site of pain) and in combination with an extrasegmental 
application (different limb) showed significant hypoalgesic effects during stimulation, and 
for 20 minutes post-stimulation (Chesterton et al 2003). This latent effect of intervention 
indicates involvement of supraspinal mechanisms as shown in the animal models.  
 
In a series of related studies, Chen and Johnson (2010a; 2010b; 2011) investigated the effect 
of TENS frequency manipulation on different types of experimental pain (pressure, cold and 
ischaemic pain) in an effort to identify the most efficacious frequency of TENS stimulation. 
All studies employed repeated measure, crossover designs and adequate sample sizes in an 
effort to avoid the acknowledged limitations of previous research into TENS on 
experimental human pain (Chen et al 2008).  
 
The first study in the series investigated the effects of HF-TENS (80Hz) and LF-TENS (3Hz) on 
Pressure Pain Threshold (PPT) in 32 healthy volunteers (Chen and Johnson 2010a). HF-TENS 
was found to more effectively prolong time taken to report PPT than LF-TENS. The authors 
discussed these findings and related the findings to segmental, spinal mechanisms. 
Unfortunately, as PPT was only measured during stimulation, no conclusions could be drawn 
regarding any latent effect of TENS. Also, in an effort to standardise the stimulation and 
examine the effects of frequency of stimulation, all other parameters except frequency of 
TENS were kept constant. This may have inadvertently resulted in a lack of effectiveness for 
LF-TENS, which is normally delivered at longer pulse widths and higher intensity.  
 
The second published study employed the same study design and TENS stimulation on a 
model of cold-pressor pain (Chen and Johnson 2010b). As this experimental pain model 
allows pain to develop over time, pain threshold and pain intensity at 5 and 15 minutes was 
recorded as the outcome measures. Contrary to the first study, LF-TENS was found to be 
more efficacious, increasing time to pain threshold and pain intensity at 5 and 15 minutes. 
The authors suggest this finding may be due to LF-TENS increasing blood flow to the 
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periphery and thus warming the hand. This has, in previous studies, been associated with 
LF-TENS at intensities that generate phasic muscle contractions and thus a pump action for 
mobilising blood to the hand. In the current study, the intensity of LF-TENS was maintained 
below motor threshold and thus there should be no muscle activation to stimulate this 
warming effect. The authors state however, that as the participants controlled the intensity 
of the TENS, there may have been some muscle activation (Chen and Johnson 2010b).  
 
In the final study of the series, the same study design was employed with the addition of a 
placebo TENS condition (Chen and Johnson 2011). The authors used the Submaximal Effort 
Tourniquet Test (SETT) to induce ischaemic pain in the upper limb of healthy volunteers and 
examined the effects of the three TENS conditions on pain intensity (VAS) at 1 and 2 
minutes into pain and the Short-Form McGill Pain Questionnaire (SF-MPQ) one minute after 
release of pain. Similar to the first study on pressure pain, HF-TENS was found to reduce VAS 
scores of pain intensity compared to that achieved with LF-TENS. No differences were 
observed in the SF-MPQ measures of pain intensity. The reduction in pain intensity as 
measured by the VAS was suggested to be an effect of an increased rate of firing of afferent 
fibres with HF-TENS and thus changes to the concentration of neurotransmitter in the dorsal 
horn of the spinal cord (Chen and Johnson 2011). This however, was conjecture based on 
previous research on animal models of pain and the authors reinforce the need for further 
study on human models of pain to confirm mechanisms of action.  
 
4.5.3: Summary:  
Overall, the current evidence for the neurophysiological mechanisms of TENS does not 
provide comprehensive explanations for the observed effects. Neurophysiological studies on 
animal models of pain have shown that LF-TENS activates μ-opioid, 5-HT2 and 5-HT3 
receptors whilst HF-TENS acts through δ-opioid receptors and increasing gamma-
Aminobutyric acid (GABA) (Sluka et al 1998; Sluka et al 1999; Kalra et al 2001; 
Radhakrishnan et al 2003; Sluka et al 2005; Sluka et al 2006; Maeda et al 2007; DeSantana et 
al 2009). These mechanisms are yet to be confirmed in humans. Current research into the 
effects of TENS on experimental pain in humans has produced mixed results. This is mainly 
due to a myriad of study designs, outcome measures and TENS settings employed (Chen et 
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al 2008). Nevertheless, clinical pain syndromes are different from experimental pain. The 
different frequencies of TENS may have different effects on pain related to disease due to 
the individual and unique variations between patients.  
 
4.6: EVIDENCE FOR THE USE OF TENS FOR PAIN RELIEF:  
TENS has not been tested as a method of pain relief for IC. Not only has TENS not been 
tested as an effective method of pain relief of IC, but also the potential for HF-TENS verses 
LF-TENS patterns of TENS to affect different portions of the IC pain experience has not been 
tested.  
 
A review of the effects of TENS on IC pain is therefore impossible due to the lack of 
published studies. When searching with keywords “transcutaneous electrical nerve 
stimulation”, “transcutaneous nerve stimulation” and “intermittent claudication”, no 
studies are found that could be included in a review of TENS for IC pain. In an effort to 
establish whether TENS works for other painful conditions, a general ‘review of reviews’ was 
conducted to ascertain an overall view of the state of the literature.  
 
Many of the early publications on TENS were either anecdotal or case reports and research 
on TENS did not involve RCTs (Sluka and Walsh 2003). Whether or not randomisation is 
employed has been demonstrated to affect the internal validity of research trials (Kunz and 
Oxman 1998). For example, 17/19 non-randomised studies excluded in a systematic review 
by Carroll et al (1996) indicated that TENS had a positive result on pain relief, whereas the 
randomised studies included in the review, indicated a negative effect of TENS on pain 
relief. Randomisation is employed to minimize overestimations of treatment effects making 
RCTS the `gold standard' of studies that are seeking to answer a question regarding clinical 
efficacy (Schulz et al 1995).  
 
Collections of RCTs are often synthesized into a systematic review, to provide a summary of 
data for a clinical question regarding efficacy. Sometimes the data from the studies in a 
systematic review are combined in a meta-analysis in an attempt to overcome the problem 
of reduced statistical power in studies with small sample sizes. Many studies produce 
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inconclusive findings due to having too few participants (Ottenbacher and Maas 1999). With 
these concerns in mind, the results of systematic reviews, meta-analyses and adequately 
powered RCTS are the focus of this section of the critical review.  
 
The outcomes of systematic reviews and meta-analyses pertaining to the efficacy of TENS in 
various painful conditions are summarised in Table 4.1. This overview shows that all of the 
outcomes of these systematic reviews are inconclusive. The authors of the reviews explain 
that the reason for this is that many clinical trials are excluded from systematic reviews due 
to poor methodological quality. Hence, only a few methodologically robust studies may be 
available to analyse and draw conclusions. These reviews will be discussed in detail in an 
effort to summarise the key conclusions.  
 
Table 4.1: Overview of recent reviews of the clinical efficacy of TENS  
Reference  Clinical Condition  Number of 
Studies  
Outcome  
Carroll et al (2000) Chronic Pain  19 Inconclusive  
Brosseau et al (2003)  Rheumatoid Arthritis of the 
hand  
3 Inconclusive  
Nnoaham and Kumbang 
(2008) 
Chronic Pain  25 Inconclusive  
Khadilkar et al (2008) Chronic Low Back Pain  4 Inconclusive  
Rutjes et al (2009) Osteoarthritis of the knee 13 Inconclusive  
Walsh et al (2009) Acute Pain  12 Inconclusive  
Hurlow et al (2012) Cancer Pain  3 Inconclusive  
 
Carroll et al (2000) reviewed the effects of TENS on chronic pain. Included studies were 
limited to RCTs that compared TENS to control, sham TENS or other active TENS and utilised 
a subjective measure of pain intensity or relief. Chronic pain was defined as pain of at least 3 
months duration and no limits were placed on sample size (Carroll et al 2000). Overall, 18 
publications were included, covering nineteen RCTs as two RCTs were included within one 
publication. Meta-analysis was not possible due to heterogeneity of study designs. The 
findings of the review were conflicting with both positive and negative effects of TENS 
reported. The reason for the inconclusive results for TENS was mainly due to the 
heterogeneity of the studies included. The authors purposely employed broad inclusion 
  
82 
criteria in an effort to improve the number of studies to be evaluated. This tactic resulted in 
a wide range of conditions studied and a variety of methodological choices thus true 
synthesis and analysis was not possible. This issue of heterogeneity between studies relates 
back to the initial question of the review: to review the effects of TENS on chronic pain. As a 
population, chronic pain includes a diverse range of conditions and even within the same 
condition, no two patients will present with the same experience of pain (Melzack 2001). It 
is therefore not necessarily beneficial to attempt to summarise the effects of TENS in such a 
varied population and may be more useful to focus on a single chronic pain condition.  
 
Brosseau et al (2003) chose to focus on just one chronic pain condition: Rheumatoid 
Arthritis (RA) in the hand. Again they limited their review to RCTs but also included 
Controlled Clinical Trials (CCTs). They included studies that used any type of TENS 
intervention in patients with diagnosed RA where the primary outcome measure was pain. 
Nine potential articles were found but only three met the inclusion criteria for the review. 
The outcome of the review was inconclusive. The reasons stated for this were again 
heterogeneity of methodologies in the included studies. All studies used slightly different 
applications of TENS and different methods to record any effects. The three included studies 
reported slightly different outcomes (Brosseau et al 2003): significant improvements in pain 
intensity compared to placebo (Abelson et al 1983); reduction in joint tenderness scores but 
not pain intensity (Langley et al 1984) and improvement in patient assessment of change in 
disease (Manheimer et al 1978). This review has addressed the limitations of that by Carroll 
et al (2000) by selecting a focussed question. This would have been ideal except they were 
again limited by the quantity and quality of the original literature.   
 
Nnoaham and Kumbang (2008) updated the review of Carroll et al (2000). They used the 
same methodology for the review and included twenty-five studies in the final analysis. 
Despite adding six new RCTs to the body of evidence, no new conclusions were possible. 
Due to the same methodological heterogeneity, analysis of the effects of TENS on chronic 
pain was inconclusive. To gain a definitive answer, further original studies are required that 





Khadilkar et al (2008) chose a specific population but one with relatively large inherent 
variation: chronic Low Back Pain (LBP). Study inclusion criterion was RCT with more than 5 
patients per treatment group. Chronic LBP was defined as pain lasting for more than 3 
months, localised between the gluteal fold and the costal margin and in the absence of 
malignancy, fracture, infection, inflammatory disorder and neurological symptoms 
(Khadilkar et al 2008). They included all types of TENS intervention except percutaneous 
stimulation (via acupuncture needles) and only focussed on comparing TENS with sham 
TENS as a control in their analysis. They included more outcomes than have been selected in 
the previous reviews, specifically pain, back pain-related functional status, health status, 
work disability and patient satisfaction. After searching, 47 potential papers were identified, 
of which, four were included in the analysis. After analysis, the authors concluded that there 
was insufficient evidence of benefit of TENS compared to placebo TENS for all outcomes. 
TENS performed slightly better on some outcomes than others with more positive effects on 
pain intensity than back pain-related functional status or health status. This is a well-
structured review of good quality studies. TENS again fails to show consistent effect. 
However, this could again be due to the population studied. In the studies reviewed, there 
was limited control of additional medication intake and applications of TENS varied amongst 
participants. Future research that examines the effects of TENS on sub-groups of chronic 
LBP utilising a pragmatic approach is required so that effects can be studied in relatively 
homogeneous populations.  
 
Rutjes et al (2009) completed a review of electrical stimulation (interferential and TENS) for 
Osteoarthritis (OA) of the knee. In this review, the authors included both randomised, and 
quasi-randomised studies of patients with confirmed OA of the knee that used pain intensity 
as the main outcome. Sixteen trials were identified that met the inclusion criteria. Thirteen 
of these investigated the effects of TENS whereas the other examined either interferential 
stimulation or pulsed electrical stimulation (Rutjes et al 2009). There was enough similar 
data to conduct meta-analyses and after combining the data from all the studies (726 
patients) the authors found a large standard mean difference (SMD) in pain intensity 
between TENS and control (-0.85, 95%CI-1.36 to -0.34) which relates to a reduction of 2.1 
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cm on a 10 cm Visual Analogue Scale (VAS) (Rutjes et al 2009). Despite this finding, the same 
problems were present in the data. Limitations in study size and lack of appropriately 
reported methodological quality and heterogeneity between studies limited the conclusions 
of the review. This is another example of a well-conducted review of a substantial amount 
of published literature that was unable to reach conclusions on the effects of TENS due to 
the heterogeneity of original studies.  
 
Walsh et al (2009) conducted a review of TENS for acute pain, classified as pain lasting less 
than 12 weeks. Studies were included if they met the criteria as a RCT of patients with 
clinical pain excluding labour and dental pain. The main outcome measure was a standard 
subject pain scale (e.g. VAS) for either pain intensity or relief. Twelve studies were included 
in the review with 5 examining the effects of TENS on procedural pain and 7 including a 
range of pain states from haemophilia, strains and fractures to postpartum uterine 
contractions (Walsh et al 2009). Meta-analysis was not possible due to inadequate statistical 
tests and insufficient reporting. Overall, there were mixed results for TENS. Depending on 
the comparison, TENS was found to be as effective, or more effective than placebo TENS, no 
treatment or another active TENS condition. Nevertheless, no conclusions can be drawn due 
to the methodological inadequacies of the evidence and the heterogeneity of the 
population.  
 
The most recent review of TENS (Hurlow et al 2012) examined the evidence base for TENS in 
cancer pain in adults and as before, they were unable to reach any conclusions except that 
large, multi-centre RCTs are required. The population investigated was patients with cancer-
related pain, cancer treatment-related pain, or both over a 3-month period. The authors 
included RCTs that investigated the effects of TENS compared to either sham TENS or no-
TENS control. Only three studies met the inclusion criteria with the main reason for 
exclusion being non-randomisation. Again, heterogeneity in the study methods did not 




4.6.1: Summary:  
The clinical efficacy of TENS remains largely inconclusive. Critical evaluation of the literature 
indicates that this may be due to heterogeneity, small sample sizes, lack of randomisation 
and in some cases the inadequacy of the stimulation parameters employed. When 
systematic reviews were able to conduct such analyses, results showed equal effectiveness 
between HF-TENS and LF-TENS at reducing pain and analgesic consumption (Osiri et al 2000; 
Bjordal et al 2003; Bjordal et al 2007; Johnson and Martinson 2007).  
 
4.7: CONCLUSION:  
TENS is an established, non-pharmacological method of pain relief, employed with success 
in numerous clinical situations. There are two main ‘types’ of TENS that have been found to 
work through distinct neurophysiological mechanisms. Current reviews of the evidence do 
not conclusively support the hypoalgesic effects of TENS on clinical pain conditions. These 
reviews however are limited due to heterogeneity in the original study designs.   
 
The possible hypoalgesic effects of TENS on IC pain have not been investigated. IC pain, 
similar to any chronic pain syndrome is a complex, multidimensional experience that is 
associated with psychosocial factors. This multifaceted nature of chronic pain conditions 
adds additional complexity to the investigation of novel analgesic interventions. Therefore, 
prior to clinical investigation, the effects of any novel analgesic intervention on 




4.8: CHAPTER 4 SUMMARY: 
The aim of this chapter was to introduce the concept of TENS as a possible useful adjunctive 
intervention for lower limb ischaemic pain. TENS has been identified as a safe, non-
pharmacological intervention for pain that is commonly used in clinical settings for relief 
from numerous painful conditions. Two main types of TENS stimulation have also been 
identified with distinct neurophysiological mechanisms of action in animal models of pain.  
 
TENS has not been tested for IC pain and the clinical evidence for the efficacy of TENS on 
other painful conditions is limited. Systematic reviews of TENS have been unable to draw 
conclusions for the effects of TENS due to methodological limitations and heterogeneity 
within the original literature.  
 
Due to the complex nature of clinical pain and thus the difficulties in evaluating outcomes in 
clinical trials, investigation of TENS on experimentally induced pain is warranted prior to 
investigating the effects of TENS on clinical IC pain. The next chapter will introduce the 
concept of experimental pain and discuss the current evidence for the effects of TENS on 




CHAPTER 5: LABORATORY-INDUCED ISCHAEMIC PAIN AND TENS  
5.1: AIM OF CHAPTER 5:  
Building on the discussion in the previous chapters, the aim of this chapter is to explore the 
concept of laboratory-induced pain as a possible method that could help address the two 
central aims of this thesis. Firstly, can laboratory-induced pain help with the investigation of 
the subjective descriptions of IC pain and secondly, can laboratory-induced pain help with 
the investigation of TENS as a possible adjunctive treatment for IC pain.  
 
The benefits of experimental pain models will be discussed with a focus on laboratory-
induced ischaemic pain (sections 5.2 and 5.3). The reported effects of TENS on this 
laboratory-induced ischaemic pain will be examined through a systematic review and the 
rationale for development of a laboratory-induced ischaemic pain method in the lower limb 
of a standing subject will be discussed (sections 5.4 and 5.5).  
 
5.2: INVESTIGATING PAIN IN CLINICAL POPULATIONS AND LABORATORY-
INDUCED PAIN:  
Clinical pain syndromes are complex in nature, with both sensory-discriminative, affective-
motivational and cognitive-evaluative components occurring simultaneously (Woolf 1979). 
These factors make patients with clinical pain syndromes less than ideal subjects for initial 
investigations into the efficacy of potential analgesics (Staahl and Drewes 2004). Clinically, 
patients often have confounding co-morbidities and are likely to be taking some form of 
medication (Staahl and Drewes 2004). Also, patients may interpret other effects of the 
intervention, e.g. effect on anxiety or depression relating to the disease, as a relief of pain.  
 
Experimental pain models can be used to achieve a number of different goals: assessment 
of analgesic efficacy; studies of psychological variables and constructs involved in pain 
experience and report of this experience; evaluation of the underlying mechanisms of pain 
and pain control; measurement development and validation; as an adjunct to clinical pain 




Experimental pain models are advantageous in pre-clinical investigation of an intervention 
as they allow some quantitative control over the input which subjects receive (Woolf 1979). 
The investigator can control the experimentally induced pain, i.e. the location, nature, 
intensity, frequency and duration, and provide quantitative measures of the psychophysical 
behavioural or the neurophysiological responses (Graven-Nielsen et al 2001; Staahl and 
Drewes 2004).  
 
There are two main limitations of using experimentally induced pain to test interventions. 
Firstly, the attempt to artificially separate the components of the pain experience, i.e. 
separating the physiological nociceptive mechanisms from pain affect, causes 
oversimplification of the sensation to the point where it becomes unlike clinical pain (Woolf 
1979). Secondly, experimental studies are unable to reproduce the physiological features 
and the accompanying psychological qualities of clinical pain in the laboratory (Gracely 
2006).  
 
Despite these reported limitations, experimentally induced pain allows the researcher the 
opportunity to obtain reproducible results in test-retest experiments in controlled 
conditions thus making them ideal for the testing of interventions (Handwerker and Kobal 
1993).  
 
5.3: A PRE-CLINICAL MODEL OF IC PAIN:  
There are a number of experimental pain models currently in use, including heat, cold, 
ischaemic, mechanical pressure, electrical and chemical. The ischaemic pain model, which 
induces ischaemic muscle pain, is the method of interest in this thesis as this seems to most 
closely reflect IC pain.  
 
The ischaemic model involves arresting blood flow to a limb using a tourniquet and 
exercising the muscles distal to the tourniquet to induce ischaemic pain (Graven-Nielsen et 
al 2003; Staahl and Drewes 2004). This experimental pain model can be viewed as having 
some physiological similarities to IC, where the atherosclerotic process in the arteries limits 
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blood flow to the limb(s), creating an ischaemic environment. What is not known however, 
is whether the pain experiences are comparable.  
 
Lewis (1932) first proposed induction of pain by muscle ischaemia. Generally, a pneumatic 
tourniquet is applied, and after a period of voluntary muscle contractions, distal to the 
tourniquet, an unpleasant tonic pain sensation develops (Graven-Nielsen et al 2001). The 
number and level of force of the contractions are important determinants for the resulting 
pain. It is thought that these aspects determine the build-up of lactate. Lactate is a by-
product of ischaemic contraction or more specifically, anaerobic metabolism is thought to 
be the main contributor to the pain induced by excitation of nociceptive C-fibres 
(Pertovaara et al 1984; Graven-Nielsen et al 2001).  
 
A standardised method of reliably inducing ischaemic pain in human subjects was developed 
by Smith et al (1966) and termed the ‘Submaximal Effort Tourniquet Technique’ (SETT). 
Ischaemic pain was induced in the arm of 15 healthy volunteers to examine the effects of 
intravenous morphine injections. This technique has been developed and adapted over time 
by a number of different authors (see Table 5.1) (Moore et al 1979; Woolf 1979; Rosenblatt 
and Hetherington 1981; Pertovaara et al 1984; Posner 1984; Roche et al 1984; Roche and 
Gijsbers 1986; Walsh et al 1995a; Foster et al 1996; Benedetti 1996; Amanzio and Benedetti 
1999; Roche et al 2002; Johnson and Tabasam 2003).  
 
5.3.1: Variations of the SETT:  
Although the SETT is a standardised method different investigators have employed different 
parameters. There are seven main parameters that can be modified: limb, subject position, 
desanguination, cuff position, cuff width, exercise load and exercise repetitions. A review of 
published studies which have used the SETT demonstrates variations in the methodologies 
employed (Table 5.1 and summarised in Table 5.2).  
 
As previously discussed, laboratory-induced ischaemic pain is hypothesised to be mediated 
by an increase in metabolites. Thus, seemingly minor changes in the force of contraction 
and the number of repetitions have the potential to drastically affect a participant’s rating 
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of pain (Pertovaara et al 1984). Despite the multitude of variations in SETT methodologies, 
ischaemic pain was successfully induced in all of the studies.  
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Table 5.1: Published studies that employed the SETT procedure to induce ischaemic pain (continued on next 4 pages)  
Authors  Smith et al (1966) Moore et al (1979)  Woolf (1979)  
Participants  45 males 2 males 
3 females  
80 males  
Limb  ND UL  ND UL  L UL  
Participant Position  Supine  Sitting  Not stated  
Desanguination  Vertical  Vertical  Vertical  
Compression Esmarch bandage applied  Esmarch bandage applied  No compression  
Desanguination 
Time  
Not specified  Not specified  60 seconds  
Cuff Position  Upper arm  Upper arm  Forearm  
Cuff Pressure 
(mmHg) 
250  200  250  
Cuff Width  3 inches  Not stated  7.5 cm  
Exercise  Hand grips  Handgrips  Handgrips  
Exercise Reps  20  20  20  
Exercises Load  7.72 kg  50% or 30% MVC  2.5 kg  
Exercises Time  2s hold/2s relax 2 s hold/ 2s relax or no hold (every 
4s) 
2s / 2s  
Started 20s after inflation  
Start Point (Time 0) Cessation of exercises  Cuff inflation  End of exercises  
End Point  Pain tolerance  
3.3–53 mins (19 median)  
Pain tolerance or 20 minutes  Pain tolerance  
Outcome measures  5 point likert scale at irregular 
intervals:  
0-100 NRS at random intervals VAS at 1 min intervals  
Important Results  Induced a reliable and comparable 
level of pain  
50% MVC and 2 second hold 
reported to be best  
TENS reduced intensity and increased 





Table 5.1 (continued): Published studies that employed the SETT procedure to induce ischaemic pain 
Authors  Rosenblatt and Hetherington (1981) Posner (1984) Pertovaara et al (1984)  
Participants  8 males  
2 females  
6 males  
6 females  
9 males  
8 females  
Limb  Not specified  D UL UL 
Participant Position  Not stated  Sitting  Not stated 
Desanguination  Vertical  Vertical  Vertical  
Compression Elastic bandage  Inflatable sleeve  Not stated 
Desanguination Time  Not specified  Not stated 60 seconds  
Cuff Position  Upper Arm  Upper arm  Upper arm  
Cuff Pressure (mmHg) 250 250 200, 250 and 300 
Cuff Width  Not stated  Not stated 14 cm  
Exercise  Handgrips  Handgrips  Handgrips  
Exercise Reps  20 Not stated 15 or 30 
Exercises Load  30lb  50% MVC 70% MVC 
Exercises Time  20 within 1 minute  2.5s hold/relax for 1 min 2s hold/relax 
Start Point (Time 0) Cuff inflation  Not stated Cessation of exercises  
End Point  Pain tolerance  Pain tolerance 15 mins  
Outcome measures  Time to pain tolerance  
VAS post pain tolerance  
VAS continuous  VAS of ischaemic and pressure 
pain  
Important Results  No difference in time to pain tolerance 
or in reported pain intensity with 
single or dual channel TENS vs. control  
SETT can be used to detect small 
changes in pain intensity with 
hypoalgesic intervention  
Higher ischaemic pain = lower 




Table 5.1 (continued): Published studies that employed the SETT procedure to induce ischaemic pain  
Authors  Roche et al  (1984) Roche and Gijsbers (1986) 
Participants  24 males 
24 females  
11 males  
12 females  
Limb  L UL L UL 
Position  Sitting  Sitting  
Desanguination  Not stated  Not stated  
Compression Not stated  Not stated  
Desanguination Time  Not stated  Not stated  
Cuff Position  Upper arm  Upper arm  
Cuff Pressure (mmHg) 250 250 
Cuff Width  12 cm  12 cm  
Exercise  Handgrips  Handgrips  
Exercise Reps  20 20 
Exercises Load  25% MVC  25% MVC  
Exercises Time  2s hold/relax  2s hold/relax  
Start Point (Time 0) Cessation of exercises  Cessation of exercises  
End Point  25 mins or pain tolerance  25 mins or pain tolerance  
Outcome measures  Pain threshold 
Pain tolerance  
VAS and PPI every minute  
MPQ at tolerance  
MPQ at tolerance and 7 days later  
Important Results  Time to threshold and tolerance increased with LF, low 
intensity TENS  
Time to tolerance and endurance increased with HF, 
high intensity TENS 
Memory of one-off ischaemic pain more effective than 





Table 5.1 (continued): Published studies that employed the SETT procedure to induce ischaemic pain  
Authors  Walsh et al (1995a) Foster et al (1996) Benedetti (1996) 
Participants  32 females  24 males 
24 females  
154 males  
186 females  
Limb  ND UL UL  UL  
Position  Sitting  Sitting  Supine  
Desanguination  Vertical  Vertical  Vertical  
Compression 7 cm wide bandage applied  Elastic bandage  Esmarch bandage  
Desanguination Time  60 seconds  60 seconds  Not stated  
Cuff Position  Upper arm  Upper arm  Upper arm  
Cuff Pressure (mmHg) 200  200 250 
Cuff Width  Not Stated  13 cm  Not stated  
Exercise  Handgrips  Handgrips  Handgrips  
Exercise Reps  20  20 12 
Exercises Load  75% MVC  75% MVC 7.2 kg  
Exercises Time  1s holds 
Completed in 1 min  
2s/1s hold/relax  2s/2s hold/relax  
Start Point (Time 0) Cuff inflation  Cuff inflation Score of 7 on NRS  
End Point  10 minutes  
(Deflated over 2 mins)  
10 minutes  
(Deflated over 2 mins) 
Pain tolerance  
Outcome measures  VAS every minute (0-12) VAS every minute  0-10 NRS 
Pain tolerance  
Important Results  Mean VAS decreased with LF-TENS 
compared to control and HF-TENS 
VAS from minutes 7-9 decreased with 
LF-TENS compared to all other groups 
No difference in VAS or MPQ 
scores between groups or over 
time 
The SETT is a useful tool with which 
to study the placebo response  
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Table 5.1 (continued): Published studies that employed the SETT procedure to induce ischaemic pain  
Authors  Amanzio and Benedetti (1999) Roche et al (2002) Johnson and Tabasam (2003) 
Participants  132 males 
97 females  
6 males 
6 females  
18 male  
12 female 
Limb  UL  L UL UL 
Position  Supine  Sitting  Not stated  
Desanguination  Vertical  Not stated  Vertical  
Compression Esmarch bandage  Not stated  Not stated  
Desanguination Time  Not stated  Not stated  1 min  
Cuff Position  Upper arm  Upper arm  Forearm  
Cuff Pressure (mmHg) 300 250 200 
Cuff Width  Not stated  12 cm  15 cm 
Exercise  Handgrips  Handgrips  Handgrips  
Exercise Reps  12 20 20 
Exercises Load  6.5 kg  25% MVC 75% 
Exercises Time  2s/2s hold/relax  2s hold/relax 2s hold/relax  
Start Point (Time 0) Cessation of exercises  End of exercises  Cuff inflation 
End Point  Pain tolerance  12 mins 12 mins  
Outcome measures  Pain tolerance  Pain threshold  
Pain tolerance  
VAS at minutes 3,6,9 and 12  
VAS every minute  
MPQ post-test 
Important Results  The expectation placebo response 
is driven by opioid system 
conditioning is not 
Placebo TENS and interferential 
increased time to pain threshold 
and tolerance  
No difference in VAS or SF-MPQ 
scores between groups- TENS vs. 





Table 5.2: Summary of variations in SETT methods employed in published studies  
Parameter Study Variations 
Limb All studies use the upper limb (UL) whether it is the dominant (D) or non-dominant (ND). 
Position All studies also have the participants supine or sitting with the arm resting on a table. 
Desanguination Desanguination of the limb is slightly different and not stated in a number of the studies. 
Cuff Position The cuff is positioned commonly on the upper arm with two exceptions where it is positioned on the forearm (Woolf 1979; 
Johnson and Tabasam 2003). 
Cuff Width  When reported, the cuff widths use varied from 7.5cm (Woolf 1979) to 14cm (Pertovaara et al 1984). 
Exercise Load Most studies calculated the participants’ Maximum Voluntary Contraction (MVC) but the force and number of contractions 
performed varied considerably. The exercise load used, ranged from 25% MVC (Roche et al 1984; Roche and Gijsbers 
1986), to 75% MVC (Johnson and Tabasam 2003; Foster et al 1996; Walsh et al 1995a). In contrast, a number of studies 
used a standardised grip tension, ranging from 2.5kg to 7.72kg rather than a percentage of MVC (Smith et al 1966; Woolf 
1979; Rosenblatt and Hetherington 1981; Benedetti 1996; Amanzio and Benedetti 1999).  
Exercise 
Repetitions 
The number of exercise repetitions ranged from 12 (Benedetti 1996; Amanzio and Benedetti 1999) to 30 (Pertovaara et al 





5.4: TENS AND LABORATORY-INDUCED ISCHAEMIC PAIN:  
TENS has been shown to be effective for some clinical pain syndromes. However, it has not 
been tested for IC pain. Prior to investigation of a novel analgesic technique on clinical pain, 
laboratory testing in healthy volunteers is advocated (Staahl and Drewes 2004; Gracely 
2006).  
 
TENS has been trialled on ischaemic pain in healthy volunteers. Reviews of these studies 
have found mixed evidence for the efficacy of TENS for ischaemic pain (Walsh 1997; Claydon 
et al 2011). These reviews however are either out of date (Walsh 1997) or their focus is not 
ischaemic pain (Claydon et al 2011). An updated, comprehensive review is indicated that 
focuses solely on the effects of TENS on experimentally induced ischaemic pain.  
 
5.4.1: Systematic Review of TENS for Ischaemic Pain in Healthy Volun teers: 
This next section will describe a systematic review conducted to evaluate the current 
evidence for the hypoalgesic effects of TENS on experimentally induced ischaemic pain on 
healthy volunteers.  
 
5.4.1.1: Methodological Considerations: 
To be able to evaluate and establish the hypoalgesic efficacy of TENS for ischaemic pain, 
methodologically robust trials are required. The essential components of study design that 
help to ensure methodological rigour will now be briefly considered.  
 
Randomisation and blinding have been shown to affect the internal validity of research 
studies (Schulz et al 1995; Kunz and Oxman 1998). By randomising group allocation, 
participant characteristics and confounding variables will be more likely to be distributed 
equally between the groups (WHO 2005). These variables may include baseline values of 
outcome measures or general participant characteristics. In non-randomised trials, bias is 
often evident and the direction and extent of this bias is often impossible to predict (Kunz 
and Oxman 1998). Randomisation is therefore an essential aspect of trial design when trying 
to avoid or minimise this type of bias. Another form of bias common in research trials is 
measurement bias. Measurement bias can be minimised by using sufficient blinding of 
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participants and researchers. If participants or researchers involved in providing or 
measuring the outcomes of a study are not blind to group or treatment allocation they may 
respond differently and thus consciously or subconsciously affect the measurement of 
outcomes (Sim and Wright 2000). Without double blinding of both the researcher and the 
participant, treatment effects can be overestimated by an average of 17% (Schulz et al 
1995). Blinding and randomisation are therefore two key aspects of trial design without 
which, treatment effects may be inflated and bias introduced into the outcomes.   
 
5.4.1.2: Search Strategy:  
The electronic databases Scopus, AMED, CINAHL, MEDLINE and Science Direct were 
searched for relevant Randomised Controlled Trials (RCTs) published in English within the 
period from 1960-2011. The search terms used and combinations for these databases are 
detailed in Table 5.3 and full details of the search strategy and articles excluded are 
presented in Appendix 1. Hand searches of reference lists were also conducted to reduce 





Table 5.3: Details of the search strategy employed in this systematic review.  
Database  Field  Keywords Combinations Results 
Scopus Full 
Text  
1. Transcutaneous electrical nerve 
stimulation 
2. TENS  
3. Isch*mic pain  
4. Transcutaneous Nerve Stimulation 
5. TNS  
6. Electrical Stimulation  
(1 OR 2) AND 3 
(4 OR 5) AND 3 







1. Transcutaneous electrical nerve 
stimulation 
2. TENS  
3. Isch*mic pain  
4. Transcutaneous Nerve Stimulation 
5. TNS  
6. Electrical Stimulation 
(1 OR 2) AND 3 
(4 OR 5) AND 3 






1. Transcutaneous electrical nerve 
stimulation 
2. TENS  
3. Isch*mic pain  
4. Transcutaneous Nerve Stimulation 
5. TNS  
6. Electrical Stimulation 
(1 OR 2) AND 3 
(4 OR 5) AND 3 
6 AND 3 
25 
 
5.4.1.3: Inclusion Criteria and Methodological Assessment:  
To be included in the review, studies had to be:  
 Randomised Controlled Trials  
 Conducted on healthy human volunteers  
 Used an induced ischaemic pain model  
 Compared TENS to Placebo and/or Control  
 Used pain as the primary outcome measure  
 
Standardised data extraction tables were used to summarise the data from each study 
(Appendix 1) and a modified Jadad Scale (Claydon et al 2011) (Appendix 3) was used to 
evaluate the quality of each study (Jadad et al 1996). This methodological rating scale was 
chosen because it addresses randomisation and blinding which have been established as 
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factors that affect the internal validity of trials (Schulz et al 1995; Kunz and Oxman 1998). 
The Jadad scale was used to categorise trials into high and low quality. A study was deemed 
to be high quality if it scored 3 or more points (out of 5) and low quality if it scored 2 or 
fewer (Claydon et al 2011).  
 
5.4.1.4: Data Analysis:  
The studies included in the review are reported using descriptive analysis and qualitative 
review. Due to methodological differences further quantitative analysis was not possible.  
 
5.4.1.5: Results:  
Figure 5.1 details the outcomes of the search strategy. Six RCTs were included in the final 
review. All studies employed a version of the SETT to the upper limb of healthy volunteers. 
Various study designs and variations of the SETT were employed along with different TENS 
stimulation parameters. Details of the full texts reviewed and reasons for exclusion are 
displayed in Table 5.4.  
 
Methodological Quality:  
Study quality of the research included in the review ranged from scores of 1-5 on the 
modified Jadad scale (Table 5.5). Three studies were classified as high quality (Walsh et al 
1995a; Foster et al 1996 and Chen and Johnson 2011), with Chen and Johnson (2011) 
scoring the maximum of 5 points. All studies performed randomisation of some kind 
although only two described their methods (Roche et al 1984; Chen and Johnson 2011). The 
three high quality studies also managed to perform double blinding of the researcher and 
participant (Walsh et al 1995a; Foster et al 1996; Chen and Johnson 2011). The other studies 
were either single-blinded (Johnson and Tabasam 2003) or no blinding was reported at all 
(Rosenblatt and Hetherington 1981; Roche et al 1984). In terms of statistical power, all 
studies were underpowered except Chen and Johnson (2011) who achieved the required 26 






Figure 5.1: PRISMA diagram detailing the outcome of the search strategy. Details of 






Table 5.4: Full-text articles screened and reasons if excluded from final review 
Author: Year: Reason for Exclusion:  
Woolf  1979 No randomisation  
Rosenblatt and Hetherington 1981 
 Roche et al  1984 
 
Walsh et al  1995a 
 
Foster et al  1996 
 
Johnson and Tabasam 2003 
 Brown et al  2007 No placebo or control  
Chen and Johnson 2011  
 
Table 5.5: Articles included in the review and scores for methodological quality related to the modified Jadad scale (Appendix 3).  
Study 
Randomisation Blinding Statistical Power 
Score Quality General Outcome 
1 2 3 4 5 
Rosenblatt and Hetherington 1981 Yes No No No No 1 Low Negative 
Roche et al 1984 Yes Yes No No No 2 Low Positive 
Walsh et al 1995a Yes No Yes Yes No 3 High Positive 
Foster et al 1996 Yes No Yes Yes No 3 High Negative 
Johnson and Tasbasam 2003 Yes No No No No 1 Low Negative 





General Outcomes:  
Table 5.5 also provides the general outcomes for each study included in the review. Two of 
the high quality studies (Walsh et al 1995a; Chen and Johnson 2011) reported positive 
results for the effects of TENS on ischaemic pain along with Roche et al (1984). The other 
three reported no difference between TENS and either placebo or control conditions 
(Rosenblatt and Hetherington 1981; Foster et al 1996; Johnson and Tabasam 2003). There 
appears to be a slight trend towards positive outcomes in high quality studies.  
 
Comparison Against Control/Placebo/Sham: 
As the application of electro-physical modalities has been shown to be associated with 
significant placebo effects a placebo, or sham, intervention is essential to any study of the 
effects of TENS (Johnson and Bjordal 2011). It is important therefore, to examine the control 
conditions employed in the studies under review.  
 
The two earliest studies examined the effects of TENS compared to a no-TENS control 
(Rosenblatt and Hetherington 1981; Roche et al 1984). The control condition consisted of 
the same SETT procedure with no intervention. These studies also did not report any 
blinding procedures, both methodological choices that can lead to overestimation of 
treatment effects (Schulz et al 1995). Rosenblatt and Hetherington (1981) reported no 
difference in time to pain tolerance or reduction in pain intensity with TENS but Roche et al 
(1984) observed an increase in time to pain threshold and tolerance with LF/LI-TENS and an 
increase in time to pain tolerance and endurance with HF/HI TENS. The positive results 
reported by Roche et al (1984) are thus questionable and maybe if compared with a placebo 
control, would not be evident.  
 
The other studies included in this review employed both a placebo intervention and a 
control condition. The placebo conditions were reported as being identical to the active 
conditions although no current reached the participant. The participant is informed that the 
dosage of the intervention is at sub-threshold levels and they may, or may not perceive any 
stimulation. Walsh et al (1995a) even encouraged participants to alter the stimulation 
intensity similar to the other experimental conditions so that the experience was as similar 
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as possible without the application of current. The success of participant belief in placebo 
was reported by Walsh et al (1995a) and Foster et al (1996) mentioning the “several subject 
in the placebo group reported to have experienced sensations beneath the electrodes” 
(Foster et al 1996, p302). Of the studies that compared TENS to both placebo and control 
conditions, two of the high quality trials reported positive effects of TENS compared to 
placebo for pain intensity as measured by a VAS (Walsh et al 1995a; Chen and Johnson 
2011) and the sensory component of the SF-MPQ (Chen and Johnson 2011). The other high 
quality trial found no differences between all groups (Foster et al 1996). Johnson and 
Tabasam (2003) also reported no change in VAS or SF-MPQ with TENS compared to placebo 
or control. The fact that two of the high quality studies reporting positive effects of TENS do 
so compared to placebo, increases the importance of the findings. The negative findings in 
the other studies will be explored further in the section relating to stimulation parameters.  
 
Methodological Differences and Outcomes: 
Despite all studies meeting the inclusion criteria, they all employed slightly different 
methodologies to assess the effects of TENS on induced ischaemic pain. All studies used a 
version of the SETT as devised by Smith et al (1966) and all tested one, or both of the most 
common types of TENS (HF or LF-TENS) (Table 5.6). Nevertheless, the actual parameters of 
the SETT and TENS employed differed between the studies. 
 
SETT METHOD  
Four of the six studies followed the method described by Smith et al (1966) and applied a 
tourniquet to the upper arm to induce ischaemic pain (Rosenblatt and Hetherington 1981; 
Roche et al 1984; Walsh et al 1995a; Foster et al 1996). The two most recent studies from 
the same centre however, applied the tourniquet to the forearm to induce ischaemia 
(Johnson and Tabasam 2003; Chen and Johnson 2011). The reasons for this methodological 
change are well explained however; this fundamental change to the induction of ischaemia 
may have affected the pain participants experienced and thus the hypoalgesic effects of 
TENS. The authors report that the “pain intensity ratings were similar to those previously 
reported by other groups using the same technique” (Johnson and Tabasam 2003, p 214), 
which is fair but the quality and nature of the development of induced pain is not described. 
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This is a crucial point of interest for the current study that aims to examine the relationships 
between TENS and the development of ischaemic pain.  
 
The most common cuff pressure used was 200mmHg (4/6 trials) with the older studies using 
250mmHg (Rosenblatt and Hetherington 1981; Roche et al 1984). The exercise used within 
the SETT procedure to induce ischaemic pain is hand gripping against a specified force. Most 
studies asked participants to complete 20 of these exercises (5/6) with Chen and Johnson 
(2011) selecting 15 instead. Seventy-five percent of participants’ maximum grip strength 
was the most popular force (4/6) again with the older studies using either 30lb for all 
participants (Rosenblatt and Hetherington 1981) or maximum grip strength (Roche et al 
1984). Both cuff pressure and degree of exercise has been shown to be positively related to 
intensity of pain produced by the SETT (Pertovaara 1984). As the studies of Rosenblatt and 
Hetherington (1981) and Roche et al (1984) employed both increased cuff pressure and an 
increase level of exercise it could be concluded that participants in these studies 
experienced greater intensity of pain. Mean time to pain tolerance in these two studies is 
comparable: 9.7 minutes for Rosenblatt and Hetherington (1981) and 10.8 minutes for 
Roche et al (1984). All other studies limited the time for the SETT and thus did not report 
time to tolerance.  
 
Another important difference in the methods of pain induction was that of SETT duration. 
Rosenblatt and Hetherington (1981) and Roche et al (1984) both used 25 minutes as the 
maximum time whereas the other studies used 12 minutes (Walsh et al 1995a; Foster et al 
1996), 10 minutes (Johnson and Tabasam 2003) or 2 minutes (Chen and Johnson 2011). The 
benefit of the longer duration of pain is that the effects of TENS can be examined over a 
prolonged period and thus the effects on different aspects of the pain experience 
investigated (i.e. pain threshold, tolerance, endurance, intensity and quality). Important to 
note however, is that despite the 25 minutes allowed in the studies by Rosenblatt and 
Hetherington (1981) and Roche et al (1984), mean time taken to report pain tolerance was 
approximately 10 minutes. Therefore the 10-12minutes employed by three of the other 
studies should be sufficient to allow examination of the complete pain experience (Walsh et 
al 1995a; Foster et al 1996; Johnson and Tabasam 2003). The study design of Chen and 
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Johnson (2011) was slightly different, requiring each participant to complete three 
consecutive inductions of pain in one session. From an ethical perspective, the shortened 
period of pain is understandable in this design as it would be unreasonable to expect 
participants to complete consecutive, prolonged experiences to ischaemia. Nevertheless, 
the results must be interpreted in this context and any conclusions only apply to the initial 
experiences of ischaemic pain (i.e. threshold levels).  
 
PAIN MEASUREMENT 
All studies employed a measure of pain intensity upon which the effects of TENS was 
evaluated. Rosenblatt and Hetherington (1981) measured time taken to report pain 
tolerance and Roche et al (1984) recorded time to pain threshold and pain endurance. All 
studies employed a Visual Analogue Scale (VAS) to measure pain intensity at different time 
points. Most commonly, a VAS was conducted every minute during pain induction and at 
the end of cuff deflation to measure ‘current pain intensity level’. Roche et al (1984) used 
the Present Pain Intensity (PPI) of the MPQ but all others employed a 10cm line with 
anchors relating to ‘no pain; and ‘worst pain imaginable’ (Walsh et al 1995a; Foster et al 
1996; Johnson and Tabasam 2003; Chen and Johnson 2011). Rosenblatt and Hetherington 
(1981) only recorded one VAS measurement, immediately after deflation of the cuff.  
 
All studies with the exception of Rosenblatt and Hetherington (1981) also used a version of 
the McGill Pain Questionnaire (MPQ). Participants were asked to complete the 
questionnaire at the end of the SETT procedure in relation to the ‘worst pain experienced’. 
Roche et al (1984) and Foster et al (1996) used the full version whereas the other three 
studies asked participants to complete the Short-Form MPQ (Walsh et al 1995a; Johnson 
and Tabasam 2003; Chen and Johnson 2011).  
 
TENS PARAMETERS  
There are not definitive agreed stimulation parameters for HF and LF-TENS. It is generally 
agreed that HF-TENS consists of frequency between 50 and 100Hz, pulse duration of 
between 50 and 200μsec and intensity set to participant evaluation of a ‘strong, but 
comfortable’ sensation (Charlton 2005). LF-TENS is classified as a frequency between 2 and 
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4Hz, pulse duration 100-400μsec and intensity of ‘tolerance threshold’ (as high as the 
participant can tolerate) (Charlton 2005). In addition, electrode placement has been shown 
to be an important variable relating to the hypoalgesic effects of TENS (Chesterton et al 
2003; Brown et al 2007). Again, only general recommendations exist where HF-TENS is to be 
applied over the painful region and LF-TENS at either acupuncture points, trigger points or 
over the painful region (Charlton 2005). The final characteristic that is important for the 
dosing and efficacy of TENS is timing (Walsh et al 1995b). TENS is thought to elicit 
immediate and latent hypoalgesic effects (Johnson 1991). Therefore the relationship 
between the time TENS stimulation begins and the time that pain experience begins is key 
to the effects observed. This relationship and the specific effects of TENS have not been 
conclusively established although both HF and LF-TENS are recommended to be switch on 
for 30 minutes (Charlton 2005).  
 
Most of the studies in the review adhered to these settings. However as most of the studies 
included in the review aimed to test the efficacy of different stimulation parameters of 
TENS, between-study variation is common (Table 5.6). With this in mind, rather than 
attempting to generalise across the studies, each application of TENS will be discussed in 
turn and then general points synthesised within the discussion.  
 
Rosenblatt and Hetherington (1981) aimed to investigate the ability of single, or dual 
channel TENS to alleviate ischaemic pain. The authors reported that no changes were 
observed in time to report pain tolerance or in VAS scores. They used HF-TENS with a 
frequency of 100Hz, pulse duration of 40μsec; intensity determined as ‘maximum tolerated 
intensity’ and applied either through 2 (single), or 4 (dual) electrodes just proximal to the 
cuff (Table 5.6). These stimulation settings do not fit into the recommended settings for HF-
TENS. The frequency is appropriate although the pulse duration is too short, stimulation 
intensity too high and electrodes are not placed over the region of pain. In addition, TENS 
stimulation was turned on only just before the start of the SETT. This choice would have 
been sufficient if the participants had continued with the SETT for the whole 25 minutes 
(close to the recommended 30 minutes). However as mentioned previously, participants 
reached tolerance in a mean time of 9.7 minutes (Rosenblatt and Hetherington 1981). This 
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means that, on average, participants were not receiving the recommended dose of TENS 
stimulation. The negative finding for TENS may therefore be a result of the insufficient 
application of TENS rather than no evidence of effect.  
 
Roche et al (1984) set out with the aim of recording the differences in response of healthy 
subjects to ischaemic pain when treated with TENS. LF/LI-TENS was found to increase time 
to pain threshold and tolerance and HF/HI-TENS was found to increase time to pain 
tolerance and increase the endurance of pain. In this low quality, non-blinded study, three 
dosages of TENS were investigated (see Table 5.6). The authors attempted to investigate 
different combinations of frequency and intensity, with one HI HF-TENS condition and two 
LF-TENS conditions (one with LI and one with HI). The HF-TENS condition settings are 
detailed in Table 5.6 and again they do not fit with the recommended dosage. The 
frequency is within the correct range but the pulse duration was too long (1000μsec) and 
intensity too strong. However, the electrode placement and duration of stimulation were 
appropriate. For the LF-TENS conditions, the frequency and electrode placement were 
suitable but the pulse duration was again too long (100,000μsec). The design aimed to 
investigate the effects of different stimulation intensities. Therefore the ‘barely perceptible’ 
intensity used for the LF/LI-TENS group is understandable. The study was generally low in 
quality with no blinding of researcher, no repeated measures and limited statistical testing 
as there was no attempt to quantify any baseline differences between groups that could 
have accounted for the results observed.  
 
Walsh et al (1995a) conducted a high quality, double-blind investigation that aimed to 
compare the effects of HF and LF-TENS on induced ischaemic pain. Overall, the researchers 
found that LF-TENS reduced mean pain intensity compared to HF-TENS and control and this 
was especially evident from minutes 7-9 where VAS scores were decreased in the LF-TENS 
group compared to HF-TENS and placebo. The TENS setting used for the two interventions 
are detailed in Table 5.6. The parameters chosen align with the current guidance, except for 
the pulse duration for HF-TENS (>200μsec) and the intensity of LF-TENS (not maximum 
tolerated). A significant positive however, was the fact that the researchers encouraged 
participants to control and alter the intensity of stimulation, something which has been 
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shown to increase the hypoalgesic effects of TENS (Pantaleão et al 2011). Nevertheless, as 
the authors’ aim was to compare HF against LF-TENS, the decision to maintain the other 
parameters at equal levels strengthens any conclusions regarding the effects of frequency. 
The only point of criticism of this study is the experimental design. There was no 
randomisation of entry into the condition i.e. all participants completed intervention 
condition second. By always completing the intervention condition second, regardless if it is 
control, placebo or TENS, there is the possibility of a fear, training, or familiarisation effect 
(Shanahan et al 2006). If participants have a bad experience, they could be more fearful and 
thus there is an increased chance of a Type II error (false negative). Conversely, if 
participants become accustomed to the experience, they are likely to be less fearful and 
thus the chance of a Type I error (false positive) is increased. This effect may be evident and 
explain the results found in the study by Walsh et al (1995a). There was a trend of 
decreasing mean VAS in all groups, including control, possibly indicating a familiarisation 
effect. Also, mean VAS was reduced to a greater extent in the placebo group compared to 
HF-TENS (Walsh et al 1995a). Adding in a familiarisation session and randomising the entry 
into each condition (as in the study by Chen and Johnson (2011)) can help reduce the impact 
of this phenomenon (Shanahan et al 2006). Overall, this well-designed and conducted study 
indicated a positive effect of LF-TENS on induced ischaemic pain.  
 
Foster et al (1996) also examined the effects of different TENS stimulation settings on 
induced ischaemic pain. With the study design and parameters selected, the authors found 
no differences in measure of pain intensity or quality. The primary focus of this high quality 
study was to examine the effects of changing pulse duration. Four different combinations of 
TENS settings were chosen and assessed in a similar design to that employed by Walsh et al 
(1995a) (see Table 5.6). The settings tested align with the current guidance on the most 
efficacious TENS parameters although the combination of LF-TENS with short pulse duration 
(50μsec) is not advocated (Charlton 2005). The intensity of LF-TENS used is also not optimal. 
Similar to the study by Walsh et al (1995a), participants were encouraged to control their 
own intensity. However, for both types of TENS this was stated as ‘strong but comfortable’, 
not ‘maximum tolerated’ for LF-TENS. Also, as in the study by Walsh et al (1995a) the 
electrode placement was not ideal for both types of TENS. The researchers used points, 
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proximal to the cuff for stimulation (Table 5.6). This decision is suitable for LF-TENS but not 
for HF-TENS which should be applied over the painful area, in the case of the SETT, the 
forearm. The authors in the discussion address these limitations in settings of intensity and 
electrode placement and recommendations are made that future studies should examine 
stronger intensities and stimulation over the site of pain. This study also has the same 
limitations in terms of design as discussed with Walsh et al (1995a). Intervention was 
conducted secondary to baseline. In contrast to Walsh et al (1995a), no familiarisation effect 
is evident in the results presented. In general, the study by Foster et al (1996) is high quality 
study but limited in terms of TENS stimulation parameters employed which might explain 
the lack of hypoalgesic effects observed.  
 
 The study by Johnson and Tabasam (2003) was classified as low quality due to the lack of 
description of randomisation or double-blinding procedures (Table 5.5). The aim of the 
study was to compare the effects of HF-TENS and interferential current (another electro-
physical modality) on ischaemic pain. HF-TENS was concluded to have no effect on 
ischaemic pain above placebo. However, the authors felt that the TENS parameters used 
were insufficient. The settings used are detailed in Table 5.6 and adhere to the guidance 
previously discussed so this conclusion is confusing. Nevertheless, the design of the 
experiment may have led to a Type II error as previously described. As the order of 
interventions was not randomised and the intervention conducted during the second SETT 
(24-48 hours after the first), participants, knowing what they were to experience, attributed 
more fear to the stimulus and thus reported higher scores of pain intensity, nullifying the 
hypoalgesic effects of TENS.  
 
The study that scored the highest on the modified Jadad scale in terms of quality was that of 
Chen and Johnson (2011). The aim of this study was to build upon the research previously 
conducted and evaluate the effects of HF and LF-TENS on experimental ischaemic pain but 
with a special focus on the quality of the trial and thus the reliability and validity of the 
results. The conclusions drawn were that both types of TENS reduced pain intensity 
compared to placebo but HF-TENS was more effective than LF-TENS (Chen and Johnson 
2011). One of the key improvements compared to the other studies was the sample size and 
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experimental design. Forty-eight participants (24 male) were recruited and entered into a 
double blind, repeated measures, experiment where order of entry into the three 
conditions (HF-TENS, LF-TENS and Placebo) was randomised along with participant group. 
This helped to reduce the chance of Type I or Type II errors, increase internal validity and 
reduce the chance of measurement bias. The TENS settings employed align with the 
guidance and current evidence, apart from intensity of LF-TENS which could be higher (Table 
5.6). The statistics used to test for any effects were also very detailed and robust. Complex 
general linear models and post-hoc tests were used to test for within and between-group 
differences in VAS and SF-MPQ scores.  
 
The possible limitations of this study are the version of the SETT used and the brevity of 
ischaemic pain induced. Similar to the study of Johnson and Tabasam (2003) from the same 
research centre, the authors employed the SETT procedure to the forearm and TENS 
electrodes to either side of the cuff (Table 5.6). The forearm SETT has both benefits and 
limitations. Originally devised due to participant reports of widespread paraesthesia with 
the upper arm SETT, the forearm SETT has been reported to induce pain in the region of the 
hand, similar in intensity to that when the cuff is applied to the upper arm (Johnson and 
Tabasam 2003). What is not clear however, is what pain is being induced and evaluated. 
Pertovaara (1984) described two distinct components of SETT-induced pain: mechanical cuff 
pain and ischaemic pain distal to the cuff. In the original model of the SETT (Smith et al 
1966), the muscles being exercised were distal to the cuff and thus allowed to work freely in 
an ischaemic environment, inducing pain. In the forearm version of the SETT, the muscles 
being exercised by the handgrip exercises are, to a greater extent, underneath the cuff. Due 
to the pressure exerted by the cuff, these muscles may not be able to function as before and 
thus reduce the intensity, and possibly the quality of pain induced. Conversely, the severity 
of mechanical pain experienced may be increased. As the pressure is directly on the muscles 
attempting to work, the mechanical forces may be felt more acutely. Participants may 
therefore report a mixture of mechanical and ischaemic pain due to the proximity of the 




In the study by Chen and Johnson (2011), when pain was induced, participants were asked 
to continue for 2 minutes. As discussed above, this is understandable in terms of the overall 
study design although it could affect the conclusions relating to TENS. The maximum pain 
intensity reported was a mean VAS score with LF-TENS at 1 minute of 48.42 and a mean PRI 
score of 17.21 at baseline (Chen and Johnson 2011). This is similar to that reported by Walsh 
et al (1995a) for the mean VAS throughout 12 minutes of the SETT. This indicates that 
participants were experiencing similar levels of pain despite the minimal length of time. 
Unfortunately, the raw data from the study by Walsh et al (1995a) is not available to 
examine the development of pain over time. However, it has been noted in previous studies 
that ischaemic pain induced by the SETT gradually increases over time (Roche et al 1984; 
Johnson and Tabasam 2003). As the mean value of pain intensity over 12 minutes reported 
by Walsh et al (1995a) has been matched in the first minute by participants in the study by 
Chen and Johnson (2011) it suggests that the pain induced by the forearm SETT is in fact 
more severe than that produced by the upper arm SETT employed by Walsh et al (1995a). 
Overall, and despite these differences in pain induction, both types of TENS have been 
shown to be effective at reducing pain intensity in the most high quality study available.  
 
5.4.1.6: Summary: 
The aim of this review was to evaluate the current evidence for the hypoalgesic effects of 
TENS on experimentally induced ischaemic pain in healthy volunteers. Six studies met the 
inclusion criteria and were assessed in terms of methodological quality and reported results.  
 
All studies investigated a form of HF-TENS. Four out of the six studies found no effect of HF-
TENS on either VAS or MPQ scores (Rosenblatt and Hetherington 1981; Walsh et al 1995a; 
Foster et al 1996; Johnson and Tabasam 2003). HF-TENS frequencies tested varied from 80-
110Hz with the lower frequency proving the most effective application (Table 5.6 and 5.7). 
Chen and Johnson (2011) found that HF-TENS at 80pps reduced SPRI scores of the MPQ 
compared to placebo and VAS ratings compared to placebo and LF-TENS at 3pps.  
 
Four of the studies also investigated the effects of LF-TENS on induced ischaemic pain 
(Roche et al 1984; Walsh et al 1995a; Foster et al 1996; Chen and Johnson 2011). Of these, 
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three reported hypoalgesic effects over control or placebo (Roche et al 1984; Walsh et al 
1995a; Chen and Johnson 2011). LF-TENS settings varied within and between the studies 
with frequencies of 3-5Hz (Table 5.6).  
 
Of the six studies identified for inclusion in this review, three were of low quality and results 
were often conflicting and confusing. Assessment of low quality most commonly reflected 
lack of double blinding procedures and limited statistical power due to small sample sizes 
and between-subject designs. The conflicting or negative results were most commonly as a 
result of poorly chosen TENS stimulation settings. Future research must aim to avoid these 
pitfalls by designing double-blinded, randomised, repeated measures experiments with 
sufficient sample size to detect effects. Also, by using standardised TENS settings and 
altering just one parameter each time, the specific effects and optimal settings for each 
parameter might be identified.  
 
Overall, in the three high quality studies (Walsh et al 1995a; Foster et al 1996; Chen and 
Johnson 2011), two reported significant hypoalgesic effects of TENS for induced ischaemic 
pain. It can be concluded that, when using sufficient stimulation parameters in robust study 
designs, TENS is effective at reducing induced ischaemic pain in healthy volunteers.  
 
The aim of this review was to establish the current state of the published evidence 
regarding TENS and laboratory-induced ischaemic pain. If achieved this would allow the 
evaluation of the current understanding of the effects of TENS on ischaemic pain and also 
provide some indication regarding which parameters have been found to be the most 
effective for the reduction of ischaemic pain. In the context of this thesis, this informs the 




Table 5.6: Overview of TENS parameters employed in the review  
Study  TENS Parameters Duration SETT n per 
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Table 5.6 (continued): Overview of TENS parameters employed in the review. 
Study TENS Parameters Duration SETT n per group 
General  Frequency  Pulse Intensity  Electrodes 
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Table 5.7: Overview of the findings of the studies included in the review  
Study Findings 
Rosenblatt and Hetherington 1981 No change in time to pan tolerance 
No difference in VAS scores  
(Student’s t-test) 
Roche et al 1984 LF/LI-TENS increased time to threshold and tolerance 
HF/HI-TENS increased time to tolerance, endurance and decreased MPQ-PRI scores 
(Student’s t-test)  
Walsh et al 1995a LF/HI-TENS reduced mean VAS compared to control and HF-TENS  
Mean VAS decreased with P-TENS compared to HF-TENS 
LF/HI-TENS decreased VAS in minutes 7-9 compared to all  
No change in MPQ 
(1-way ANOVA)  
Foster et al 1996 No differences in VAS or MPQ scores between groups or over time.  
(Difference scores and ANOVA) 
Johnson and Tasbasam 2003 No difference in VAS scores from control or placebo  
No difference in SF-MPQ between groups  
(Difference scores and 2-way repeated measures ANOVA/ 1-way ANOVA for MPQ) 
Chen and Johnson 2011 HF-TENS reduced VAS compared to LF-TENS and placebo  
VAS increased with placebo and even more with LF-TENS compared to control  
Both TENS reduced SPRI compared to placebo  




5.5: LOWER LIMB LABORATORY-INDUCED ISCHAEMIC PAIN:  
IC pain most commonly occurs in the lower limb, and when standing. Despite these 
promising results of TENS in the upper limb as noted above, it is not known whether TENS 
will produce the same results in the lower limb.  There are a number of important 
physiological differences between the upper and lower limb such as the composition of 
muscle fibre types and different vascular and neural networks (Johnson et al 1973; Scott et 
al 2001).  
 
Johnson et al (1973) performed autopsy examinations of 36 muscles from 6 male subjects 
and found a larger proportion of type I muscle fibres in the lower limb compared to a larger 
proportion of type II (a and b) muscle fibres in the upper limb. Type II, or fast-twitch muscle 
fibres have been shown to have more capacity than slow-twitch fibres to work anaerobically 
due to a greater glycolytic potential (Zierath and Hawley 2004). In an ischaemic 
environment, as in laboratory-induced ischaemic pain, type I fibres may thus fatigue more 
rapidly and result in a greater accumulation of the by-products of anaerobic metabolism and 
a different experience of pain.  
 
Due to this difference in muscle fibre composition and thus possibly development and 
experience of ischaemic pain, it is not clear whether TENS would produce the same effects 
as in the upper limb. In addition, IC pain occurs when walking. The need to function in pain 
adds an extra dimension to the experience, which is not replicated in the SETT. After the 
initial exercise, the upper limb is rested throughout the rest of the procedure. Requiring the 
limb to function during pain may affect the hypoalgesic effects of TENS.  
 
5.5.1: Pilot Studies of Lower Limb Laboratory-Induced Ischaemic Pain:  
A series of pilot studies conducted at Queen Margaret University in healthy volunteers have 
adapted the upper limb SETT (Woolf 1979; Roche et al 2002) to the lower limb and applied it 
in supine or standing laboratory subjects (Roche et al 2007; Mackay et al, unpublished 




The first study developed the lower limb method in supine participants and compared 
outcomes between the standardised upper limb SETT procedure and the adapted lower 
limb SETT procedure. The outcomes were compared in terms of: a) tissue ischaemia as 
measured with Laser Doppler Flowmetry (LDF); b) pain intensity during ischaemia as 
measured with a Numerical Rating Scale (NRS) and c) subjective description of pain as 
measured with the MPQ (Roche et al 2007) (Table 5.8). The researchers found that the 
modified SETT successfully induced ischaemia in the lower limb, as measured by LDF. 
Despite this success, the induced ischaemia was recorded at a lower level than that 
measured in the upper limb. Also, the pain reported in the lower limb was found to be 
similar in quality but less intense than that in the upper limb (Roche et al 2007).  
 
The second study examined the pain induced in the lower limb SETT in the sitting and 
standing subject to investigate the effects of body position on the pain reported (Mackay et 
al, unpublished observations 2007). The authors reported that pain intensity and time to 
pain threshold and tolerance increased when standing.  
 
Most recently in the third study, the lower limb SETT methodology was developed in the 
standing subject, inducing pain similar in quality and intensity to the upper limb method 
(Simpson, unpublished observations 2007). Reliable levels of pain were induced in a 
repeated measures design and TENS was found to prolong time to pain tolerance.  
 





Table 5.8: Summary of pilot studies investigating lower limb ischaemic pain  
Study Roche et al (2007) 
Sweers, unpublished 
observations (2007) 
Mackay et al, unpublished 
observations (2007) 
Simpson, unpublished 
observations (2007)  
Study Design UL-SETT vs. LL-SETT TENS for LL-SETT Pain in LL-SETT TENS for LL-SETT 
Participants  10 males 21 females 20 males 17 females 
Position Supine Supine  Sitting and Standing Standing 




Pain Tolerance  
Pain Endurance  
21-NRS  
Post Occlusive Reactive 
Hyperaemic response (PORH) 
measured by Laser Doppler 
Flowmetry 
Pain Threshold 
Pain Tolerance  
Pain Endurance  
VAS at 1 minute intervals  
Pain Threshold 
Pain Tolerance  
Pain Endurance  
VAS at 1 minute intervals 
Pain Threshold 
Pain Tolerance  
Pain Endurance  
VAS at 1 minute intervals 
Findings  LL-SETT induces pain 
comparable to that with the 
UL-SETT  
HF-TENS increased time to 
pain threshold and tolerance 
compared to no-TENS control 
LL-SETT induced pain in the 
sitting and standing subject 
however, intensity was greater 
when standing.  
TENS increased pain 
tolerance but not 






5.5.2: TENS for Laboratory-Induced Lower Limb Ischaemic Pain:  
Two of these pilot studies also conducted preliminary investigations into the effect of TENS 
on the induced ischaemia (Roche et al 2007; Simpson, unpublished observations 2007). 
When compared to control, TENS was found to increase the time before the report of ‘pain 
threshold’ and ‘pain tolerance’ but it did not reach significance in supine and standing 
subjects (Roche et al 2007; Simpson, unpublished observations 2007). Despite these 
preliminary indications of TENS efficacy for lower limb induced ischaemic pain, the 
generalisation of these results to a wider population and to clinical IC pain is limited due to 
their low sample sizes and the need for further control of the experimental design. Further 
laboratory research must address methodological weaknesses i.e. introduce larger sample 
size and a standardised, randomised and controlled design including placebo TENS before 
trialling TENS in a clinical IC pain population.  
 
5.5.3: Future Directions:  
The studies discussed here have completed important groundwork, refining the lower limb 
method, identifying limitations and recommending areas for development. A further study 
that begins to address these limitations and refines the procedure would be beneficial as a 
preliminary validation of this lower limb model. A valid and reliable method of inducing 
lower limb ischaemic pain could be useful for investigation of the qualities of ischaemic 
pain, and how those qualities respond to TENS without the influence affective-evaluative 
impact of chronic pain. It is anticipated for example that laboratory-induced ischaemic pain 
may have similar sensory-discriminative qualities to IC but have fewer affective-motivational 
and cognitive-evaluative components. Such a non-chronic profile of the sensory-
discriminative components of ischaemic pain could be a useful way to examine how TENS 
affects the common sensory experience of IC pain.  
 
5.6: CONCLUSION:  
Currently there is an established method for inducing ischaemic pain in the upper limb. 
TENS has been shown to be effective in reducing this pain. This cannot be extrapolated to 
the clinical population however, due to the physiological differences between the upper and 
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lower limbs. There has been initial development of a lower limb method of inducing 
ischaemic pain. TENS has been shown to be effective in reducing this pain. These results 
cannot be extrapolated to the clinical population either however, due to methodological 
limitations. The lower limb method requires development and the effect of TENS on the 
pain induced needs to be investigated.  
 
5.7: CHAPTER 5 SUMMARY: 
The aim of this chapter was to explore the concept of laboratory-induced pain as a possible 
method that could help address the two central aims of this thesis. Laboratory-induced pain 
has been shown to be useful in the study of pain syndromes and for the testing of 
interventions. Experimental pain is useful as it allows study of the pain experience without 
the confounding comorbidities of clinical pain and affords some control over the quality of 
pain experienced. Of the different methods of inducing experimental pain, the ischaemic 
pain model (SETT method) appears to induce pain through similar physiological mechanisms 
to that experienced with IC. The SETT method induces pain in the upper limb of healthy 
volunteers in sitting and has been used to examine the pain experience and test 
interventions including TENS. A systematic review of the effects of TENS showed that when 
appropriate stimulation parameters were employed, TENS has a hypoalgesic effect on the 
SETT-induced ischaemic pain.  
 
IC pain however, occurs in the lower limb and when standing, both of which factors may 
alter the pain experience. With this is mind, a series of pilot studies have adapted the SETT 
method to a standing, lower limb application. The effect of TENS on this lower limb 
ischaemic pain was investigated with trends towards hypoalgesia reported. Prior to further 
study or adoption of this lower limb method, it is important that the procedure is refined 
and the reliability of the induced pain investigated. Also further study is required that 
examines the hypoalgesic effects of TENS in larger populations and to be accepted as a pre-
clinical model of IC pain, the subjective qualities of the pain experience induced by this 
lower limb method must be compared to those in IC pain.   
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CHAPTER 6: LITERATURE REVIEW SUMMARY AND STUDY RATIONALE  
6.1: AIM OF CHAPTER 6: 
The aim of this chapter is to summarise the aims and objectives discussed in Chapter 1 
whilst integrating the literature and concepts discussed in Chapters 2-5. A series of studies 
designed to address these aims will then be discussed, indicating how each study is 
designed to address the questions of this programme of research.  
 
6.2: SUMMARY OF LITERATURE REVIEW AND RESEARCH QUESTIONS: 
The clinical problem of IC is well established and associated with decreased physical and 
psychological function and decrease in quality of life. Understanding of the IC pain 
experience is limited and issues have been identified with current management strategies. 
Pain, and especially chronic pain, is a complex, multidimensional experience with sensory-
discriminative, affective-motivational and cognitive-evaluative components. These 
components are affected by numerous psychological and social factors including situation, 
beliefs, experience, culture, attention and behaviour. Understanding the subjective 
descriptive qualities and the associated psychosocial factors of any pain experience is 
valuable when attempting to understand observed effects and designing management 
strategies. Currently IC pain is lacking in this respect. A recording and evaluation of the 
subjective descriptions of IC pain could be an effective means of improving the 
understanding and management of patients with IC.  
 
Current management of IC consists of risk factor modification, exercise therapy and 
pharmacological management. All of these management strategies have been shown to be 
effective although one problem that has been identified is a lack of adherence to exercise 
therapy. The experience of IC pain has been identified as one possible explanation for this 
poor adherence to exercise therapy but no hypoalgesic interventions have been 
investigated in an attempt to reduce the burden of IC pain. TENS is a low-cost, non-
pharmacological hypoalgesic intervention shown to have hypoalgesic effects for other 
chronic pain conditions. TENS has been shown to have hypoalgesic effects on induced 
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ischaemic pain in the upper limb of healthy volunteers. TENS could be useful as an 
adjunctive intervention for IC that reduces the experience of pain and increases walking 
performance. It has not however been investigated for induced ischaemic pain in the lower 
limb or for IC pain.  
 
There are therefore two central research questions addressed in this thesis:  
 What qualities characterise the subjective description of IC pain?  
 What are the effects of TENS on measures of pain and walking performance in patients 
with IC?  
 
6.3: AIMS AND OBJECTIVES OF THIS PROJECT:  
From these two questions, the aims of this project are formulated. One aim is to investigate 
the subjective description of the multidimensional qualities of ischaemic pain. The second 
aim is to investigate the hypoalgesic effects of TENS on lower limb ischaemic pain and 
walking performance in patients with IC.  
 
These aims can be addressed through four clear objectives that are linked to four distinct 
studies:  
 
Objective 1: to develop and validate the mSETT in the lower limb of healthy volunteers. 
This objective aims to establish the mSETT as a reliable method of inducing ischaemic pain in 
the lower limb of healthy volunteers. This will contribute to both aims of the project by 
establishing a method that allows investigation of the subjective descriptive qualities of 
lower limb ischaemic pain and examination of the effects of TENS on these qualities.  
 Study 1: An examination of the test re-test reliability of the ability of the mSETT to 
induce consistent levels of pain was conducted (Chapter 7). A laboratory study is 
proposed that examines the pain induced by the mSETT in healthy volunteers. The 
ability of the mSETT to induce comparable levels of pain on separate occasions will 




Objective 2: to investigate the effects of TENS on the pain induced by the mSETT. This 
objective contributes evidence regarding the effects of TENS on lower limb ischaemic pain 
and more specifically which aspects of the pain experience are affected by TENS 
intervention. Again this objective will contribute to both aims as MPQ descriptions of 
ischaemic pain will be recorded and the effects of TENS on lower limb ischaemic pain 
investigated.  
 Study 2: An investigation into the hypoalgesic effects of HF-TENS on mSETT induced 
pain in healthy volunteers (Chapter 8). Following the validation study another 
laboratory study is proposed that investigates the effects of HF-TENS and Placebo 
TENS (P-TENS) on reports of mSETT-induced pain intensity and quality as measured 
by the MPQ.  
 
Objective 3: to investigate the effects of TENS on pain and walking performance in 
patients with IC. This objective is central to the attempt of this thesis to address the 
identified clinical problem of IC. Both aims will be addressed by investigating the effects of 
TENS on IC pain and walking performance and recording of the descriptions of clinical 
ischaemic pain with the MPQ.  
 Study 3: An investigation into the hypoalgesic effects of HF and LF-TENS on measures 
of pain and walking performance in patients with IC (Chapter 9). A clinical, Medical 
Research Council (MRC) phase IIa,  ‘proof of concept’ study is proposed that 
investigates the effects of TENS on walking performance in patients with PAD and IC. 
This study will also examine the psychosocial aspects of IC pain and relationships to 
walking performance.   
 
Objective 4: to record and compare the subjective descriptions of the pain experience 
associated with IC and mSETT induced pain. This objective will specifically address the first 
aim of the project: to investigate the subjective description of ischaemic pain. By comparing 
descriptions of pain between the clinical IC population and healthy volunteers experiencing 
the mSETT, the subjective descriptions of lower limb ischaemic pain can be explored.  
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 Study 4: A post hoc examination of the pain descriptions as recorded by the MPQ in 
patients with IC and healthy volunteers experiencing mSETT induced pain (Chapter 
10). The specific subjective nature and quality of IC pain will be compared to that 
induced by the mSETT.  
 
6.4: CHAPTER 6 SUMMARY: 
The aim of this chapter was to summarise the aims and objectives discussed in Chapter 1 
whilst integrating the literature and concepts discussed in Chapters 2-5. After reviewing the 
literature, two clear research questions have been identified. In an attempt to address these 
questions, research aims and objectives are proposed. The following five chapters will 
describe and discuss the execution of this plan and explore the results of each stage. Finally, 
the last chapter will reflect back on these original aims and discuss any conclusions that can 




CHAPTER 7: EXPERIMENT ONE - TEST-RETEST RELIABILITY OF THE 
MODIFIED SETT (MSETT)  
7.1: AIM OF CHAPTER 7:  
TENS is a possible useful adjunctive intervention for clinical lower limb ischaemic pain in the 
form of IC. Prior to clinical investigation, it is common and prudent for novel hypoalgesic 
interventions to be tested on a pre-clinical model of pain. The SETT method is an established 
method for inducing ischaemic pain in healthy volunteers. TENS has been shown to reduce 
induced ischaemic pain in the upper limb of healthy volunteers using the SETT method. It 
has not been tested for lower limb ischaemic pain. Due to the physiological differences 
between the upper and lower limbs, an experimental method of inducing lower limb 
ischaemic pain would be useful to test the effects of TENS prior to clinical evaluation in IC 
pain.  
 
A series of pilot studies have modified the SETT to a lower limb application. The test-retest 
reliability of pain induced by the lower limb SETT (mSETT) method has not been 
investigated. This issue requires consideration for the development of the mSETT as an 
experimental model of pain. Therefore, the following investigations were undertaken to 
address this reliability issue and thus address the research aim to develop a robust 
experimental method of inducing lower limb ischaemic pain. 
 
The aim of this chapter is to describe the investigation of the test-retest reliability of the 
mSETT. The methods employed will be described and the findings discussed.  
 
7.2: METHOD:  
7.2.1: Design:  
This study was designed to assess the test-retest reliability of the mSETT method of inducing 
pain, thus informing the substantive study examining the effect of TENS on induced, lower 
limb ischaemic pain as described in Chapter 8 of this thesis. Each participant completed the 
protocol on two separate occasions, at least three weeks apart, with the same investigator. 
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Data were collected such that the test-retest reliability could be estimated through 
Intraclass Correlation Coefficient (ICC). The study was granted ethical approval by the 
University Research Ethics Committee.  
 
7.2.2: Participants:  
A convenience sample of 11 participants (7 male) with a mean age of 28 years (range = 21-
35 years) was recruited from the University’s student population. Each participant received 
an information sheet and exclusion criteria questionnaire (Appendix 4 and 5). No participant 
was excluded from the study, the experimental procedure was explained and written 
informed consent was obtained (Appendix 6).  
 
7.2.3: Measures:  
7.2.3.1: Pain:  
Pain threshold was defined as the time in seconds to “the moment discomfort turns to pain” 
and was indicated by the participant saying, “pain now” (Melzack and Wall 1996; Roche et al 
2002). Pain tolerance was defined as the time in seconds to “the moment the subject 
reports that he is no longer able to tolerate the pain” and was indicated by the participant 
stating, “stop” (Melzack and Wall 1996; Roche et al 2002). Pain endurance was defined as 
the time in seconds between pain threshold and pain tolerance (Roche et al 2002).  
 
Pain intensity was measured using a 21-point Numerical Rating Scale (21-NRS): a numerical 
scale ranging from 0 to 20, with labels of “no pain” and “unbearable pain” respectively. 
Participants were asked to choose a number between 0 and 20 which best reflects their 
current pain intensity. The NRS has been found to be valid, reliable and practical for use in 
both laboratory and clinical pain (see section 3.5.1) (Jensen et al 1986; Bolton and Wilkinson 
1998).  
 
A McGill Pain Questionnaire (MPQ) was administered retrospectively, within 5 minutes of 
the participant reporting ‘pain tolerance’. The participant was asked to describe the pain 
they experienced at pain tolerance. The MPQ is valid and reliable in the laboratory setting 
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(Klepac et al 1981) and can provide information regarding the pain qualities and intensity 
associated with different pain syndromes (Dubuisson and Melzack 1976; Jerome et al 1988; 
Katz and Melzack 1991; Dworkin et al 2009).  Pain Rating Index (PRI) scores from the MPQ 
were recorded and analysed as a measure of the sensory, reactive and overall nature of the 
ischaemic pain at the point of tolerance (Melzack 1975; Roche et al 1984).  
 
7.2.3.2: Psychosocial: 
When measuring any pain experience it is essential that psychosocial factors are considered 
and recorded (Katz and Melzack 1999). Psychological factors related to pain have been 
shown to affect sensitivity to experimental pain (Rainville et al 2005; George et al 2006; 
Hirsh et al 2008).  
 
Specifically, fear of pain and pain self-efficacy independently predict time to pain threshold 
and tolerance in healthy volunteers experiencing laboratory-induced pain (George et al 
2006; Vancleef and Peters 2011). Therefore, in the current study, measures of pain self-
efficacy and fear of pain were employed to quantify the levels of these psychological 
variables between participants.  
 
Pain self-efficacy was measured using the Pain Self-Efficacy Questionnaire (PSEQ) (Nicholas, 
2007). This measure was recorded at the end of the testing session with each participant 
rating how they felt the pain they had just experienced would affect them if suffered daily. 
Pain-related fear was measured using the Fear of Pain Questionnaire (FPQ) (McNeil and 
Rainwater, 1998).   
 
7.2.3.3: Physiological:  
Physiological measures were used to monitor each participant’s physiological reaction to 
ischaemia and pain. There are no established guidelines for monitoring the systemic 
response to ischaemia. Recent literature has highlighted some systemic effects of 
tourniquet use.  Due to the increase in circulating blood volume, pressor response and the 
response to pain, heart rate and systolic blood pressure can be elevated through inducing 
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ischaemia via tourniquet (Kam 2007).  Therefore, blood pressure, heart rate and oxygen 
saturations were measured throughout the experimental procedure and the experiment 
was stopped immediately if any were outwith normal limits. Blood pressure was measured 
every 2 minutes using a digital blood pressure monitor (UA-767PAC, A&D Medical, Tokyo, 
Japan). A systolic pressure of 30mmHg above or below resting pressure acted as a cut-off for 
the procedure and the cuff was deflated immediately. No testing sessions were terminated 
due to a change in blood pressure. Participants’ heart rate (HR) and oxygen saturations 
(SpO2) were measured continuously throughout the experimental procedure using a vital 
signs monitor (Vital Signs Monitor 300 Series, Welch Allyn, Bucks, UK). A normal range of 
more than 70% age-related maximum HR (maximum HR = 220-age) and less than 95% SpO2 
was used and the experiment was stopped if the readings strayed outwith these values.  
 
7.2.4: Study Procedure:  
Each participant attended for testing on two occasions, at least three weeks apart, for 
approximately 1 hour. Each testing session was divided into three sections (Figure 7.1).  
1. Introduction and Baseline Data Collection
2. Familiarisation Session 
3. mSETT Procedure
 
Figure 7.1: Experiment procedure. 
 
7.2.4.1: Introduction and Baseline Data Collection:  
Participant descriptive data was recorded including date of birth, height, weight, heart rate, 
blood pressure, oxygen saturations and the circumference of their non-dominant thigh 
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(15cm above the proximal border of the patella with the knee resting in extension on the 
plinth).  
 
7.2.4.2: Familiarisation Session:  
The participant completed a familiarisation session where the mSETT procedure was 
followed as detailed in section 7.2.4.3, with three exceptions:  
1. Participants rested for 5, rather than 20 minutes prior to the mSETT as no reports of 
pain were being recorded i.e. the full rest period was not required.  
2. The procedure was stopped 30 seconds after pain threshold rather than continuing 
to pain tolerance so that the participants did not become fatigued but managed to 
experience the nature of the development in pain intensity 
3. No measures of pain were recorded as this session aimed just to allow the 
participant to experience the sensation.  
 
Any participant questions or errors in experimental technique were addressed prior to 
commencing the procedure for the full testing session.  
 
7.2.4.3: mSETT Procedure:  
A modified lower limb SETT (mSETT) was used to induce pain for a maximum duration of 20 
minutes. This was adapted from the standardised upper limb SETT (Woolf 1979; Roche et al 
1984; Roche et al 2002).   
 
The upper limb SETT procedure, although employed with different parameters in different 
publications, has six common sequential components (Figure 7.2): 1) Rest period; 2) 
Desanguination; 3) Occlusion of blood flow; 4) Submaximal effort exercise; 5) Period of 





Figure 7.2: Modified Submaximal Effort Tourniquet Test (mSETT) procedure.  Key: 1-Rest Period; 2-Limb Elevated; 3-
Desanguination; 4-Cuff Inflated; 5-Standing in test position and backpack on; 6-Single-leg heel raise exercises; 7-Backpack 
removed; 8-21-NRS at irregular intervals; 9-Cuff Deflated over 2 mins.  
The familiarisation session consisted of only 5 minutes rest period and terminated 30 seconds after pain threshold reported.  
The baseline session followed the procedure but no TENS was applied.  
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Rest Period:  
After baseline measurements of heart rate (HR), blood pressure (BP) and saturation of 
oxygen (SaO2), the participant was asked to rest on the plinth, in a supine position, for 20 
minutes. During this time, participants were asked to “close their eyes and rest” (Figure 7.3).  
 
 
Figure 7.3: Participant relaxation, supine on plinth 
 
After 15 minutes of relaxation on the plinth, the elastic bandage (Tubigrip: Size E, Seton 
Healthcare Group, Oldham, UK) and sphygmomanometer (20cm width; Bainbridge™, 
Trimline Medical Products, NJ, USA) were positioned on the participant’s non-dominant 
lower limb (Figure 7.4).  
 
 
Figure 7.4: Equipment placed on the participant’s non-dominant lower limb with 






After 20 minutes of the rest period the plinth was raised so that the participant’s legs were 
positioned at more than or equal to 45 degrees of hip flexion (Figure 7.5). This position was 
held for 60 seconds, after which the sphygmomanometer cuff was inflated.  
 
 
Figure 7.5: Desanguination of the participant’s limb with the equipment in place  
 
Occlusion of Blood Flow:  
The cuff was inflated to 40mmHg above the participant’s baseline systolic BP over 30 
seconds with the limb in the above position. Once the cuff had reached the set pressure the 
stopwatch was started. The participant’s legs were then lowered and they were helped into 
a standing position at the side of the plinth (Figure 7.6).  
 
In the standing position the participant was asked to place their dominant foot on 
mechanical weighing scales. These scales were used to provide immediate feedback to the 
participant and researcher regarding the amount of weight being supported by the 
dominant leg. The participant was asked to keep the reading on the scale below 5kg. This 
technique was employed to help standardise the experimental procedure and encourage 








Figure 7.6: Participant standing next to plinth with cuff in place, dominant leg on 
weighing scales and support on either side 
 
Submaximal Effort Exercise: 
Once the participant was positioned in standing, a weighted backpack was placed on their 
back (Figure 7.7). This was a standard backpack (Pax 25; Lowe Alpine International, Treviso, 
Italy) with 40kg of weight secured inside (total weight 40.5kg). The researcher lifted the 
backpack from the floor and helped the participant position it in place on their back and 
adjust the straps for comfort.   
 
The time from completion of cuff inflation to commencing the exercises was always 1 
minute.  
 
The participant completed 20 repetitions of single-leg heel raises. A series of tones on a 
recording instructed the participant when to start and stop each exercise. When the tone 
sounded the participant plantar-flexed their non-dominant ankle and raised their heel off 
the ground (Figure 7.8). This position was held for the duration of the tone (2 seconds). 
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When the tone ceased, the participant relaxed their heel back down to the ground for the 
duration of the relax phase (2 seconds) (Figure 7.9).  
 
 
Figure 7.7: The weighted backpack on the participant ’s back   
 
 
Figure 7.8: Heel raise exercise. Contraction phase with the non-dominant (left) heel 
raised off the ground. The dominant heel is raised in order to maintain minimal 
contact with the scales and ensure the leg being tested is performing maximal 





Figure 7.9: Heel raise exercise- relax phase with the non-dominant (left) heel 
returned to the ground  
 
In summary, the submaximal effort exercise was single-leg heel raises mainly achieved using 
contraction of the muscles of the non-dominant lower limb. The participants performed 20 
repetitions of 2sec/2sec, (contraction/relax) against their body weight and 40.5kg of the 
backpack.  
 
Period of Induced Pain:  
Once the participant had completed the exercises the backpack was removed by the 
researcher and they were instructed to stand as still as possible, only on their non-dominant 
leg for the rest of the procedure (Figure 7.6). The participant was also instructed to “keep 
the knee of their non-dominant leg ‘unlocked’ throughout” i.e. in a small amount of knee 
flexion (Figure 7.10). The rationale for this was to help ensure that the muscles of the leg 
being tested were actively contracting throughout the procedure and thus working in an 
ischaemic environment. The researcher monitored knee flexion throughout and prompted 





Figure 7.10: Experimental position with the participant’s non -dominant knee 
‘unlocked’ i.e. in a small amount of knee flexion during the experimental procedure  
 
The participants remained in this position throughout the experimental procedure. They 
were instructed to report pain threshold and pain tolerance. The participant indicated these 
points by saying “pain now” and “stop” respectively. Perceived pain intensity was recorded 
throughout with the 21-point Numerical Rating Scale (21-NRS): a numerical scale ranging 
from 0 to 20, with labels of “no pain” and “unbearable pain” respectively. The participant 
rated their pain at intervals using the 21-NRS, prompted by the audio track. These ratings 
were at fixed, irregular intervals of 30, 35, 40, or 45 seconds. These intervals were irregular 
in sequence but the same in each test to allow comparison. The irregular intervals were 
used with the aim of blinding the participant to how long they had tolerated the pain. The 
recording asked them to “rate their pain on a scale of 0-20 where 0 represents no pain at all 
and 20 represents the point of unbearable pain”.  
 
The NRS has been found to be the superior method of rating pain intensity in terms of 
validity, reliability and practicality compared to VAS, box scales and verbal rating scales 
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(Jensen et al 1986, Bolton and Wilkinson 1998).  The use of 21 levels provides the optimum 
sensitivity to changes in pain intensity (Jensen et al 1994).  
 
Release Occlusion of Blood Flow:  
When the participant reached a score of 20 on the 21-NRS or reported Pain Tolerance by 
saying, “stop”, the experiment was ceased immediately. The cuff was deflated, the time 
recorded and the participant helped to sit back on the plinth. The equipment was removed 
and the participant instructed to rest on the plinth. After the participant had rested for 2 
minutes, the researcher administered an MPQ asking the participant to describe the pain 
they experienced at the point of Pain Tolerance.  
 
7.2.5: Statistical Analysis:  
Graphical analysis of raw test-retest pain data and intraclass correlation coefficient analysis 
was used to examine the test-retest reliability of the mSETT. A two-way, mixed effects 
Intraclass Correlation Coefficient (ICC) was selected (Random effect = participant, Fixed = 
rater). An ICC value of more than 0.6 (defined as ‘substantial’ reliability (Eliasziw et al 1994)) 
was set as the minimal acceptable level. Confidence Intervals (CI) at 95% were computed for 
the ICC values to identify the precision of the reliability coefficient and the limits within 
which the true typical error in the population was likely to reside. The standard error of 
measurement (SEM) was calculated for the change values to provide a quantitative indicator 
of the test-retest reliability of the mSETT and the measurement of pain threshold, tolerance 
and endurance. A repeated measures ANOVA was used to test for variation in the measures 




7.3: RESULTS:  
The participants were 11 healthy volunteers (7 male, 21-35 years) without previous 
experience of TENS or any known pathology or contraindication to the mSETT or TENS. No 
participant dropped out and none were excluded from analysis.  
 
Individual participant data for both trials is displayed in Table 7.1 and Figures 7.11-13. Time 
taken to report pain threshold and tolerance were similar between trials for each 
participant. The positive mean change for each of the measures indicates a possible practice 
or familiarisation effect with the mSETT.  
 
Scatter plots of individual scores for each measure are shown in Figures 7.14-7.16. Repeated 
measures ANOVA showed no differences between the values and ICC estimates for each of 
the outcomes are detailed in Table 7.2 (F10,10 = 6.561, p = .003; F10,10 = 25.764, p < .001; F10,10 
= 24.715, p < .001). Estimates of test-retest reliability were satisfactory with coefficients 
more than 0.7 for all three measures.  
 
The ICC estimate for pain threshold was the lowest of the outcomes with a wide 95% CI 
(Table 7.2). This indicates ‘substantial’ reliability although the ‘true’ population estimate 
may be considerably different (95%CI ICC = 0.28-0.92).  
 
The 95% CI’s were narrow for pain tolerance and endurance, indicating good precision of 
the correlation estimates. The Standard Error of Measurement (SEM) (measured in seconds) 
indicates the degree of change, which represents ‘real’ variation rather than measurement 




Table 7.1: Individual participant data for change in each measure with the mSETT.  
 Change (Trial 2-Trial 1) 
Participant Threshold (secs) Tolerance (secs) Endurance (secs) 
1 9 9 0 
2 11 153 142 
3 44 105 61 
4 3 12 9 
5 14 6 -8 
6 -19 50 69 
7 20 165 145 
8 9 48 39 
9 29 52 23 
10 -5 27 32 
11 -13 15 28 
Mean 9.3 58.4 49.1 
SE 5.46 17.30 15.72 
 
 
Table 7.2: ICC estimates for time to pain threshold, tolerance and endurance 
(measured in seconds).  
 Threshold Tolerance Endurance 
Mean Trial 1 (SD)  118.1 (27.8) 427.5 (139.4) 309.4 (119.5) 
Mean Trial 2 (SD)  127.4 (21.6) 485.8 (156.8) 358.5 (143.7) 
Mean Difference (SD) 9.3 (18.1) 58.4 (57.4) 49.1 (52.1) 
ICC 0.74 0.93 0.92 
95% CI 0.28-0.92 0.75-0.98 0.74-0.98 
SEM (secs) 14.18 41.49 40.65 
95% SEM (secs) 28.36 82.58 81.30 






Figure 7.11: Individual participant data for time taken to report Pain Threshold 
(secs) in both trials.  
 
 
Figure 7.12: Individual participant data for time taken to report Pain Tolerance 





Figure 7.13: Individual participant data for Pain Endurance (secs) in both trials.  
 
 
Figure 7.14: Scatterplot of time taken to report pain threshold in both trials. Line 





Figure 7.15: Scatterplot of time taken to report pain tolerance in both trials. Line 
represents y=x. 
 




7.4: DISCUSSION:  
The value of an experimental pain method is its ability to reduce the erroneous variables 
inherent in clinical pain, and provide a platform for the investigation of the pain induced 
(Woolf 1979). An experimental method of inducing pain must therefore have good test-
retest reliability in terms of the pain induced.  
 
The results of this study indicate that participants experiencing mSETT-induced pain report 
comparable levels of pain on separate occasions. The intra-rater ICCs were excellent for 
time to report pain tolerance and pain endurance with the relatively narrow CIs showing the 
high degree of accuracy of the correlation estimates (Table 7.2). The ICC for pain threshold 
was also substantial however; the 95%CI was somewhat larger than with pain tolerance or 
endurance (Table 7.2). This suggests that even though the measurement of pain threshold 
with the mSETT is reliable, measures of pain tolerance and endurance are more so and thus 
should be used as primary outcomes for any studies employing the mSETT. This is a similar 
finding to that of Nicolaï et al (2009b) with the graded treadmill test. In this test of clinical 
ischaemic pain, there is greater variability in the measure of pain threshold (Initial 
Claudication Distance (ICD)) compared to pain tolerance (Absolute Claudication Distance 
(ACD)).  
 
The SEM for each measure shows small variability with each less than 14% of the mean. This 
highlights a consistency of pain reported by the participants during the mSETT procedure. 
The mSETT is therefore an appropriate method of inducing experimental pain in this 
population.  
 
There is no published literature that examines the test-retest reliability of the pain induced 
by the mSETT in the lower limb of healthy volunteers. The current study has found that by 
following a specific experimental protocol, a consistent intensity of pain can be induced in 




7.5: IMPLICATIONS AND CONCLUSIONS:  
The reliability of a measure is linked to the specific population and the specific conditions in 
which one wishes to apply the measure (Streiner and Norman 2008). This study contributes 
evidence that participants undergoing the mSETT procedure report consistent and reliable 
levels of pain tolerance and endurance.  
 
7.6: CHAPTER 7 SUMMARY: 
The aim of this chapter was to describe the investigation of the test-retest reliability of the 
mSETT. This investigation has shown that mSETT induces comparable levels of pain intensity 
over two occasions. Time taken to report pain threshold, pain tolerance and pain endurance 
was similar within participants on two separate sessions.  
 
The mSETT is therefore a reliable method of inducing pain in the lower limb of healthy 
volunteers and as such can be used to investigate the effects of interventions. The next 
chapter describes such an investigation. The effects of TENS on lower limb ischaemic pain 
will be examined using the mSETT as the method of inducing ischaemic pain in the lower 





CHAPTER 8: EXPERIMENT TWO - THE EFFECTS OF TENS ON MSETT-
INDUCED PAIN  
8.1: AIM OF CHAPTER 8:  
Prior to the investigation of the effects of TENS on clinical IC pain, robust investigation into 
the effects of TENS on lower limb ischaemic pain in a more controlled laboratory 
environment is indicated. The effects of TENS on experimentally induced, lower limb 
ischaemic pain have been previously investigated in small, pilot studies with varying 
methodologies (Roche et al 2007; Simpson, unpublished observations 2007). Promising 
hypoalgesic results have been observed, although methodological weaknesses limit the 
strength of the conclusions. In the previous chapter, the mSETT procedure was found to be 
a reliable method of inducing lower limb ischaemic pain in healthy volunteers. The study 
described in this chapter, aims to address the limitations of the previous investigations and 
examine the effects of TENS on mSETT-induced, lower limb pain in standing, healthy 
volunteers.  
 
The aim of this chapter is to investigate mSETT-induced, lower limb ischaemic pain and the 
effects of High Frequency (120Hz) TENS (HF-TENS) on measures of pain, compared to 
Placebo TENS (P-TENS).  
 
8.2: POWER CALCULATION:  
The primary outcome measure was pain tolerance and from a review of the literature an 
accepted effect size was 0.8 (Roche et al 1984). A power calculation was performed to 
determine the sample size required to support statistical analysis at 80% power and a two-
tailed 5% significance level. The study was powered to detect a large within-participant 
effect (≥ 0.8; (Cohen 1988)) between the TENS and control using a repeated measures 
ANOVA. To detect such an effect with 80% power at a two-tailed 5% significance level, 16 





8.3: METHOD:  
8.3.1: Design:  
Initially, the study was designed as a repeated-measures experiment with each participant 
completing the experimental procedure on four occasions, experiencing all conditions: No-
TENS, P-TENS, HF-TENS and LF-TENS. The university ethics committee did not feel that the 
possible outcomes of the research warranted this degree of participant involvement and 
thus advised that the design should be changed to minimise the burden on participants. 
Therefore, a single blind, placebo-controlled, repeated measures study design was selected 
as this maintained the benefits of the repeated measures design was proposed. The new 
design required participants to endure two episodes of induced pain rather than four. This 
new study design reduced the burden on the participants however it was not feasible to 
recruit enough participants required in the power calculation. This meant that the design 
restricted the evaluation of the effects of TENS. Rather than three TENS conditions (P-TENS, 
HF-TENS and LF-TENS) there was only enough time to recruit and compare two conditions. 
P-TENS was felt to be an essential component when investigating the effects of TENS.  When 
consulting the literature around TENS and experimental ischaemic pain, HF-TENS was more 
often found to be the most effective mode and thus chosen for use in this study.  
 
Ethical approval for the adjusted study design was obtained from the University Research 
Ethics Committee. The participants were randomised, using block randomisation, into either 
HF-TENS or P-TENS group. Each participant attended for one session that lasted 
approximately 2 hours where they completed two separate episodes of induced pain with 
the modified Submaximal Effort Tourniquet Test (mSETT).  One mSETT was with no 
intervention (baseline) and the other with either P-TENS or HF-TENS intervention. The order 
of entry into the two study interventions was alternated. Fifty per cent of the participants in 






Figure 8.1: Flow diagram of participant study progression 
 
8.3.2: Participants:  
Prospective participants were recruited by email advertisement from the University’s 
student population. Each participant received an information sheet (Appendix 4). Once each 
participant had read the information sheet and indicated that they were willing to take part 
in the study they were issued with an exclusion criteria questionnaire before providing 
written consent (Appendices 5 and 6). The exclusion criteria were reviewed at the testing 
session to ensure each participant understood the questionnaire and did not have any 
contraindications to electro stimulation and the mSETT. Participants were stratified by 
gender and then block-randomised to one of the two experimental groups.  
 
8.3.3: Procedure:  
The testing session followed the procedure as described in Chapter 7. However in this case 
the mSETT procedure was completed twice in the same testing session (Figure 8.1).  
  



















(n = 8)(n = 8)  (n = 8) (n = 8)
P-TENS Group (n = 16) HF-TENS Group (n = 16)
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8.3.4: TENS Procedure:  
A standard, single-channel TENS machine was used for all sessions (NeuroTrac 3 ™, Verity 
Medical Ltd, Surrey, UK). Placement sites were determined by the participant’s report of 
where they experienced pain during the familiarisation mSETT. These sites were prepared 
using an Alcowipe (Universal Hospital Supplies Ltd, UK) and a standard sharp/blunt skin 
sensation test using single use sterile Neurotips (Owen Mumford Ltd, Woodstock, Oxford, 
UK). A segmental electrode application was employed using self-adhesive carbon rubber 
electrodes measuring 5x5cm (PhysioMed PALS® electrodes, Glossop, UK). Electrodes were 
attached to the TENS unit via dedicated manufacturer leads. The placement sites were 
commonly over the gastrocnemius muscle belly (Figure 8.2), at least 2cm apart. The superior 
electrode was positioned so that it covered the superior edge of the pain described and the 
inferior electrode similarly so that it covered the inferior edge of the area of pain. The 
electrodes once in place, were covered by the elastic bandage used for desanguination and 
remained in place throughout the experimental procedure (Figure 8.3).  
 
 
Figure 8.2: Common electrode placement sites with one electrode immediately 
superior and one immediately inferior to the Gastrocnemius muscle belly on the 





Figure 8.3: The experimental set up including an example of the stimulation site s 
just visible beneath the elastic bandage  
 
The TENS machine was a portable dual channel device with an asymmetrical biphasic 
waveform, which was calibrated prior to use using a digital recording oscilloscope and 
tested manually by the examiner prior to each testing session. The stimulation parameters 
were selected based on those commonly used in clinical practice and identified as 
efficacious in the TENS literature (Chen et al 2008). The TENS unit was calibrated to 120Hz, 
200μs and patient determined intensity of “strong but comfortable”.  
 
The Placebo stimulation was achieved using the same TENS unit and programmed settings. 
However, a different lead was used with an undecipherable break in the wires, covered by 
electrical tape (Figure 8.4).  
 
This allowed the unit to be switched on and appear as if current was being applied but no 
current reached the participant. For the purpose of blinding, the participants were told that 
different dosages of TENS were being tested, some of which where the stimulation might 
not be perceivable even though the device is working (Roche et al 2002; Johnson and 





Figure 8.4: The wires used for HF-TENS and P-TENS stimulation 
 
8.3.5: Measures:  
Prior to the experiment, participants completed two questionnaires. Pain self-efficacy was 
measured using the Pain Self-Efficacy Questionnaire (PSEQ) (Nicholas 2007) and pain-related 
fear was measured using the Fear of Pain Questionnaire (FPQ) (McNeil and Rainwater III 
1998). The scores on these questionnaires were used to establish baseline parity between 
the groups and thus help limit the effects of these psychosocial variables on the reporting of 
pain intensity between the groups. 
  
Pain Threshold is defined as “the least experience of pain which a participant can recognise” 
(Merskey and Bogduk 1994). In the present study, it was defined to the participants as the 
time in seconds before “the moment discomfort turns to pain” and indicated by the 
participant saying, “pain now” (Melzack and Wall 1996; Roche et al 2002). Pain Tolerance is 
defined as “the greatest level of pain which a participant is prepared to tolerate” (Merskey 
and Bogduk 1994). For the purposes of the current study it was defined as the time in 
seconds before “the moment the participant reports that he/she is no longer able to 
tolerate the pain” and indicated by stating; “Stop” (Melzack and Wall 1996; Roche et al 
2002). Pain Endurance was computed as the time in seconds between pain threshold and 
pain tolerance (Roche et al 2002).  
 
Pain Intensity was measured using a 21-point Numerical Rating Scale (21-NRS): a numerical 
scale ranging from 0 to 20, with labels of “no pain” and “unbearable pain” respectively. The 













These ratings were at fixed, irregular intervals of 30, 35, 40, or 45 seconds. These intervals 
were irregular in sequence but the same in each test to allow comparison. The irregular 
intervals were used with the aim of blinding the participant to how long they had tolerated 
the pain. The recording asked them to “rate their pain on a scale of 0-20 where 0 represents 
no pain at all and 20 represents the point of unbearable pain”. The NRS has been found to 
be the superior method of rating pain intensity in terms of validity, reliability and practicality 
compared to VAS, box scales and verbal rating scales (Jensen et al 1986, Bolton and 
Wilkinson 1998).  The use of 21 levels provides the optimum sensitivity to changes in pain 
intensity (Jensen et al 1994).   
 
A McGill Pain Questionnaire (MPQ) was administered retrospectively, within 5 minutes of 
the participant reporting ‘pain tolerance’. The participant was asked to describe the pain 
they experienced at pain tolerance. The MPQ is valid and reliable in the laboratory setting 
(Klepac et al 1981) and can provide information regarding the pain qualities and intensity 
associated with different pain syndromes (Dubuisson and Melzack 1976; Jerome et al 1988; 
Katz and Melzack 1991; Dworkin et al 2009).  Pain Rating Index (PRI) scores from the MPQ 
were recorded and analysed as a measure of the sensory, reactive and overall nature of the 
ischaemic pain at the point of tolerance (Melzack 1975; Roche et al 1984).  
 
8.3.6: Statistical Analysis:   
All data are normally distributed and expressed as mean (standard error (SE)). A 2 x 2 
factorial repeated measures Analysis of Variance (ANOVA) was used to analyse the data for 
time to pain threshold, tolerance and pain endurance. Factors were TENS type (2 levels, P-
TENS/HF-TENS) entered as a between-subjects factor, and intervention (2 levels, no TENS/ 
TENS intervention) entered as a within-subjects factor. Independent student’s t-tests and 
graphs of mean values were used to examine direction of effects.  
 
Mean 21-NRS scores were analysed using a 2 x 18 factorial, repeated measures ANOVA to 
examine for any within-group effects of Intervention. Factors were intervention (2 levels, no 
TENS/TENS intervention) entered as a within subjects factor and time point (18 levels, every 
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NRS time point until all participants reached pain tolerance) entered also as a within-
subjects factor. Between-subjects effects of TENS on pain intensity were analysed by 
calculating difference scores for 21-NRS (i.e. variation from baseline) for all participants as a 
method of standardising inter-participant variability (Foster et al 1996). To achieve this, 
participants 21-NRS score at baseline was subtracted from that with HF-TENS or P-TENS for 
each time point during the mSETT. Group means of these difference scores are presented in 
graphical format and analysed using a one-way ANOVA.  
 
Pain Quality, measured by the PRI of the MPQ, was also analysed using a 2 x 2 factorial, 
repeated measures ANOVA. Again, time point (2 levels, pre/post intervention) was entered 
as a within-subjects factor and group (2 levels, P-TENS/HF-TENS) as a between-subjects 
factor. The full analysis plan is detailed in Figure 8.5 to aid clarity.  
 










8.4: RESULTS:  
The participants were 32 healthy volunteers (18 male, mean age 28 years, range 19-47) 
without previous experience of TENS or any known pathology that could cause pain. During 
testing, 1 participant dropped out and 4 were excluded from analysis. The dropout was due 
to not wishing to continue with the experiment and the exclusions from analysis were due 
to not understanding and completing the experimental instructions correctly. Two 
participants were from the P-TENS group and no further volunteers were recruited. Figure 
8.6 summarises this information and displays the progress of participants through the study.  
 
 
Figure 8.6: CONSORT diagram displaying the progression of participants through the 
study. 
 
A total of 27 healthy volunteers were included in the analysis (16 male; mean age 27 years, 
range 19-47). Groups were similar in terms of demographic data, psychosocial measures and 




Table 8.1: Mean (SE) baseline data for all participants. p value represents result of 




p value  P-TENS HF-TENS 
Age (years) 26.9 (1.14) 25.5 (0.97) 28.2 (1.99) 0.242 
BMI (kg/m2) 24.1 (0.49) 23.9 (0.66) 24.3 (0.75) 0.702 
HR (bpm) 67.9 (1.66) 67.0 (2.29) 68.9 (2.45) 0.586 
BP (sys) (mmHg) 121.5 (1.47) 120.2 (2.22) 122.6 (1.97) 0.423 
PSEQ 21.0 (2.27) 19.5 (3.32) 22.4 (3.18) 0.535 
FPQ 85.37 (3.70) 87.4 (7.27) 83.50 (2.65) 0.623 
Pain Threshold (secs) 125.4 (4.61) 129.0 (6.22) 122.1 (6.86) 0.635 
Pain Tolerance (secs) 396.3 (16.36) 407.5 (26.30) 386.0 (20.55) 0.299 
Pain Endurance (secs) 270.9 (14.73) 278.5 (24.82) 263.9 (17.36) 0.310 
 
8.4.1: Pain Intensity:  
8.4.1.1: Pain Threshold, Tolerance and Endurance:  
Table 8.2 details the time taken for participants to report pain threshold and pain tolerance 
and the calculated pain endurance in both groups. These measures are shown with no 
intervention (baseline) and with TENS intervention.  
 
Table 8.2: Mean (SE) time (secs) to pain threshold, pain tolerance and pain 
endurance for both groups with TENS and with no intervention (baseline) 
  Baseline Intervention 
P-TENS Group Pain Threshold 129.0 (6.2) 132.9 (5.8) 
 Pain Tolerance  407.5 (26.3) 450.9 (27.8) 
 Pain Endurance  278.5 (24.8) 318.1 (25.7) 
HF-TENS Group Pain Threshold 122.1 (6.9) 151.4 (8.9) 
 Pain Tolerance  386.0 (20.6) 585.0 (30.4) 




A two-way Analysis of Variance (ANOVA) was conducted to examine the effect of 
intervention (no TENS versus TENS) and TENS type (P-TENS versus HF-TENS) on the 
measures of pain threshold, tolerance and endurance.  
 
The dependant variables were normally distributed for the groups formed by the 
combination of the intervention and TENS type as assessed by the Shapiro-Wilk test. There 
was homogeneity of variance between groups as assessed by Levene's test for equality of 
error variances. Results are reported with a measure of effect size, partial eta-squared (ηp
2).  
 
A significant effect of intervention was observed for time to pain threshold (F (1,25) = 
16.304, p < 0.001, ηp
2 = .395), time to pain tolerance (F (1,25) = 37.681, p < 0.001, ηp
2 = .601) 
and pain endurance time (F (1,25) = 33.166, p < 0.001, ηp
2 = .570) (Figures 8.7-8.9). This 
indicates that these measures of pain intensity change with TENS intervention (P-TENS 
and/or HF-TENS).  
 
The interaction between intervention and TENS type was found to be significant for time to 
pain threshold (F (1,2) = 6.865, p = 0.015, ηp
2 = .215), time to pain tolerance (F (1,25) = 
14.586, p = 0.001, ηp
2 = .368) and pain endurance (F (1,25) = 12.662, p = 0.002, ηp
2 = .336) 
(Figures 8.7-8.9). This indicates that one group changed over time to a greater extent than 
the other for each measure. No significant effects were found for TENS type alone.  
 
Independent student’s t-tests examining for differences between the groups found no 
difference at baseline or with intervention for time to pain threshold. Significant differences 
were found between groups with intervention for time to pain tolerance and endurance (t 





Figure 8.7: Mean time taken to report pain threshold at baseline and with 
intervention in both groups. Change from baseline with intervention was significant 
for both groups. Error bars represent 95% confidence intervals.  
 
 
Figure 8.8: Mean time taken to report pain tolerance at baseline and with 
intervention in both groups. Change from baseline with intervention was significant 
for both groups. However, change with HF-TENS was greater than that with P-TENS. 





Figure 8.9: Mean pain endurance at baseline and with intervention in both groups. 
Change from baseline with intervention was significant for both groups. However, 
change with HF-TENS was greater than that with P-TENS. Error bars represent 95% 
confidence intervals. 
 
8.4.1.2: 21-NRS Scores:  
Figures 8.10-12 display the 21-NRS scores recorded during the mSETT. Mean scores are 
shown for both groups at baseline (Figure 8.10), with intervention (Figure 8.11) and the 
mean difference scores (Figure 8.12). A common pattern of increasing pain intensity over 
time was observed in both groups with no intervention (Figure 8.10). All participants 
reached pain tolerance by time point 12 (9 minutes). There were no differences between 
the groups at any time point.  
 
Figure 8.11 details the mean pain intensity with HF-TENS and P-TENS interventions. All 
participants in the P-TENS group had reached pain tolerance by 11 minutes and all 
participants in the HF-TENS group had reached pain tolerance by 13 minutes (Figure 8.11) 
Mean scores at each time point were compared with baseline using one-way, repeated 
measures ANOVA. For P-TENS, no differences between the reported pain intensity were 
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found. Mean 21-NRS scores were significantly reduced with HF-TENS however from the 6th 
to the 10th minutes (p < .05).  
 
Both HF-TENS and P-TENS groups showed a mean reduction in pain intensity, as indicated by 
the negative values in Figure 8.12. Apart from the 3rd minute, participants in the HF-TENS 
group reported a greater reduction throughout pain duration compared with P-TENS. Scores 
with HF-TENS intervention were significantly lower in the 4th minute and from the 6th to the 








Figure 8.10: Mean 21-NRS scores during baseline mSETT with no intervention.  There were no differences between the groups at 









Figure 8.11: Mean 21-NRS scores during intervention mSETT in A) the HF-TENS and 
B) the P-TENS groups. No significant changes from baseline were observed at any 
point in the P-TENS group. Mean 21-NRS scores were significantly lower than 
baseline from minute 6 to 10 in the HF-TENS group  







Figure 8.12: Mean individual change in 21-NRS scores throughout the mSETT in both groups. Change with HF-TENS was greater 
than with P-TENS in the 4th minute and then from the 6 th to the 9th minute. Significant differences between groups indicated by * 




8.4.2: Pain Quality:  
Table 8.3 details the Total PRI (TPRI), Sensory PRI (SPRI) and Reactive PRI (RPRI) scores in the 
P-TENS and HF-TENS groups. PRI scores are shown with no intervention (Baseline) and with 
TENS intervention (TENS).  
 
Table 8.3: Mean (SE) PRI scores for both groups with placebo and with TENS 
intervention.  
  Baseline TENS 
P-TENS Group TPRI 27.4 (2.2) 23.2 (1.8) 
 SPRI 15.9 (1.3) 13.4 (1.0) 
 RPRI 11.5 (1.1) 9.80 (1.0) 
HF-TENS Group TPRI 30.9 (3.2) 24.6 (2.9) 
 SPRI 19.2 (1.7)  15.1 (1.8) 
 RPRI 11.7 (1.7) 9.50 (1.4) 
 
A two-way ANOVA was conducted that examined the effect of intervention (no TENS versus 
TENS) and TENS type (P-TENS/HF-TENS) on PRI scores. The dependent variable, PRI score, 
was normally distributed for the groups formed by the combination of the intervention and 
TENS type as assessed by the Shapiro-Wilk test. There was homogeneity of variance 
between groups as assessed by Levene's test for equality of error variances. Results are 
reported with a measure of effect size, partial eta-squared (ηp
2).  
 
A significant effect of intervention was observed for TPRI scores (F (1,25) = 11.829, p = 
0.002, ηp
2 = .321), SPRI scores (F (1,25) = 10.644, p = 0.003, ηp
2 = .299) and RPRI scores (F 
(1,25) = 6.871, p = 0.015, ηp
2 = .216). This indicates that all PRI scores changed over time 
with TENS intervention (P- and/or HF-TENS).  
 
No significant effects were found for the interaction of intervention and TENS type of TPRI, 
SPRI or RPRI scores (F (1,25) = 0.223, p = 0.641, ηp
2 = .009; F (1,25) = 0.896, p = 0.353, ηp
2 = 
.035 and F (1,25) = 0.038, p = 0.847, ηp
2 = .002 respectively). These results indicate that 
neither group changed over time to a greater extent than the other. No significant effect of 
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TENS type on TPRI, SPRI or RPRI was found (F (1,25) = 0.729, p = 0.401, ηp
2 = .028; F (1,25) = 
1.714, p = 0.202, ηp
2 = .064 and F (1,25) = 0.053, p = 0.820, ηp
2 = .002 respectively).  
 
Figures 8.13-15 display the mean PRI scores in both groups over time. TPRI scores with 
intervention (HF and P-TENS) were lower than at baseline (mean difference, 5.55; 95% CI, 
2.23-8.87; p = 0.002) (Figure 8.13). The same was true for SPRI (mean difference, 3.22; 95% 
CI, 1.19-5.25; p = 0.003) and RPRI (mean difference, 2.33; 95% CI, 0.50-4.16; p = 0.015) 
(Figures 8.14 and 8.15).  
 
 
Figure 8.13: Mean TPRI scores at baseline and with intervention in both groups. 
Change from baseline with intervention was significant for both groups. No 
differences were found between the groups (two-way repeated measures ANOVA). 






Figure 8.14: Mean SPRI scores at baseline and with intervention in both groups. 
Change from baseline with intervention was significant for both groups. No 
differences were found between the groups (two-way repeated measures ANOVA). 
Error bars represent 95% confidence intervals.  
 
 
Figure 8.15: Mean RPRI scores at baseline and with intervention in both groups. 
Change from baseline with intervention was significant for both groups. No 
differences were found between the groups (two-way repeated measures ANOVA). 
Error bars represent 95% confidence intervals.  
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8.5: DISCUSSION:  
This experiment used a novel mSETT methodology to induce ischaemic pain in the lower 
limb. The results indicate that both High Frequency TENS (HF-TENS) and Placebo TENS (P-
TENS) reduced pain compared to no intervention. However, when compared to P-TENS, HF-
TENS delayed pain perception and pain tolerance for longer; and lowered pain levels to a 
greater extent, over a longer period of time. HF-TENS therefore had a greater impact on 
several aspects of the mSETT-induced pain experience than P-TENS.  
 
HF-TENS is proposed to act by activating large diameter mechanoreceptors (Aβ-fibres), delta 
(δ)-opioid receptors and increasing gamma-Aminobutyric acid (GABA) in the dorsal horn of 
the spinal cord (Sluka and Walsh 2003; DeSantana et al 2008; Chen and Johnson 2011). This 
mechanism of action is associated with immediate, localised, segmental inhibition as 
conceived by the original gate control theory (Melzack and Wall 1965; Andersson 1979; 
Sluka and Walsh 2003). It is these mechanisms that appear to explain the hypoalgesic 
effects of HF-TENS observed in this study. As highlighted in Figure 8.7, HF-TENS had an 
immediate effect. The mean delay in the initial perception of pain in the HF-TENS group was 
29.3 seconds, representing a 24% increase from baseline. Once pain was perceived, HF-TENS 
reduced the severity of the pain and increased the time it took participants to reach and 
report pain tolerance by an average of 199.0 seconds, an increase of 52% compared to 
baseline. The effect of the delay in pain threshold and pain tolerance, and the reduction of 
pain intensity between these two points, was to extend pain endurance by 163.7 seconds 
i.e. 64% longer than baseline.  These data, as shown in Figures 8.7-9, indicate an inhibition 
of the perception of pain initially at pain threshold, during the minute-by minute endurance 
of pain, and at the point of pain tolerance i.e. at three key points across the induced 
ischaemic pain experience in volunteers.   
 
Figure 8.10 represents the level of pain being experienced without any intervention. Lower 
limb induced ischaemic pain increased steadily and gradually over time, in both groups. 
When interventions were applied (Figure 8.11 and 12), the P-TENS group reported mild 
reductions in mean pain scores throughout the period of induced pain. In contrast, HF-TENS 
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showed a more extreme dip and longer lasting reduction of mean pain scores over time. The 
reduction of mean pain intensity with HF-TENS was significantly lower than that with 
placebo at seven points throughout the pain experience. Furthermore, as shown in Figures 
8.10 and 12, the reduction in mean pain scores with HF-TENS was greatest when pain 
intensity would normally have reached its highest levels had TENS not been applied i.e. from 
the 6th to the 9th minutes. These results suggest that spinal gating inhibition is strong over a 
relatively short period. It is nevertheless gradually overcome when there is on-going 
nociceptive input, in this case from cuff-induced ischaemia, occurring over an average pain 
endurance of 432.5 ± 26.4 seconds (approximately 7 minutes) (Figures 8.11 and 8.12).  
 
Table 8.3 shows the mean MPQ scores of intolerable pain reported retrospectively by 
participants completing their Baseline and TENS trials. Significant reductions in Sensory pain 
from HF-TENS, and in Sensory and Reactive pain from P-TENS contributed to significantly 
lower Total MPQ scores of intolerable pain in both groups (Table 8.3 and Figures 8.13-15). 
The application of both a placebo and active TENS (HF-TENS) appears to have lowered the 
level of participants’ tolerance for pain. Figure 8.12 shows that pain intensity was modified 
in both HF-TENS and P-TENS conditions during the first two-thirds of the period of pain 
endurance. The pain returned however to higher levels during the latter one-third. In the 
case of HF-TENS, there was resurgence in pain intensity over the latter 2-3 minutes. This 
suggests that the TENS-induced inhibition ceased to be effective. Participants in the HF-
TENS condition may have found the resurgence of pain following a period of relatively mild 
pain to be intolerable, sooner than was the case in their baseline condition. Only sensory 
pain scores were significantly reduced in the HF-TENS condition resulting in significant 
reduction in the HF-TENS Total PRI (Table 8.3). This result suggests that pain reduction with 
HF-TENS was founded on a reduction in sensory perception of noxious input, supporting the 
hypothesis of spinal and/or peripheral inhibition.  
 
Participants in the P-TENS group experienced considerably less of a drop, and resurgence, of 
pain than did the HF-TENS group. P-TENS pain levels dipped only slightly over the first 6 
minutes of ischaemic pain. They then remained at the same level for several minutes, a level 
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that was reported as intolerable (Figure 8.12). It was suggested to participants with P-TENS 
that they were being given a real treatment for their pain. The significant reduction in both 
their Sensory and Reactive MPQ scores with P-TENS suggest a significant placebo effect, 
involving psychologically driven, physiological mechanisms of pain relief (Roche et al 1984; 
Amanzio and Bendetti 1999; Amanzio et al 2001; Roche et al 2002). Both sensory and 
reactive pain scores from the MPQ were reduced with P-TENS. This resulted in an overall 
reduction in PRI scores and supports the psychologically driven physiological mechanisms of 
placebo hypoalgesia (Amanzio et al 2001).  
 
Overall, the results suggest that both physiological and psychological mechanisms of pain 
inhibition were activated by the application of TENS in this laboratory study. However, HF-
TENS was found to be more effective.  
 
The results of this experimental study using mSETT are in line with the previous results 
indicating delayed perception of pain and modified pain scores in induced lower limb 
ischaemic pain (Roche et al 2007). The effect of HF-TENS on the mSETT method therefore 
appears to be replicable using this methodology. Furthermore, HF-TENS in both upper limb 
and lower limb induced ischaemic pain, delays pain tolerance (Woolf 1979; Roche et al 
1984) and decreases pain intensity as measured with linear pain scales (Woolf 1979; Roche 
et al 1984; Johnson and Tabasam 2003; Chen and Johnson 2011). A recent study (Chen and 
Johnson 2011) showed that HF-TENS (vs. LF and Placebo TENS) reduced pain intensity during 
the first 2 minutes of induced upper limb ischaemic pain. This study is the first to report 
results of TENS on lower limb induced ischaemic pain and it shows initial and extending 
reductions of pain intensity over several more minutes than do Chen and Johnson (2011) for 
upper limb pain. These results, shown over approximately 12 minutes of testing suggest a 
potential utility of TENS for clinical ischaemic pain in the lower limb.  
 
8.6: CONCLUSIONS:  
The modified Submaximal Effort Tourniquet Test (mSETT), used to induce lower limb 
ischaemic pain gave a detailed picture of the ischaemic pain curve, and its inhibition in 
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healthy volunteers. HF-TENS modified three key aspects of the ischaemic pain experience 
over time: pain threshold, pain tolerance and pain endurance. HF-TENS also reduced pain 
intensity measured with a numerical pain scale during ischaemia. Interestingly it also 
lowered the psychological point at which participants reported pain intolerance as 
measured with an MPQ. This preliminary study on lower limb induced ischaemia showed 
that HF-TENS had both physiological and psychological effects.  
 
8.7: CHAPTER 8 SUMMARY: 
TENS is a possibly useful, yet untested adjunctive intervention for IC pain. Prior to 
investigation in clinical populations, it is important to study the effects of TENS on a pre-
clinical model of IC pain. The mSETT has been developed to possibly fulfil this role as it 
induces ischaemic pain in the lower limb of healthy volunteers. The aim of this chapter was 
to describe the investigation of TENS for pain induced by the mSETT.  
 
HF and P-TENS were applied to the calf of volunteers undergoing the mSETT. Both 
applications of TENS were found to increase the time taken to report pain threshold, pain 
tolerance and pain endurance. There was no difference between the interventions for time 
to pain threshold but HF-TENS was found to increase time to pain tolerance and endurance 
greater than P-TENS. HF-TENS was also found to decrease pain intensity to a greater extent 
than P-TENS between the 3rd to the 9th minutes.  
 
These findings indicate that TENS is effective at reducing laboratory-induced, lower limb 
ischaemic pain. This finding adds weight to the proposition that TENS may be an effective 
intervention for IC pain. The next chapter examines this proposition by investigating the 





CHAPTER 9: EXPERIMENT THREE - THE EFFECTS OF TENS ON PAIN 
AND WALKING PERFORMANCE IN PATIENTS WITH PAD AND IC 
9.1: AIM OF CHAPTER 9:  
A aim of this thesis is to investigate the hypoalgesic effects of TENS on lower limb ischaemic 
pain and walking performance in patients with IC. Chapters 7 and 8 have established a 
reliable method for inducing ischaemic pain in the lower limb of healthy volunteers and 
examined the hypoalgesic effects of TENS on this induced pain. These studies form the 
important pre-clinical investigation of TENS as a possible intervention for IC and TENS has 
been found to have hypoalgesic effects on ischaemic pain induced in the laboratory.  
 
Prior to being confirmed as a useful clinical intervention for patients with PAD and IC, the 
effects of TENS on clinical IC pain must be examined. Also, the potential for the main 
different types of TENS to maximally affect pain and function must be investigated. This 
chapter aims to describe a pilot investigation of the effects of two different stimulation 
patterns of TENS on measures of pain and walking performance in patients with PAD and IC.  
 
9.2: POWER CALCULATION:  
As this was designed as a MRC phase IIa, ‘proof of concept’ trial, the sample size was set 
prior to the power calculation. The sample size of 40 participants in two groups (20 per 
group) at 80% power and a two-tailed 5% significance level could detect a large effect (≥ 0.8; 
(Cohen 1988)) between each of the TENS groups and placebo TENS control group using 
repeated measures ANOVA.  
 
9.2.1: Clinically Significant Difference:  
A 60% improvement in ACD has been quoted as a worthwhile improvement in walking 
distance (Oakley et al 2008). As TENS has not been tested on IC pain, there is no evidence 
that it may achieve this worthwhile increase. However, in laboratory studies of the effects of 
TENS on experimentally induced ischaemic pain, a 50-70% reduction in time to pain 
threshold and pain tolerance has been demonstrated (Roche et al 1984; Chen and Johnson 
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2011). If this effect of TENS on experimental ischaemic pain transfers to an improvement in 
walking performance in the clinical population, it will be a worthwhile intervention.  
 
9.3: METHODS:  
9.3.1: Design:  
Ethical approval for the study was obtained from the local National Health Service Research 
Ethics Committee (Tayside Committee on Medical Research Ethics B). The study design is an 
experimental, patient-concealment, placebo-controlled, MRC phase IIa, ‘proof-of-concept’ 
trial. The participants were randomised, using block randomisation, into either HF-TENS or 
LF-TENS group (Appendix 7). Each participant attended for two sessions at least 24 hours 
apart and lasting approximately two hours each time. A treadmill protocol (Gardner et al 
1991) was completed by the participant at each session, the first with the TENS intervention 
and secondly with P-TENS (Figure 9.1). The order of the sessions was not randomised 
because of the training effect of the treadmill test (Gardner et al 1991). In the current study, 
the active TENS condition was conducted first so that any increase in walking distance 
compared to P-TENS condition might be attributed to TENS.   
 
9.3.2: Participants:  
Prospective participants with stable PAD and IC, who met the study inclusion and exclusion 
criteria, were recruited from the vascular outpatient clinic at Ninewells Hospital, Dundee. 
Each participant received an information sheet and ‘opt-in’ slip (Appendix 8). If they were 
willing to take part in the study, they returned the ‘opt-in’ slip and were contacted to 
arrange the testing sessions. At the first testing session, the exclusion criteria were reviewed 
with the participant before providing written consent (Appendix 9). Figure 9.2 displays the 
common clinical journey of patients with PAD and IC and the relationship with the current 










Figure 9.2: A flow diagram illustrating the relationship between the normal patient 
journey and that of the current study. The normal clinical journey of a patient with 
PAD and IC at the centre where the study participants were recruited is shown on 
the left. In grey, the current study journey. 
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9.3.2.1: Inclusion and Exclusion Criteria:  
The inclusion and exclusion criteria reflect that used currently in the TENS and PAD 
literature and helps to ensure the safety of the participants in the study (McDermott et al 
2009; Chen and Johnson 2011).  
Inclusion:  
 Clinical diagnosis of PAD and stable IC of more than 3 months duration  
 Fontaine stage II 
 Resting ABPI less than 0.90 in at least one leg  
 Walking limited only by claudication 
 Independent and safe mobility (no walking aids) 
 Cognitively stable and able to follow instruction (MSQ 10/10, MMSE 30/30)  
Exclusion:  
 Less than 40 years of age  
 Planned surgical or endovascular intervention for PAD 
 Any leg ulceration  
 Any Exercise-limiting co-morbidities e.g. congestive cardiac failure, angina, 
dyspnoea, MSK or neurological impairment  
 Co-morbidities causing pain in the lower limb  
 Ataxic gait or history of increased falls (unsafe for treadmill walking)  
 MI ≤6 months ago, Cardiac arrhythmia or Cardiac pacemaker 
 Current or previous sensation abnormalities in the lower limbs e.g. severe peripheral 
neuropathies 
 Cognitive deficits  
 Epilepsy 
 Medical diagnosis or self-reported psychiatric illness 
 Previous experience of using TENS  




9.3.3: Procedure:  
The first testing session, lasting approximately 2 hours, is divided into six sections (Figure 
9.3). The second testing session, lasting approximately 1 hour, follows the same procedure 
as the first session without steps 2 and 3 (Figure 9.4). Each step of the procedure will now 
be described in more detail.  
 
 
Figure 9.3: First testing session procedure  
 
 




9.3.3.1: Cardiac Assessment:  
Prior to the start of the testing session, a vascular medicine specialist undertook a cardiac 
assessment. The participant’s heart was assessed by auscultation and if any abnormalities 
were evident, the participant was excluded from the study.   
 
9.3.3.2: Initial Interview and Descriptive Data:  
An initial interview was conducted between the participant and the researcher. The study 
procedure was explained in detail and any questions addressed by the researcher.  
 
Each participant completed four short questionnaires (Appendix 10):  
1. Walking Impairment Questionnaire (Regensteiner et al 1990)  
2. Pain Self-Efficacy Questionnaire (Nicholas 2007)  
3. Pain Catastrophising Scale (Sullivan et al 1995)  
4. Tampa scale of Kinesiophobia (Miller et al, 1991 (unpublished); Vlaeyen et al 1995) 
 
These questionnaires aimed to provide data on walking impairment (1), and psychosocial 
factors including fear of pain (2), pain self-efficacy (3) and pain catastrophising (4). These 
questionnaires were chosen as they have all been shown to be valid and appropriate 
measures in a clinical population and they provide a good indication of the psychosocial 
aspects of PAD and IC.  
 
9.3.3.3: Familiarisation Session:  
A familiarisation session was completed as per the Gardner Treadmill Protocol (Gardner et 
al 1991) (Appendix 11). The participant was connected to a 12-lead Echocardiograph (12-
lead ECG) (GE CASE Premium Stress System), which recorded continuously throughout the 
procedure. The treadmill protocol was explained and the participant practiced walking on 





The self-report method of rating claudication symptoms was explained (1-5 scale where 
1=None; 2=Onset; 3=Mild; 4=Moderate and 5=Severe, relating to symptoms of 
claudication). Further safety instructions were also issued: the participants were reminded 
to report any feelings of pain separate from claudication and any feelings of dizziness/light-
headedness immediately so that the test can be stopped. This series of events took less than 
10 minutes to complete and the participant walked for a maximum of 30 seconds at each 
treadmill speed.  
 
9.3.3.4: Rest Period and ABPI:  
A rest period was then observed where the participant lay on a hospital bed in the testing 
room for 15 minutes. During this period, the participant’s Ankle Brachial Pressure Index 
(ABPI) was measured using a handheld Doppler probe (Huntleigh Doppler D9000). Systolic 
blood pressures were measured in the right and left brachial, dorsalis pedis and posterior 
tibial arteries (McDermott et al 2006). The ABPI was calculated by dividing the mean of the 
dorsalis pedis and posterior tibial pressures in each leg by the mean of the brachial 
pressures. Five minutes prior to the end of the rest period the TENS machine was applied to 
the participant’s calf and switched on.  
 
9.3.3.5: Gardner Treadmill Test:  
The participant was helped onto the treadmill and the treadmill protocol commenced. This 
method requires the participant to walk at a normal pace on a treadmill. As the test 
proceeds, the gradient of the treadmill will increase by two degrees every two minutes. 
However, there is no increase in speed. The participant is asked to report when they reach 
their Initial Claudication Distance (ICD) i.e. when they first experience claudication 
symptoms. The participant then continues to walk until they report that they have reached 
their Absolute Claudication Distance (ACD) i.e. they cannot walk any further due to 
claudication symptoms. The treadmill is then stopped and the participant helped onto a bed 




Functional Claudication Distance (FCD) is another measure used with the Gardner Protocol 
(Kruidenier et al 2009b; Nicolaï et al 2010). The principle is that patients with PAD and IC 
rarely walk to ACD daily. It has been found that they have a ‘Functional Claudication 
Distance’ (FCD), a level of pain at which they stop walking. This measure was explained to 
each participant and they were asked to indicate when they reached the point at which they 
would normally stop during the treadmill protocol. This allows the effects of the different 
types of TENS to be examined on a measure that is more relevant to the participant’s daily 
function.  
 
Once the participant reported ACD or 20 minutes of walking was completed, the treadmill 
was stopped, the participant is helped back to the bed and the TENS machine switched off.  
 
Validity and Reliability:  
The Gardner treadmill protocol is the most commonly used and validated method of 
inducing clinical ischaemic pain in patients with PAD (Kruidenier et al 2009b). Treadmill 
testing is the gold standard of measuring walking performance in patients with PAD 
(Coughlin et al 2006; Le Faucheur et al 2008).  
 
In terms of reliability, test-retest intra-class reliability coefficients (ICC) between R = 0.89 
and 0.95 have been found for ACD (Gardner et al 1991; Nicolaï et al 2009b). In a recent 
meta-analysis, Nicolaï et al (2009b) examined the reliability of treadmill tests in patients 
with PAD. They compared studies that had investigated the reliability of either constant or 
graded (Gardner) treadmill protocols and used ICD and ACD as outcome measures. Eight 
studies were included of 658 patients. The ICC for ICD indicated that the two protocols were 
equally reliable although for ACD, the Gardner protocol is significantly more reliable with an 
ICC of 0.95 compared to that with constant protocol of between 0.76-0.91 (Nicolaï et al 
2009b). There have been no further investigations of the reliability of the Gardner treadmill 




9.3.3.6: MPQ:  
Pain quality was recorded using a retrospective MPQ (Melzack 1975) administered 5 
minutes after the participant completed the treadmill protocol. The MPQ consists of a 
vocabulary of adjectives from which the participant chooses appropriate words to describe 
the particular qualities of IC pain sensation and accompanying feelings of distress and 
intrusion (Melzack 1975; Dworkin et al 2009).  
 
9.3.4: TENS Procedure:  
The TENS machine was applied 5 minutes prior to each treadmill test and continued 
throughout the procedure. Each participant received one type of active TENS (HF-TENS or 
LF-TENS) during their first treadmill test. On the second treadmill test, all participants 
received P-TENS as a control.  
 
A standard TENS machine was used (NeuroTrac 3 ™, Verity Medical Ltd, Surrey, UK). 
Placement sites were determined from the report of the participants, relating to where they 
usually experience IC pain when walking. These sites were prepared using an Alcowipe 
(Universal Hospital Supplies Ltd, UK) and standard sharp/blunt skin sensation testing was 
completed over the area using single use sterile Neurotips (Owen Mumford Ltd, Woodstock, 
Oxford, UK). A segmental electrode application was employed using self -adhesive carbon 
rubber electrodes measuring 5x5 cm (PhysioMed PALS® electrodes, Glossop, UK). The 
placement sites were commonly over the gastrocnemius muscle belly, at least 2cm apart. 
The superior electrode was positioned so that it covered the superior edge of the pain 
described and the inferior electrode similarly so that it covered the inferior edge of the area 
of pain. The electrodes were attached to the TENS unit via the dedicated manufacturer 
leads.  
 
The TENS machine was a portable dual channel device with an asymmetrical biphasic 
waveform, which was calibrated prior to use using a digital oscilloscope and tested manually 
by the examiner prior to every testing session. The stimulation parameters were selected 
based on those commonly used in clinical practice and identified as efficacious in the TENS 
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literature (Chen et al 2008). The TENS unit was calibrated to 120Hz, 200μs and patient 
determined intensity of “strong but comfortable” for the HF-TENS stimulation. For LF-TENS, 
the unit was calibrated to 2Hz, 200μs and patient determined intensity of “strong but 
comfortable and slight muscle twitch”.   
 
The Placebo stimulation was achieved using the same TENS unit and programmed settings. 
However, a different lead was used with a break in the wires, covered by electrical tape with 
the aim of making it inconspicuous (Figure 7.13). This allowed the unit to be switched on 
and appear as if current was being applied. This was checked and confirmed with the use of 
an oscilloscope as above. For the purpose of blinding, the participants were told that 
different ‘dosages’ of TENS were being tested and that some of these dosages, stimulation 
might not be perceivable.  
 
9.3.5: Statistical Analysis:  
Figure 9.5 summarises the analysis procedures followed. The mean scores for ICD, FCD and 
ACD were positively skewed (0.930 to 1.615) and showed heteroscedascity (p < 0.05 
Levene’s test i.e. increasing variance in SD). Therefore, a log (10) transformation was applied 
to normalise the data. However, transformation did not address the variance within the 
data and thus non-parametric statistics were used to analyse the data.  
 
Wilcoxon Signed Ranks tests were used to examine for within group differences in treadmill 
measures. Individual changes in ICD, FCD and ACD between P-TENS and Active TENS were 
calculated for each participant. Distance walked with P-TENS was subtracted from that with 
Active TENS. The median was then calculated for each group and used for analysis using 
Mann-Whitney U tests. Individual percentage change was also calculated for ICD, FCD and 
ACD. The difference between the two sessions was calculated as a percentage of the 
distance walked with P-TENS. These percentages were employed as a method to examine 
the effect of TENS on walking distance, regardless of baseline ability. For each group, the 
median percentage change was calculated. These values were used for analysis and 
differences between groups examined with Mann-Whitney U tests. Wilcoxon signed ranks 
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tests were also used to examine for differences in PRI score within the groups and Mann-
Whitney U tests were employed to examine for any changes between groups.  
 
The data were then pooled in an effort to examine the overall effects of the application of 
TENS. Data for all participants with Placebo TENS was compared to those with Active TENS 
using Wilcoxon Signed Ranks tests.  
 
Interrelationships between measures were analysed using bivariate Spearman’s correlation 
coefficients. Treadmill measures with placebo TENS were taken as ‘baseline’ data and 
analysed for any relationships with demographic variables. The same analysis was used to 
examine the relationships between measures with TENS intervention, termed 
‘experimental’ measures.  
 
Multiple linear regression analyses were used to investigate the predictors of 1) Baseline 
ACD and 2) Change in ACD (ΔACD). Similar to the method employed by Kruidenier et al 
(2009a) the simultaneous (‘enter’) method was used to add all pre-selected variables into 
the regression analysis in one step. A maximum of eight predictor variables was set to 
reduce the possibility of Type I or II errors (Topliss and Costello 1972; Todeschini et al 2004). 
Included in the models were the factors reported in published literature as the best 
predictors of walking distance in patients with PAD and IC (ABPI, BMI and WIQ) (McDermott 
et al 1999; Kruidenier et al 2009a). Added to the models were any additional variables found 
to correlate most closely with ACD and ΔACD in the current study (PSEQ and Change in TENS 
intensity (ΔmA) respectively).  
 
Statistical significance was set at p = 0.05 (two-tailed) and analysis was performed using 











9.4: RESULTS:  
9.4.1: Participants:  
The participants were 40 patients with PAD and IC without previous experience of TENS or 
other exercise limiting pathologies. They were recruited by the principal researcher via oral 
explanation of the study at the claudication clinic. Four participants were excluded from 
analysis due to non-completion of the experimental procedure. Three had exercise-limiting 
co-morbidities and one was unable to walk safely on the treadmill. Thirty-six participants 
were included in the analysis (29 male, mean age 70 years, range = 54-87 years). Figure 9.6 
summarises this information and displays the progress of participants through the study.  
 
 
Figure 9.6: CONSORT diagram displaying the progression of participants through the 
study. 
 
Demographic data for the participants are detailed in Table 9.1. The high BP and ABPI 
recordings were due to diabetes-related incompressible vessels and inaccurate blood 
pressure readings. The disease-specific functional measure (WIQ) is representative of PAD 
patients with Fontaine Stage II Claudication (Nicola et al 2009a). The scores recorded with 
the psychosocial measures (PSEQ, PCS and TSK) were similar to those reported in patients 
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with chronic pain conditions (van Damme et al 2002; Nicholas et al 2008; Roelofs et al 
2011).  
 
Table 9.1: Demographic and baseline data for all participants included in the study. 
The p values stated relate to independent student’s t-tests (two tailed) of the group 
values.  
 All HF-TENS Group LF-TENS Group  
 Mean SD Min Max Mean SE Mean SE p value 
Age (years) 70 8.0 54 87 68 1.8 71 1.9 0.344 
BMI (kg/m2) 28 4.2 22 39 29 1.0 27 1.0 0.261 
HR (bpm) 71 9.4 53 94 71 2.0 71 2.4 0.986 
BP (mmHg) 146 18.1 110 202 147 5.2 146 3.2 0.943 
ABPI (AU) .63 .164 .24 .99 .70 .041 .57 .031 0.020* 
WIQ (%) 48 19.5 6 91 50 4.9 45 4.3 0.482 
PSEQ (0-60) 40 12.5 10 60 40 2.7 41 3.2 0.714 
PCS (0-52) 12 12.1 0 40 13 3.0 11 2.7 0.588 
TSK (17-68) 38 7.9 25 54 39 1.6 37 2.1 0.418 
ICD (m) 86 51.7 22 271 85 15.5 88 8.1 0.867 
FCD (m) 202 127.1 70 545 222 32.4 182 27.4 0.351 
ACD (m) 259 169.2 99 806 268 39.4 250 41.4 0.750 
PRI (0-78) 21 7.9 2 38 20 1.9 23 1.8 0.219 
 
Table 9.1 Key:  
BMI = Body Mass Index  
HR = Heart Rate  
BP = Systolic Blood Pressure  
ABPI = Ankle Brachial pressure Index (measured in arbitrary units (AU))  
WIQ (%) = Walking Impairment Questionnaire 
PSEQ (0-60) = Pain Self Efficacy Scale  
PCS (0-52) = Pain Catastrophising Scale  
TSK (17-68) = Tampa Scale of Kinesiophobia  
ICD = Initial Claudication Distance  
FCD = Functional Claudication Distance  
ACD = Absolute Claudication Distance  
PRI (0-78) = Pain Rating Index 
 
 
Table 9.1 details the demographic data for the participants in each group. The groups are 
similar in terms of demographic and disease data except for ABPI. The LF-TENS group had a 
significantly lower mean ABPI (t(34) = 2.442) (Table 9.1).  
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9.4.2: Within Group Profiles (HF-TENS and LF-TENS vs. P-TENS):  
Treadmill data were not normally distributed therefore non-parametric tests were used for 
analysis. Data are presented as median and inter quartile range (IQR).  
 
ICD, FCD and ACD (metres) with placebo and with active TENS for each group are detailed in 
Table 9.2 and in Figure 9.7. Median walking distance increased with TENS intervention in 
both groups, except FCD with HF-TENS and ICD with LF-TENS. Wilcoxon Signed Ranks tests 
of treadmill measures showed significant differences in all measures between placebo and 
HF-TENS (Table 9.2). For LF-TENS, the difference was significant only at ACD (Mdn = 228 and 
179, Ws = 39, z = 2.025, p = 0.043, r = 0.48). There was no change in PRI scores for either 
group (Table 2).  
 
Table 9.2: Median (IQR) ICD, FCD and ACD (in metres) and PRI scores for both 
groups with placebo and with TENS intervention. * = significant change within 
group.  
  Placebo Intervention p Ws r 
HF-TENS Group ICD 61 (68) 82 (112) .004* 18 .69 
 FCD 187 (175) 175 (303) .025* 34 .53 
 ACD 211 (244) 212 (297) .025* 34 .53 
 PRI 19 (8.5) 24 (13.3) .476 48 .17 
LF-TENS Group ICD 81 (38) 76 (50) .965 85 .01 
 FCD 151 (130) 158 (114) .687 62 .16 
 ACD 179 (153) 228 (218) .043* 39 .48 
 PRI 24 (11.5) 21 (17) .601 74 .12 
 
9.4.3: Between Group Profiles (HF-TENS vs. LF-TENS):   
Table 9.3 details the median change and median percentage change in the measures for 
both groups. There was an increase in all measures from baseline in both groups.  Mann-
Whitney U tests showed significant differences between the groups only for change, and 
percentage change in ICD (Mdn = 26 with HF-TENS and 6 with LF-TENS, U = 268, z = 2.073, p 
= 0.038, r = 0.49 and Mdn = 43 with HF-TENS and 9 with LF-TENS, U = 267, z = 2.088, p = 
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0.037, r = 0.49 respectively). Figures 9.8 and 9.9 illustrate these findings, showing the 
increases in FCD and ACD in both groups and the greater increase in ICD in the HF-TENS 
group.  
 
Table 9.3: Median (IQR) change and percentage change in ICD, FCD, ACD and PRI 
scores for HF and LF-TENS groups. * = significant change between groups. 
  HF-TENS Group LF-TENS Group p U r 
Change ICD 26 (71) 6 (67) .038* 268 .49 
 FCD 26 (70) 4 (55) .268 298 .26 
 ACD 30 (76) 23 (93) .887 329 .03 
 PRI 0.5 (6.3) 1.5 (11.3) .949 331 .01 
% Change ICD 43 (64) 9 (79) .037* 267 .49 
 FCD 9 (38) 3 (32) .393 306 .20 
 ACD 13 (30) 18 (43) .752 323 .07 








Figure 9.7: Graphs of A) ICD, B) FCD and C) ACD with placebo and intervention for 
both groups. Significant differences were found for ICD, FCD and ACD with HF-TENS 
(p = .004, .025 and .025 respectively). For LF-TENS, only difference observed was in 




Figure 9.8: Boxplots representing change in walking measures with intervention in 
both groups. Error bars = IQR. The only significant difference between the groups 
was for change in ICD.  
 
 
Figure 9.9: Boxplots representing percentage change in walking measures with 
intervention in both groups. Error bars = IQR. The only significant difference 




9.4.4: Pooled treadmill analysis:  
With the aim of analysing the overall effects of TENS on walking performance, the treadmill 
walking measures were pooled between the groups. This resulted in overall median ICD, 
FCD and ACD distances for all participants with Placebo and with Active TENS (Figure 9.10). 
When these data were analysed, ICD, FCD and ACD were found to increase with Active 
TENS. The greatest effect of TENS was observed for ACD: 176m to 211.5m with a moderate 
effect size of 0.49 (Figure 9.10). Despite the pooling of the data, variance in the sample was 
still significant (see the error bars in Figure 9.10).  
 
  
Figure 9.10: Median ICD, FCD and ACD for all participants with Placebo and Active 




9.4.5: Interrelationships between variables:  
9.4.5.1: Descriptive and Baseline Measures:  
Correlations between the baseline measures in all participants are detailed in Table 9.4. 
Significant relationships were observed between Age and BMI (rs = 0.52, p = 0.001), BMI and 
PSEQ score (rs = 0.39, p = 0.019) and HR and PCS score (rs = 0.36, p = 0.030).  
 
Scores on the WIQ were related to those on the PSEQ and PCS (rs = 0.66, p < 0.001 and rs = -
.37, p = 0.025 respectively) along with FCD and ACD (rs = 0.56, p < 0.001 and rs = 0.46, p = 
0.005 respectively). PSEQ responses showed the largest number of correlations with 
significant relationships found with PCS (rs = -.62, p < 0.001), TSK (rs = -.62, p < 0.001), FCD 
and ACD (rs = 0.44, p = 0.007 and rs = 0.37, p = 0.026 respectively) and also with PRI of the 
MPQ (rs = -.34, p = 0.042).  
 
PCS scores were related to those on the TSK (rs = 0.57, p < 0.001). Treadmill measures were 
highly correlated with each other but not with the measures of disease (ABPI) or pain (PRI) 
(Table 9.4). Heart rate at ICD and ACD was negatively related to BMI (rs = 0.42, p = 0.016 and 
rs = 0.44, p = 0.011 respectively). Heart rate at ACD was also related to WIQ score (rs = 0.36, 
p = 0.39) (Table 9.4).  
 
9.4.5.2: Experimental Measures:  
Correlations between the experimental measures are detailed in Table 9.5. Significant 
relationships were found between BMI and Change in ICD (ΔICD) (rs = 0.34, p = 0.040) along 
with change in TENS Intensity and change in ACD (r2 = 0.35, p = 0.040).  Change in ICD and 
FCD was related to Heart Rate at ICD (rs = 0.47, p = 0.005 and rs = 0.47, p = 0.006 




Table 9.4: Spearman’s Correlation Coefficients between baseline measures in all participants  
 
 Age  BMI BP (sys) HR ABPI WIQ PSEQ PCS TSK ICD FCD ACD HR ICD HR ACD 
BMI -.522**              
BP (sys) .245 -.032             
HR -.099 -.197 -.138            
ABPI -.262 .296 -.037 -.177           
WIQ .054 -.177 .068 -.136 .060          
PSEQ .253 -.388* .314 -.261 -.073 .657**         
PCS -.087 .198 -.230 .362* -.110 -.373* -.621**        
TSK -.041 .299 -.329 .177 .003 -.288 -.621** .565**      
ICD .169 -.200 .113 -.019 -.139 .253 .325 -.066 .004      
FCD .057 -.115 .121 -.058 .058 .555** .439** -.086 -.195 .775**     
ACD .031 -.148 .056 -.045 -.017 .458** .371* -.116 -.140 .788** .905**    
HR ICD .165 -.417* .318 .287 -.078 .259 .245 -.089 -.098 .320 .269 .099   
HR ACD .090 -.438* .277 .293 .027 .360* .314 -.149 -.187 .288 .336 .161 .933**  
PRI -.200 .079 -.165 .286 -.136 -.243 -.340* .294 .144 -.234 -.227 -.134 -.170 -.232 









 Age BMI BP (sys) HR ABPI ΔmA  WIQ PSEQ PCS TSK ΔICD ΔFCD ΔACD ΔPRI HR ICD 
ΔICD -.116 .344* -.185 -.003 .067 .004 -.008 -.218 .328 .260      
ΔFCD .030 -.118 -.191 .051 .058 .218 -.073 -.079 .076 .043 .519**     
ΔACD .088 -.055 -.075 -.246 .163 .350* -.100 -.072 -.082 .057 .262 .506**    
ΔPRI -.147 .322 .061 .034 -.207 -.082 .212 -.049 .061 .201 .015 -.160 -.091   
HR ICD .165 -.417* .318 .287 -.078 .168 .259 .245 -.089 -.098 -.474** -.469** -.306 -.008  
HR ACD .090 -.438* .277 .293 .027 .260 .360* .314 -.149 -.187 -.536** -.437* -.340 .016 .933** 
* Correlation is significant: p < 0.05 (2-tailed). ** Correlation is significant: p < 0.01 (2-tailed).  
 
Table 9.5 Key:  
ΔmA = change in TENS intensity;  
ΔICD = change in ICD;  
ΔFCD = change in FCD;  
ΔACD = change in ACD;  
ΔPRI = change in PRI score.  
HR ICD = Heart Rate at ICD 





9.4.6: Predictors of ACD and Change in ACD:  
9.4.6.1: ACD 
Enter regression analysis was performed for ACD with placebo using four predictor 
variables: ABPI, BMI, WIQ and PSEQ. A significant model emerged (F4,31= 3.050, p = 0.31), 
adjusted R2 = 0.19. Variables entered into the model are shown in Table 9.6. Collinearity 
diagnostics indicated that any relationships between the predictor variables did not affect 
the regression model (shown by tolerance values greater than 0.10 Table 9.6).   
 
Table 9.6: Multiple regression analysis for ACD. 
Predictor Variable Standardised Beta p Tolerance 
ABPI -.008 .960 0.888 
BMI -.052 .764 0.788 
WIQ .326 .108 0.594 
PSEQ .241 .247 0.555 
 
9.4.6.2: Change in ACD 
Enter regression analysis was performed for ΔACD using five predictor variables: ABPI, BMI, 
WIQ, PSEQ and ΔmA. A significant model emerged (F5,30= 4.829, p = 0.002), adjusted R
2 = 
0.35. Variables entered into the model are shown in Table 9.7. Only ΔmA was found to be a 
significant predictor of ΔACD. Collinearity diagnostics indicated that any relationships 
between the predictor variables did not affect the regression model (shown by tolerance 
values greater than 0.10 Table 9.7).   
 
Table 9.7: Multiple regression analysis for ΔACD. 
Predictor Variable  Standardised Beta  p  Tolerance 
ABPI .108 .474 0.837 
BMI -.129 .412 0.771 
WIQ -.220 .222 0.594 
PSEQ -.080 .667 0.540 
ΔmA .633 .000 0.869 
 
9.4.7: Summary of Analysis and Results:  













9.5: DISCUSSION:  
The study discussed is a ‘proof of concept’ study and the results must be interpreted as 
such. Nevertheless, the results of this study show that compared to placebo, TENS increases 
walking performance in patients with IC. These results indicate that TENS is an effective 
intervention that allows patients with IC to walk further before onset, and while 
experiencing pain.   
 
The different types of TENS employed in this study were found to affect distinctive aspects 
of the pain experience. ICD, FCD and ACD increased with HF-TENS whereas only ACD 
increased with LF-TENS. This indicates different mechanisms of hypoalgesia and possibly 
distinct neurophysiological effects of the different frequencies of TENS. Conclusions 
regarding the potential of either of these types of TENS to be more effective than the other 
for this patient population are outwith the scope of this study.  
 
The only predictor of change in walking performance with intervention was patient-
controlled intensity of TENS. This finding indicates that the changes in walking performance 
observed were related to the application of TENS and more specifically, the decisions of the 
patient to increase the intensity of TENS stimulation to overcome the pain experienced.  
 
The contribution of this study to the issues of improving walking performance in patients 
with PAD and IC is novel. No other study in the published literature has examined the effects 
of using TENS while exercising on walking performance in this patient population.  
 
An evaluation of these findings will be presented and discussed below in relation to the 
context of this thesis, other findings in the published literature and possible future 




9.5.1: TENS and increased walking performance:  
The original research question was: ‘what are the effects of TENS on walking performance in 
patients with IC?’ The results of the current study suggest that compared to placebo TENS, 
HF-TENS and LF-TENS increase treadmill walking performance in patients with PAD and IC.  
 
As discussed in Chapter 8, HF-TENS is proposed to act by activating large diameter 
mechanoreceptors (Aβ-fibres), delta (δ)-opioid receptors and increasing gamma-
Aminobutyric acid (GABA) in the spinal cord and is associated with immediate, localised, 
segmental inhibition as conceived by the original gate control theory (Melzack and Wall 
1965; Andersson 1979; Sluka and Walsh 2003; DeSantana et al 2008; Chen and Johnson 
2011). LF-TENS was originally theorised to act on smaller diameter nociceptive afferents, 
brainstem structures and supraspinal descending pathways, releasing endogenous opiates 
centrally and peripherally (Sjolund et al 1977; DeSantana et al 2008). It was thought that LF-
TENS did not induce hypoalgesia immediately but takes a few minutes to provide effective 
pain relief due to its more complex mechanisms (Le Bars 2002). However, more recent 
research has cast doubt on this distinction between the mechanisms of action of these two 
types of TENS (Radhakrishnan and Sluka 2005). Nevertheless, the originally proposed 
mechanisms of action and characteristics of hypoalgesia seem to be evident in the current 
study.  
 
Figures 9.8 and 9.9 shows the change in treadmill walking distances in both groups with 
scores above zero representing an increase in walking distance with TENS intervention. 
Increases in ICD, FCD and ACD were observed in the HF-TENS group suggesting an 
immediate and prolonged hypoalgesic effect. The increases in median ICD and ACD with HF-
TENS were found to be significant with effect sizes of 0.69 (p = 0.004) and 0.53 (p = 0.025) 
respectively (Table 9.2). In the LF-TENS group, there was a decrease in median ICD but 
increases in FCD and ACD suggesting a delayed but effective hypoalgesic effect at tolerance. 
The increase in ACD with LF-TENS was found to be significant with an effect size of 0.48 (p = 
0.043) (Table 9.2). These findings suggest that HF-TENS had an immediate and lasting effect, 
reducing pain at the mild (ICD) and more severe parts of the pain experience (FCD and ACD). 
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With LF-TENS however, hypoalgesic effects are evident only when the pain was severe (ACD) 
indicating a delayed action. Therefore the results from this study appear to support the 
proposed segmental, spinal mechanisms of HF-TENS and supraspinal, delay-action opiate 
mechanism of LF-TENS.  
 
The effects of HF, and LF-TENS stimulation have been examined extensively within the 
published literature. Due to the complex nature of clinical pain and the limited ability to 
control stimulation and experience, investigations have been conducted on experimental 
pain. Mixed effects have been reported from studies employing a multitude of different 
stimulation parameters (Chen et al 2008; Claydon et al 2011). Due to this variation, 
definitive evidence of dose-related effects of TENS frequency is limited (Chen et al 2008; 
Claydon et al 2011). Parameter combinations have been found to elicit different effects 
depending on pain model investigated (Claydon et al 2011).  
 
Experimental ischaemic pain provides an ideal method of examining the differential effects 
of TENS parameters on the pain experience. Induction of ischaemic pain allows investigation 
of pain through the full time course: from pain threshold to tolerance and during the steady 
development of intensity throughout (Woolf 1979). Of the studies that have investigated 
the effects of TENS frequency on induced ischaemic pain, mixed results are reported (Roche 
et al 1984; Walsh et al 1995a; Foster et al 1996; Chen and Johnson 2011). In the most recent 
high quality study, not included in the reviews by Chen et al (2008) or Claydon et al (2011), 
the effects of HF-TENS was compared to LF-TENS in a model of upper limb ischaemic pain 
(Chen and Johnson 2011). Unfortunately, due to the use of a modified method of pain 
induction and repeated measures design, time to pain threshold and tolerance was not 
recorded. The authors reported that compared to P-TENS, a decrease in pain intensity was 
observed with HF-TENS at 1 and 2 minutes however, with LF-TENS, an increase in pain 
intensity was observed at the same time points (Chen and Johnson 2011). These findings 
suggest that HF-TENS is more effective in reducing pain intensity at the initial stages of the 
pain experience (all mean VAS scores were less than 50mm, or 5 out of 10 i.e. mild to 
moderate levels of pain (Buer and Linton 2002)). These findings are similar to those in the 
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current study of clinical ischaemic pain. At the pain threshold level of the pain experience, 
the time to perception of pain was prolonged with HF-TENS whereas with LF-TENS the 
median time to pain threshold (ICD) actually decreased, suggesting an increase in pain 
intensity (Table 9.2 and Figure 9.7a).  
 
The different effects observed with HF and LF-TENS are hypothesised to be a result of a 
more effective electrical paraesthesia induced with greater frequencies stimulating ectopic 
impulses and producing abnormal patterns of neural activity (Kiernan et al 1997; Mogyoros 
et al 2000). As LF-TENS produces little or no paraesthesia, the initial experience of pain 
would be unaffected. When the pain experience develops to become more intense, LF-TENS 
stimulation of μ-opioid receptors and release of serotonin and action at 5HT2 and 5HT3 
receptors becomes effective and a reduction in pain is observed at near-tolerance levels. In 
the study by Chen and Johnson (2011), mean pain intensity score with LF-TENS at minute 2 
was lower than at minute 1 possibly indicating the beginnings of a hypoalgesic effect 
although this reduction was also observed with no-TENS and P-TENS to a similar extent. This 
general reduction in pain, regardless of the intervention may indicate the endogenous 
opioid response to the induction of pain, thus somewhat masking the effect of LF-TENS.  
 
Compared to P-TENS, median change in ACD with HF-TENS was 30 metres (m) and with LF-
TENS, 23m. This relates to percentage increases of 13% for HF-TENS and 18% with LF-TENS 
(Table 9.3 and Figure 9.9). As mentioned at the beginning of this chapter, a 60% 
improvement in ACD has been suggested as a worthwhile improvement in walking distance 
for patient with IC (Oakley et al 2008). The effect of TENS on IC pain does not achieve this 
level of improvement although the current study was designed in such a manner that would 
lead to underestimation of the effect of TENS. As a familiarisation or training effect has been 
shown with the Gardner treadmill test (Labs et al 1999), P-TENS condition was examined on 
the second testing session for every participant so that any effect of TENS could not be 
confused with general improvement in completing the testing procedure. By the nature of 
this design, any effect of TENS observed would be underestimated. The training effect for 
the Gardner treadmill protocol has been found to be 10% for ACD (Labs et al 1999). With 
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this in mind, the significant increases of 13 and 18% with HF and LF-TENS may move closer 
to the proposed clinically worthwhile improvement. When compared to placebo, 
improvements in ACD of approximately 30% have been found with IC medication (Momsen 
et al 2009). The change in ACD with TENS intervention, taking into account the possible 
treadmill training effect (10%) is close to this level of improvement (increase of 23% and 
28% compared to placebo).  
 
TENS has been shown to elicit a strong placebo response (Roche et al 1984; Marchand et al 
1993; Roche et al 2002). A placebo response is an important finding, especially in patients 
with chronic pain. Reduction in reported pain with placebo analgesia is achieved through 
complex and integrated psychological and physical mechanisms including ‘expectations’ and 
endogenous opioid release (Benedetti 1996; Montgomery and Kirsch 1997; ter Riet et al 
1998; Price et al 1999; Amanzio and Benedetti 1999). Chronic, clinical pain syndromes are 
complex in nature, with both sensory-discriminative and affective-evaluative components 
occurring simultaneously (Woolf 1979; Gustin 2011). In these patient populations, a placebo 
response may indicate that the intervention, in addition to being physiologically effective, 
may be employed as a coping strategy, reducing affective-evaluative components i.e. pain-
related fear and catastrophising or increasing pain self-efficacy (Price et al 1999). Overall, 
placebo interventions may decrease the level of pain perceived and therefore have the 
possibility to increased function and quality of life, reducing the burden of the pain and 
achieving the initial aim of the intervention. This hypoalgesic ability of placebo intervention 
has been demonstrated within this thesis (Chapter 8). Compared to no intervention, P-TENS 
was found to increase time to pain tolerance and pain endurance of experimentally induced, 
lower limb ischaemic pain. Unfortunately, the design of the current clinical study of IC pain 
does not allow for such a comparison. Active TENS was found to increase walking distance 
compared to placebo TENS but what is not known is the degree of effect compared to no 
intervention. Nevertheless, clinical trials of new interventions must be placebo-controlled to 
determine unequivocal and replicable physiological effects. The current study achieves this 
for TENS and walking performance in patients with IC. Future research should however aim 
to quantify the placebo effect and therefore absolute effects of active TENS on walking 
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performance in patients with PAD and IC. This can be achieved through including a control 
condition where no intervention is given in addition to the P-TENS control.  
 
9.5.2: Frequency parameters of TENS and walking performance:  
The secondary research question was: does HF-TENS increase measures of walking 
performance more than LF-TENS? The results of the study suggest that HF-TENS is more 
effective at increasing walking performance in patients with PAD and IC at lower levels of 
pain (ICD), but not towards walking tolerance (FCD and ACD).  
 
Median ICD and ACD increased with HF-TENS whereas only FCD and ACD increased with LF-
TENS (Table 9.2 and Figure 9.7). Between-group comparison of the median individual 
change in these measures found that only change in ICD was significantly greater with HF-
TENS than with LF-TENS (r = 0.49, p = 0.038) (Table 9.3). This result suggests that compared 
to LF-TENS, HF-TENS is more effective at reducing the initial burden of IC pain at threshold 
levels. When the levels of pain increase however, both types of TENS are effective at 
prolonging tolerance and therefore increasing walking performance in patients with PAD 
and IC (Table 9.3 and Figures 9.8 and 9.9).  
 
To reduce the effect of inter-participant differences in walking performance and pain 
between the groups, individual change in ICD, FCD and ACD was calculated as a percentage 
of their baseline distance. The group median for each of these measures was then 
calculated and compared (Table 9.3 and Figure 9.9). Similar to the mean change, the only 
difference between the groups was in ICD (r = 0.49, p = 0.037) (Table 9.3). Otherwise, the 
mean percentage change in the measures was comparable between the groups, indicating 
that there is no difference between the two selected TENS frequencies in increasing walking 
distance at near tolerance levels of pain in this population.  
 
These findings relate to those of the within-subject analysis of TENS. HF-TENS appears to be 
more effective than LF-TENS at reducing the initial perceptions of pain and prolonging time 
to pain threshold. This has been hypothesised as a function of the more effective electrical 
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paraesthesia induced with the higher frequency of stimulation eliciting ectopic impulses and 
abnormal patterns of neural activity (Kiernan et al 1997; Mogyoros et al 2000). The 
perception of this electrical paraesthesia ‘masks’ the experience of pain and thus prolongs 
the time before pain threshold is reported. As LF-TENS does not induce such paraesthesia as 
effectively and is actually considered to induce an uncomfortable, just below pain threshold 
stimulation, the limited effects on the initial perceptions of pain are anticipated.  An 
important question however, is what is important, or more effective, for increasing physical 
activity in patients with PAD and IC? For example, does reducing the initial experience of 
pain increase daily walking performance or is it more important to prolong the time to 
tolerance of the pain? No published study has specifically examined when, and why patients 
with PAD and IC limit their walking distance. Kruidenier et al (2009b) suggested that there is 
a ‘functional claudication distance’, individual to every person where they decide to stop 
walking. This seems to be determined by previous experiences and beliefs regarding the 
meaning of pain (Kruidenier et al 2009b). This level, as measured in the current study, is 
similar or near pain tolerance indicating that this is the most important outcome in the 
evaluation of walking distance in patients with PAD and IC. There was no difference in FCD 
between the groups although when examining the individual group difference, despite a 
median decrease, FCD was significantly increased with HF-TENS compared to P-TENS (Table 
9.2).  
 
9.5.3: Pooled Analysis of TENS:  
Due to the nature of this small, phase IIa, ‘proof of concept’ study, a central question was 
the evaluation of the safety and efficacy of TENS for walking performance in PAD and IC. 
With this goal in mind, both groups of TENS data were pooled for analysis in an effort to 
establish the effects of ‘TENS intervention’ compared to placebo.  
 
TENS was found to be a safe intervention with no adverse events or reactions to the 
intervention. Compared with P-TENS, ICD, FCD and ACD were found to increase with TENS 
intervention (Figure 9.10). The primary outcome of the study was ACD as this has been 
shown to be the most reliable treadmill measure (Nicolaï et al 2009b). ACD increased by a 
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median of 35.5m with TENS intervention (p = 0.003, Figure 9.10). This result represents a 
moderate effect of TENS on walking performance (r = 0.49) and provides the important 
groundwork for further study of TENS as an intervention for PAD and IC.  
 
Despite this significant effect of TENS, a large variance was observed in the results, 
demonstrated by large error bars in Figure 9.10. This large variance indicates that walking 
distances varied between participants. No further examination of this variance was possible 
due to the small sample size. However, it indicates a possible limitation of this study. The 
inclusion criteria required participants to have Fontaine stage II claudication (pain on 
walking but not at rest) but did not limit participants within a certain distance. This 
approach to participant recruitment was chosen so that any results from the study could be 
generalised to a greater population. These decisions regarding selection criteria led to a 
diverse sample of participants recruited with a mean baseline ACD of 259m but a non-
normally distributed and positively skewed range from 99 to 806m (Table 9.1 and Figure 
9.7). The results from this pooled analysis of TENS are therefore even more significant 
considering the effects observed and the inherent variation in the sample. This large 
variation in walking ability has been encountered before in small studies of patients with 
PAD and IC (Gardner et al 2008; Serizawa et al 2012) and only studies with greater numbers 
or more strict inclusion criteria, and thus less generalisation, have overcome this limitation. 
A larger sample would allow participants to be grouped by baseline walking ability and 
effects studied within these smaller, more homogeneous populations. Future studies should 
be aware of this inherent variance within the population and either control for it using 
inclusion criteria or build in scope for examination when selecting the sample size and 
statistical analysis.  
 
The change in walking distance with TENS intervention represents an increase in ACD of 20% 
compared to placebo (Figure 9.10). A change of approximately 37% has been reported as a 
clinically meaningful change in ACD for patients with IC (De Backer et al 2009). The change 
with TENS found in the current study falls short of this mark. However, it could be argued 
that despite this, TENS warrants further investigation. The clinically meaningful difference is 
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calculated from studies examining longer-term interventions. TENS as an intervention is 
normally prescribed similar to medication with a view to it becoming integrated within the 
overall management of a painful condition (Sluka and Walsh 2003; Johnson 2007). Also, 
establishing optimal dosage of the parameters of TENS has been shown to require a 
prolonged period of use and personal experimentation (Johnson et al 1991; Johnson 2007). 
With further refinement of the TENS parameters and if investigated as a long-term 
intervention rather than an immediate change in behaviour, it is feasible to propose that 
TENS could achieve this clinically meaningful level of improvement in walking distance.  
 
9.5.4: Interrelationships between measures:   
Bivariate correlation analysis was conducted on the baseline measures to examine any 
interrelationships. Table 9.4 details the results with the significant relationships highlighted 
in bold. A number of significant correlations were found within the data.  
 
Strong, significant positive relationships were found between the treadmill measures. These 
results indicate common, proportional differences between ICD, FCD and ACD in patients 
with IC (i.e. ICD was commonly one third of the distance of ACD). Also, the pattern of pain 
development over time is generally similar, regardless of the distance walked. This 
observation indicates similar and consistent mechanisms of pain experience across 
participants. The proportional relationship between threshold and tolerance of pain, and 
thus walking distance, suggests a reliable development in pain intensity during walking 
between participants. Further analysis of individual walking distances showed that an 
individual’s ICD was approximately 40% of their ACD (Mean % (95%CI) = 38 (33-43)). In 
addition, FCD was found to be 80% of ACD with no intervention = 81% (75-86).  
 
With TENS intervention, these proportions changed slightly. ICD decreased to 35% (29-42) 
and FCD decreased to 75% (69-82) respectively. These changes may suggest that rather than 
TENS producing a ‘shift’ in all aspects of the pain experience, ACD is most affected. As this is 
only a basic post hoc analysis on preliminary data, further investigation and more 
comprehensive analysis are required before any conclusions can be drawn. The implication 
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however, if the observed relationships persist, is that patients with IC walk further with 
TENS and this is due to an increase at the more severe portion of the pain experience.  
 
The only published study that has examined the IC pain experience and specific hypoalgesic 
effects during treadmill walking is that by Treat-Jacobson et al (2011). These authors 
examined the effects of 12 weeks of different exercise interventions (treadmill training, arm 
ergometry, a combination of both or usual care) on the ‘pain trajectory’. A simple 6-point 
verbal/ numerical rating scale (0 = no pain; 1 = mild claudication pain, onset of pain; 3 = 
moderate pain; and 5 = severe pain, with no verbal descriptors at points 2 or 4), was used to 
record immediate pain intensity every 30 seconds during a graded treadmill protocol at the 
start and end of 12 weeks of the intervention. Due to their method of recording pain 
intensity, complex analysis and non-reporting of raw data, time taken to pain threshold and 
tolerance were not available for analysis. The authors’ detailed analysis did however 
indicate a common trajectory of increasing pain over time similar to the current study. 
Interestingly however, different interventions were found to affect the pain experience in 
different ways with treadmill training increasing walking time when the pain was most 
severe and arm ergometry increasing time before the onset of pain (Treat-Jacobson et al 
2011). The authors did not speculate or discuss which aspect of the ‘pain trajectory’ was 
most important to modify for purposes of increasing function and quality of life in patients 
with PAD and IC. However, treadmill training resulted in the greatest increase in overall 
walking time.  
 
Scores on the WIQ were positively related to FCD and ACD. The WIQ is widely used as an 
outcome measure for studies investigating interventions aimed at improving function in 
patients with PAD and IC (Matsuo and Shigematsu 2010). In the current study, the 
relationships observed between WIQ and the treadmill measures indicate that self-reported 
walking performance is related to actual walking performance on a treadmill. This suggests 
that the WIQ is a valid tool for measuring walking performance in patients with PAD and IC. 
Participant WIQ score was related positively to the PSEQ, and negatively to the PCS 
indicating that there is a relationship between this measure of walking performance and 
 207 
 
psychosocial aspects of pain. These results follow the theorised mechanisms suggested in 
the literature for pain self-efficacy and pain catastrophising (Lorig et al 2001; Edwards et al 
2011).  
 
For pain self-efficacy, higher scores on the PSEQ indicate increased confidence in the ability 
to overcome pain and thus an increase in functional performance. Asghari and Nicholas 
(2001) found that in a sample of patients with chronic pain, self-efficacy beliefs predicted 
pain and avoidance behaviours even when controlling for pain severity, pain chronicity, age, 
gender, physical disability, depression, neuroticism and catastrophising. Specifically, 
increased pain self-efficacy beliefs were found to be predictive of reduced avoidance 
behaviours. From the reporting of the study, it was not clear whether the sample examined 
included patients with IC and therefore, the results cannot be directly extrapolated. 
Nevertheless, the results of the current study suggest similar relationships are present in 
this sample of IC pain as an increase in score on the PSEQ was found to relate to an increase 
in walking performance in patients with IC pain.  
 
Pain Catastrophising can be defined as “an exaggerated negative orientation toward actual 
or anticipated pain experiences” (Gatchel et al 2007, p602). Higher scores in the PCS 
indicate higher pain catastrophising, which relates to increased attention to pain and 
decreased functional performance (Martin et al 1996). To date, no published research has 
examined the role of catastrophising in patients with PAD and IC. In the current study the 
negative relationships observed between scores of the PCS and WIQ indicate that an 
increase in pain catastrophising is related to a decrease in walking performance. Pain 
catastrophising has been shown to: independently predict depression in a general chronic 
pain population (Turner et al 2000); is related to increased pain intensity in patients with 
back pain (Buer and Linton 2002); and in patients with fibromyalgia, pain catastrophising is 
related to increased activity in the regions of the brain associated with the attention, 
anticipation and emotional response to pain (Gracely et al 2004). The levels of 
catastrophising recorded in the current study are similar to those reported in the study by 
Buer and Linton (2002). A median score of 12 was reported by patients with moderate, 10 
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with mild and 9 with no back pain (Buer and Linton 2002). In the current study, patients with 
IC reported a mean score of 12 on the PCS, similar to that of patients with moderate back 
pain. Due to this similar level of reported catastrophising, it could be assumed that pain 
catastrophising may have a similar impact for patients with IC as it does for those with back 
pain. However, unlike in back pain patients, there was no relationship between 
catastrophising and pain intensity (PRI score) and score of the PCS was not related to 
measures of walking performance as has been shown in a more general pain population 
(Turner et al 2000). The only other variables related to PCS were the scores on the PSEQ and 
TSK. This indicates that rather than a direct relationship with pain and function, the 
influence of pain catastrophising in patients with IC is mediated through other psychosocial 
measures.  
 
PSEQ scores were related to the largest number of other variables. Significantly negative 
relationships were found with BMI, PCS, TSK and PRI scores (Table 9.4). These results 
indicate that scores on the PSEQ and therefore pain self-efficacy beliefs are related to a 
large proportion of other variables in this population. The relationships between pain self-
efficacy and the other measures in patients with PAD and IC warrants further investigation. 
Currently, nothing has been published regarding the role of pain self-efficacy in the disease 
experience of PAD and IC.  A number of studies have highlighted general self-efficacy beliefs 
as an important factor in cardiovascular disease. Relationships have been identified 
between self-efficacy and cardiovascular lifestyle in general cardiovascular diseases (Sol et al 
2011), prescribing habits in patients with PAD (McDermott et al 2010) and walking ability in 
patients with PAD and diabetes mellitus (Collins et al 2010). In this study by Collins et al 
(2010), 145 patients with PAD and diabetes were recruited and asked to complete a series 
of self-report measures including the Self-Efficacy for Managing Chronic Diseases scale. 
Participant score on this scale was used to divide the sample into those with high or low 
self-efficacy. This rough dichotomous measure was then found to be related to walking 
distance on a treadmill, WIQ score and scores of physical functioning quality of life (Collins 
et al 2010). Due to the method of measurement and analysis, only general relationships 
could be identified. The results of these studies along with that of the current study suggest 
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self-efficacy and pain self-efficacy are important mediators of numerous variables and are 
strongly related to walking performance and function in patients with PAD.  
 
Despite the observed relationships between pain self-efficacy and function in this study, 
overall pain intensity was not found to relate to measure of walking performance. PRI scores 
also were not found to be related to any of the treadmill measures or measures of function 
(Table 9.4). This suggests that rather than physiological measures of the disease, or pain 
itself, it is the psychological/psychosocial measures associated with the pain experience that 
are the most strongly related to walking performance and function in this population.  
 
Table 9.5 shows the bivariate correlation coefficients between the measures at baseline and 
the experimental measures of walking performance with intervention. Of the experimental 
measures, the only significant relationships were positive and between ΔICD and BMI, and 
ΔACD and ΔmA. The relationship between BMI and ΔICD suggests that patients with a 
greater BMI had a greater increase in initial walking distance with TENS. The positive 
relationship between change in ACD and change in TENS intensity suggests that patients 
who increased TENS intensity to a greater extent through the test had a greater increase in 
walking distance.  
 
These findings indicate that the participants in this study used TENS as a coping strategy to 
help them overcome their pain and walk further. Results from this study show that utilising 
TENS more effectively (i.e. increase the intensity) was related to a greater increase in 
walking distance. This follows the theory of pain self-efficacy where, if someone believes 
that they can overcome an obstacle, they are more likely to do things that help them 
achieve this goal (Bandura 2012). This may suggest that pain self-efficacy could be a 
predictor of effective use and benefit from TENS. It is beyond the scope of the current study 
to make these conclusions. Nevertheless, if further research confirms this relationship, this 
may prove to be an novel avenue for research and may stimulate further clinical questions 
e.g. if the beneficial effects of TENS are related to pain self-efficacy, should interventions 




There are no published studies that have investigated the relationship between TENS and 
pain self-efficacy. One study by Luijpen et al (2004) found that TENS increases self-efficacy in 
patients with cognitive impairments. However, this was general self-efficacy and not related 
to pain. Future research might look to explore the link between pain self-efficacy and TENS 
and if present, investigate possible methods that could capitalise on the relationship and 
enhance the hypoalgesic effects of TENS.  
 
9.5.5: Predictors of Walking Performance:  
The final research questions were: what measures, if any, predict walking performance at 
baseline and which, if any, predict change in walking performance with intervention? As 
ACD was the primary outcome of the study, ACD and ΔACD were chosen for the linear 
models. Enter regression analysis was used to examine which measures most significantly 
predict baseline ACD and ΔACD.  
 
For the baseline ACD, the model consisted of ABPI, BMI, WIQ and PSEQ. The model entered 
was a significant fit for that data although no standardised Beta values for individual 
predictors were found to be significant (Table 9.6). The overall model was found to predict 
19% of the variance in ACD. The small, standardised Beta values for BMI or ABPI were not 
found to be significant and the standard errors in Beta values were large indicating only 
general relationships with ACD. These findings indicate that scores on the WIQ and pain self-
efficacy are the greatest determining factors of walking tolerance measured in this sample 
of patients with IC.  
 
Table 9.7 shows the results from the regression analysis of ΔACD. Change in TENS intensity 
was found to be the best predictor of ΔACD. Overall, the model was found to predict 
approximately 35% of the variance in ΔACD and it was a significant fit for the data.  
 
Again, small, standardised Beta values and large standard errors of these values were 
observed for the physiological measures indicating only general relationships with the 
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outcome variable. This was also true for WIQ and PSEQ scores. Conversely, the large 
standardised Beta value and comprehensive significance of change in TENS intensity 
observed in this model indicates that it is a strong factor in the overall model with a small 
change in intensity relating to a large increase in walking distance.  
 
Regression analysis for measures of walking performance at baseline, found the 
psychological measures of self-reported walking performance and pain self-efficacy to be 
the best predictors of ACD in this sample of patients with PAD and IC. This indicates that 
psychological factors associated with pain have a significant impact on the experience of 
living with PAD and IC, greater than the commonly measured, physiological factors of ABPI 
and BMI.  
 
Previous published studies have examined the psychological burden of PAD and IC. 
However, none has examined the effects of the specific psychosocial aspects of the chronic 
pain experience. The first reported studies to discuss the psychological effect of PAD and IC 
were Pell (1995), Currie et al (1995), Chetter et al (1997) and Klevsgard et al (1999). Whilst 
investigating quality of life measures in patients with PAD and IC, these studies noted a 
relationship between decreased positive psychological variables and Quality of Life (QoL) 
and walking ability (Klevsgard et al 1999). Chetter and colleagues (1999) investigated and 
recommended the use of the SF-36 health questionnaire for patients with PAD and IC to 
help measure and manage the marked decrease in QoL in the population (Chetter et al 
1997). Klevsgard et al (1999) examined responses on the Nottingham Health Profile and the 
Sense of Coherence Scale in 168 patients with IC compared to 102 controls. They found that 
patients with IC had significantly lower scores on all aspects of quality of life compared to 
controls. Specifically, measures of pain, physical mobility and emotional reactions were 
predictive of health status. Sense of coherence, i.e. the resources that allows people to 
manage tension, reflect on their resources and mobilise them to employ effective coping 
and find solutions to their health-related issues (Eriksson 2006), was also found to be a 
mediating factor between physiological severity of ischaemia and quality of life (Klevsgard et 
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al 1999). This well designed study was the first to suggest this link between psychological 
beliefs and quality of life in IC, independent of disease severity.  
 
Breek et al (2001) also investigated quality of life in patients with IC. Significantly poorer 
scores on the domains recording: physical health and level of independence; pain and 
discomfort; energy and fatigue; mobility, activities of daily living; dependence on medication 
and treatments; working capacity; negative feelings; recreation and leisure; and overall QoL 
and general health were recorded in patients with PAD and IC. The authors made a point of 
noting the limited relationship between walking distance and QoL. A stronger association 
was found between walking ability and dependence on medication and treatment (Breek 
2001).  
 
Further analysis of the relationships between psychological factors and QoL/ function was 
conducted by McDermott et al (2003) who investigated the relationship between depressive 
symptoms and lower extremity functioning (6-minute walk distance and walking velocity). 
They found significant relationships when adjusting for age, sex, race, ABPI, number of 
comorbidities, current smoking and antidepressant medications. Aquarius et al (2005) 
examined the effects of disease status and Type D (depressive) personality on outcomes in 
patients with PAD and IC. Type D personality was found to be associated with increased risk 
of impaired QoL and perceived stress irrespective of disease status (Aquarius et al 2005). 
More recently, research has been conducted that further examined the relationship 
between depression and decreased quality of life in patients with PAD. Smolderen et al 
(2008) reported that prevalence of depression was high in this sample of PAD patients. 
Clinical depression was present in 16% of participants and scores on the depression scale 
were independently related to treadmill walking distance (Smolderen et al 2008). In a 
separate study the same research group compared the health status and disease burden of 
PAD to that in Chronic Heart Failure (CHF) (Smolderen et al 2009). Differences were 
observed between the conditions with increased impairment in physical health in PAD and 




All of these studies highlight a central role of psychological factors, specifically depression, 
in the physical function and quality of life in patients with PAD. These studies are often 
cross-sectional ‘snapshots’ of groups of patients seeking care for their condition so they may 
not be representative of the whole population or change over time. The study by Smolderen 
et al (2008) was the only study to perform substantial follow-up. Depressive symptoms were 
found to be stable over 18 months. In addition, the measure of depression was found to be 
independently related to walking distance on the treadmill but not to disease severity as 
measured by the ABPI (Smolderen et al 2008). This suggests that the depressive symptoms 
observed are related to physical function, and thus possibly the experience of IC pain. 
Causality is not established however. Depression is a common feature of chronic pain 
conditions and, along with learned helplessness, has been shown to impact on quality of life 
and physical function (Keefe et al 2004; Gatchel et al 2007). Similar to patients with PAD and 
IC, the nature of the relationship between chronic pain and depression is yet to be 
conclusively established. To date, all studies of depressive symptoms in patients with PAD 
have been conducted on participants who also experience claudication. To begin to further 
examine the relationship between PAD, IC and depression, future research could explore 
the same symptoms in patients with asymptomatic PAD with long-term follow-up to 
investigate how these symptoms relate to the development of IC pain.  
 
Despite this acknowledgement of the role of psychological well-being and PAD, published 
qualitative literature that explores the intricacies of psychological aspects of PAD and IC is 
minimal and there is only one study found to date that investigates the effects of 
psychological intervention for PAD and IC (Cunningham et al 2011). In a well-designed RCT, 
patients with IC who received brief psychological intervention (2, one-hour sessions where 
illness and walking beliefs were addressed and a personalised action plan agreed upon) 
were found to have increased total number of steps per day at the four-month follow-up 
compared to those who received normal care (Cunningham et al 2011). Similar to the 
current study, this trial highlights the major limiting function of psychological factors and 




Qualitative research has examined the barriers and facilitators for walking in patients with 
PAD and IC (Galea et al 2008). Barriers included lack of energy, fatigue, lack of motivation, 
perceived time constraints, lack of knowledge and uncertainty regarding benefits of walking, 
exercise-induced pain, the need to take breaks due to pain and confusion about the benefits 
and harm caused by pain. The facilitators identified were psychological strategies such as 
goal setting and positive self-talk, social support, cognitive and behavioural pain-coping 
strategies, the availability of walking programs and the availability of a resting place when 
walking. Again, these results support the current findings and highlight the role of pain, and 
more specifically the psychological aspects of the pain experience as major determinants of 
walking adherence and/or performance in patients with PAD and IC.  
 
The findings of facilitators such as motivation, goal setting, positive self-talk and coping 
strategies are all features associated with self-efficacy (Bandura 2012) as are the barriers 
reported by Galea et al (2008) of uncertainty about the benefits of walking. The confusion 
about the benefits and harm caused by pain are features related to pain-related fear and 
avoidance behaviours (Vlaeyen et al 1995). The results of the current study therefore seem 
to support those of the study by Galea et al (2008). Future studies could investigate these 
barriers and facilitators in further depth to gain a better understanding of walking in this 
population. This information could then be used to develop and test interventions for 
promoting physical activity and walking performance.  
 
Previous research has shown that there is a strong association between PAD and decreased 
QoL/health status. This link has been found to be more closely related to psychological than 
physiological or physical measures. The current study adds to these conclusions by 
suggesting a specific effect of psychosocial aspects of the pain experience on walking 
performance. Further research should examine this link further with the aim of identifying 
the psychological constructs that have the greatest effect on physical function and QoL in 
PAD and IC. Once identified, interventions that target these specific constructs may be able 




9.6: CONCLUSIONS:  
Patients with IC experience a gradual build-up of pain to tolerance when exercising. This is 
similar to the ischaemic pain curve discussed earlier (Chapter 8) and the distinct aspects of 
this pain experience are used to quantify walking performance. Pain threshold (ICD) and 
pain tolerance (FCD/ACD) are used as outcomes.  
 
The current study aimed to investigate the effects of two types of TENS (high and low 
frequency) on the pain experienced and walking performance in patients with PAD and IC. 
The results indicate that TENS increases the distance walked before tolerance. Both types of 
TENS were found to increase walking performance although HF-TENS was more effective at 
prolonging time to pain threshold.  
 
TENS increases treadmill walking performance in patients with PAD and IC with change in 




9.7: CHAPTER 9 SUMMARY: 
To investigate the effects of TENS for IC pain, 40 participants with PAD and IC were recruited 
to this phase IIa study. Participant walking performance and report of pain during the 
Gardner treadmill test with either HF or LF-TENS was compared to that with placebo TENS.   
 
The main finding of this preliminary study is that compared to placebo, walking tolerance 
distance (ACD) increased with both HF and LF-TENS stimulation. ICD and FCD also increased 
with HF-TENS. However, no differences in ICD or FCD were observed with LF-TENS.  
 
The only observed difference between the groups was for ICD. The difference in walking 
distance with TENS intervention was greater with HF-TENS compared to LF-TENS. When the 
data for both groups was pooled, TENS was found to increase all measures of walking 
performance compared to placebo. When examining change in ACD using multiple linear 
regression, participant-controlled change in intensity of TENS stimulation was the only 
variable found to significantly predict a change in ACD.   
 
In conjunction with the laboratory study of TENS for lower limb ischaemic pain described in 
Chapter 8, the results of this study fulfil the aim of this thesis: to investigate the hypoalgesic 
effects of TENS on lower limb ischaemic pain and walking performance in patients with IC. 
TENS appears to be an effective intervention in reducing the perceived intensity of 
ischaemic pain and increasing walking distance. The current studies are however, 
preliminary and thus further investigation of TENS for IC is required prior to its acceptance 




CHAPTER 10: COMPARISON OF EXPERIMENTAL AND CLINICAL 
ISCHAEMIC PAIN  
10.1: AIM OF CHAPTER 10:  
In Chapter 8 the hypoalgesic effects of TENS on mSETT induced ischaemic pain in the lower 
limb of healthy volunteers was established. Chapter 9 reported similar findings in a sample 
of patients with IC pain walking on a treadmill. The mSETT model of laboratory ischaemic 
pain was used as a pre-clinical model of IC pain due to its apparent face validity: inducing 
ischaemic pain in the lower limb. What is not known however is whether the pain 
experience induced by the mSETT is similar to that of clinical IC.  
 
The subjective qualities of the experience of IC pain have not been fully explored in the 
literature. Thus, comparison of pain induced by the mSETT with clinical IC pain is limited. 
During the studies reported in Chapters 8 and 9, descriptions of pain were recorded using 
the MPQ. This chapter will describe and discuss the preliminary exploration of these 
descriptions of pain. The subjective qualities of pain reported by patients with IC pain will be 
compared with those reported by healthy volunteers with the mSETT. The analysis aims to 
examine similarities and differences in the pain experienced. Three concepts were 
examined: 1) the descriptive qualities of the pain, 2) the intensity of these qualities and 3) 
the overall pain experience.  
 
The aim of this chapter is therefore to analyse and compare the pain experience recorded 
during the studies described in Chapters 8 and 9. This analysis will contribute to addressing 
the aim of the thesis: to investigate the subjective description of the multidimensional 
qualities of ischaemic pain. If achieved, this improved understanding of the experience of 
lower limb ischaemic pain could inform future examinations of the impact of lower limb 




10.2: METHODS:  
10.2.1: Design:  
This is a post-hoc analysis of data gathered in two previous studies (described in Chapters 8 
and 9). Data gathered during the experiments was aggregated with the different studies 
forming two groups (clinical and laboratory). An analysis was conducted on the MPQ 
descriptions of the pain experienced by patients with IC when walking on a treadmill and 
healthy volunteers during the mSETT.  
 
10.2.2: Participants:  
Thirty-six patients with IC made up the clinical group and twenty-seven healthy volunteers 
comprised the laboratory group. Recruitment and inclusion/exclusion criteria were as 
previously described (Chapters 8 and 9).  
 
10.2.3: Study Procedure: 
Patients with IC completed a standardised treadmill test. Healthy volunteers completed the 




Participants were asked to describe the pain they experienced at pain tolerance using the 
vocabulary of the MPQ.  
 
10.2.5: Statistical Analysis:  
Data were collated, graphed and analysed for similarities and differences between the 
groups focussing on the central concepts of descriptive quality, intensity, and overall pain 
experience.   
 
To examine the descriptive quality of the two pain experiences, the Number of Words 
Chosen (NWC) and percentage utilisation of MPQ subclasses were calculated for both 
groups. A cut-off of greater than 50% utilisation was selected as an indication of agreement 
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amongst the participants (Chen and Treede 1985). More than 50% utilisation was selected, 
as this would indicate that the majority of participants in the group felt that an adjective 
from that subclass adequately represented a part of the pain experience.  
 
The intensity of the experience was explored through the ranks of adjectives in the 
subclasses with more than 50% utilisation. Using the method described by Melzack et al 
(1985), the weighted-rank of adjectives chosen was calculated and compared between the 
groups (Jerome et al 1988; Strong 1999). For an overall assessment of the pain experience, 
Pain Rating Index (PRI) scores were calculated and compared (Melzack et al 1985; Chen and 
Treede 1985; Jerome et al 1988; Strong 1999). These data were normally distributed (p > .05 
on Shapiro Wilk test) therefore independent student’s t-tests were used to compare the 
scores between the groups.  
 
Statistical significance was set at p = 0.05 (two-tailed). Analysis was performed using SPSS 





10.3.1: Participants:  
The participants were 36 patients with IC and 27 healthy volunteers. The groups differed in 
age (Table 10.1). 
 
Table 10.1: Participants included in the analysis with clinical or induced ischaemic 
pain.  
 Clinical  Laboratory 
Number of Participants 36 27 
Mean Age (range) 68 (53-85) 26 (18-45) 
 
10.3.2: Descriptive Qualities:  
The Number of Words Chosen (NWC) of the MPQ is a general measure of pain description. 
NWC can provide an overall indication of the severity and descriptive qualities of pain. In the 
current study, participants in both groups selected similar numbers of words to describe the 
pain experience (Table 10.2). The mean total NWC in the laboratory group was greater than 
that in the clinical group. This greater number of words chosen was not limited to one sub-
dimension of the MPQ with similar proportional differences between the groups in sensory 
and reactive subclasses (Table 10.2).  
 
Table 10.2: Mean (SE) NWC in each group.  
 Clinical Laboratory 
Total 9.1 (0.64) 10.8 (0.58) 
Sensory 4.9 (0.34) 5.6 (0.31) 
Reactive 4.2 (0.38) 5.1 (0.32) 
 
NWC provides an overall indication of questionnaire utilisation between the groups. The 
next part of the analysis aimed to examine whether the words chosen to describe the pain 
experience in both groups came from similar subclasses and thus described similar qualities 




Subclass utilisation was similar in both groups. Seven subclasses were utilised by greater 
than 50% of participants in the clinical group (1, 5, 9, 11, 16, 18 and 20) (Figure 10.1). The 
majority of laboratory participants also utilised the same subclasses. However, they also 
frequently utilised four other subclasses (7, 8, 14 and 17) (Figure 10.1).  
 
10.3.3: Intensity:  
Table 10.3 displays the subclasses and adjectives of the MPQ along with their classifications 
and rank. Highlighted by shading and with an asterisk are the subclasses with more than 
50% utilisation by clinical participants. The rank of adjective indicates its intensity compared 
to the other adjectives in the same subclass. In an effort to identify and compare the 
perceived intensity between groups the most commonly chosen adjective (mode adjective) 
was identified for each subclass with more than 50% utilisation in both groups (Table 10.4). 
The most frequently chosen adjective was the same for each group in three of the seven 
subclasses. For the other four subclasses, laboratory participants more commonly selected a 








Table 10.3: Classification of subclasses and ranked adjectives included in the MPQ. Subclasses highlighted by shading and an * are 
those with more than 50% utilisation by the clinical group.  
Subclass 
Adjectives and Rank 
1 2 3 4 5 6 
1 Temporal* Flickering  Quivering  Pulsing  Throbbing  Beating  Pounding  
2 Spatial  Jumping  Flashing  Shooting     
3 Punctuate pressure Pricking  Boring  Drilling  Stabbing  Lancinating   
4 Incisive Pressure  Sharp  Cutting  Lacerating     
5 Constrictive pressure* Pinching Pressing  Gnawing  Cramping  Crushing  
6 Traction Pressure Tugging Pulling   Wrenching      
7 Thermal Hot  Burning  Scalding  Searing    
8 Brightness Tingling  Itchy  Smarting  Stinging    
9 Dullness* Dull  Sore  Hurting  Aching  Heavy   
10 Sensory Miscellaneous Tender  Taut  Rasping  Splitting    
11 Tension* Tiring  Exhausting      
12 Autonomic  Sickening  Suffocating      
13 Fear Fearful  Frightful  Terrifying     
14 Punishment Punishing  Gruelling  Cruel  Vicious  Killing   
15 Affective-evaluative-sensory miscellaneous  Wretched  Blinding      
16 Evaluative* Annoying  Troublesome  Miserable  Intense  Unbearable   
17 Sensory-miscellaneous  Spreading  Radiating  Penetrating  Piercing    
18 Sensory-miscellaneous* Tight  Numb  Drawing  Squeezing  Tearing   
19 Sensory  Cool  Cold  Freezing     




Table 10.4: Mode adjective chosen in subclasses with more than 50% utilisation in both 
groups. Classification of subclasses is also included.  Note the higher rank of word chosen in 
the laboratory group for categories 1, 9, 11 and 16 (highlighted in bold). 
 
Classification  Subclass  
Mode Adjective 
Clinical Laboratory 
Sensory 1.Temporal Throbbing Pounding 
5.Constrictive Pressure Cramping Cramping 
9.Dullness Aching  Heavy  
Affective 11. Tension Tiring Exhausting 
Evaluative  16. Evaluative  Troublesome  Unbearable  
Miscellaneous 18. Sensory-Miscellaneous  Tight Tight 
 20. Affective-Evaluative-Miscellaneous Nagging Nagging 
 
10.3.4: Overall pain experience:  
The Pain Rating Index (PRI) score of the MPQ provides an overall measure of pain intensity. 
There are two different interpretations of the score: PRI Scale (PRI (S)) and PRI Rank (PRI 
(R)). The PRI (S) is the sum of all the ranks of each adjective whereas the PRI (R) is the sum of 
weighted adjective ranks as previously described (Melzack et al 1985). For the current 
analysis, both measures will be examined.  
 
10.3.4.1: PRI (S) 
All PRI (S) data are displayed in Table 10.5. Mean Total PRI (S) scores in the clinical group 
were significantly lower than the laboratory group. Similar findings were evident for both 
sensory and reactive subclasses (Table 10.5).  
 
10.3.4.2: PRI (R) 
Mean Pain Rating Index Ranked (PRI (R)) scores followed a similar pattern with laboratory 
participants reporting higher overall pain intensity (Table 10.5). Significant differences were 
found for total, sensory and reactive scores.  
 
When examining the mean weighted-rank of adjective chosen, the difference in PRI scores 
can be seen to be the result of a lower rank of word chosen in the majority of subclasses by 
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participants in the clinical group (Figure 10.2). Apart from subclasses 3, 8, 10, 17 and 19, the 
mean weighted-rank of adjective chosen was greater in the laboratory group (75% of the 
total subclasses). In addition, for all subclasses with more than 50% utilisation in both 
groups, the mean weighted rank of adjective was greater in the laboratory group (1, 5, 9, 11, 
16, 18 and 20) (Figure 10.2).  
 
Table 10.5: Mean (SE) PRI scores for both groups. Statistics represent independent 
student’s t-tests (two tailed). 
 
  Clinical Laboratory t (62) p 95% CI r 
PRI (S) Score Total  21.25 (1.32) 29.00 (1.83) 3.517 .001 3.4-12.2 .41 
 Sensory  14.47 (0.82) 17.43 (1.05) 2.259 .027 0.3-5.6 .28 
 Reactive  6.78 (0.71) 11.57 (0.93) 4.179 .000 2.5-7.1 .47 
PRI (R) Score  Total  20.03 (1.49) 28.21 (2.03) 3.330 .001 3.3-13.1 .39 
 Sensory  11.75 (0.80) 14.46 (0.93) 2.228 .030 0.3-5.2 .27 






Figure 10.2: Graph of the difference in mean PRI (R) scores between the groups for all subclasses. Positive scores indicate 





















10.4: DISCUSSION:  
The pain experience associated with IC has not been fully explored in the literature. This 
study provides the first comparison of clinical and experimental ischaemic pain in the lower 
limb. The results of this study suggest that ischaemic pain is a complex, multi-dimensional 
experience although a few key qualities appear to emerge.  
 
10.4.1: IC Pain:  
The first objective of this study was to provide a comprehensive description of the 
subjective qualities of IC pain. The most commonly selected adjectives to describe clinical IC 
pain were (in descending order): ‘aching’, ‘throbbing’, ‘troublesome’, ‘tight’, ‘cramping’, 
‘tiring’ and ‘nagging’. This represents 3 sensory (aching, throbbing and cramping), 1 affective 
(tiring) and 3 evaluative or miscellaneous (troublesome, tight and nagging) subclasses. The 
three sensory adjectives chosen to describe the pain experience suggest a nociceptive pain 
experience related to an ischaemic environment (Lang et al 2009). These correlate with the 
words use to anecdotally describe IC in the clinical literature (Olin et al 2010).  
 
Rüger et al (2008) investigated the pain experience associated with chronic ischaemia in the 
lower limbs of patients with PAD. One hundred and two participants were recruited with 
varying degrees of PAD (61 with Fontaine stage II and 41 with stage III or IV) from an 
inpatient ward in a large teaching hospital. These authors employed a number of 
questionnaires including the Short Form McGill Pain Questionnaire (SF-MPQ) with the aim 
of recording the subjective nature of the pain experience. The sensory descriptors ranked 
highest by participants with IC were ‘stabbing’, ‘cramping’ and ‘aching’. The only affective 
descriptor to be ranked highly was ‘tiring-exhausting’. In participants with Chronic Limb 
Ischaemia (CLI), sensory descriptors of ‘stabbing’, ‘hot-burning’ and ‘tender’ along with 
affective descriptors ‘tiring-exhausting’ and ‘punishing-cruel’ were ranked highest (Rüger et 
al 2008) (Table 10.6). Quality of pain is similar between the current study and that of Rüger 
et al (2008) and across the sub-groups (CLI, IC and Healthy volunteers). Further analysis is 
limited due to the different measures employed. The SF-MPQ does not allow the choice of 
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all the adjective present in the original MPQ. The results of the study by Rüger et al (2008) 
for describing the qualities of ischaemic pain are therefore limited.  
 
Sensory adjectives describing constrictive pressure (cramping) and dullness (aching) were 
highlighted in both studies. The punctuate pressure adjective of ‘stabbing’ was rated highly 
by patients in the study by Rüger et al (2008) although this was utilised by less than a third 
of participants in the current study (Figure 10.2). Temporal sensations (throbbing/pounding) 
were common amongst healthy volunteers and those with IC in the current study. However, 
they were not chosen frequently in the previous study (Rüger et al 2008). Healthy 
volunteers chose ‘thermal’ and ‘brightness’ descriptors. Adjectives ‘hot’ and ‘tingling’ were 
selected most frequently in the current study but this finding was only repeated in the CLI 
sample of Rüger et al (2008) (hot-burning) (Table 10.6).  
 
The affective dimensions of ischaemic pain seem to be focussed on ‘tension’ 
(tiring/exhausting) and ‘punishment’ (punishing-cruel/ gruelling). These factors were 
highlighted in both studies with punishment exclusively linked with CLI and laboratory-
induced ischaemic pain (Table 10.6).  
 
The SF-MPQ does not include evaluative or miscellaneous subclasses and therefore 
comparison with the current study is limited. The current study highlighted three specific 
evaluative and miscellaneous subclasses that may be integral to the ischaemic pain 
experience. The evaluative subclass of the MPQ was utilised by 81% of patients with IC and 
100% of healthy volunteers in the current study. The rank of adjective however, was 
different indicating different intensity between the groups. Patients with IC most commonly 
chose the word ‘troublesome’ whereas healthy volunteers selected ‘unbearable’. This may 
be a reflection of the temporal aspect of the two pain experiences i.e. the chronic nature of 
IC compared to the acute, transient nature of mSETT-induced pain. Patients with IC are 
more accustomed to the pain and therefore see it as annoying but have learnt to manage it 
effectively. Healthy volunteers, who are experiencing a new pain experience, may not know 




Other subclasses that were commonly utilised by participants in the current study were 
those that represent sensory-miscellaneous and affective-evaluative-miscellaneous (Table 
10.6). Over three quarters of patients with IC and healthy volunteers selected an adjective 
from subclass 18 with ‘tight’ being the most frequently chosen in both groups. Descriptors 
‘nagging’ and ‘spreading’ were similarly commonly utilised by both groups although less 
frequently (approx. 60 and 50% utilisation respectively).  
 
Table 10.6: Summary of the current descriptions of ischaemic pain in the literature 
compared with the results from the current study. Reported here are the highest 
ranked descriptors from the SF-MPQ (Rüger et al 2008) and the most commonly 
utilised adjectives from the MPQ (Current Study).  
 
Study Rüger et al (2008) Current Study 
Sample IC (n=61) CLI (n=41) IC (n=36)  mSETT (n=27) 







































From this general analysis, ischaemic pain due to claudication is characterised by a sensory 
experience of ‘aching’ and ‘cramping’ along with feelings of tiredness and fatigue 
contributing to the affective component. These descriptors are similar to those described in 
other nociceptive pain experiences (Wilkie et al 2001; Dobratz 2008) and suggest afferent c-
fibre activity related to tissue ischaemia (Hiatt 2001). The experience of healthy volunteers 
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with induced ischaemic pain and patients with CLI is slightly different. Additional, and 
different sensory aspects are described including ‘stabbing’ and ‘hot’ along with the 
affective aspect of punishment. This suggests a different, or additional aspect to the pain 
experience. Rüger et al (2008) hypothesised a neuropathic component of the pain 
experienced by patients with CLI associated with long-term ischaemia affecting perfusion of 
neural tissues. The findings in the current study with healthy volunteers appear to indicate 
similar mechanisms. The method of inducing ischaemia using a pneumatic cuff has been 
shown to produce ischaemia in peripheral tissues and thus must be reducing blood flow to 
peripheral tissues (Roche et al 2007; Seenan et al 2008). The results of the current study 
may suggest however that the mSETT method induces too much occlusion to be comparable 
to the IC pain experience. Patients with IC have varying degrees of lower limb vessel 
occlusion although not enough reduction in blood flow to cause pain at rest. By using a cuff 
inflated to 200mmHg (at least 60mmHg above any participant’s systolic blood pressure), a 
greater degree of occlusion of blood vessels may have been achieved. In addition to a 
greater restriction of blood flow, the neural tissues are likely to be compressed due to the 
general pressure produced by the pneumatic cuff (Sato et al 2012).  
 
Dubuisson and Melzack (1976) classified a number of pain syndromes by their ‘descriptive 
clusters’ from the MPQ. By highlighting any adjective chosen by more than 33% of 
participants, they identified important adjectives that classify specific pain experiences. 
Applying the same analysis to the data in the current study, core sets of adjectives are 
identified for IC pain and experimental ischaemic pain (Table 10.7). These ‘clusters’ are 
similar to those identified with the previous analysis (Table 10.6) that followed the analysis 
employed by Chen and Treede (1985). Overall, the resulting clusters of adjectives are not 
too dissimilar. For IC pain, the sensory adjective ‘hot’ was added to the list and the 
evaluative adjectives ‘troublesome’ and ‘spreading’ were removed. In the sample of healthy 
volunteers describing experimental ischaemic pain, the sensory adjective ‘tingling’ is 
removed; the affective adjective ‘tiring’ added; the evaluative adjective ‘nagging’ removed 




Table 10.7: Summary of the results from the two different methods of analysis.  
Analysis 
Mode adjective in subclasses with 
>50% utilisation  
Adjective with >33% 
utilisation overall 











































When following the analysis of Dubuisson and Melzack (1976) the descriptive clusters of 
adjectives are similar, yet unique, when compared with other pain syndromes (see Table 3.2 
in Chapter 3). IC pain shares some sensory adjectives with back, arthritic and menstrual pain 
but is unique in the inclusion of ‘hot’. For affective adjectives, ‘tiring’ is commonly used to 
describe menstrual, labour and back pain. The evaluative and miscellaneous adjectives used 
to describe IC pain are not included in the clusters describing the pain syndromes examined 
by Dubuisson and Melzack (1976).  
 
IC pain therefore appears to be a unique pain experience, characterised by specific sensory, 
affective and evaluative adjectives. In terms of pain intensity, IC pain has not previously 
been quantified. Melzack (1984) collated PRI scores of the MPQ, recorded in different 
clinical pain syndromes with the aim of comparing severities. In the current study, a mean 
PRI score of 21.25 was recorded for IC pain (Table 10.5). Using the data reported by Melzack 
(1984) this places IC pain above toothache, arthritis and fracture pain but below labour, 
back, cancer and phantom limb pain. No real conclusions can be drawn from this arbitrary 
ranking of pain syndromes, which are all complex, multifaceted and unique to the individual. 
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However, it does indicate that IC pain is an intense experience and worth further 
investigation.  
 
Studies conducted to date indicate that the ischaemic pain experience is one characterised 
by specific sensory, affective and evaluative perceptions. Sensory-discriminative 
components focus on adjectives of ‘cramping’, ‘aching’ and ‘stabbing’; affective-
motivational components ‘tiring’ or ‘exhausting’ and cognitive-evaluative components 
‘spreading’, ‘tight’ and ‘nagging’ (Table 10.6 and 10.7). This is comparable to other pain 
experiences in quality and intensity although it has its own unique features. This study 
provides a small but important initial step towards a comprehensive description of the 
experience of IC pain.  
 
10.4.2: Clinical and Laboratory-Induced Ischaemic Pain:  
The second objective of this study was to examine the qualitative experience of 
experimentally induced ischaemic pain in the lower limb of healthy volunteers. This 
description was then compared with the descriptions of the experience of IC in an effort to 
evaluate the possibility of using the mSETT method of inducing ischaemic pain as a model of 
IC pain for pre-clinical testing of analgesic interventions.  
 
The most commonly selected adjectives to describe experimental ischaemic pain were: 
‘heavy’, ‘unbearable’, ‘cramping’, ‘exhausting’, ‘tight’, ‘hot’, ‘pounding’, ‘tingling’, 
‘spreading’, ‘nagging’ and ‘gruelling’. Comparing these adjectives to those chosen by 
patients with clinical ischaemic pain, the pain experience induced by the mSETT seems to be 
a mixture of that associated with IC and more severe CLI (Table 10.6). The sensory 
subclasses representing temporal, constrictive pressure and dullness were commonly 
utilised, similar to the pain experience of IC. However, thermal adjectives, uniquely selected 
to describe the CLI pain experience, were commonly selected to describe mSETT-induced 
pain (Table 10.6). A similar pattern was reflected in the affective subclasses. All populations 
selected adjectives relating to ‘tension’ (tiring/exhausting) although participants with either 
CLI or mSETT pain uniquely selected adjectives from the subclass representing ‘punishment’ 
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(punishing/gruelling) (Table 10.6). These findings indicate that the mSETT induces pain that 
is more intense than IC pain and more like that experience by patients with CLI.  
 
Similar conclusions can be drawn from the analysis of PRI scores. Mean PRI scale, and mean 
PRI rank scores with mSETT were significantly greater than with IC pain (Table 10.5). For the 
mSETT to be utilised as a pre-clinical model of IC pain, it must induce a comparable quality 
and intensity of pain. The perceived intensity of a pain experience can be defined by 
sensory, affective and evaluative components (Melzack and Casey 1968). These components 
are interdependent and relate to the individual perception and experience of a situation. A 
strength of the current study was the use of the full MPQ that aims to measure these 
components of the pain experience and thus indicate where modifications can be made to 
more closely align the pain experiences of the mSETT and clinical IC. Differences were 
observed between the reported experiences in each of the three components (Table 10.6). 
This indicates that there may be multiple factors accounting for the observed differences in 
overall experience.  
 
In terms of sensory experience, adjectives that were either equally, or more intense were 
selected to describe mSETT compared to IC pain (Table 10.6). These findings may suggest a 
more severe ischaemic environment experienced with the mSETT procedure compared to 
that of IC. The ischaemic environment experienced during the mSETT is determined by the 
parameters chosen so small changes in the mSETT procedure could change the pain 
experience to more accurately reflect that of IC. This could be achieved through a reduction 
in the number of repetitions or the amount of force required in the submaximal exercise; a 
reduction in the pressure in the pneumatic cuff or the degree of pressure that the 
participants are required to maintain through the leg being tested. By changing the mSETT 
procedure, the sensory experience of IC pain may be more closely matched.  
 
For the affective and evaluative components of the pain experience, it may be more 
challenging to attempt to match the experiences. The affective and evaluative components 
relate to an individual’s mood, motivation, attitudes, beliefs and past experiences and these 
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are not as easily manipulated. Fundamentally, the two experiences are somewhat different. 
The mSETT is an acute, transient, laboratory-induced pain in healthy volunteers and IC is a 
chronic, illness-related pain experience in a generally elderly population. Due to these 
inherent differences in situation and therefore meaning of the experience for the 
participant, the affective and evaluative components will naturally be dissimilar. The higher 
rank of affective words chosen by participants describing the mSETT may be related to a 
greater degree of attention directed towards the ‘novel’ pain experience compared with 
patients with IC, who have daily leg pain. This relates to the ‘interruptive’ nature of pain 
(Eccleston and Crombez 1999) where pain is selected as cue to urge escape from a 
dangerous situation. If the pain has been experienced repeatedly over time, this urge to 
escape may have been suppressed: learning has occurred and the stimulus is now 
interpreted as ‘not dangerous’ and thus the affective response is reduced (Eccleston and 
Crombez 1999; Moore et al 2012). This obstacle is not likely to be overcome in laboratory 
setting. Even if the healthy volunteers were subjected to repeated tests to acclimatise them 
to the experience it would still not reflect the multifaceted experience of living with a 
chronic disease such as IC that causes daily pain and limits most daily activities (Gibson and 
Kenrick 1998; Wann-Hansson et al 2008; Egberg et al 2012).   
 
A laboratory pain model will not be able to reflect the unique feelings and emotional 
response of the clinical pain syndrome. The central aim of a laboratory model is to reduce 
the confounding variables associated with the clinical condition so that the effects of 
interventions on the common, physiologically driven, sensory experience can be studied. 
With this in mind, future study should focus on manipulating the sensory experience to 
match that reported in patients with IC.  
 
The mSETT induces a pain experience comparable to IC. It is established however, that 
clinical pain syndromes are complex and multidimensional with sensory, affective and 
evaluative components occurring simultaneously (Woolf 1979). These factors make patients 
with clinical pain syndromes less than ideal subjects for initial investigations into the efficacy 
of potential analgesics (Staahl and Drewes 2004). Clinically, patients often have confounding 
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co-morbidities and are likely to be taking some form of medication and may interpret other 
effects of the intervention, e.g. effect on anxiety or depression relating to the disease, as a 
relief of pain (Staahl and Drewes 2004). Experimental pain however, affords a degree of 
control over these possibly confounding variables and thus is used to study pain, its 
consequences and the effects of interventions. Consequently, the nature and purpose of an 
experimental pain method is not to mirror clinical pain in all its components; as if it did, it 
would not be fulfilling its purpose of eliminating the erroneous variables associated with 
clinical pain. What might be expected is for experimental pain to be similar in sensory 
experience. The current study demonstrates this function for the mSETT. The sensory 
experience is similar to that experienced with IC pain, and with further refinement may 
become even closer. The mSETT can therefore be seen as a suitable pre-clinical model of IC 
pain.  
 
10.4.3: Limitations to this Approach for Validation of the mSETT:  
This study addressed two objectives of the research programme: to investigate the 
subjective description of ischaemic pain and to perform an initial validation of the mSETT as 
a pre-clinical model of IC pain. These objectives were successfully achieved. However, there 
are important limitations that must be acknowledged.  
 
One factor to consider is the age of the participants included. The clinical sample had a 
mean age of 68 years whereas the sample of healthy volunteers had a mean age of 26 years. 
Gagliese and Melzack (2003) have identified that report of the quality of pain changes with 
age. A number of reasons for this difference have been speculated upon. It has been 
suggested that due to the increased chance of experiencing pain as a consequence of age, 
reports of pain reduce as it is seen as normality. The difference may also be attributed to 
normal age-related changes within brain tissue or a different understanding of the words 
employed within the MPQ (Gagliese and Melzack 2003). Regardless of the possible reasons, 
it presents a limitation of this study, as the clinical sample is considerably older than the 
healthy volunteers. This introduces inherent differences in reports of pain quality and thus 
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reduces the power of the comparison of pain experiences. Future studies could aim to 
match participants on age between samples.  
 
Another limitation of this study is the circumstance in which the clinical pain was recorded. 
MPQ descriptions of pain were completed immediately after a maximal treadmill test. This 
test is not something this group of patients complete on a regular basis and their normal 
experience of pain is during everyday walking activities. For the purposes of this study, it 
was important that this method was employed to ensure some parity of stimulus between 
participants. This also allowed for a possibly more valid pain experience to compare with the 
laboratory-induced pain due to its, transient, maximal and experimental nature. Future 
investigations looking to further investigate the IC pain experience may choose to do this in 
a different manner. For example, if the aim is to record the normal, everyday occurrence of 
IC pain, it may be more effective to use a postal survey method and ask participants to 
complete MPQs for the pain they experience during different activities of daily living.  
 
Overall, these limitations may reduce the power of the initial validation of the mSETT and 
the external validity of the IC pain description. Nevertheless, the methodological choices 
that led to these limitations were either made due to feasibility of the project or as a 




10.5: CHAPTER 10 SUMMARY: 
This chapter aimed to analyse and compare the pain experiences recorded during the 
studies described in Chapters 8 and 9. This analysis was completed in an effort to examine 
the pain experience of IC and compare this experience to that induced by the mSETT. This 
analysis thus explored the subjective descriptions of IC pain whilst also evaluating the ability 
of the mSETT to act as a pre-clinical model of IC pain. 
 
The findings of this analysis indicate that IC pain is a multidimensional experience. It is 
characterised however by certain key adjectives. Sensory-discriminative components focus 
on adjectives of ‘cramping’, ‘aching’ and ‘stabbing’; affective-motivational components 
‘tiring’ or ‘exhausting’ and cognitive-evaluative components ‘spreading’, ‘tight’ and 
‘nagging’. This pain experience is similar to those recorded in other chronic pain syndromes 
with sensory components reflective of a nociceptive pain experience related to ischaemia 
(Lang et al 2009).  
 
The pain experience of the mSETT is similar to that of IC although more intense. Similar 
subclasses of adjective were used to describe mSETT and IC pain. However, the precise 
adjectives chosen were commonly more intense and reflected those recorded with patients 
with critical ischaemia. Nevertheless, the mSETT can be seen to induce pain similar in nature 
to IC and is thus a suitable pre-clinical model. With more investigation and slight 






CHAPTER 11: AN INVESTIGATION INTO PATIENTS’ EXPERIENCES  OF 
USING TENS FOR DAILY LIFE WITH PAD AND IC  
11.1: AIM OF CHAPTER 11:  
The aims of this thesis are 1) to investigate the subjective description of the 
multidimensional qualities of ischaemic pain and 2) to investigate the hypoalgesic effects of 
TENS on lower limb ischaemic pain and walking performance in patients with IC. The first 
aim has been addressed by the studies described in Chapters 8 and 9 and the analysis 
described in Chapter 10. The analysis of MPQ descriptions of laboratory and clinical 
ischaemic pain indicate that it is a unique experience, characterised by certain adjectives. 
The second aim was also addressed by these studies. TENS was found to increase time to 
pain threshold, tolerance and endurance in laboratory ischaemic pain and increase walking 
distance on the treadmill in patients with IC. An important question however, not addressed 
in any of these studies is: if provided with a TENS machine and training for use at home, 
would patients with IC use the device and do they feel that it is a useful adjunctive 
intervention for their disease?  
 
The following chapter will describe a study that was conducted with the aim of beginning to 
address this question. This study took the form of a pragmatic, qualitative follow-up 
investigation to the clinical study of TENS described in Chapter 9. First, the methods 
employed and findings of the study will be discussed (sections 11.2 and 11.3). This will then 
be put into the context of previous research concerning the lived experience of PAD and IC 
(section 11.4).  
 
11.2: METHOD:  
11.2.1: Methodological Justification:  
The aim of this study was to explore the patient experience of using TENS at home for daily 
life with PAD and IC. As this aim of the study was concerned with individually constructed 
meanings, a qualitative approach was assumed with the aim of exploring the participants’ 




There is no distinct definition of qualitative research. The principles are employed in 
different ways depending on the discipline and concept of interest. In general terms, 
qualitative research can be described as “an empirical method of investigation aiming to 
describe perception and experience of the world and its phenomena” (Neergaard et al 2009 
p1). Within qualitative research there are three commonly utilised approaches: ethnography 
(Geertz 2001), grounded theory (Glaser and Strauss 1967) and phenomenology (Sokolowski 
2000).  
 
Ethnography is a qualitative research design that focuses on exploring the cultural 
phenomena in a group of people (Savage 2000). There is no single agreed definition of 
ethnography although one accepted description is that an ethnographical study is 
characterised by a mixture of qualitative and quantitative data collection, importantly 
including participant observation through prolonged fieldwork with associated time and 
resource implications (Savage 2000). The main limitation of adopting an ethnographic 
approach is the considerable time and resource implications. To be able to complete the 
process rigorously, extensive fieldwork is required to enable participant observation, which 
also has ethical implications (Alcadipani and Hodgson 2009). Ethnography however is 
especially suited to exploring and developing theory of behaviour in a group of individuals. 
As the current study aimed to elucidate the participants’ individual experiences of using 
TENS at home, ethnography was not deemed an appropriate approach.  
 
Grounded theory is concerned with developing theory through systematic collection and 
analysis of data (Glaser and Strauss 1967; Corbin and Strauss 1990). Characterised by clear 
methodological choices and specific steps in analysis, grounded theory is a commonly 
employed methodology in the healthcare literature. Grounded theory therefore describes 
the general methodology for developing theory that is ‘grounded’ in data that has been 
systematically collected and analysed (Corbin and Strauss 1990). Criticisms of grounded 
theory include the ability of the researcher to ‘ignore’ all related theories and 
preconceptions until later on in the analysis process. This ‘bracketing’ of knowledge is 
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difficult to achieve (Allan 2003). Nevertheless, as a description of well-developed qualitative 
research methods there are a number of useful principles that can be employed as elements 
in non-grounded theory research (Corbin and Strauss 1990). As the current study was not 
aiming to develop a ‘theory’ of participant experience of using TENS, grounded theory was 
not employed.  
 
Distinct from ethnography and grounded theory, phenomenology is a method of study that 
focuses on the phenomenon, or more specifically, the perception of phenomena by the 
subjects under examination (Sokolowski 2000). To achieve this perspective, thick description 
is used to explore how the subject consciously experiences reality. They are encouraged to 
engage with the world and make sense of it directly and immediately. The ultimate aim of 
phenomenology is to develop understanding regarding lived experiences by exposing 
assumptions about the ways of knowing (Starks and Brown Trinidad 2007). There are many 
benefits of this approach and phenomenology has allowed great development in the 
understanding of human consciousness and subjectivity (Giorgi 2005). This method could be 
useful for the current study as it examines the participants’ experiences of using TENS for 
daily life with PAD and IC. However, there are challenges when adopting a 
phenomenological approach. Due to a strict philosophy and specific approach, qualitative 
research termed ‘phenomenology’ often is unable to follow the correct methods of the 
approach (Giorgi 2006). These difficulties in achieving true phenomenological study are 
especially true in a healthcare context where research questions do not tend to lend 
themselves to a purely philosophical approach (Norlyk and Harder 2010). Any variation in 
method can cast doubt on the findings thus intricate planning and careful analysis is 
required to ensure success (Caelli 2001; Giorgi 2006).  
 
Due to perceived limitations with these approaches and the difficulties experienced when 
attempting to employ strict theoretical approaches in a changing healthcare research 
context, new qualitative methodologies have developed. These include, interpretive 
phenomenology (Benner 1994), interpretive description (Thorne et al 1997; Thorne 2008) 
and qualitative description (Sandelowski 2000, 2010). These methodologies are built upon 
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the foundation of the methodologies mentioned above although they are more practice-
focussed and aim to answer specific questions rather than focussing on theorising 
phenomena (Thorne 2011).  
 
As the aim of the study was to explore the participants’ lived experience of using TENS at 
home for PAD and IC, a phenomenological approach was assumed. The collection and 
analysis of the data however could also be described as qualitative description as a 
conscious attempt was made to stay as ‘close to the data’ as possible and limit the influence 
of any of the researchers’ preconceived perceptions (Sandelowski 2010).  
 
Qualitative description does not possess strict boundaries in terms of methodological 
choices. Rather it is a series of principles that guide systematic inquiry. The important 
characteristic of qualitative description is that it is founded in existing knowledge, 
thoughtful linkages and clinical experience rather than the more classically theory-driven 
approaches of phenomenology and grounded theory (Sandelowski 2000; Neergaard et al 
2009; Sandelowski 2010). A central difference between qualitative description and the other 
methods mentioned above is the method and aim of the research process. Qualitative 
description does not aim for thick description (ethnography), theory generation (grounded 
theory) or interpretive meaning of an experience (phenomenology). Rather the focus of 
qualitative description is to produce a “rich, straight description of an experience or an 
event” (Neergaard et al 2009, p 2). This type of analysis fits with the aims of the current 
study: to explore participants’ experiences of using TENS, not to generate theory regarding 
the use of TENS at home for PAD and IC. Criticisms of qualitative description question 
whether ‘pure description’ is possible as there will always be a level of interpretation by the 
researcher during the analysis. As discussed by Sandelowski (2010), qualitative description 
does not claim absence of interpretation, just limited interpretation as with any descriptive 
analysis (Giorgi 1992). Therefore, a phenomenological-based, qualitative description 




11.2.2: Design:  
Ethical approval for the study was obtained from the local National Health Service Research 
Ethics Committee. The study design was a pragmatic, phenomenological, focus group study. 
All participants were provided with a TENS machine, training and instructed to use it daily. 
After one month, all participants were invited to attend a focus group where they discussed 
their experiences. Prior to, and after the trial one month later, participants were asked to 
complete four short questionnaires (Figure 11.1).  
 
 
Figure 11.1: Study procedure 
 
11.2.3: Participants:  
A sample of 6 patients with stable PAD and IC were recruited from the original study 
population (Chapter 9). All 36 participants were approached via letter (Appendix 12) and the 
first 6 to reply were recruited for this study. Each participant received an information sheet 
and consent form (Appendices 13 and 14). If they were willing to participate in the study, 
they were asked to return the consent form along with a reply slip (Appendix 15) in a pre-




11.2.3.1: Inclusion and Exclusion Criteria:  
The inclusion and exclusion criteria used for this phase of the study are the same as that 
used in the previous clinical study.  
 
Inclusion:  
 Clinical diagnosis of PAD and stable IC of >3 months duration  
 Fontaine stage II 
 Resting Ankle Brachial Pressure Index (ABPI) <0.90 in at least one leg  
 Walking limited only by claudication 
 Independent and safe mobility (no walking aids) 
 Cognitively stable and able to follow instruction (MSQ score of 10, MMSE score of 
30)  
 Proficient in English (able to read and complete the questionnaires)  
Exclusion:  
 <40 years of age  
 Planned surgical or endovascular intervention for PAD 
 Any leg ulceration  
 Any Exercise-limiting co-morbidities e.g. congestive cardiac failure, angina, 
dyspnoea, MSK or neurological impairment  
 Co-morbidities causing pain in the lower limb  
 Ataxic gait or history of increased falls (unsafe for treadmill walking)  
 MI ≤6 months ago, Cardiac arrhythmia or Cardiac pacemaker 
 Current or previous sensation abnormalities in the lower limbs e.g. severe peripheral 
neuropathies 
 Cognitive deficits  
 Epilepsy 
 Medical diagnosis or self-reported psychiatric illness 




11.2.4: Procedure:  
11.2.4.1: Initial Meeting:  
Participants attended for an initial meeting, held in a private meeting room within the 
University campus. During this meeting, their informed consent was obtained, they 
completed two questionnaires and they were issued with a TENS device and trained in its 
operation by the primary researcher. They were also issued with step-by-step written 
instructions (Appendix 16), information, spare batteries and electrodes. The participants 
were informed that the device was being investigated for its effects on pain and walking 
performance. Any further questions or queries from the participants were addressed and 
the day and time for the focus group arranged. 
 
11.2.4.2: Second Meeting:  
At the end of one calendar month, participants returned to the same room at the university 
for the second meeting. The primary researcher facilitated a focus group discussion. An 
independent researcher was present to make notes on interactions and body language. 
Both researchers were familiar with the focus group topic guide (Figure 11.2). This guide 
was developed and the focus group carried out in a manner consistent with 
recommendations by Barbour (2008). The guide was developed by the primary researcher 
and reviewed by a clinical specialist in PAD who works with patients at the recruitment site 
and with specialists in focus group research. The primary researcher assumed the role of 
interview moderator for the focus group.  
 
The participants were introduced to the procedure of the focus group and completed four 
questionnaires. They were then asked to comment on the statements presented by the 
interview moderator (see Appendix 17). Discussions were audiotaped and an independent 
researcher took supplementary notes during the discussions. At the end of the focus group, 
participants were debriefed and an overview of the discussion presented by the moderator. 
Participants were invited to comment on the summary and to indicate any discussion points 





Figure 11.2: The focus group Topic Guide employed within this study.  
Focus Group Topic Guide:  
 
Start with introducing focus group and purpose of discussions: to elicit participants’ experiences of 
living with PAD and IC and using TENS for walking.  
 
 Thank you very much for coming along today. Can you please, as an introductory task, tell us 
your name and something you like to do in your spare time?  
 You have all been invited along to this discussion as you have PAD and IC and have been 
issued with a TENS machine for the past month. I’d like you to speak freely and explain your 
own opinions and experiences in the discussion.  
 I am going to read out a series of statements that will relate to your experiences. I would like 
you all to respond to these statements, contributing your opinions and sharing your views 
with each other  
 
Present these statements, one at a time, to the participants (prompts if required)  
 
 “Going for a walk is not a problem for me”  
 What factors, if any, affect your decision to go for a walk?  
 How do you feel when you know you have to walk somewhere? 
 Do you ever walk for pleasure/exercise?  
 “There is nothing that I can do to about my disease”  
 Have you received/sought any advice?  
 What do you know about the disease?  
 How did you find this out?   
 What treatment options are available?  
 “The worst part of the disease is the pain”  
 What frustrates you most about the disease?  
 When you think about your medical problems, what first jumps into your mind?  
  “TENS is the perfect treatment for walking in IC”   
 Does TENS make any difference to you?  
 How does it affect your walking?  
 Does its effectiveness wear off?  
 “TENS is easy to use for people with PAD and IC”  
 What would you change about it?  
 Would you use it differently?  
 “TENS is not for me”  
 What is it about using TENS that you don’t like?  
 Do you like the feeling of the stimulation?  
 Are you self-conscious when using TENS?  
 Do you tell people you are using it?  
 “TENS reduces the pain experience of IC”  
 What changes, if anything, about the pain you feel in your legs when you use TENS?  
 Does it work in any other way?  
 Do you have any other thoughts about TENS and/or walking activity that we may not have 
discussed already?  
 246 
 
11.2.4.3: Questionnaires:  
Participants were asked to complete four questionnaires during the study (Appendix 18):  
1. International Physical Activity Questionnaire (IPAQ) (Craig et al 2003) 
2. Vascular Quality of Life Questionnaire (VASCUQOL) (Morgan et al 2001) 
3. Short Form McGill Pain Questionnaire 2 (SF-MPQ-2) (Dworkin et al 2009) 
4. Patient Global Impression of Change Scale (PGIC) (Farrar et al 2001)  
 
At the initial meeting participants completed the IPAQ and VASCUQOL with the aim of 
recording a baseline of function and quality of life. At the second meeting, participants 
completed the IPAQ and VASCUQOL along with the MPQ-SF-2 and PGIC as a general 
indication of pain quality/intensity and their impression of the effects of TENS intervention.  
 
11.2.4.4: Analysis:  
When conducting qualitative research it is important to be explicit regarding the definition 
of terminology (Braun and Clarke 2006). This is necessary as commonly used terms such as 
coding, category or theme often have different meanings for different researchers. The 
meanings of these terms as far as this research is concerned are indicated below.  
 
Coding  
Coding is the process of identifying and labelling a transcript. Coding recognises words, 
sentences or sections that can be summarised by a short key word or short phrase. For the 
purposes of the current study, coding was used to identify meaning units.  
 
Category  
During qualitative analysis, categories are used to group and organise the coding of data. 





A theme can be defined as the classification of discrete concepts (Ryan and Bernard 2003). A 
theme should convey an important and common characteristic within the data and relate to 
the overall category.  
 
Sub-Theme  
As themes are a collection of discrete concepts they often contain a range of sub-themes. 
Sub-themes can be defined as “themes-within-a-theme” (Braun and Clarke 2006 p92). 
Especially common in large and complex themes, sub-themes help to provide structure and 
define the constituent parts of the overall theme.  
 
Process of Analysis:  
The discussions were transcribed verbatim, including non-verbal expressions such as silence 
and laughter. The text was analysed using manifest and latent content analysis (Berg 2009). 
Manifest content analysis focuses on the explicit words and their denotations whereas 
latent content analysis concerns the implicit ‘meaning’ and aims to capture the structural 
meaning of the text (Berg 2009). For the purposes of this study, manifest content analysis 
was used to describe the experience of living with PAD and IC and practical issues with using 
TENS. Latent content analysis was used to elucidate the meaning of these experiences and 
how they relate to general quality of life.  
 
The text was read, and reread independently by the primary researcher (CS) and a second, 
neutral researcher who was not part of the original research (0-2 months post data 
collection). Both of the readers identified ‘meaning units’ within the text i.e. words and 
phrases thought to carry a meaning of importance for the research questions (Wann-
Hansson et al 2008; Berg 2009). Similar to the analysis employed by Wann-Hansson et al 
(2005), each meaning unit was tested and explored using the questions:  
1. ‘What is it about?’  
2. ‘What does it mean?’  




These questions allowed the meaning units to be sorted into sub-themes, themes and 
categories. Initially, meaning units were sorted under the two main categories: ‘Living with 
PAD and IC’ and ‘TENS for daily life with PAD and IC’. An open-coding technique was 
employed to identify descriptive sub-themes that were ‘grounded’ in the data e.g. ‘grin and 
bear it’ or ‘coping with pain’.  
 
Once completed, the researchers met to discuss the sub-themes identified. Differences in 
analysis were addressed through discussion and reflection. The main source of discussion 
related to meaning units that were ‘double-coded’. Some meaning units appeared to relate 
to more than one of the identified sub-themes and discussion was required to come to a 
decision about which to retain. This discussion was held in the light of the overall analysis to 
ensure that the meaning units were coded under the sub-theme they best represented. 
Throughout this process, the focus remained on the manifest content of the meaning units.  
 
When agreement was reached, the researchers sorted the data by sub-theme and discussed 
their possible latent content. Through these discussions grouping of common sub-themes 
led to the formation of the themes e.g. ‘acceptance, adaptation and control of pain and 
disease’ (See Appendix 19 and Table 11.3).  
 
This process included constant reflection, discussion and re-evaluation by both researchers 
(2-3 months post data collection). All participants were sent an abridged report that 
included brief descriptions and examples of the themes for ‘member validation’ (3-4 months 
post data collection). All participants were in agreement that these themes accurately 




11.3: FINDINGS:  
11.3.1: Participants:  
Five participants (4 men) attended the focus group. The sixth participant withdrew due to 
illness unrelated to the study. Participant demographic data is detailed in Table 11.1.  
 
All participants were aged 55 or over, (mean age = 70.4, range = 55-82 years). The length of 
time from original diagnosis ranged from 6 months to 6 years. All participants had ilio-
femoral disease and ABPIs ranging from 0.41 to 0.81. The mean values were similar to those 
of all the participants in the main study (Table 11.1). In general, participants in this follow-up 
study had more severe disease (lower ABPI), shorter walking distances and lower WIQ 
scores. Participant 1’s ICD, FCD and ACD were considerably greater than the other 
participants, skewing the distribution (shown by the difference between the mean and 
median). Participant 4’s PCS score was greater than the other participants within this study 
and also greater than the mean for all the clinical study participants. This indicates that they 
have greater catastrophic beliefs related to pain. Participant 1 also reported the highest 
level of activity in the IPAQ and greatest quality of life as measured by the VASCUQOL, 
linking with their greater walking distances. The oldest participant (No. 2) had the lowest 
reported IPAQ and VASCUQOL scores along with the lowest ABPI although their ICD, FCD 
and ACD was comparable to the other participants (Table 11.1).  
 
All participants had coexisting illnesses other than PAD with the most common being 





















Ankle Brachial Pressure Index  
Initial Claudication Distance (m)  
Functional Claudication Distance (m) 
Absolute Claudication Distance (m) 
Walking Impairment Questionnaire (%) (Greater score = less impairment) 
Pain Self-Efficacy Questionnaire (Greater score = greater pain self-efficacy)  
Pain Catastrophising Scale (Greater score = greater catastrophising beliefs) 
Tampa Scale of Kinesiophobia (Greater score = greater pain-related fear)  
International Physical Activity Questionnaire (1-3; 1=Inactive, 2=Minimally 
Active, 3=HEPA Active)  
Vascular Quality of Life Questionnaire (0-6; greater = greater quality of life)  
Short Form McGill Pain Questionnaire 2 (0-10; 0 = no pain, 10 = worst possible 
pain)  
Patient Global Impression of Change Scale (Activity Limitation = 1-7; >4 = 
positive change; TENS = 0-10; 5 = no change, lower = more improvement) 
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Table 11.1: Participant demographic data at baseline. Coloured shading represents comparison between participants with darker 





(months) ABPI ICD FCD ACD WIQ PSEQ PCS TSK IPAQ VASCUQOL 
1 68 24 0.57 270 931 1200 49 56 5 33 3 4.8 
2 82 24 0.41 99 160 181 13 28 19 39 1 3.4 
3 71 6 0.61 25 94 117 42 38 6 40 3 4.3 
4 76 72 0.51 43 87 135 32 37 5 30 1 4.1 
5 55 36 0.81 48 135 165 45 48 37 39 3 4.3 
Mean 70 32 0.58 97 281 360 36 41 14 36 2 4.2 
Median 71 24 0.57 48 135 165 42 38 6 39 3 4.3 
Chapter 9 Mean  70 NA 0.63 86 202 259 48 40 12 38 NA NA 
The mean and median values are reported as an aid for interpreting the results of the study and for comparing with the mean for the overall study 
population described in Chapter 9 (also included). Highlighted in bold and in outline are the variables with a large change between mean and median values 
suggesting the presence of an outlier. 
 
 
Table 11.2: Participant data at baseline and follow-up (post TENS). Coloured shading represents comparison between participants 
as well as pre and post TENS.  
 
Participant 
IPAQ VASCUQOL  
SF-MPQ2 
PGIC Scale 
Baseline Follow-up Baseline Follow-up Activity Limitation TENS 
1 3 3 4.8 4.8 0.7 6 1 
2 1 2 3.4 3.9 1.1 2 5 
3 3 3 4.3 6.1 0.5 4 2 
4 1 1 4.1 4.6 0.2 2 5 




11.3.2: Methodological Considerations:  
The aim of the current study was to conduct a primary evaluation of use of TENS for daily 
life in a group of patients with PAD and IC. To achieve this aim, focus group discussions and 
content analysis were selected as the methodology of choice.  
 
To date, all qualitative studies examining the experience of living with PAD have used semi-
structured, individual interviews to gather the data. The current study employed a focus 
group methodology with the aim of being more natural, encouraging participant interaction 
and allowing contrasting opinions to be easily explored (Kitzinger 1994; Wilkinson 1998; 
Berg 2009).  
 
Manifest and latent content analysis (Berg 2009) were employed in an attempt to describe 
all aspects of ‘the experience of living with PAD and IC’ and ‘using TENS at home for daily life 
with PAD and IC’. Manifest content analysis was used to elicit the descriptive and functional 
meanings of the discussions while latent content analysis aims to focus on the underlying 
meaning of the discussions (Berg 2009). There are multiple meanings present in data and 
there is no right meaning, only the most accurate meaning from a particular perspective 
(Downe-Wamboldt 1992). This type of analysis seemed to encompass all the possible 
meanings and provide the richest interpretation of the data.  
 
Lincon and Guba (1985) proposed four criteria that should be considered when evaluating 
interpretive analysis to improve trustworthiness: 1) credibility, 2) transferability, 3) 
dependability and 4) conformability.  These criteria can be viewed as corresponding to: 1) 
internal validity; 2) external validity/ generalisability; 3) reliability and 4) objectivity in the 
positivist research paradigm (Shenton 2004).  
 
The issue of credibility was addressed in this study by examining and employing similar 
methods to the previous literature in the area. Also, at the end of the data collection and 





Due to the nature of qualitative research, the findings are context-dependent and the issue 
of transferability is thus debated. Nevertheless, to enable the clearest extrapolation of the 
results, participant demographic data was collected and is presented here along with other 
information to describe the specific context and aid in the generalisability of the findings.  
 
It is argued that credibility somewhat ensures dependability in qualitative research (Lincon 
and Guba 1985). Shenton (2004) indicates that further steps can be taken to increase the 
repeatability of the study and thus the intrinsic dependability. Therefore, with this is mind, 
this report includes detailed descriptions of the research design, data collection and data 
analysis.  
 
As the primary researcher was involved in the original study and immersed in the project, 
there is a considerable risk to the conformability of the research. To combat these issues, 
two main methodological issues were addressed. Firstly, to provide a clear ‘audit trail’ the 
analysis tables including verbatim quotations are included in the appendices (Appendix 19). 
This allows independent examination of the analytical steps. In addition, a second 
researcher who was naïve to the project analysed the transcripts independently and both 
researchers reviewed all analytical decisions.  
 
11.3.3: Themes:  
Before examining the experience of using TENS, it is important to establish the context in 
which it was being used. To this end, the experiences of this specific group of patients of 
living with PAD and IC will first be discussed followed by that of using TENS.  
 
The experience of living with PAD and IC was found to be characterised by feelings of 
frustration linked to a number of aspects of the disease. This was interpreted through five 
themes (Table 11.3). These themes will be explored alongside verbatim quotations from the 
focus group discussions. The experience of using TENS in daily life was characterised by a 
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combination of benefit and disappointment. These themes will be explored in turn with 
specific reference to the experience of living with PAD and IC.  
 
Table 11.3: Summary of interpretation of patients’ experiences of living with PAD 
and IC and using TENS for daily life in patients with PAD and IC  
Category: Living with PAD and IC Category: TENS for daily life with PAD and IC 
Themes:  Sub-themes: Themes:  Sub-themes: 
Frustration  Transient pain  
‘Grin and bear it’  
Social limitation  
Pain  Sensation  
Walking ability  
Pain  Fear  
Disease perception  
Physical limitation  
Control  Benefit  
Limited physical and 
social functioning  
Walking ability  
Transient pain  
Social activities  









Physical Limitation  
Walking ability  
Risks and benefit  









Attitudes and beliefs  
Benefits of walking  
Expectations  
Physical and social 
functioning 
Social activities  
Walking ability  
 
11.3.3.1: The experience of living with PAD and IC:  
 
Frustration:  
The main emotion interpreted from the participants’ discussions was frustration. The 
frustration was related to the transient and mild nature of the pain experience. They felt 
that the pain is not severe. However it is significantly disabling. It seemed to be this contrast 
 255 
 
that frustrated the participants. This indicates possibly that if the pain was more intense 
their limited mobility would be validated somewhat? This lack of intensity also seemed to be 
related to the transient nature of the pain i.e. the pain disappears as soon as they stop 
walking; therefore the pain is not perceived as being particularly intense.  
 
[P5] when it goes away you are like, well fine but when you go away again back it 
comes again so you stop again. That is, it is more frustrating than anything 
*P4+ that’s the worst part of this bloody pain, it’s the frustration of the pain … it’s not 
going to kill you but it is really debilitating … the thing is its sore but once you stop, it’s 
gone … that’s what puzzles me all the time … you think, oh god and you sit down and 
all of a sudden, bang and it’s not there 
 
[P4] But as I say they say ‘grin and bear it‘ but this has been going on for years and 
years for me, it’s like having a leg off- grin and bear it so you just, what can you do? 
 
[P5] there is only one thing that takes the pain away and that is when you sit down … 
that takes the pain away … and the frustrating thing is you only have to sit for half a 
minute if at that and it is away. Then you walk again and it comes back 
 
Similar to when participants discussed their pain, feelings of frustration were key 
components when discussing any limitations in lifestyle.  The feelings of frustration 
expressed by the participants were primarily related to social situations that they are not 
able to participate in fully as before.  
 
[P5]: the same as when you are walking to the football with them we have got a good 
bit, maybe, hmm I don’t know, 20 minute walk from the ground to the bus well, I’m 
like, miles behind them cause I cannae keep up with them ken what I mean. And even a 
lot of them are a lot older than me and they can ……… and you say to yourself ‘how?’ 
it’s the most annoying thing but once I stop like, I just need a minute and away I go 
again and its fine for maybe another couple of minutes then I have to stop again. 
That’s the most frustrating thing about it- you have got to stop. 
 
Along with frustration related to attempted participation there was also frustration related 
to an inability to participate. Simple tasks and Activities of Daily Living (ADL) are not possible 
and this lack of ability to fulfil their perceived role is reported as frustration.  
 
[P4] and it is that bloody frustration and then you think you will not bother coming the 
next time, I am just stuck indoors now and I can’t even go out in the garden to help the 
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missus and she’s like get yourself indoors, it’s that frustrating, it’s not the pain. It’s just 
up here (points to head) it’s not the pain 
 
Even when they do participate, it is not necessarily personal frustration about their ability to 
complete the task, but that they feel as though they are an inconvenience to others that 
frustrates them more.  
 
*P4+ you are a nuisance to them …. cause you are taking so long … it is, that’s the worst 
part about this pain, it’s the frustration 
 
A few participants expressed feelings of frustration related to the lack of options and the 
fact that healthcare practitioners just tell them that they need to put up with it.  
 
*P4+ it is, they keep saying ‘grin and bear it’ and that’s all I have been doing for years 
and years now……..  
[P5] yeah, me too- the very same; I'm just like, it will be 5 year, maybe 6 years I have 
had it and you just have to put up with it. 
 
As well as their own understanding, the patients report feelings of frustration related to 
others’ understanding of their condition and specifically the pain.  
 
[P4] the thing is you bleeding, you just think you can go on a bit more, a bit more and 
then you say no I can’t and you stop and the pain is gone ………. it’s funny, you know 
you can’t explain it to people what it is like unless they have had it you know like you 
*P5+ that’s what I’m saying, other people dinnae understand what the pain that you go 
through, ken what I mean? 
 
Pain:  
The discussions were interpreted to have a focus on the pain, a difficult convergence of a 
transient, yet chronic experience. Participants describe a classically intermittent experience 
that they were able to control to an extent although they also reported frustration 
regarding the chronicity of the prolonged experience with no perceivable endpoint. 
 
Pain was interpreted as the defining factor of the disease rather than the general systemic 
arterial disease that they are suffering. This is understandable as the pain is the daily, 
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debilitating symptom. Nevertheless, it is interesting that none of the participants discussed 
the general disease process and its implications. This could have been because they were 
attending this study that focussed on reducing the pain in their legs with TENS and therefore 
may have thought the focus of interest was pain. However, it could be a more general 
indication related to the way in which PAD and IC are managed and the education and 
advice these patients have received.  
 
[Moderator: I want you to just think about your health in general, what first jumps into 
your mind, what’s the first thing you think about?+ 
[P2] the pain in my leg. 
[P5] the leg, exactly. 
[P2] it stops you doing everything really. 
*P5+ that’s the only thing really, thing that bothers me, is the legs. 
[General agreement] 
 
Most of the participants had been advised to use paracetamol as pain relief. Often the 
reason provided for this was that this is the strongest form of analgesia they can take due to 
interactions with their other medications. The participants were laughing at this as they feel 
that paracetamol is inadequate as pain relief. They feel they need stronger painkillers and 
that, if provided, they would help.  
 
[P3] Paracetamol is what they say [General laughter] 
[P3] I might as well have a couple of sweeties …… I can’t have anything stronger than 
paracetamol because of the other things I am on but I might as well have a sweetie for 
all the good it does, it doesn’t make any difference 
 
This is a passive solution and indicates the biomedical-based beliefs of some of the 
participants. They feel as though they need an ‘intervention’ to ‘fix’ their pain and they have 
no control over their situation.  
 
When asked what they feel restricts their participation in normal activities, the participants 
report it is the pain rather than any limitation in ability to mobilise. Of course, this could be 
argued to be one and the same thing. This focus on the pain however, indicates that the 
patients perceive that it is the pain that limits their quality of life and participation in normal 
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Activities of Daily Living (ADLs), rather than the decreased mobility. In terms of interventions 
to address these issues, strategies that reduce the impact of pain may be most effective.  
 
Limited Physical and Social Functioning:  
Another theme that was interpreted from the discussions relating to pain was that of 
walking ability. Participants discussed this as an important factor of the disease. In essence, 
it seemed to be the fact that their pain and disability was outwardly obvious and therefore, 
embarrassing to them. This was especially evident in social situations when their 
impairment affected their participation.  
 
[P5] see the likes of when you have to carry on you try to keep up with them (the 
football crowd) ……. you start walking like all kind of funny like you have done the toilet 
in your pants, but you do because my brother has said to me many times, 
 
The environment was reported as an important factor that determined physical activity in 
this group of patients. This is another important factor to be cognisant of when planning 
general lifestyle interventions for IC.  
 
[P1] well em, not particularly. I can walk on golf courses if it is nice and flat and it is 
soft, going for a walk on hard roads is a problem for me and climbing up hills 
 
Along with not being able to complete normal household chores or social activities, the 
disease seems to affect participants Quality of Life (QoL) in other ways. Walking a dog would 
be greatly helpful for this patient population in terms of exercise and general cardiovascular 
health. However, because of the experience of pain and a lack of adequate counselling and 
support, they are dissuaded.   
 
*P2+ I couldn’t even contemplate having a dog now because I wouldn’t be able to walk 
it 
 
This feeling of frustration related to being an inconvenience to their friends and family was 




[P2] to come and do something, the first thing you think of is how much walking is 
involved …… and will I just be a damned nuisance if I go because I will be trailing back 
and behind the others …. you know? And you just don’t go 
 
This non-participation due to the pain was true also for hobbies although there seemed to 
be a greater attempt to adapt and continue participation in some activities. This is very 
positive and important for maintaining activity and general cardiovascular health. Not all 
participants had managed to continue with their hobbies and it would be important to 
ascertain what contributed to this participant’s decision process and try to instil this in 
others with IC.  
 
*P4+ it’s the same on the golf course, I’ve had to give up golf because you cannae, you 
cannae get, you pay to play 18 holes and you cannae get round, you get round about 8 
and that’s it, and your mates are saying ‘come on’ and you say I wish I could come on 
but that’s it and so I’ve stopped playing the golf and I’ve taken the bowling up and 
that’s helped me a hell of a lot, the bowling, and that 3 days a week for about 2 hours 
and I really look forward to that and funny enough when you are on there bowling, 
from the car to the bowling green your pain is there but once you get on the bowling 
green it is gone 
 
Acceptance, adaptation and control of the pain and disease:  
The text exposed a degree of acceptance by the participants related to the pain they 
experience.  
 
[P5] you just have to put up with it because you will get it, you will get the pain every 
day so you just have to get used to it, put up with it 
 
This could be interpreted as positive acceptance of the pain. However, the last four words of 
the sentence (‘put up with it’) seem to convey negative connotations. A lack of acceptance 
may suggest that the disease is seen as finite i.e. that they will not always experience the 
pain but it is something they just have to put up with for now.  
 
The participants’ general approach to the disease and pain was that they were stuck with it 
and nothing was going to change, or there is nothing they can do to change it. This also 
relates to participating in activities where, in some cases, they feel they just have to get on 
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with it because they want to do the activity and that means more to them than avoiding the 
pain.  
 
*P5+ because I don’t want to sit in that house, ken what I mean? ………. no way, so you 
just have to put up with it. 
[P4] yep, the world’s always saying to me ‘grin and bear it’ 
*P2+ ‘grin and bear it’. 
[P5] exactly. 
*P4+ and that’s been happening for 6 years, ‘grin and bear it’ 
 
Participants all displayed a clear understanding of the control they have over the pain. They 
know it will go away if they stop walking although this is contrasted with the distinct feeling 
of lack of control related to the long-term course of the disease and prognosis for the pain.  
 
*P3+ that’s your tablet isn’t it? That’s your simple cure- just stop walking and there is 
no pain 
 
*P5+ you have got to stop, ….. your mind is saying to you, ‘stop and it will go away if 
you stop’ …..  that’s right, it does go away yeah so you say to yourself, “what’s the 
point?” 
 
Participants seemed to feel that it was important to mention and discuss the fact that they 
hadn’t changed because of the disease. This could indicate that they don't feel that the 
disease has affected them too much but this was not borne out in the rest of the 
discussions. It might be that the patients are motivated to present a strong outward image 
in front of their peers. However, it could be that they are employing denial as a coping 
strategy i.e. they are not ready to accept the degree to which they are limited by the 
disease.  
 
*P5+ I've not changed, you just get on with it and that’s it. You get used to it ken 
 
The understanding that walking can help the condition seemed to be empowering for the 
participants. They are aware that their condition is progressive and in this participant’s case, 
inoperable, so to have something they can do to reduce the effect of the disease or slow its 




*P1+ I don’t think there is very much I can do about it …. well, what they told me was 
my problem is inoperable and em, the best thing I can do is walk as much as possible 
 
*P3+ if it is going to stop it getting worse, that’s what I am doing, I will keep doing it. 
Obviously, you would like a cure for it but it’s not going to happen overnight is it? 
 
[P1] because the chances are the more you walk the blood vessels sometimes kick into 
play  …… that’s what I have been told. And I think that my playing golf bears that out 
 
Nevertheless, others with less apparent knowledge and understanding feel as though there 
is nothing they can do about the condition. This lack of perceived control seems to lead 
them towards passive coping where the medical staff have the power and will eventually 
find a ‘cure’. This approach at face value may indicate a perceived lack of control but it may 
just be the way they have chosen to cope i.e. they feel they are powerless and thus attribute 
all the power to healthcare staff rather than being frustrated by trying to control something 
that they are unable to.   
 
*P3+ if what you are doing is going to help in the future. I can’t see you getting a pill 
that will cure it, obviously it is going to be something surgical I would imagine 
 
[P4] there is nothing you can do to change it.   
*P5+ yeah, well that’s what I think, that’s my theory as well 
 
[P4] You look back and the things I have got to take I think I am taking these because 
the doctor says to take them but is it making any difference? Say if I was to stop them, 
would it make it worse? 
 
The treatment options or the methods with which they can control the disease contribute to 
a sense of ‘grin and bear it’. Due to the perceived lack of effect of their options they feel as 
though they just need to get on with it, and/or accept that they will experience the pain.  
 
Participants discussed common strategies they employ to cope with the pain. They reported 
that when walking, they’re constantly evaluating where the next place is that they can get a 
seat and rest. It was important to note that they all reported making an effort to hide the 
fact that they needed a rest. They described going into shops, stopping to look in shop 
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windows, stopping to cross the road or pretending that they were waiting for a bus at a bus 
stop. This indicates an embarrassment or just motivation to hide their limited walking ability 
from strangers.  
 
[P2] but even before it is sore I think if you are walking you are very conscious of 
knowing, now I can get a seat just along there or there or I have seen me go into a 
shoe shop because they have the bits you can sit to try on shoes, I'm no trying on 
shoes, I just need a seat 
 
Some participants displayed a strong sense of control and seem to be coping well with the 
disease. This involved continuing with hobbies and general daily activities despite the pain.  
 
*P1+ one of them said to me, ‘I don’t know how you can play golf’ but you have just got 
to, if you want to get on with your life you just have to do these things 
 
This statement can be interpreted as demonstrating a greater level of acceptance of the 
disease and lifestyle limitation. This acceptance seems to have led to an increased ability to 
cope with the disease and a willingness to not allow it to limit their lifestyle. Other 
participants also displayed similar behaviour/ beliefs:  
 
[P2] when I am doing the ironing and things like that when you are standing you know 
for a while, and you have got to, you know the washing and ironing is done in small 
lots so you are not faced with a huge pile and standing for ages and I certainly can’t do 
any gardening, I've had a gardener for quite some time but I couldn’t do it 
 
By changing the way they approached their tasks they are able to cope with the disease and 
continue to achieve a level of independence.  
 
Overall, the participants most commonly referred to the general coping strategy of just 
getting on with life. As they feel there is nothing much they can do, or they are doing all 
they can, they have to just ‘grin and bear it’.  
 
[P3] and they have tried that treadmill with putting all the things on you and that and 
the lad explained at the time, it’s not going to cure you, we are researching it now to 
see what it is, and until you find out what is causing it but they already told me it’s the 
narrowing of the arteries that’s causing it and basically the smoking is causing that. So 
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there is not really a cure for it is there? Unless they take an artery out and replace it 
and I don’t see that happening. I mean and you get to our age, well not P5 but myself 
like, is it worth the while? Just put up with the pain I certainly wouldn’t rush along for it 
(surgery). 
[P5] no way, you just put up with it 
 
With appropriate education and management of expectations, it may be possible to affect 
and improve behaviour change and compliance with management strategies. This 
participant, when discussing taking medications displays knowledge and a good 
understanding of the reasons for taking them and therefore appears to have no problem 
with it.  
 
[P3] I have to take one too but it’s a preventative measure 
 
Contrast this with another participant who does not appear to have sufficient knowledge to 
understand and accept the management strategies. This is important when planning any 
intervention or management strategy: it must be accompanied by comprehensive 
educational input to help enhance patient understanding and engagement.  
 
[P4] You look back and the things I have got to take I think I am taking these because 
the doctor says to take them but is it making any difference? Say if I was to stop them, 
would it make it worse? 
 
Knowledge and Understanding:  
Another common aspect amongst the participants was a lack of knowledge regarding the 
pain experienced.  The participants indicated that the mechanisms behind the pain had not 
been explained fully to them and they had inferred this as healthcare staff not really 
knowing what is happening. It is important to note that they did not mention seeking this 
information independently from other sources. A lack of knowledge in the mechanisms of 
pain has been shown to result in pain-associated fear and avoidance behaviours (Leeuw et 
al 2007). As the participants see the pain as being from an unknown origin, they are unsure 




*P4+ it’s like when you say, you’re walking and when you stop and you sit down for two 
minutes and it gone and you think, that’s fine, and you get up again and it starts 
again. That’s what nobody has ever said to me, this is what’s happening with this 
disease, because it is a disease. Well you say it is there one minute and it is gone the 
next, you get up again and its come again, so but they have never explained to me 
what it is 
 
[P4] if they could explain to you what is causing the pain and if they say look, we can’t 
give you anything, well they can’t give you anything to get rid of the pain, maybe it 
helps ease the pain but you can’t get rid of it. If they could explain to you what’s 
happening and you could say oh, fair enough then 
 
In addition, even when the education is appropriate and relevant, it appears that patients 
do not always follow it.  
 
*P5+ and it’s alright for the doctor to say ‘lose weight, that will help’ but I’m not a big 
eater anyway so my biggest problem is cheese but I’m no gonna want to stop a things 
that I love just because the pain because how should I? I like to go for a pint at the 
weekend with the boys, I’m no gonna stop it …… because I don’t want to sit in that 
house, ken what I mean? 
 
The participants demonstrated a general lack of knowledge and understanding of the 
disease process in general. This uncertainty is not helpful, as patients do not know what 
they could do to affect their prognosis. The general assumption from the participants and 
therefore their approach to the disease is one which interprets it as an ‘acute’ condition i.e. 
they feel this is an inconvenience but eventually it will be ‘cured’. This is an incorrect 
perception as PAD is merely an initial indication of systemic arterial disease that commonly 
progresses to myocardial infarction or cerebrovascular accident (White and Gray 2007). It is 
therefore essential that patients with PAD accept this truth and work to modify their 
cardiovascular risk factors to reduce the chances of further cardiovascular complications 
(Milani and Lavie 2007).  
 
The participants seemed to have some understanding of this. However, they were not sure 
or hadn’t been reassured that what they were thinking was correct. With this uncertainty 




*P3+ I have only got it in one leg but I presume if I hadn’t taken the medication it would 
have spread to the other leg? 
*P4+ it is my right leg that bothers me too. If I hadn’t have stopped the smoking, would 
it have got worse? 
 
*P5+ that’s what he said to me, the only option is surgical, well that was like 2 years 
ago and I don’t know if anything has changed now but that was the only thing he said 
to me would help was that thing like you said ….. the stent or taking another bit out of 
my leg and putting it in but he said that is the last option 
 
The participants articulated pain-related fear. This was expressed as a concern regarding the 
possibility of causing damage by walking in pain.  
 
[P3] you know it is going to get worse …… it would be interesting to try to go further 
just to see what damage you would do but then it is too late by then 
 
As mentioned above, these beliefs are a direct consequence of patients’ knowledge and 
understanding of the disease. The beliefs expressed during the focus group discussions 
reflected a sense of fear of pain/ (re) injury.  
 
[P5] the pain is telling you to stop 
 
*P3+ it’s not permanent damage, you are not doing it permanent damage because 
eventually you will stop but if you pushed how far, you have done the treadmill you 
stop there because you are frightened to go a bit further because you don’t know what 
you are doing to yourself 
 
The participants reported feelings of frustration relating to other people’s understanding of 
their condition. The thing they felt was least understood was the transient nature of the 
pain.   
 
[P4] the thing is you bleeding, you just think you can go on a bit more, a bit more and 
then you say no I can’t and you stop and the pain is gone …. It’s funny, you know you 
can’t explain it to people what it is like unless they have had it, you know like you 
 
One participant suggests that the surgeon doesn't actually know what is happening with 
their disease and therefore doesn't know how to fix it. This could imply a number of 
different things: 1) that this patients feels that they could be and they need to be ‘fixed’; 2) 
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they have either had a conversation with their doctor who has given them poor advice/ 
education or they have chosen to interpret advice in this way; 3) they don't understand 
what is happening in their disease and they truly believe nobody else does, therefore they 
think it might be all in their head. Either way, the resultant feeling is of helplessness i.e. they 
can’t do anything about it so they have to ‘grin and bear it’.  
 
[P4] you know you think what the hell is the matter because once you stop as you said, 
once you stop the pain is gone ….. that’s what puzzling me all these years and it has 
been going on almost 10 years now and I keep saying to the surgeon and all that and 
they said we could tell you what the problem is and we could fix it but we don’t know 
what the problem is so all this is probably helping. But it is frustrating the problem you 
know is just in here (points to head) you just have to grin and bear it 
 
When presented with the option of surgery that might reduce their pain and increase their 
function, one participant refused due to the risk of amputation. This indicates that although 
they report great frustration related to their pain and disability, this is not severe enough to 
warrant risking amputation. It could be interpreted that they feel they are able to ‘grin and 
bear it’ at the moment so they do not need surgery.  
 
*P4+ as soon as they say you could lose your leg that’s me, forget about it, grin and 
bear it 
 
With appropriate education and advice, participants demonstrated good coping strategies 
and behaviour change. When instructed to walk as much as possible along with the 
knowledge that it might help with the disease, one participant demonstrated clear 
understanding of the benefits of walking. This indicates that with limited ways in which they 
can exert control of the disease, appropriate information and understanding of ways in 
which they can have an effect on their condition and disability have an impact.  
 
[P1] if I'm told by my doctors anyway without the TENS machine that the more I walk, 




11.3.3.2: TENS for daily life with PAD and IC:  
 
Pain: 
When using TENS during hobbies and ADLs, participants reported a positive effect. One 
participant reported that they experienced less pain than normal.  
 
[P1] a golf course that is quite difficult to walk and I used it and I did have some pain 
but certainly nothing like what I would have expected to experience. 
 
The pain reduction reported when using TENS appears to reflect Gate Control mechanisms 
of analgesia (Melzack and Wall 1965). The TENS employed seemed to work immediately to 
delay the perception of pain and continue through the experience, reducing the overall 
intensity.  
 
[P3] yeah, it sort of numbed the pain, more concentrated, you know instead. The 
tingling takes it away right away, the initial pain. It was definitely as I say, it has got 
potential; it is working on the right lines, it’s not taking the pain away, just covering it 
 
Control:  
One of the participants found that TENS helped them so much that they have ordered some 
more equipment for the TENS machine with a view to purchasing their own. This indicates 
that TENS helped to foster a sense of control over the pain for this participant and they feel 
they would like to continue using it.  
 
[P1] I will tell you how much I found how good, I have already been out and ordered, 
not that I have used them but I have ordered myself some new pads 
 
Expectations:  
Another participant didn't think that the TENS machine was useful for them. They reported 
that they still experienced pain and therefore they think TENS doesn't work. This indicates 
that this participant’s expectations were maybe not properly managed i.e. they thought 




*P5+ I would say it is easy to use but I don’t think it is any good for the disease, well 
that’s just my personal opinion, it didn’t do me any good. Well the pain was still there 
when I was using it 
 
When discussing the numbing nature of TENS together, it was reported to be positive as less 
pain was experienced. Nevertheless, despite this discussion some participants were not 
satisfied suggesting that they were expecting a greater degree of pain reduction.   
 
[P5] I still definitely got the pain with it when I did use it, did you P3? 
[P3] oh aye. Aye. I still had it but it was a different form of pain 
[P5] right 
[P3] it was sort of numbing, not so sore but it was still there 
 
*P2+ I didn’t feel that this sort of alleviated the pain at all, I was aware of the pulsing as 
you are saying but to me it wasn’t making things any better 
 
In subsequent conversation, the participant reporting a positive experience of TENS here 
explains that they had prior experience of TENS. This prior knowledge may have had an 
influence on their expectations of TENS and thus partially explain their positive reaction.  
 
[P3] my friend, she bought one, they told her it was a frozen shoulder, she bought one 
out of the chemist and was using it for about three weeks and she said, perfect, it 
worked perfect for her. She saw that one likes and the one she got was a lot smaller 
and she used it for 15 minutes in the morning and 15 minutes at night, shoulder is 
gone. She has had these injections and that and they didn’t do anything for her, so I 
mean, it must be good isn’t it? 
 
Another participant who reported a positive experience of using TENS also had a similar 
experience of TENS. They seem to display clear expectations of the effect of TENS. Even 
though they think this person had a different type of machine, they realise it works in a 
similar way and therefore any effects it might have had are attributed to TENS.  
 
[P1] I met a friend, a girl on the golf course and she, somebody had told me she had a 
TENS machine and I spoke to her and she has got some Japanese, I can’t remember 
what it is called but she found it on the internet and she must be the same sort of thing 
as the Japanese one, probably a wee bit more sophisticated than the TENS machine 
because I think she said she paid £70 for it but it has obviously got pads and she uses it 





When discussing how easy the TENS units were to use, participants reported little 
difficulties. One common issue were the wires leading to the electrodes. They suggested a 
wireless system, or one that they could just attach to their leg rather than their belt would 
be an improvement.  
 
*P1+ I don’t think there is any way that I could think to be improved just the fact that if 
it is on your legs, you have got to put the wires up through your trousers and then gets 
onto your belt 
 
They also reported slight embarrassment when other people observed the unit attached to 
their belt. Nevertheless, this didn't affect them too much as the pain is such that they are 
happy to endure slight embarrassment to achieve some relief.  
 
[P3] even adults were querying what it was. I am willing to try anything 
*P2+ that’s true, I’d try anything as well whatever might work 
 
The way the participants reported using TENS varied through the group. In general, they put 
it on when they knew they were going to be walking for a prolonged period of time. This 
was explained either as TENS was not needed for shorter journeys, or that it was too much 
hassle to put it on and off all the time. This is an important factor to consider when 
prescribing TENS for IC. Also, the device could be modified so that it is easier to put on/ take 
off which may help to increase the ‘usability’ of the device.  
 
[P1] it means I could walk further if I wanted to. The times I have used it....... I use it 
now only if I am going to be playing 18 holes of golf, I wouldn’t put it on if I had to 
walk down the street to pick something up at the shop it is quite difficult with me it is 
on a slight hill when I am walking home I feel a slight pain but I wouldn’t put the TENS 
machine on to do that 
 
More continuous use was reported in other participants. This seems to be more efficient. 
However, there are possible caveats. As they are using the pads and device for prolonged 
periods it would be important to constantly monitor the skin for any breakdown or adverse 
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reaction to TENS. These complications however, were not reported by any of the 
participants 
 
*P3+ every day, maybe not so much at the weekends but during the week and I didn’t 
put it on today because I was coming here. I would put it on in the morning and take it 
off at night and when I needed it I switched it on 
 
Use of TENS was not simple for all participants. This is a common issue amongst new users 
of TENS. For future studies and clinical utilisation of TENS, the ease of use should be more 
thoroughly addressed.  
 
[P1] is it easy to use? I would say for the majority of people, yes but I am one of these 
technophobe when it comes to any I find anything like that difficult but that is not to 
say it, that is only because of me, I think most folk would find it quite simple 
 
Another factor that affects the usability of the device is the feeling of the stimulation. One 
participant in the study reported this. They had a bad experience in the training session 
where they turned the intensity up too far so that it was unpleasant for a short while and 
this seems to have affected their use of the device, as they did not want to experience this 
again.  
 
*P5+ the thing about it for me was the tingling in my legs with it. I can’t bear it 
*P4+ oh I didn’t mind that, I enjoyed that, the tingling in your legs, aye it helped 
 
The participants in the study used TENS in different ways. They were not instructed to do 
anything in particular, as one of the objectives of this evaluation was to ascertain how they 
might use TENS independently. In general, most of the participants used the device when 
they knew they were going to be walking for a prolonged period. Half of the participants 
kept the device on all day and just turned it on whenever it was needed.  
 
[P2] yes, I put it on in the morning and had it on all day 
[P4] I used it three times a week for 3 hours up and down between the bowling green 




Physical and Social Functioning:  
Overall, TENS helps to increase walking ability and this has a direct impact on the 
psychological wellbeing of the participants. This participant reported being able to walk 
further with the TENS. However, it was the fact that they didn't experience the 
embarrassment of needing to stop and ‘shake their leg’ that they focussed on primarily.  
 
*P1+ if I didn’t have the TENS and this particular course I'm thinking, I could never get 
round that course without stopping and having to shake my leg and wait a minute 
which becomes quite embarrassing when you are playing with someone and you are 
holding them up 
 
The participants walked further and experienced less pain while doing so. They seem to be 
able to push themselves further so they are walking with ischaemia, rather than up to the 
point of ischaemia.  
 
[P3] it numbed the pain, you maybe walked a wee bit further. I did notice a couple of 
times my foot went numb when I had the machine on. Well that has happened before 
without the machine but it seemed to come on a bit earlier 
 
Nevertheless, there remained an indication that even though they could walk further, they 
might not want to. Further investigation is required to examine the determinants of walking 
in this group of patients although from the discussions observed in this study it could be 
suggested that a lack of knowledge and understanding of the disease process is a 
contributing factor.  
 
[P1] it means I could walk further if I wanted to. 
 
When using TENS for social activities and hobbies the participants found that it helped them 
walk further and participate more effectively. They didn't report that it took the pain away 
completely but it allowed them to walk further and cope with the pain better than without 
TENS.  
 
[P1] I find I could get round when I am using it now this is a golf course that is quite 
difficult to walk and I used it and I did have some pain but certainly nothing like what I 
would have expected to experience. So to answer your question I would say that the 
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TENS machine definitely lessens the pain whether I could, I can’t definitively say that it 
totally takes the pain away. 
 
11.3.4: Summary:  
The experience of living with PAD and IC was found to be characterised by feelings of 
frustration related to pain, decreased walking ability, decreased quality of life and 
knowledge and understanding of the disease. Other common themes related to coping and 
‘living with the disease’ were identified through participant discussions.  
 
Issues identified in terms of management were a lack of education about the disease 
process, possible self-management strategies and mechanisms of pain.  Future studies 
should examine the effects of implementing a structured educational and counselling 
programme for patients with PAD and IC. This may help address many of the aspects 
discussed including fear of pain, acceptance and adaptation to a chronic condition, increase 
feeling of control and thus develop positive coping strategies, encourage self-management 
strategies including walking and maintenance of hobbies, develop understanding of 
treatment options and expectations of their prognosis. This should also include family and 
friends to help reduce the feelings of frustration related to the perceived lack of 
understanding by significant others.  
 
The experience of using TENS at home for PAD and IC was interpreted as being one 
characterised by general benefit but also unrefined. Participants reported decreases in pain 
and increases in walking ability leading to increased participation and decreased feelings of 
helplessness. However, these benefits were limited and some participants didn't experience 
any perceived benefit from TENS. With further exploration during the discussions, common 
issues were uncovered including patient expectations and ease of use of the device. Future 
studies should aim to investigate TENS as a possible intervention for IC as it shows promise. 
However, the issued described should be addressed. Patient expectations need to be more 




11.4: DISCUSSION  
11.4.1: Background: 
The literature surrounding the experience of living with PAD and IC will now be summarised 
in an effort to place the results from the current study in context.  
 
Table 11.4 summarises the findings of previous studies next to those from the current study. 
The earliest reported qualitative analysis of PAD and IC was that by Gibson and Kenrick 
(1998). They interviewed 9 participants, 3-18 months post-surgery and used grounded 
theory to identify the themes related to the experience of living with PAD. ‘Pain’, 
‘powerlessness’, ‘someone else’s problem’ and ‘shrinking horizons’ were identified as 
themes in the context of the disease process (Table 11.4).  
 
Treat-Jacobson et al (2002) investigated the patient perspective on health-related quality of 
life. Thirty-eight patients with PAD were interviewed regarding their experience of living 
with the disease and the nature of the effect on their quality of life. The transcripts were 
analysed using a grounded theory approach and seven themes emerged (Table 11.4).   
 
Wann-Hansson et al (2005) continued the trend with a qualitative study where 24 patients 
at varying stages of the disease were interviewed about their experience of living with PAD. 
The interviews were conducted with specific reference to waiting for surgical intervention 
and three main themes were identified (Table 11.4). In a similar study, the same authors 
conducted a study where 14 patients were interviewed at 6 months, and 2 ½ years post-
surgery (Wann-Hansson et al 2008). Both of these studies, in contrast to the previous, used 
manifest and latent content analysis to examine the data collected. Again, three main 
themes were identified and these related to the aims of the study i.e. the experience of PAD 
post-surgery (Table 11.4).  
 
Galea et al (2008) used focus groups to identify barriers and facilitators to walking in 
patients with IC. They identified a number of personal and environmental factors that 
contributed to walking activity in this population (Galea et al 2008). The evidence and 
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rationale for walking was well summarised indicating that walking helps to prevent disease 
progression, increase walking distance (pain-free and maximal) and contributes to an overall 
increase in physical activity (Galea et al 2008).  
 
Egberg et al (2012) conducted the only qualitative study to focus on the experience of solely 
patients with IC. Interviews were employed with 15 patients that aimed to garner their 
experiences of pain, mobility, daily life and social life (Egberg et al 2012). Thematic analysis 
was conducted on the transcribed data and 6 themes were identified (Table 11.4).  
 
The current study is the only one that employs focus group discussion to gather the original 
data. Similar to Egberg et al (2012), only patients with IC were included but the text was 
analysed using content analysis in the same manner as Wann-Hansson et al (2005; 2008). 
The themes emerging from the current study are now discussed and compared in turn to 
the findings of these and other studies of the experience of living with PAD.  
 
 
Table 11.4: Summary of main themes identified in studies on the experience of living with PAD and IC  
Study  Gibson and Kenrick 
(1998) 




Wann-Hansson et al 
(2008) 
Egberg et al 
(2012) 
Current Study 
Participants 9 patients with PAD 
who had bypass 
surgery in the past 18 
months  
38 patients with PAD- 
varying severity (IC, 
rest pain and ulcers)  
24 patients with 
PAD- varying 
severity (IC, rest 
pain and ulcers) 
75% ischaemic 
ulcers 
14 patients with PAD at 
6 months and 2.5 years 
post-surgery 
15 patients with 
IC  




Grounded Theory  
Interviews  






Manifest and latent 
content analysis  
Interviews  
Thematic analysis  
Focus Group  
Manifest and latent 







Shrinking horizons  




Limitation in physical 
functioning  
Limitation in social 
and role functioning  
Compromise of self  
Uncertainty and fear  
Adaptation to the 
effects of the disease 
and demonstration of 
resiliency  
Being limited by 
the burden  
Striving to relieve 
the burden  
Accepting and 
adapting to the 
feeling of the 
burden  
Becoming better but 
not cured  
Recapturing control 
over life  





Moving around in 
a new way  
Feeling 
inconvenient 





in daily life  
To lead a 
strenuous life  
Frustration  
Pain  
Limited physical and 
social functioning  
Acceptance, 
adaptation and 





11.4.2: Themes:  
11.4.2.1: Frustration  
The feelings of frustration expressed by the current study participants seem to be common 
across previous studies. Frustration was identified related to a number of aspects of the 
disease. Treat-Jacobson et al (2002) found that physical, psychosocial and emotional 
disability and a lack of control over the disease lead to frustration, helplessness and despair.  
Galea et al (2008) in a study of barriers and facilitators to walking with PAD found that 
participants describe feelings of frustration and unease relating to ‘being noticed’ by others 
when stopping for a rest. This finding, related to others’ understanding of the disease and 
their associated embarrassment was also highlighted by Wann-Hansson et al (2005). They 
found that irritation and frustration were expressed related to the fact that other people 
were unaware of the pain and suffering and this has an impact on relationships.  
 
Gibson and Kenrick (1998) proposed a link between coping strategies employed and 
frustration. They suggested that people undergoing surgery may use passivity, dependency 
and lack of knowledge as coping strategies since trying to be in charge of a situation that 
they cannot control may lead to frustration (Gibson and Kenrick 1998).  
 
These sources of frustration could be minimised through educational strategies. With more 
knowledge and thus understanding by patients and their significant others, feelings of 
frustration may be reduced (Williams et al 1998; Schillinger et al 2002; Gazmararian et al 
2003).  
 
11.4.2.2: Pain  
Pain was found to be the most influential factor in patients’ everyday life (Wann-Hansson et 
al 2005). Everything revolved around strategies to relieve pain and reduce the impact on 
daily life.  
 
‘Pain’, ‘a burden’ or ‘leg discomfort’, were identified as major themes in a majority of the 
studies (Table 11.4). Pain was the most common symptom reported by participants, it was 
found to be unpredictable and had a great impact on daily life (Wann-Hansson et al 2005). 
The pain was described as a cramp and could be visualized as “a rope being pulled tighter 
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and tighter, as if the leg were being twisted, or being blown to pieces, or that it hurt so 
much that they felt nauseous” (Egberg et al 2012 p6) and burning, throbbing, pressure, 
bursting, stabbing and a terrible cramp (Wann-Hansson et al 2005). 
 
Strategies to relieve or cope with pain were also a major component of the discussions. 
Behavioural coping strategies have been identified as stopping for a rest, massaging their 
leg, limping, massage; rubbing, smearing the foot and touching (Wann- Hansson et al 2005; 
Galea et al 2008). Cognitive strategies for coping with pain included ignoring it, distracting 
or diverting attention and positive self-statements (Galea et al 2008). These are similar to 
those implemented by individuals with other pain syndromes (Boothby et al 1999). These 
strategies to relieve pain and promote circulation were interpreted as fostering a sense of 
control (Wann-Hansson et al 2005).  
 
Similar to the current study, patients did not like taking analgesics for pain either due to side 
effects or because they were ineffective and they preferred to find alternative strategies 
(Wann-Hansson et al 2005).  
 
Patients with PAD generally believe that walking is good for PAD/IC but confusion regarding 
the benefits or harm caused by pain during walking is a commonly reported issue (Galea et 
al 2008). They are unsure of the extent to which pain should be tolerated and what effect it 
is having (Galea et al 2008). This was also demonstrated in the current study. For patients 
with IC, walking acts as both a stimulus and a therapy for pain. This results in exceptional 
circumstances for engaging in walking (Galea et al 2008). If the pain can be reduced, even 
just a little bit, it might help them engage with the essential therapy that is walking. 
 
Further information regarding the nature of the pain and how these patients cope with it is 
required (Wann-Hansson et al 2005). Nevertheless, it seems that education regarding the 
mechanisms of pain and simple, pain-relieving interventions might help to reduce the pain-




11.4.2.3: Limited physical and social functioning  
PAD is a chronic experience with lifestyle changes and associated with a physical, social and 
emotional burden (Wann-Hansson et al 2005; Egberg et al 2012). Limitations in social 
activities resulted in a loss of interest and inspiration and contributed to involuntary 
isolation and huge emotional strain (Wann-Hansson et al 2005; Egberg 2012). This did not 
seem to be the case in the current study. Participants described a great interest in social 
activities, they just felt they could not do them or when they did, their performance was 
unsatisfactory.  
 
Scheduled walking sessions and supervised exercise programmes offer structure and 
consistency, motivation and companionship of like individuals (Galea et al 2008). Having a 
walking partner who understands the need for taking rest breaks and what is happening 
with the disease helped patients overcome the pain (Galea et al 2008). This relates to the 
need for information and education for families and significant others along with organised 
and structured walking groups or exercise classes.  
 
Wann-Hansson et al (2008) suggested that age could be a contributing factor to the 
decrease in physical and social function.  
 
11.4.2.4: Acceptance, adaptation and control of the pain and disease 
The experience of living with PAD can be seen within the concept of transition (Wann-
Hansson et al 2008). Essential properties of the transition process for chronic conditions are: 
awareness, engagement, change and difference, time span, critical point and events (Meleis 
et al 2000). Awareness relates to education and understanding of the condition and the 
realistic expectations of recovery. Engagement and change require appropriate coping 
strategies and acceptance of adaptation e.g. change in hobbies or method of completing 
ADLs. This has to occur over time and there will be crucial points where patients’ 
continuation will be challenged. Egberg et al (2012) found that the disease and disability is 
hard to accept for patients with PAD and IC due to the nature of the symptoms: they feel, 
and appear to others, healthier than they actually are. This is an important aspect to 
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address with tailored education strategies that stress the severity of the disease and with a 
focus on the presence of systemic, progressive atherosclerosis. Wann- Hansson et al (2008) 
found that post-surgery, patients did realise over time that the condition was probably not 
going to get better and this made them focus on at least not getting worse. This supports 
the proposition that challenging patient expectations and helping them engage with the 
chronicity of their disease could have positive effects on their engagement with self-
management strategies (Lawn et al 2011).  
 
A focus on curative measures (surgery) may affect patients’ perceptions of their disease 
leading them to expect a cure and limit ‘acceptance’ (Gibson and Kenrick 1998). Currently, 
the medical system manages PAD as an acute illness as evidenced by the modes of 
treatment and the lack of structured rehabilitation, education and support to facilitate 
patients’ adjustment to their illness (Gibson and Kenrick 1998; Wann-Hansson et al 2008). 
Beliefs that focus on a passive ‘cure’ or some type of ‘fix’ have been found to independently 
predict poorer functioning in patients with chronic pain (Turner et al 2000). These beliefs 
may have been reinforced by the current study. This study was focussed on a device that 
passively intervenes to reduce their pain; TENS therefore may reinforce these types of 
beliefs. Further study of interventions for IC should include an educational component 
where participants’ beliefs about their disease and the pain are explored and unhelpful 
beliefs challenged.  
 
Management of coronary artery disease includes well-established physical and psychological 
rehabilitation interventions and thorough education and understanding of patients and the 
general population. This method of management has been shown to encourage acceptance 
and empowerment leading to successful self-management (Dusseldorp et al 1999). Further 
focus on these principles of management in the PAD population is required as the current 
medical care and reliance on medications/surgery may evoke a feeling of helplessness and 




Effective coping strategies result in containment of uncomfortable feelings, generation of 
hope, enhancing of self-esteem, maintenance of relationships and maintenance of health 
status (Miller 2000). Trying to do the best to prevent further deterioration has been found 
to be a strategy that patients use to gain a sense of control of their disease (Wann-Hansson 
et al 2008). The most important ‘rule’ for patients’ with PAD and IC is to stop smoking and 
this could be seen as a coping strategy as it is one thing which the patient alone can control 
(Gibson and Kenrick 1998).  
 
In terms of walking, cognitive and behavioural pain-coping strategies were the most 
frequently mentioned facilitators for walking (Galea et al 2008). Companion and walking 
partners have been shown to provide a source of emotional support, primarily through 
verbal persuasion (Galea et al 2008). Support for patients with PAD should therefore include 
strategies to maintain a sense of normality, along with a focus on keeping symptoms under 
control with information about behavioural changes such as risk factor modification, 
exercise therapy and structured education programmes (Wann-Hansson et al 2005).  
 
11.4.2.5: Knowledge and understanding 
Patients with PAD waiting for intervention have difficulties with coping with self-image and 
functioning, feelings of depression, frustration and uselessness and need to have a sense of 
control over the future (Leech 1982 as cited by Wann-Hansson et al 2005). It is therefore 
important to manage patients’ expectations prior to treatment with information and 
education regarding the course and progression of the disease thus reducing stress and 
anxiety (Wann-Hansson et al 2005). Galea et al (2008) found that correct information from 
medical practitioners resulted in social coping strategies and increased the motivation to 
walk. Instructions to walk were heeded when the benefits were explained clearly i.e. 
walking will help to prevent further progression, not cure your disease (Galea et al 2008).  
 
The experience of living with PAD has been shown to result in a need to 1) understand, 2) 
adapt and 3) accept the physical limitations of the disease (Wann-Hansson et al 2005). 
However, questioning advice provided might entail acknowledging doubts in the efficacy of 
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the treatment (Gibson and Kenrick 1998). This obstacle was combated by use of social 
support and reasoning or accepting that the powerlessness and decrease in quality of life 
were a result of ‘old age’ (Wann-Hansson et al 2005).  
 
Participants’ uncertainty about the condition and lack of knowledge pertaining to the 
benefits of walking for intermittent claudication are cognitive barriers for engaging in 
regular activity (Galea et al 2008). Collins et al (2011) investigated the effects of a video-
based educational experience on knowledge of PAD and adverse events, dietary habits, and 
exercise behaviours. They found that a series of 4 videos increased self-report knowledge of 
1) the disease and possible cardiovascular events, 2) risk factors, 3) the fact that walking is 
beneficial and 4) that poor circulation is a disease (Collins et al 2011).  
 
Uncertainty and fear of doing something wrong when walking in pain affected patient 
adherence to exercise at the initial stages post diagnosis but over time it became more of a 
routine (Wann-Hansson et al 2008). One way to gain control was to assume the expert role 
regarding taking medicines, exercising, bandaging wounds and seeking information about 
PAD (Wann-Hansson et al 2008).  
 
An increase in knowledge and understanding can help patients with PAD accept the 
chronicity of the disease. Wann-Hansson et al (2008) identified a change of roles when 
chronicity was accepted where spouses took control over chores and getting a 
cleaner/gardener helped to make life more manageable. This was hard at first but works 
well when transition process is completed and is less likely to encourage feelings of 
frustration (Wann-Hansson et al 2008).  
 
Information and education must include ‘downwards comparisons’ (the ability to compare 
oneself favourably to another in a similar situation) and family or significant others to help 
minimise the impact of PAD on their lives and increase the efficacy of intervention (Wann-
Hansson et al 2008). Downwards social comparison is the theory that someone who is 
“experiencing negative affect can enhance their subjective through comparison with a less 
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fortunate other” (Wills 1981, p 245).  In the case of patients with PAD and IC, this might be 
through comparison with another person with PAD and IC whose disease is more 
progressed. Also, increased knowledge and understanding about the prognosis of their 
disease by the patient and their significant others may help to foster a sense of control over 
their condition, if not their prognosis.  
 
11.4.3: Strengths and Limitations of the Study:  
The purpose of this study was to explore the experience of patients with PAD and IC using 
TENS at home. It was hoped that the findings could inform further investigation of TENS for 
PAD and IC and provide an insight into the possible clinical use of TENS for IC pain.  
 
As the use of TENS in patients with PAD and IC had not previously been investigated, there 
was no established method for investigation or comparison. This study was designed as a 
pragmatic, follow-up investigation with the aim of generating descriptive and clinically 
informative data.  
 
The outcomes of the study support previous investigations of the experience of living with 
PAD and IC, highlighting a condition characterised by feelings of frustration. These negative 
feelings were commonly associated with pain but also with accepting and adapting to a 
chronic illness and adjusting to limited physical and social functioning. The experience of 
using TENS was characterised by feelings of benefit and usefulness but also disappointment 
at the lack of comprehensive analgesic effect. These are novel and informative findings. 
However, there are a number of methodological choices that have impacted on their 
credibility, transferability and dependability.  
 
The sample recruited to this study was selected to reflect patients with PAD and IC that 
would likely be provided with a TENS machine in a clinical situation. TENS is commonly 
provided to those who express an interest and who are suitable for the intervention. It is 
also provided only after a trial period that tests for efficacy. Purposive, pragmatic sampling 
included participants who participated in a treadmill study of TENS for IC (Chapter 9). All 
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participants were invited to participate in a ‘follow-up’ phase of the study and the first six to 
reply were included. This method of sampling was chosen as the participants included in the 
clinical study met the inclusion criteria of patients with stable Fontaine stage II claudication, 
limited comorbidities and no contraindications to TENS stimulation. Recruiting in this 
manner also imitated the clinical setting. The treadmill study could be considered as the trial 
period and the method of including those first to respond imitated patients indicating 
interest in trying TENS. These sampling choices allowed the study to reflect the clinical 
situation and thus increase the credibility or ecological validity of the study however they 
may have had a negative effect on transferability.  
 
This manner of recruitment that purposively included those who had already experienced 
TENS and who were most interested in trying TENS at home could have resulted in the 
collection of disproportionately positive experiences of using TENS at home. Their 
inclination towards trying TENS may have predisposed them to report positive experiences. 
The study findings may therefore not be typical and representative of all patients with PAD 
and IC.  
 
Conversely, these recruitment strategies may have targeted those who were most 
desperate to find a solution for their pain and thus were most interested to try TENS. These 
participants may therefore be characterised by more severe experiences of pain and/or a 
poor state of coping with their condition. These factors may have led to more negative 
experiences reported if TENS did not represent the relief for which they were searching. To 
address these potential challenges to the credibility, transferability and objectivity, future 
studies should attempt to recruit a more diverse sample and elicit the experiences of a 
wider range of patients with PAD and IC.  
 
Another factor that may have detrimentally affected the credibility of the findings of this 
study is the inclusion of the primary researcher as the focus group moderator. As the 
researcher conducted all aspects of the studies, the participants may not have discussed 
their use of TENS with the same, unbiased honesty if an independent researcher had 
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moderated the focus group. The participants may have felt that they did not want to cause 
‘disappointment’ by discussing and recording negative experiences.  
 
Nevertheless, by acting as the focus group moderator the primary researcher was in the 
ideal position to help direct the discussion and probe what they felt were particularly 
pertinent points. An independent researcher with less knowledge and understanding of the 
clinical condition and the research field may have failed to take the same opportunities. 
Therefore, using the primary researcher acting as the focus group moderator could also be 
considered a strength of this study as it may have allowed further exploration and 
elucidation of important aspects of the experience of using TENS for PAD and IC.  
 
On reflection, this connection with the study and understanding of the clinical area by the 
focus group moderator could have had additional negative effects on the generation of data 
and credibility of the study. As the moderator of the focus group was invested in the study, 
they may have inadvertently affected the discussion by directing it towards positive aspects 
of the experience of using TENS. This may have biased the findings of the study towards 
positive effects of TENS. Conversely the researcher, being cognisant of their positionality, 
may have directed the discussion towards the negative aspects by overcompensating. For 
future studies, it is important that the moderator of the focus group is an independent 
researcher so that there is less chance that their positionality may affect the data collection. 
Nevertheless, this independent researcher should possess a depth of understanding 




11.5: CHAPTER 11 SUMMARY: 
This study sought to investigate the experience of using TENS at home for daily life with PAD 
and IC. The findings support the previous work describing the experience of living with PAD 
and IC: a life characterised by feelings of frustration associated with pain, accepting and 
adapting to a chronic illness and adjusting to limited physical and social functioning. The 
experience of using TENS for IC was characterised by benefit but also disappointment. 
Different patients had different experiences that seem to be determined primarily by 
expectations and underlying walking ability or physical functioning. This is the only study to 
date that explores the experience of using TENS for IC and also the only known qualitative 
study on PAD and IC that utilises a focus group methodology.  
 
Overall this study adds a unique perspective to the literature in this area and highlights 
possible areas for future research including the potential therapeutic potential of TENS as an 




CHAPTER 12: GENERAL DISCUSSIONS AND CONCLUSIONS:  
12.1: AIM OF CHAPTER 12:  
Research has shown that IC is a complex, chronic pain problem that is associated with 
decreased physical and psychological function and decreased quality of life in patients with 
PAD. Despite good medical management of IC (risk factor reduction, exercise and 
pharmacological therapy), the problems of reduced adherence to exercise therapy and 
inadequate relief of pain remain, and continue to limit optimal outcome from current 
management. Poor adherence to exercise therapy, for example, leads to an increase in the 
risk of morbidity and mortality, especially from associated cardiovascular complications.  
 
This programme of research examined the efficacy of TENS as a safe, adjunctive therapy for 
IC. TENS is a possible adjunctive intervention for IC pain and if successful could prove to be a 
useful, inexpensive, non-pharmacological intervention that reduces the experience of IC 
pain and/or improves walking performance. TENS may therefore help to increase adherence 
to exercise therapy, and by so doing, reduce the chance of patients progressing to develop 
more serious cardiovascular disease.  
 
The research programme also examined the subjective descriptions of IC pain, which 
currently is an unknown factor, because these may be of assistance in designing and 
determining the efficacy of therapies for IC.  
 
A literature review was therefore conducted to establish the current state of the relevant 
evidence base. Figure 12.1 reminds the reader of the rationale for the directions taken 
during this programme of research. A chapter-by-chapter summary of key points emerging 







Figure 12.1: Flow diagram summary of the literature review and the research 





Two broad research questions were identified as encapsulating all of the above and thus 
were addressed within this thesis:  
1. What qualities characterise the subjective description of IC pain?  
2. What are the effects of TENS on measures of pain and walking performance in 
patients with IC?  
 
These two questions led directly to the two aims of the project: 1) to investigate the 
subjective description of IC pain and 2) to investigate the effects of TENS on measures of 
pain and walking performance in patients with IC. These aims were addressed through a 
series of studies previously described and discussed within this thesis, which included 
clinical and laboratory investigations in healthy volunteers.  
 
This chapter will present the central discussions and conclusions of this thesis. The main 
findings of the research programme will be discussed in relation to the research aims. 
Conclusions regarding these findings will be offered and implications and recommendations 
discussed. The limitations of this programme of work and how these limitations have 
affected the conclusions drawn will also be discussed.  
 
12.2: SUMMARY OF KEY FINDINGS FROM THE CURRENT PROJECT:   
The findings of this project will be summarised in relation to the separate studies and with 
reference to the research aim to which they contribute.  
 
The first study was the validation study of the mSETT, developed to induce ischaemic pain in 
the lower limb of healthy volunteers. The purpose of the study of mSETT-induced pain was 
to contribute towards the first research aim: to investigate the subjective description of IC 
pain. The mSETT procedure was developed with the purpose of creating a pre-clinical model 
of IC pain and was found to reliably induce pain in the lower limb of healthy volunteers. 
Test-retest reliability was established over two occasions in terms of time taken to report 




By completing a post-hoc analysis on MPQ data collected in the laboratory and clinical 
studies, the first research aim was addressed. The reports of ischaemic pain recorded using 
the MPQ in participants with PAD and IC and from healthy volunteers experiencing the 
mSETT, compared the subjective qualities of the two pain experiences. A cluster of 
adjectives (3 sensory-discriminative, 1 affective-motivational, and 2 cognitive-evaluative) 
characterised the IC pain experience. These adjectives are similar to those used to describe 
nociceptive pain related to an ischaemic environment and correlate with words used 
anecdotally to describe IC in the clinical literature. The pain experience associated with the 
mSETT was similar in quality to that reported by patients with PAD and IC. Laboratory pain 
was however rated as being more severe and intense than clinical IC pain as measured by 
the MPQ. This suggests that although inducing pain that is similar in quality i.e. through the 
same neurophysiological mechanisms, the parameters of the method require modification 
prior to being accepted as a model of IC pain.   
 
The second laboratory study addressed the second research aim. The mSETT procedure as 
developed in the first study was employed to test the effects of HF-TENS on lower limb 
laboratory ischaemic pain. These effects were compared with P-TENS in a repeated 
measures design. HF-TENS was found to increase time to report pain threshold, tolerance 
and pain endurance compared to No-TENS control and P-TENS. Pain intensity was reduced 
with HF-TENS from the 3rd to the 8th minute during testing compared to baseline and this 
effect was found to be greater than P-TENS in the 3rd minute and then from the 5th to the 8th 
minute. For pain quality, mean sensory, reactive and total PRI scores of the MPQ were 
reduced with both TENS interventions (P-TENS and HF-TENS). No difference was found 
between the groups. It was concluded therefore that HF-TENS has hypoalgesic effects on 
induced ischaemic pain in the lower limb of healthy volunteers.  
 
A clinical study of TENS for pain and walking performance in a sample of participants with 
PAD and IC was conducted to address the second research aim. Forty participants with PAD 
and IC were recruited from a claudication outpatient clinic to participate in a phase IIa, 
‘proof of concept’ study. The effects of HF and LF-TENS compared to P-TENS were 
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investigated in a repeated measures design. In relation to walking distance, HF-TENS was 
found to increase time to ICD, FCD and ACD compared to P-TENS. Only ACD increased with 
LF-TENS compared to P-TENS. In a between-group comparison, HF-TENS was found to 
increase ICD more than LF-TENS. However, no difference between the groups was found for 
FCD or ACD. When the data were pooled and the effects of ‘TENS intervention’ analysed, 
significant changes in ICD, CD and ACD were found with a median change in ACD of 35.5m 
compared to P-TENS. Positive relationships were observed between all measures of walking 
performance (ICD, FCD and ACD) indicating a common, consistent development of pain over 
time. Positive relationships were also found between baseline measures of FCD, ACD, WIQ 
and PSEQ. Negative relationships were observed between PCS and PSEQ, PRI and PSEQ, BMI 
and PSEQ and PCS and WIQ. For the experimental measures, the only positive relationships 
were observed between ΔICD and BMI and between ΔACD and change in TENS intensity. No 
relationships were found however, between either the most common physiological measure 
of PAD and IC severity (ABPI), or measures of pain intensity (PRI) and measures of walking 
performance. This suggests that walking distance in patients with IC is not related to disease 
severity and pain intensity. Multiple regression analysis was performed on ACD and ΔACD. 
Significant models were produced that explained variance in both variables. No variable was 
found to independently predict ACD. However, change in TENS intensity was found to 
predict ΔACD.  
 
The following overall conclusions can be drawn from the results of this ‘proof of concept’ 
study: TENS is associated with an increase in walking performance in patients with PAD and 
IC, with HF-TENS being more effective than LF-TENS. The effect of TENS therefore merits 
further investigation in this population. The results of the correlations and regression 
analysis also warrant further investigation. These data suggest a central role of pain and its 
associated psychosocial factors in walking performance for patients with PAD and IC.  
 
In addition to the original aims of the programme of research, a study was conducted with a 
small sample of participants from the original clinical study. TENS had been shown to 
improve treadmill walking performance for patients with PAD and IC. However, an 
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important question arising from the research was: if provided with a TENS machine and 
training for use at home, do patients with IC use the device and do they feel it is a useful 
adjunctive intervention for their pain? A pragmatic, qualitative follow-up study was 
designed and six participants were recruited from the original clinical cohort. The 
experience of living with PAD and IC was found to be characterised by feelings of frustration 
related to pain, decreased walking ability, decreased quality of life and poor knowledge and 
understanding of the disease. The experience of using TENS at home for PAD and IC was 
characterised by general feelings of benefit but also disappointment. Unrealistic expectation 
of effect was a common theme along with ease of use. Overall, TENS was judged to be of 
benefit for daily life with PAD and IC although further study is required to explore the issues 
identified and to investigate any benefits in terms of health and quality of life.  
 
12.3: GENERAL DISCUSSIONS:  
The following section aims to discuss the general findings of the studies included in this 
programme of research. The implications of these findings for clinical practice and further 
research will be explored with special reference to how they relate to other research 
conducted in the area. The limitations of this programme of research will also be addressed. 
Finally, overall conclusions will be presented to complete the thesis.  
 
12.3.1: General Findings Related to Research Aim 1:  
12.3.1.1: The pain experience of IC is characterised by specific descriptive 
adjectives and the mSETT could provide an adequate laboratory representation  
When investigating the effect of a painful condition on patient quality of life, or when 
designing interventions for painful conditions, an understanding of the sensations that are 
to be reduced is helpful (Dubuisson and Melzack 1976; Galer et al 2000; Holtan and 
Kongsgaard 2009). Similarly, to interpret the effect of an intervention requires investigators 
to have an appreciation of the different components of the pain experience. This 
understanding commonly stems from an appreciation of the subjective description of the 
pain experience. Prior to the commencement of this research programme, the subjective 
description of the pain experience of IC had not been investigated. Thus, the results of these 
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investigations of the IC pain experience could help improve the understanding of the 
multidimensional nature of IC pain and inform the investigation of novel therapies that 
target IC pain.  
 
The examination of IC pain in this thesis involved recording patients’ reports of pain 
immediately after completing a maximal treadmill test (Chapter 10). Analysis of these 
reports identified a group of adjectives that seem to characterise the experience of IC pain. 
This exploration of IC pain represents an important step towards a greater understanding of 
the pain experience.  
 
A similar investigation was also conducted in laboratory-induced lower limb ischaemic pain 
with the aim of developing a pre-clinical model of IC pain (Chapter 10). MPQ descriptions of 
pain were recorded from healthy volunteers immediately after completing the mSETT 
procedure. The adjectives selected were compared to those selected by patients with IC and 
analysed for similarities and differences. The results showed that when describing mSETT-
induced pain, healthy volunteers commonly chose adjectives that were similar to those 
selected by patients with IC pain. They did however tend to select adjectives that described 
a more intense pain, similar to that recorded in patients with more progressed lower limb 
atherosclerosis and profound ischaemia. These findings suggest that the mSETT procedure 
successfully induces ischaemic pain although it seems to be more severe than that 
experienced by patients with IC.  
 
As discussed in Chapter 10, the differences between the two pain experiences are most 
likely due to the mechanisms and situational aspects of induction. The degree of ischaemic 
environment created using the mSETT method is readily manipulated (Pertovaara et al 
1984). Thus slight changes in the parameters employed in the mSETT may result in an 
experience that is more similar to IC pain. These changes could address the differences in 
the sensory-discriminative aspects of the pain experience. The affective and evaluative 
aspects of the clinical pain experience will be harder to match in the laboratory situation. 
However, this inability to match the affective and evaluative components of the pain 
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experience is one of the cornerstones of experimental models of pain. The advantage of 
experimental pain is the ability to induce pain that is unaffected by the confounding co-
morbidities and psychological aspects of disease present in clinical pain. Therefore it is 
unrealistic and somewhat counterproductive to strive for a model of induced lower limb 
ischaemic pain that mirrors the affective and evaluative components of IC pain.  
 
12.3.1.2: The mSETT is a reliable method of inducing lower limb ischaemic pain in a 
small sample of volunteers  
One of the aims of this research programme was to develop and evaluate a method of 
inducing ischaemic pain in the lower limb of healthy volunteers. The mSETT method 
described in Chapter 7 achieves this aim by inducing consistent and safe levels of pain, albeit 
in a small sample. Test-retest reliability was established over two occasions and the quality 
of pain induced was also explored and compared to clinical ischaemic pain.  
 
No published study has attempted to develop such a method. There are no previous reports 
of the test-retest reliability of any experimental ischaemic pain method. Therefore the 
findings of this study have value as a new laboratory method of inducing lower limb 
ischaemic pain.  
 
The current examination of this method is within a small sample (n = 11). Pain 
measurements were only examined over two occasions and no inter-rater reliability was 
assessed. A reliable method could provide a laboratory model of IC pain and be used to 
examine the interaction of the pain experience with daily tasks and interventions. Also, as a 
laboratory model of ischaemic pain, this can be used in the same way as the upper limb 
SETT has been employed. For example, it can be used for the testing of analgesic 
interventions (Smith et al 1966; Posner 1984; Benedetti 1996; Amanzio and Benedetti 
1999). It can also be employed for laboratory testing of the relationships between 
psychosocial variables and the experience of pain e.g. attention and fear of pain (Moore et 
al 2013). Moreover, the method can be used for examining the effects of TENS parameters 
(Claydon et al 2011; Chen and Johnson 2011); similar to the study described in Chapter 8 of 
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this thesis. This first development of the mSETT is a unique contribution to laboratory of 
pain and for ischaemic disease.  
 
12.3.1.3: Psychosocial variables correlate with walking performance in patients with 
IC 
The pain experience of IC is thought to be a central determinant of walking performance in 
patients with PAD (Hiatt 2001; Egberg et al 2012). In the current study however, the central 
role of pain intensity in determining walking distance in patients with PAD and IC was not 
comprehensively supported. The analysis of relationships between variables in the clinical 
study found no direct relationships between pain intensity (PRI score) and ACD. Clinical 
thinking based on a biomedical model of health (related to the relationship between pain 
intensity and function) would predict a strong relationship between the two as ACD is 
conceptualised as a measure of pain tolerance (Oka et al 2006). However, the 
biopsychosocial literature on chronic pain has shown a central role for psychosocial 
variables in the pain experience of chronic disease. These results therefore point to the 
need to examine psychosocial measures related to disease, pain and function in IC.  
 
The measures found to be related to ACD were WIQ score (rs = -.46, p = 0.005) and PSEQ 
score (rs = 0.37, p = 0.026). The WIQ is a self-report assessment of walking ability that is 
closely correlated with treadmill walking measures (Regensteiner et al 1990; McDermott et 
al 1998). Therefore these results were expected. The conclusion regarding this observed 
relationship is that the participants in the study are accurate in estimating their walking 
ability and the questionnaire records this sensitively.  
 
Despite the lack of relationship between pain intensity and the clinical variable ACD, the 
positive relationship between PSEQ and ACD indicates that pain beliefs related to self-
efficacy (a motivating aspect of the pain experience) play a central role in walking 
performance in patients with PAD and IC. PSEQ score is a measure of the responder’s 
confidence, or self-efficacy, in their ability to perform tasks despite their pain (Nicholas 
2007). The positive relationship between this and ACD suggests that a patient with PAD and 
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IC who has increased self-efficacy beliefs related to their pain, walks a greater distance on 
the treadmill.  
 
In general, these results confirm the lack of strong associations between biomedical 
variables and pain intensity in chronic disease. They do however indicate a central role for 
psychosocial variables in mediating between pain and functional performance.  
 
As discussed previously, pain is a complex experience, not just defined by the intensity of 
the experience. Associated psychosocial factors, and particularly self-efficacy, have been 
shown to have significant effects on many aspects of health and function across a variety of 
pain conditions (Keefe et al 2004; Turner et al 2005; Woby et al 2007; Nicholas 2007). The 
unique results of this programme of research indicate that psychosocial factors and 
predominantly pain self-efficacy are also influencing factors on walking performance in 
patients with PAD and IC.  
 
These results can now add to the growing evidence that psychosocial factors play a major 
role in the experience of PAD and IC, and in influencing the outcomes from exercise therapy. 
Depression has been identified as a common negative psychological feature of PAD and IC 
(Smolderen et al 2008; Garnefski et al 2009). Pain self-efficacy can now be identified as a 
positive variable in PAD, which may help to counteract depression in coping with PAD and 
IC. Collins et al (2010) and Sol et al (2011) have shown the important role of general self-
efficacy beliefs in patients with PAD. Neither of these studies however, reported on pain-
related self-efficacy as identified in the current programme of research. The self-efficacy 
measure chosen for this study is a psychometrically designed measure for illuminating self-
efficacy specifically for completing activities despite pain (Nicholas 2007). The use of this 
measure in this research programme has allowed identification of the role of pain-specific 
self-efficacy in patients with PAD and IC.  
 
Finally, although pain catastrophising has been found to be important in certain 
musculoskeletal pain conditions (Quartana et al 2009), this was not found to be the case for 
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the patients in the present study. One explanation may be that catastrophising has less 
influence for patients with PAD as they have grown very used to their daily pain problem 
and thus do not develop catastrophising thoughts to the same degree as those with other 
chronic pain syndromes. For example, patients with back pain have often had their lives 
suddenly interrupted by pain and a sudden decrease in function. These patients have been 
shown to exhibit high levels of pain catastrophising (Buer and Linton 2002). Patients with 
PAD, on the other hand, experience a more gradual development of pain and loss of 
function. They also experience IC pain daily, perhaps hourly, on movement. Patients with 
PAD may have adapted more to the condition and thus avoid the extremes of pain 
catastrophising. 
 
As said before, these findings are from a small sample, are recorded with self-report 
measures that are not designed for use in IC pain and employed in a cross-sectional design. 
A future study could investigate the influence and relationships between these psychosocial 
factors in a larger, longitudinal study of patients with PAD and IC. This type of investigation 
could further elucidate the specific relationships between these psychosocial variables and 
pain and function whilst also possibly providing indications of causality. Such a study could 
also be combined with the adaptation of questionnaires to test these constructs specifically 
in an IC population.  
 
12.3.1.4: Living with PAD and IC is characterised by feelings of frustration  
The findings of the follow-up focus group study replicate those of previous reports on the 
experience of living with PAD and IC (Wann-Hansson et al 2005, 2008; Galea et al 2008; 
Egberg 2012). However, this study identified patients’ specific attention to pain, the 
consequences of this pain and their constant search for relief. In addition, the current study 
identified a lack of knowledge and understanding related to their disease and their pain. 
These features indicate a stronger focus on the impact of pain on the individual with PAD 
than has previously been the case. As such, they represent unique additions to our 




An overriding feeling of frustration was a common characteristic of these experiences and 
may influence patients’ ability to cope with their disease. The biopsychosocial approach to 
chronic pain has highlighted that negative emotions such as frustration (or negative mood 
such as depression) heightens the intensity of pain (Gatchel et al 2007). That individual 
patients seemed to be negatively impacted by their frustration suggested that their 
frustration was related to a decrease in motivation, which was in turn linked to a perceived 
lack of control over their pain and their disease. These findings are common amongst those 
with long-term conditions (Kennedy et al 2007) but have not been fully explored in PAD and 
IC. Addressing these complex emotions is not a simple task however; one common strategy 
employed with success is patient education and self-management (Lorig et al 2001, 2008; 
Macdonald et al 2008). Therefore, interventions that focus on empowering patients with 
PAD and IC through education and self-management may help them to gain some feelings of 
control over their pain and disease and reduce the negative feelings of frustration.   
 
The results of this thesis therefore support the recommendation for structured self-
management and patient education. However, this researcher, having worked with the 
patient sample, noted that this recommendation is currently not implemented effectively. 
Therefore patient education and self-management for patients with PAD and IC, with an 
emphasis on an understanding of the disease and coping techniques is required (Criqui 
2001; Olin et al 2010). In addition to self-management and educational interventions that 
focus on their disease, education regarding pain is a crucial novel element that should be 
included. Development and evaluation of robust evidence-based strategies for improving 
patient empowerment through knowledge and understanding should be a priority for future 
research in PAD and IC (McDermott et al 2011).  
 
12.3.1.5: Summary:  
The first aim of this programme of research was to investigate the subjective description of 
IC pain. By addressing this aim, unique and novel contributions have been made to research 
and clinical practice. Clusters of adjectives included within the MPQ have been identified as 
characterising the subjective pain experience of IC and laboratory induced lower limb 
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ischaemic pain. The mSETT method has been shown to be a reliable means by which lower 
limb ischaemic pain can be induced in healthy volunteers. In patients with IC, psychosocial 
variables and specifically pain-related self-efficacy beliefs have been found to be associated 
with walking performance. Finally, the experience of living with PAD and IC has been shown 
to be associated with feelings of frustration that seem to stem from a lack of understanding 
about their disease, their pain and the possibility of gaining relief from pain.  
 
12.3.2: General Findings Related to Research Aim 2:  
12.3.2.1: TENS decreases mSETT-induced pain and increases walking performance in 
PAD and IC 
Chapter 5 included a systematic review of the effects of TENS on induced ischaemic pain. 
The review found that despite variation in study design and TENS settings employed, HF-
TENS is associated with hypoalgesic effects on induced ischaemic pain. The studies included 
in this review examined the effects of TENS on ischaemic pain in the upper limb. As part of 
this programme of research, the effects of HF-TENS were investigated on induced ischaemic 
pain in the lower limb of healthy volunteers as a precursor for investigating the effects of 
TENS on IC pain (Chapter 8). Compared to placebo, time taken to report pain threshold, pain 
tolerance and pain endurance all increased with HF-TENS, with mean changes of 24%, 52% 
and 64% respectively. These changes in intensity are comparable to those found by Chen 
and Johnson (2011) with similar TENS settings. An approximate mean reduction in pain 
intensity of 50% was observed with HF-TENS during the first 2 minutes of the upper limb 
SETT (Chen and Johnson 2011).  
 
HF-TENS also appeared to affect all aspects of the IC pain experience in the clinical study 
indicating similar effects to those observed in the laboratory. The effects of LF-TENS were 
also examined in this population. Only the high intensity (tolerance/ACD) part of the pain 
experience was affected with LF-TENS stimulation. This suggests that LF-TENS had no effect 
on the less intense (ICD), or even ‘near tolerance’ (FCD) parts of the pain experience. Earlier 
research has suggested that this is a function of its extrasegmental mechanisms of action 
(Sluka and Walsh 2003). The most recent research however, refutes these assumptions and 
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has shown that HF and LF-TENS work through the same neurophysiological mechanisms 
(Radhakrishnan and Sluka 2005). The latent hypoalgesic effects have been reported to be a 
result of the higher stimulation intensity, rather than the difference in stimulation frequency 
(Lee et al 1985; Ma and Sluka 2001). It has been proposed that LF-TENS stimulation is more 
severe in sensation and thus actually augments the pain experience until the delayed 
descending mechanisms become effective (Chen and Johnson 2011). These proposed 
mechanisms could explain the effects of LF-TENS on IC pain seen in this study.  
 
Since no other published study has examined the effects of TENS for patients with IC there 
are no results for direct comparison of effects. Most interventions for walking performance 
in patients with PAD and IC involve pharmaceutical therapy (Momsen et al 2009; Squires et 
al 2011), surgery (Frans et al 2011), a training regime (Mazari et al 2011) or complex 
interventions (Cunningham et al 2011).  
 
A clinically meaningful improvement in walking distance for patients with IC is suggested to 
be an improvement of approximately 37% in ACD compared to placebo (De Backer et al 
2009). In the current study, ACD increased by a median distance of 30m with HF-TENS and 
23m with LF-TENS (13% and 18% change respectively). This is a modest change in walking 
distance and does not reach the reported clinically meaningful improvement. It is important 
to note however, that this clinically meaningful change is calculated using studies of 
interventions delivered over a period of time (3 to 12 months) (De Backer et al 2009). It 
could be considered that if delivered over a longer period of time, the initial improvement 
observed with TENS may increase to become clinically meaningful as participants’ exercise 
performance improves with training and adjustment of TENS to the individual’s optimal 
settings (Johnson et al 1991).  
 
The only published literature regarding a similarly immediate and brief intervention for 
walking performance in PAD and IC is by Oakley et al (2008). The authors investigated the 
use of Nordic poles for walking performance in patients with IC. Pain-free walking distance 
(ICD) was found to increase by 52m (69% increase from baseline), and maximum walking 
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distance by 79m (38% increase from baseline) (Oakley et al 2008). This increase is greater 
than that found in the current study. However, due to the lack of placebo intervention, it is 
impossible to compare directly with the current study results. Also, the intervention is 
somewhat different. Nordic pole usage causes changes in the biomechanics of walking and 
thus the muscle groups used whilst walking will be altered. This means that the patients 
may not experience the full benefits associated with training of normal gait and thus the 
muscles will not be working in an ischaemic environment (Hiatt et al 1996; Beckitt et al 
2012). Nevertheless, irrespective of the benefits of other interventions for IC, the aim of 
TENS is to reduce the experience of pain and as such its use may be more likely in tandem 
with interventions like Nordic poles, medication, self-management and patient education.  
 
In patients with IC and compared to P-TENS, ICD, FCD and ACD increased with HF-TENS and 
ACD increased with LF-TENS. However, no change in pain intensity was observed in either 
group. This indicates that even though the participants walked further, they were walking 
until pain reached the same intensity level. The results from this study suggest that TENS 
improves walking performance and encourages patients to walk further into the ischaemic 
environment.  
 
12.3.2.2: TENS has no effect on pain intensity despite increasing walking distance  
The reasons why patients with IC reach walking intolerance have not been conclusively 
examined (Parr et al 2008). Current opinion is that tolerance is a result of haemodynamic 
changes in the lower limb leading to fatigue and pain (Hamburg and Balady 2011). 
Increasingly, published literature has failed to establish relationships between measurable 
haemodynamic and physiological variables and walking performance (Szuba et al 2006; Parr 
et al 2008; Kruidenier et al 2009a).  
 
One central question is: is it pain, fear, muscle fatigue or something else that stops patients 
with IC from walking further? As reported in Chapter 8, HF-TENS increases time to reach 
pain threshold, tolerance and prolongs pain endurance in experimental ischaemic pain. This 
finding was replicated in the clinical sample (Chapter 9) where ICD, FCD and ACD increased 
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with HF-TENS intervention. No effect on muscle function has been found with TENS (Sluka 
and Walsh 2003). TENS has however, been shown to be effective at reducing ischaemic pain 
(Chen and Johnson 2011; Seenan et al 2012). These findings suggest that the increase in 
walking performance observed in this study is a result of TENS prolonging the time to pain 
tolerance. Consequently, this indicates that some aspect(s) related to the pain experience 
has a central role in the termination of walking in patients with IC.  
 
This finding is also supported by the fact that in the current study, no change in pain 
intensity was found with TENS. The lack of reduction in pain intensity suggests that the 
participants stopped walking when they reached the same levels of pain on both occasions. 
The difference therefore was that with TENS, this level of pain occurred after a greater 
distance had been walked.  
 
12.3.2.3: Summary:   
The second aim of this programme of research was to investigate the effects of TENS on 
measures of pain and walking performance in patients with IC. HF-TENS was shown to have 
a hypoalgesic effect on induced ischaemic pain in the lower limb of healthy volunteers. As a 
novel and untested intervention for IC pain, TENS applied to the lower limb of patients with 
IC was found to increase treadmill walking performance. However, despite increasing 
walking performance in patients with IC, TENS was not found to reduce overall pain 
intensity. This suggests that pain is a central determinant of walking performance in patients 
with IC. Again, by addressing this research aim, unique and novel contributions have been 
made to research and clinical practice.  
 
12.3.3: Clinical implications of the present f indings: 
The clinical implications of the current programme of work are limited due to the nature of 
the studies completed. Nevertheless, there are a number of important conclusions worthy 
of discussion. The pain experience of IC was found to be characterised by specific adjectives 
included in the MPQ. TENS was found to reduce the intensity of laboratory ischaemic pain 
and increase walking distance in patients with clinical lower limb ischaemic pain. These 
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findings warrant further investigation which could lead to clinical implications for the 
management of PAD and IC.  
 
12.3.3.1: Assessment and interventions that address the psychosocial aspects of 
PAD and IC:  
With the aim of exploring the nature and qualities of IC pain, the relationships between 
baseline variables and treadmill walking distance were analysed. The significant 
relationships between psychosocial measures of pain (PSEQ) and treadmill measures (FCD 
and ACD), and the lack of relationships between treadmill measures and physiological 
variables (ABPI and BMI) suggest that the psychological aspects of pain are significantly 
associated with walking performance in this sample of patients with PAD and IC. The small 
sample size of the study means that these findings might not be representative of the 
population although the concept is worth further investigation. Previous studies have 
highlighted the role of general psychological and psychosocial factors in PAD and IC 
(Smolderen et al 2008; Garnefski et al 2009) but none have investigated the specific effect 
of pain-related psychological variables. Parr et al (2008) also found a lack of relationships 
between physiological measures and walking performance. If proven to exist, the 
relationships between psychological variables related to pain (i.e. pain self-efficacy) and 
walking performance could be a focus for effective clinical intervention. In other chronic 
pain syndromes, increased positive pain self-efficacy beliefs have been shown to relate to 
improvements in physical functioning and social participation, independent of pain intensity 
or disease severity (Turner et al 2005; Wong et al 2010). Currently, there are no reports of 
similar interventions for patients with PAD and IC. If the relationship between pain self-
efficacy and walking distance in patients with IC is proven, interventions that target these 
beliefs may be an important clinical implication.  
 
The qualitative follow-up study that examined the experience of using TENS at home for IC 
uncovered some key common themes of living with PAD and IC and using TENS at home for 
pain relief. Similar to previous studies that have examined the qualitative experience of 
living with PAD and IC (Gibson and Kenrick 1998; Wann-Hansson et al 2005, 2008; Egberg et 
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al 2012), frustration was found to be a core component of the experience with lack of 
knowledge and understanding of the disease and prognosis. This repetition of findings 
strengthens the level of evidence and reinforces the need for healthcare practitioners 
involved in PAD to engage with these issues and address them.  
 
In fact, methods to address these identified issues have already been developed. Lauret et 
al (2012) reported on a national integrated care network that has been developed in the 
Netherlands for patients with PAD and IC. This network involves modifying the care of 
patients with PAD around a chronic care model that includes integrated working of all 
healthcare practitioners, patient education and coordinated supervised exercise. There has 
been no evaluation of its success as yet but it seems to address some of the issues 
highlighted by the current study.  
 
12.3.3.2: The mSETT as a method of inducing ischaemic pain in the lower limb of 
healthy volunteers and as a pre-clinical model of IC pain:  
One major outcome of this body of work is the development of the mSETT method of 
inducing ischaemic pain in the lower limb of healthy volunteers. The mSETT has been shown 
to safely and reliably induce pain over two occasions (Chapter 7). It has also been shown to 
work as a method of inducing pain for the study of an intervention (Chapter 8) and the 
sensory components of the pain induced were found to be similar to that experienced in 
clinical IC pain (Chapter 10). Further examination of the reliability over longer periods, with 
a more heterogeneous sample and investigation of the inter-rater reliability are required 
prior to its acceptance as a reliable method for inducing lower limb ischaemic pain. If shown 
to be robust under further examination, the development of the mSETT may have clinical 
implications as a novel method of inducing pain that closely reflects clinical pain experience 
in the lower limb of healthy volunteers.  
 
As a pre-clinical model of IC pain, the mSETT could be used to investigate the mechanisms of 
ischaemic pain in the lower limb. As discussed in Chapter 2, the mechanisms that lead to IC 
pain are not fully understood. The mSETT provides an opportunity to study the mechanisms 
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of pain on a model that induces ischaemia and produces pain with a stimulus shown to be 
similar to clinical IC. The mSETT method also provides an opportunity to investigate the 
effects of lower limb ischaemic pain on psychological and physical function. Experimental 
pain models are often used to investigate the effect of pain on certain psychological and 
physiological variables. The mSETT could be used to aid further understanding of the effects 
of pain, especially on lower limb function. Lastly, in the same way as it has been employed 
in the current programme of research, the mSETT may be useful for the investigation of 
interventions for pain. There are a number of current, valid and reliable methods with which 
to induce experimental pain. However, the mSETT is unique in area of pain induction (lower 
limb). It is also special in its ability, similar to the upper limb SETT, to allow the study of pain 
over a prolonged time period (pain threshold to tolerance).  
 
These functions are primarily in the ‘experimental pain’ realm and are thus not strictly 
speaking ‘clinical implications’. Nevertheless, further understanding of the mechanisms of 
ischaemic pain may help to inform clinical studies on intervention and the successful pre-
clinical testing of interventions will influence clinical research and practice.  
 
12.3.3.3: Further evidence of the hypoalgesic effects of TENS and a possible new 
application in IC pain:  
Systematic reviews of TENS for clinical pain syndromes are often limited by the 
methodological quality of the original research. Commonly, issues concern the lack of 
randomisation, blinding and the parameters chosen for TENS application (Brosseau et al 
2003; Khadilkar et al 2008; Walsh et al 2009). The findings of this research may have clinical 
implications in this regard. Segmental delivery of HF-TENS with parameters set at 120Hz, 
200μs and patient determined intensity of ‘strong but comfortable’ has been shown within 
this body of work to be effective at reducing experimental pain intensity and increasing 
walking distance of patients in pain. These findings align with those from other studies on 
experimental pain. In high quality studies on upper limb ischaemic pain, Walsh et al (1995a) 
and Chen and Johnson (2011) demonstrated hypoalgesic effects of HF-TENS delivered at 80-
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110Hz, 200 or 287μs and ‘strong but comfortable’ intensity. These settings may serve as a 
good starting point from which to explore the hypoalgesic effects of TENS.  
 
Prior to the inception of this programme of research, there was no published literature 
regarding hypoalgesic interventions specifically tested on IC pain. The results of this series of 
studies have demonstrated the efficacy of TENS in increasing treadmill walking performance 
in a small sample of patients with IC.  
 
12.3.4: Limitations of the studies included in this thesis :  
This programme of research contributes a number of novel techniques and findings. 
Nevertheless, there are also a number of limitations that can be identified in the thesis. One 
of the most fundamental aspects common to both trials was incomplete blinding. In the 
laboratory study, only the participants were blinded to the intervention. This may have 
introduced bias to the experiment and resulted in overestimation of effect (Schulz et al 
1995). Due to the nature of the application of TENS, achieving double blinding is challenging. 
As participants are asked to select their own subjective intensity level, an additional 
researcher is required to provide these instructions and answer any questions. In the 
current study, this was not feasible and it was decided that single blinding was sufficient. In 
an attempt to reduce the effect of this bias, the analysis of the data was conducted blind. An 
independent statistician coded the data so that the participant number and group were not 
known during analysis.  
 
The issue of blinding was also present in the clinical study. In this case, as a second 
researcher was present for safety reasons, double blinding was possible. The second 
researcher collected all data during the testing procedure, and the TENS was applied and 
adjusted by the participant with help from the primary researcher. This reduced the 
possibility of bias in the results and reduced the chance of a Type 1 error.  
 
One aspect of the clinical study that can be viewed as a limitation is the lack of a no-TENS 
control group. By neglecting to include a no-TENS condition it is impossible to quantify the 
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effect of ‘intervention’ or the placebo effect of TENS. This is an important and contentious 
ethical issue. It has been proposed that part of the beneficial effect of TENS is the sense of 
control and the perception of an ‘intervention’ experienced by patients when applying the 
device (Price et al 2008). Without a no-TENS group this effect cannot be quantified and thus 
the true overall effect of TENS could be underestimated i.e. increasing the possibility of a 
Type 2 error. The clinical study described within this thesis was designed as a proof-of-
concept, MRC phase IIa trial and thus a pragmatic, clinical approach was assumed. When 
investigating the effects of TENS with the aim of evaluating demonstrable, physiological 
outcomes, TENS must demonstrate efficacy above placebo and thus the study design is 
sufficient. Future studies should include a no-TENS control to allow investigation of the 
placebo response to TENS in PAD and IC.  
 
For the qualitative focus group study, the main limitation was the fact that the participants 
were not naïve to TENS and the research programme. As participants were recruited from 
the original study population, their decision to volunteer may have been affected by their 
experience of TENS during treadmill walking. This may have resulted in only those who had 
a favourable attitude towards TENS being included in the follow-up study, as those who had 
a negative experience would be less willing to use it at home for a further month. Also, their 
opinions of TENS may have been influenced by the general discussions and information 
given during the first study. Again, from a pragmatic, clinical viewpoint, it is likely that only 
patients who are open to the use of TENS will be provided with a device as an intervention. 
Also a device would normally only be provided after a trial period in which the patient 
would be encouraged to try it out and only after which they would decide whether to use it 
at home (Charlton 2005). Therefore this method of participant selection could be seen as 
sufficient.  
 
Nevertheless, it is important in future investigations into the use of TENS at home for PAD 
and IC that different sampling methods are employed. Purposive sampling could be used 
and it would allow investigators to examine the effects and experience of TENS use in 
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participants specifically chosen for their diverse characteristics and attitude towards TENS as 
an intervention.  
 
12.3.5: Future Directions:  
Analyses of the findings of this project indicate that further research is required to fully 
address the research questions identified. The direction of this research and specific 
research questions will now be discussed in turn relating to the specific chapter and studies 
from which they arise.  
 
12.3.5.1: Further laboratory investigations of mSETT-induced pain and the effects of 
TENS:  
The findings discussed in Chapters 7 and 10 represent the first in-depth investigation of 
lower limb induced ischaemic pain. The limitations of these studies have been discussed 
(section 12.3.4) and it is clear that further investigation is required to comprehensively 
validate the mSETT as a pre-clinical model of IC pain. Key objectives of this research would 
be to 1) investigate the test-retest reliability of the mSETT over more than two occasions in 
a larger sample; 2) examine the inter-rater reliability of the mSETT; and 3) investigate if 
through manipulation of the mSETT parameters a pain experience can be induced that more 
closely reflects clinical IC pain. If achieved, the refined mSETT procedure could then be 
implemented as a robust pre-clinical model of IC pain and as a reliable method of inducing 
experimental pain in the lower limb of healthy volunteers.   
 
In Chapter 8, the effects of HF-TENS on lower limb induced ischaemic pain were 
investigated. Systematic review evidence has shown that further investigation of TENS for 
ischaemic pain is required and has also identified the high quality methods required to 
achieve the appropriate level of evidence (Chapter 5) (Chen and Johnson 2011). Due to 
ethical and feasibility considerations, it was not possible to employ these methods in the 
current study. Future investigation is required to examine the effects of TENS on mSETT-
induced pain in a double blind, repeated measures trial with the appropriate number of 
participants. This type of study would also allow for investigation of the optimal settings of 
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TENS (frequency, intensity, electrode placement) for reducing lower limb ischaemic pain. 
Such an investigation would not just allow for the investigation of the neurophysiological 
mechanisms of TENS but it could also inform the study of TENS for IC pain.  
 
This model of laboratory pain may also provide a further opportunity to examine the 
relationships between psychological variables and the response to TENS. As reported in 
Chapter 9, significant relationships were found between patient controlled TENS intensity 
and pain self-efficacy. Currently no published literature could be found that investigates the 
effects of psychosocial variables on the efficacy of TENS. Future studies should include 
baseline measures of psychosocial variables when investigating the effects of TENS on 
experimental pain so that any relationships can be explored.  
 
12.3.5.2: Further clinical investigation of IC pain and the effects of TENS:  
The design and findings of the clinical study of TENS for IC pain naturally lead to further 
investigation. As a proof-of-concept trial it was proposed that TENS could be effective at 
reducing pain and increasing walking distance in patients with IC. As the findings were 
positive and no adverse events were reported, the next step is to complete a phase IIb trial. 
This involves investigating the intervention in a larger group of participants and using 
different dosages of TENS with the aim of elucidating methodology for a phase III trial (e.g. 
decisions on outcomes, endpoints and randomisation). In the current situation this would 
involve examining different TENS parameters in a repeated measures design, and including 
a no-TENS control condition. It would also investigate additional methods for recording 
outcomes e.g. NRS throughout the treadmill test, SF-MPQ rather than MPQ and laser 
Doppler measurement of local tissue blood flow to examine the local physiological effects of 
TENS.  
 
In addition to this more robust examination of the effects of TENS, the findings of the 
current study indicate the need for further investigation into the predictors of walking 
performance in patients with IC. This could be achieved within the context of the study 
described above but it may be more suited to a separate, larger scale investigation. A multi-
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centre prospective study that investigates physiological and psychological variables and 
their relationships with physical function and quality of life in patients with PAD and IC could 
help to address some of the unanswered questions.  
 
Exploring the subjective descriptions of IC pain was one of the aims of this thesis. The 
method employed when obtaining these descriptions was to ask patients with IC to 
complete the MPQ as soon as they had completed a treadmill exercise test in which they 
walked to maximal pain. This situation is an unusual one for these patients and as such they 
might have been experiencing increased levels of anxiety. The perceived meaning of the 
situation influences pain experience, thus it may not be the most ideal time to record pain 
descriptions. Future investigations should aim to record pain descriptions of IC in a more 
normal situation e.g. at home via postal survey. Also, as the pain descriptions were collected 
from a small number of participants in a certain geographical area the descriptions may not 
be generalisable to the wider IC population. To improve the generalisability, it is important 
to gather pain descriptions across a number of sites and from a larger sample of patients.  
 
In the follow-up study, the experience of using TENS at home for IC was examined along 
with the general experience of living with PAD and IC (Chapter 11). The study was designed 
as a pragmatic qualitative investigation and as such the conclusions are limited to informing 
more robust investigation by identifying initial limitations in the methodology. Future 
research should therefore address these limitations and investigate the lived experience of 
using TENS at home for IC. As mentioned above, the sample studied is not necessarily 
representative of the wider IC population. Further qualitative investigation of TENS for IC 
should aim to address this as much as possible. Also, further research should aim to increase 
the depth of investigation and thus the conclusions drawn. For example, the length of the 
trial period of TENS could be increased. Some of the participants in the current study 
expressed a desire to try TENS for a longer period of time as they felt they couldn't decide 
after only 4 weeks of use. In addition, any physiological or behavioural changes that occur in 
this population whilst using TENS should be measured. For example, this could include 
measuring physiological markers of cardiovascular health, using physical activity monitors to 
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examine any change in activity whilst using TENS, or investigation of the effect of TENS use 
on participation in exercise therapy.  
 
Other important themes identified in the qualitative study were patients’ knowledge and 
understanding and the need for community-based support that encourages patients with 
PAD and IC to increase their level of activity. Currently there is no published literature 
examining the effect of educational strategies or community support interventions for 
patients with IC. This presents an opportunity for further research. Evaluation of the current 
state of the clinical delivery and development and implementation of such interventions 
could be beneficial for this population.  
 
12.4: CONCLUSION:  
Peripheral Arterial Disease (PAD) causes significant reductions in physical and psychological 
function, resulting in a decrease in quality of life. PAD is a manifestation of more generalised 
atherosclerosis and only 20-30% of patients with PAD die of non-cardiovascular causes 
compared to approximately 75% in the general population (AHA 2012).  
 
Management of PAD is focussed on risk factor reduction and exercise therapy, both of 
which have been shown to be effective. A problem for clinicians is that patients often have 
poor adherence to exercise. A major barrier for exercise in patients with PAD is Intermittent 
Claudication (IC).  
 
IC, the cardinal symptom of PAD, is independently associated with increased levels of 
functional disability, psychological distress and increased risk of morbidity. Currently, the 
pain experience associated with IC is not fully understood and despite its highlighted 
consequences, there are no interventions recommended for IC pain.  
 
IC pain is therefore an important area that requires investigation. An improved 
understanding of the pain experience could help clinicians manage this chronic pain 
condition. Interventions that reduce the burden of IC could help to encourage adherence to 
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exercise therapy and thus reduce the risk of patients progressing to more serious 
cardiovascular disease.  
 
Transcutaneous Electrical Nerve Stimulation (TENS) is a safe, non-pharmacological and 
cheap method of providing non-invasive pain relief and may be useful for patients with PAD 
and IC. It has been shown to be effective in reducing pain and increasing function in chronic 
pain conditions but it has not been tested for IC pain.  
 
This research programme has examined IC pain and investigated the effects of TENS on 
measures of pain and walking performance. This was achieved by first developing a method 
of inducing ischaemic pain in the lower limb of healthy volunteers. HF-TENS was found to 
elicit hypoalgesic effects on this induced lower limb laboratory ischaemic pain.  
 
Both HF and LF-TENS were found to increase treadmill walking performance in patients with 
IC. Descriptions of laboratory and clinical lower limb ischaemic pain were recorded and 
compared; indicating that pain induced by the mSETT method is comparable in quality to 
clinical IC pain.   
 
The experience of living with PAD and IC and using TENS for daily life was also explored. The 
experience of living with PAD and IC was characterised by feelings of frustration and the 
experience of using TENS at home by feelings of benefit yet disappointment.  
 
The outcomes of this series of linked investigations is that the pain experience of IC is 
unique and complex and that TENS may prove to be a useful adjunctive intervention for 
walking performance in patients with IC. Further research should aim to replicate these 
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14.1: APPENDIX 1: DETAILS OF SEARCH RESULTS AND REASONS FOR EXCLUSION  
Author(s) Year Reason for Exclusion 
Hughes et al  2013 Pain not main outcome  
Venancio et al  2013 Pain not main outcome  
Atamaz et al  2012 Not Ischaemic pain 
Kim et al  2012 Not Ischaemic pain 
Kolen et al  2012 Not Ischaemic pain 
Mulvey et al  2012 Not Ischaemic pain 
Rocha et al  2012 Not Ischaemic pain 
Dounavi et al  2012 Not TENS  
Casale et al  2012 Review 
Racine et al  2012 Review 
Veening et al  2012 Review 
Aelik et al  2011 Not Ischaemic pain 
Amer-Cuenca  et al  2011 Not Ischaemic pain 
Facci et al  2011 Not Ischaemic pain 
Francis et al  2011 Not Ischaemic pain 
Fuentes et al  2011 Not Ischaemic pain 
Moran et al  2011 Not Ischaemic pain 
Pantalealo et al  2011 Not Ischaemic pain 
Choi et al  2011 Not TENS  
e Silva et al  2011 Not TENS  
Kumar and Saha 2011 Not TENS  
Pereira et al  2011 Not TENS  
Tronnier et al 2011 Not TENS  
Shipshina et al  2011 Pain not main outcome  
Claydon et al  2011 Review 
Francis and, Johnson 2011 Review 
Johnson and Bjordal  2011 Review 
Plastaras et al  2011 Review 
Bennett et al  2010 Not Ischaemic pain 
Chen and Johnson 2010 Not Ischaemic pain 
Hallen et al  2010 Not Ischaemic pain 
Kavak et al  2010 Not Ischaemic pain 
Rodrigues et al  2010 Not Ischaemic pain 
Fralich 2010 Not TENS  
Jorge Fuentes et al  2010 Not TENS  
Rossini et al  2010 Not TENS  
Hallan et al  2010 Pain not main outcome  
Jelinek et al  2010 Pain not main outcome  
Amer-Cuenca  et al  2010 Review 
Fuentes et al  2010 Review 
Hashmi et al  2010 Review 
Huang and Yu 2010 Review 
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Kones 2010 Review 
Mekhail et al  2010 Review 
Amer-Cuenca 2010 Short Survey 
Martins et al  2009 Conference Paper 
Adedoyin et al  2009 Not Ischaemic pain 
Chen and Johnson 2009 Not Ischaemic pain 
Cowan et al  2009 Not Ischaemic pain 
DeSantana et al  2009 Not Ischaemic pain 
Dickie et al  2009 Not Ischaemic pain 
Helmers et al  2009 Not Ischaemic pain 
Tuveson et al  2009 Not Ischaemic pain 
Ward et al  2009 Not Ischaemic pain 
Ward et al  2009 Not Ischaemic pain 
Bolfe and Guirro 2009 Not TENS  
Butler and Finn  2009 Review 
Deer 2009 Review 
Jeon and Huh 2009 Review 
Salinas Bueno et al  2009 Review 
Qin et al  2008 Not humans 
Sharifi et al  2008 Not humans 
Burch et al  2008 Not Ischaemic pain 
Claydon et al  2008 Not Ischaemic pain 
Satter 2008 Not Ischaemic pain 
Davis et al  2008 Pain not main outcome  
Maciel et al  2008 Pain not main outcome  
Chen et al  2008 Review 
DeSantana et al  2008 Review 
Jenrich 2008 Review 
White et al  2008 Review 
Chesterton et al  2007 Not Ischaemic pain 
Edwards et al  2007 Not Ischaemic pain 
Goroszeniuk et al  2007 Not Ischaemic pain 
Shimoji et al  2007 Not Ischaemic pain 
Tong et al  2007 Not Ischaemic pain 
Tugay et al  2007 Not Ischaemic pain 
Tuveson et al  2007 Not Ischaemic pain 
Zambito et al  2007 Not Ischaemic pain 
De Andras et al  2007 Not TENS  
Peters and George 2007 Not TENS  
Gold et al  2007 Pain not main outcome  
Foletti et al  2007 Review 
Dean et al  2006 Not Ischaemic pain 
Shanahan et al  2006 Not Ischaemic pain 
Zambito et al  2006 Not Ischaemic pain 
Buchser et al  2006 Not TENS  
Jorge et al  2006 Not TENS  
Limansky et al  2006 Not TENS  
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Tuveson et al  2006 Not TENS  
Allen 2006 Review 
Deer and Raso 2006 Review 
Gur 2006 Review 
Hoskins and Pollard 2005 Not Ischaemic pain 
Kavcic et al  2005 Not Ischaemic pain 
Adedoyin et al  2005 Not TENS  
Apkarian et al  2005 Not TENS  
Palmer et al  2004 Not Ischaemic pain 
Schubert et al  2004 Not Ischaemic pain 
Briggs et al  2004 Not TENS  
Segerdahl and Karelov  2004 Not TENS  
Tripp et al  2004 Not TENS  
Martin et al  2004 Pain not main outcome  
Akkaya and Sayin 2004 Review 
Cameron 2004 Review 
Dolan and Mendel 2004 Review 
Kavuncu and Evcik 2004 Review 
Chesterton et al  2003 Not Ischaemic pain 
Johnson and Tabasam 2003 Not Ischaemic pain 
Johnson et al  2003 Not Ischaemic pain 
Roche et al  2003 Not Ischaemic pain 
Haas et al  2002 Not Ischaemic pain 
Leffler et al  2002 Not Ischaemic pain 
Johnson and Tabasam 2002 Not TENS  
Roche et al  2002 Not TENS  
Campbell and Ditto 2002 Pain not main outcome  
Borjesson and Norssell 2001 Review 
Johnson 2001 Review 
Latif et al  2001 Review 
Naslund  2001 Review 
White et al  2001 Review 
Kosek et al  2000 Not Ischaemic pain 
Norrsell et al  2000 Not Ischaemic pain 
Presser et al  2000 Not Ischaemic pain 
Barlas et al  2000 Not TENS  
Eriksson et al  2000 Not TENS  
Blond 2000 Review 
Johnson 2000 Review 
Gracely 1999 Conference Paper 
Johnson and Tasbam  1999 Conference Paper 
Sluka et al  1999 Conference Paper 
Borjesson  1999 Not Ischaemic pain 
Börjesson and Herz  1999 Not Ischaemic pain 
Ghoname et al  1999 Not Ischaemic pain 
Hamza et al  1999 Not Ischaemic pain 






McDowell et al  1999 Not Ischaemic pain 
McDowell et al  1999 Not Ischaemic pain 
Svensson et al  1999 Not Ischaemic pain 
Talley  1999 Not Ischaemic pain 
Ghoname et al  1999 Not TENS  
McDowell et al  1999 Not TENS  
Palmer et al  1999 Pain not main outcome  
Borjesson 1999 Review 
Segerdahl 1998 Conference Paper 
Danziger et al  1998 Not Ischaemic pain 
Sawynok  1998 Pain not main outcome  
Kumar et al  1998 Review 
Sawynok  1998 Review 
Sandkahler et al  1997 Not humans 
Hardy and Hardy  1997 Not Ischaemic pain 
Kosek et al  1997 Not Ischaemic pain 
Towell et al  1997 Not Ischaemic pain 
Lowe et al  1997 Not TENS  
Wilson 1997 Not TENS  
Stanton-Hicks and Salamon 1997 Review 
Sylvan 1997 Review 
Brochet 1996 Not English  
Craig et al  1996 Not Ischaemic pain 
Robinson  1996 Not Ischaemic pain 
McDowell et al  1996 Not TENS  
Sylvan 1996 Not TENS  
Eliasson et al  1996 Review 
Hautvast et al  1996 Review 
Robinson  1996 Review 
Cristal et al  1994 Not Ischaemic pain 
Kemppainen and Petovaara  1987 Not Ischaemic pain 
Chen and Johnson 2011 
 Brown et al  2007 
 
Johnson and Tasbam 2003 
 Foster et al  1996 
 
Walsh et al  1995 
 
Roche et al  1984 
 
Rosenblatt and Hetherington 1981 





14.2: APPENDIX 2: STANDARDISED DATA EXTRACTION TABLES 
Study:  Rosenblatt and Hetherington 1981, Anesthesia 
and Analgesia 
Study aim: Evaluate the effectiveness of TENS to alleviate upper limb 
tourniquet pain as clinically encountered in anaesthesia  
Methods 
Design: Repeated measures, cross-over design  
Outcome measures: Time to pain tolerance  
Pain intensity measured by a VAS after deflation of the 
tourniquet  
Blinding: None  
TENS administered by: Researcher  
Participants  




Mean age: 29.8 years  
Intervention: 
Type of ischaemic pain: UL SETT (25 mins, 250, 20x30lb)  
No of conditions (list) Control  
Single channel TENS  
Dual channel TENS  
No per group: 10 (crossover)  
TENS device:  Medgeneral Miniceptor II  
Frequency: 100Hz  
Intensity: Maximum tolerated  
Pulse duration: 40μsec 
Electrodes (dimensions, no 
and placement): 
Dimensions not specified 
2 electrodes  
Single: One placed proximal to cuff over axillary artery and 
the other opposite circumferentially  
Dual: extra 2 electrodes in spaces between  
Stimulation duration: Throughout  
Monitoring duration: Throughout  
Placebo group methods, 
control group methods: 
No Placebo  
Control = no TENS 
Outcomes: 
Who took the measurement? 
Were they blinded? 
The researcher  
Time interval between each 
measurement: 
None- one-of measurement  
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Total number of measures 
taken: 
1 
Statistical test(s) used: Student’s t-test  
Results  
Main results: No difference in time to pain tolerance 
No difference in Pain intensity  
Authors conclusion regarding 
outcome: 
TENS has no effect on ischaemic pain.  
TENS is therefore ineffective analgesia for tourniquet pain.  
Reviewers conclusion 
regarding outcome:  
Very small numbers and questionable TENS technique.  
No statistical test data reported  
Looking for analgesia rather than hypoalgesia  
Poor TENS technique and settings  
 
 
Study:  Roche et al 1984, Pain 
Study aim: Record the differences in response of healthy subjects to 
ischaemic pain when treated with TENS  
Methods 
Design: RCT  
Outcome measures: Time to pain threshold  
Time to pain tolerance  




Blinding: None  
TENS administered by: Researcher  
Participants  
No of participants randomized: 48 
Male/female: 24/24 
Mean age: 24 
Intervention 
Type of ischaemic pain: UL SETT (25 mins, 250, 20xmax grip strength) 
No of conditions (list) 1. No TENS control  
2. HF/HI TENS 
3. LF/HI TENS 
4. LF/LI TENS 
No per group: 12 (6/6) 
TENS device:  ‘Square pulse generator’  
Frequency: 1. None  
2. 100Hz  
3. 5Hz  
4. 5Hz  
Intensity: 1. None  
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2. Maximum tolerated  
3. Maximum tolerated  
4. Perceptible prickling sensation  
Pulse duration: 1. None  
2. 1msec  
3. 100msec 
4. 100msec  
Electrodes (dimensions, no and 
placement): 
2x2cm, 2 electrodes, RU Joint and Cubital fossa  
Stimulation duration: 10 mins prior to SETT and throughout  
Monitoring duration: None post SETT 
Placebo group methods, control 
group methods: 
No stimulation, just SETT  
Outcomes: 
Who took the measurement? 
Were they blinded? 
Researcher, not blind  
Time interval between each 
measurement: 
VAS = 1 minute  
MPQ= NA 
Total number of measures 
taken: 
Max 25  
Statistical test(s) used: Student’s t-test  
Pearson’s correlation coefficient  
Results  
Main results: LF/LI TENS increase time to threshold greater than 
control   
HF/HI TENS and LF/LI TENS increase time to tolerance 
greater than control  
HF/HI TENS increase endurance time greater than 
control  
VAS scores correlated with PPI throughout  
HF/HI TENS decrease MPQ-PRI scores greater than 
control for all aspects and NWC  
Authors conclusion regarding 
outcome: 
High and low intensity TENS increases time to tolerance  
Low intensity increases time to perceive pain 
High intensity increases endurance time  
SETT induced comparable pain  
Reviewers conclusion regarding 
outcome:  
Poor design and analysis of data  
No repeated measures or attempt to quantify 
differences in groups  
Limited stats testing  
TENS may have effect but parameters chosen 
ineffective. 
 
Study:  Walsh et al 1995a, Pain 
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Study aim: Compare the effects of high and low frequency TENS on 
experimental pain using the SETT 
Methods 
Design: Repeated measures, RCT with placebo and control  
Outcome measures: VAS at time every minute throughout 
SF-MPQ for ‘worst pain’ 
Blinding: Double-blinded  
TENS administered by: Independent researcher  
Participants  




Mean age: Not stated  
Intervention 
Type of ischaemic pain: UL SETT (12 mins, ND, 200, 20x75%Max Grip) 




No per group: 8 
TENS device:  Tensaid (Hong Kong) commercial machine  
Frequency: 1. None  
2. None (not active)  
3. 110Hz 
4. 4Hz  
Intensity: 1. None  
2. ‘Midway’ (participant controlled after this point) 
3. Strong but comfortable (participant controlled 
throughout) 
4. Strong but comfortable and visible muscle contractions 
(participant controlled throughout)  
Pulse duration: 287 μsec 
Electrodes (dimensions, no 
and placement): 
2 inch self-adhesive PALS  
Erb’s point (over brachial plexus between 
sternocleidomastoid and clavicle) and just lateral to C6 and 
C7 on non-dominant side  
Stimulation duration: 10 mins prior to cuff inflation and throughout test (12 mins) 
Monitoring duration: None post-SETT 
Placebo group methods, 
control group methods: 
All participants were told that they may experience 
sensations with TENS.  
Placebo group TENS was not connected to an active socket 
but they were encouraged to alter intensity  
Outcomes: 
Who took the Researcher who was blinded to type of TENS, not 
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measurement? Were they 
blinded? 
intervention  
Time interval between each 
measurement: 
1 minute VAS  
MPQ at ‘conclusion of testing’ 
Total number of measures 
taken: 
12 VAS  
1 MPQ 
Statistical test(s) used: One-way and repeated measures ANOVA and post-hoc tests  
Results  
Main results: Mean VAS reduced with LF-TENS compared to Control and 
HF-TENS  
Mean VAS reduced with Placebo TENS compared to HF-TENS  
VAS with LF-TENS decreased to a greater extent than all 
other groups in minutes 7-9  
VAS with LF-TENS decreased to a greater extent than control 
and HF-TENS in 4th minute  
No significant differences were observed in MPQ-PRI scores  
Authors conclusion 
regarding outcome: 
TENS reduces ischaemic pain 
LF more effective than HF-TENS  
Appears that the extrasegmental pathways that LF-TENS is 
proposed to work at do not hold for these results  
Reviewers conclusion 
regarding outcome:  
Well conducted and double-blind study  
Sufficient TENS parameters used  
Good analysis and robust statistics  
No randomisation of the conditions- participants likely to 
reduce their ratings of pain as they are more used to the 
stimulation  
TENS switched on 10 mins prior to pain induction thus 
allowing LF-TENS effects to take hold?  
 
Study:  Foster et al 1996, Clinical Journal of Pain  
Study aim: Assess the hypoalgesic effects of changing TENS 
parameters on cold and ischaemic pain in healthy 
volunteers  
Methods 
Design: Repeated measures, RCT, Placebo, Contol and 4 TENS 
conditions  
Outcome measures: VAS  
MPQ 
Blinding: Double-blinded  
TENS administered by: Independent researcher  
Participants  






Mean age: 19.4 years  
Intervention 
Type of ischaemic pain: ND UL SETT (12 mins, 200, 20x75%Max Grip, 13cm)  
No of conditions (list) 1. HF-TENS / Long Pulse Duration 
2. HF-TENS / Short Pulse Duration 
3. LF-TENS / Short Pulse Duration  
4. LF-TENS / Long Pulse Duration  
5. Placebo  
6. Control  
No per group: 8 
TENS device:  120Z TENS unit (ITO Tokyo)  




5. None  
6. None  
Intensity: 1. Strong but comfortable  
2. Strong but comfortable  
3. Strong but comfortable  
4. Strong but comfortable  
5. None  
6. None  
Pulse duration: 1. 200 μsec 
2. 50 μsec  
3. 50 μsec 
4. 200 μsec 
5. None  
6. None  
Electrodes (dimensions, no 
and placement): 
Two carbon rubber electrodes with hydrogel pads 3.5 x 
5cm  
Lateral to the spinous processes of C6 and C7 and Erb’s 
point  
Stimulation duration: 23 mins prior to cuff inflation  
Switched off for 2 mins of SETT induction  
Back on for the rest  
Monitoring duration: None  
Placebo group methods, 
control group methods: 
May or may not experience sensation from TENS  
Electrodes placed but attached to a non-active socket  
Control just same as baseline  
Outcomes: 
Who took the measurement? 
Were they blinded? 
Researcher, blinded to TENS type  
Time interval between each VAS = 1 minute  
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measurement: MPQ = NA 
Total number of measures 
taken: 
VAS = 12  
MPQ = 1 
Statistical test(s) used: Used difference scores as a means of standardisation for 
inter-subject variability  
(Intervention score – Baseline) 
ANOVA  
Results  
Main results: No significant differences in VAS or MPQ scores between 
groups or over time  
Authors conclusion regarding 
outcome: 
Selected pulse durations have little effect but longer 
durations (Walsh et al 1995a- 287 μsec) have shown 
effectiveness.  
Electrode placement sites not good- needs to be over the 
site of pain 
Intensity not strong enough.  
Reviewers conclusion 
regarding outcome:  
Insufficient TENS parameters used- pulse duration, 
electrode placement, time of stimulation  
Same issues as Walsh et al 1995a in terms of design with no 
randomisation of enter into conditions  
Good double blinding and statistical analysis  
Repeated measures strong and even better to use 
difference scores  
 
Study:  Johnson and Tasbasam 2003, Physical Therapy  
Study aim: Compared the analgesic effects of TENS and IF on ischaemic 
pain in healthy volunteers  
Methods 
Design: Single-blind, placebo-controlled repeated measures 
experiment  
Outcome measures: VAS every minute  
SF-MPQ  
Blinding: Participant blinded to treatment type  
TENS administered by: Researcher  
Participants  




Mean age: 33.5 years  
Intervention 
Type of ischaemic pain: SETT (12 mins, 200, forearm, 20x75%Maxgrip) 
Cuff inflation = 0 




3. Placebo  
No per group: 10 
TENS device:  EMS model 70 interferential therapy machine  
Frequency: 1. 100Hz x 4kHz  
2. 100Hz  
3. None  
Intensity: 1. Strong but comfortable and participant controlled  
2. Strong but comfortable and participant controlled  
3. None  
Pulse duration: 1. NA 
2. 200 μsec  
3. None  
Electrodes (dimensions, no 
and placement): 
4, self-adhesive 4.5cm2 electrodes, 2 below, 2 above cuff on 
anterior and posterior forearm  
Stimulation duration: 22 mins uninterrupted  
Monitoring duration: None post SETT  
Placebo group methods, 
control group methods: 
Same machine, attached to non-active socket  
Same electrode placement and instructions that they may or 
may not experience sensations  
Post-test questionnaire proved placebo effective for all 
participants  
Outcomes: 
Who took the 
measurement? Were they 
blinded? 
Researcher not blinded  
Time interval between each 
measurement: 
VAS = 1 minute  
MPQ = NA  
Total number of measures 
taken: 
VAS = 12  
SF-MPQ = 1 
Statistical test(s) used: Analysed change scores for VAS and MPQ  
Two-way repeated measures ANOVA for VAS  
One-way ANOVA for MPQ  
Results  
Main results: No difference in VAS scores with TENS from control or 
placebo  




TENS is ineffective at reducing ischaemic pain and no better 
than IFC however, this may be due to the parameters used  
Reviewers conclusion 
regarding outcome:  
Different type of SETT with cuff on forearm  
Again no randomisation of entry into conditions which may 
affect results- decrease due to fear of increase due to 
familiarisation  




Good statistics used  
Electrode placement over pain but mechanical pain rather 
than ischaemic?  
 
Study:  Chen and Johnson 2011, Clinical Journal of Pain  
Study aim: Assess the effects of LF and HF-TENS on ischaemic pain in 
healthy volunteers  
Methods 
Design: Repeated measures, placebo-controlled, cross-over  
Outcome measures: VAS  
SF-MPQ  
Blinding: Double blind to type of TENS  
TENS administered by: Independent researcher  
Participants  




Mean age: 26.8 years  
Intervention 
Type of ischaemic pain: Familiarisation session then 3 x Forearm SETT (200, 15 x 
75% MGS, 2 mins duration) with 30 mins washout  
No of conditions (list) 1. LF-TENS 
2. HF-TENS 
3. Placebo  
4. Baseline  
No per group: N = 8  
1. LF-TENS / HF-TENS / Placebo  
2. LF-TENS / Placebo / HF-TENS 
3. HF-TENS / Placebo / LF-TENS 
4. HF-TENS / LF-TENS / Placebo   
5. Placebo / LF-TENS / HF-TENS 
6. Placebo / HF-TENS / LF-TENS  
TENS device:  Pro-TENS Nidd Valley Medical Limited UK 
Frequency: 1. 3Hz  
2. 80Hz  
3. None  
Intensity: 1. Strong but comfortable  
2. Strong but comfortable  
3. None  
Pulse duration: 1. 200 μsec  
2. 200 μsec 
3. None  
Electrodes (dimensions, no Midline of anterior and posterior forearm both sides of cuff  
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and placement): Self-adhesive 5x5cm  
Stimulation duration: 20 mins- SETT in last 5 mins of stimulation  
Monitoring duration: None post SETT  
Placebo group methods, 
control group methods: 
No current output but indicator light on for placebo  
Outcomes: 
Who took the measurement? 
Were they blinded? 
Researcher was blinded  
Time interval between each 
measurement: 
VAS = 1 minute  
MPQ = NA  
Total number of measures 
taken: 
VAS = 2 
SF-MPQ = 1 
Statistical test(s) used: 2x4 factorial repeated measures ANOVA on VAS data 
Repeated measures ANOVA for MPQ-PRI scores with 
Bonferroni correction  
Results  
Main results: HF-TENS reduced VAS scores compared to LF-TENS  
Significant effects of time and condition 
Baseline VAS lower than with placebo  
VAS with HF-TENS lower than with placebo  
VAS scores with LF-TENS were higher than placebo  
Significant effects of condition in MPQ scores  
Lower SPRI scores at baseline than with placebo and LF-
TENS  
Both TENS reduced SPRI compared to placebo  
No difference between TENS groups  
PPI significant effect for condition 
Baseline PPI scores were lower than in all other conditions  
Lower PPI with both TENS compared to placebo  
No differences between TENS for PPI  
Authors conclusion regarding 
outcome: 
HF-TENS is more effective than LF-TENS for induced 
ischaemic pain although both reduced intensity compared 
to placebo  
Reviewers conclusion 
regarding outcome:  
Excellent paper that comprehensibly compares LF and HF-
TENS for ischaemic pain 
Different SETT method used but seems to induce ischaemic 
pain  
Talking about the interaction of stimulation and pain 
increasing sensory input is interesting  
Comprehensive statistics employed and described  
Double blind as well and mixed entry of conditions which 
improves validity  
Short period of ischaemic pain doesn't allow much analysis 
of development  
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TENS on for a long period before SETT- this affects 
mechanisms at play?  
Interesting discussion of TENS affecting affective rather 
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My name is Chris Seenan and I am a PhD student from the School of Health Sciences at 
Queen Margaret University in Edinburgh.  As part of my degree course, I am undertaking a 
research project.   
 
The title of my project is:  
 
Laboratory and clinical investigation into lower limb ischaemic pain, and the 
effect of Transcutaneous Electrical Nerve Stimulation (TENS) on measures of 
pain and exercise performance  
 
This study will investigate the effects of temporary ischaemia in the leg. Ischaemia occurs 
when there is a lack of blood supply to certain tissues. This is sometimes associated with a 
pain in the region of the calf. The pain is a common problem for patients with Peripheral 
Arterial Disease (PAD) and is brought on by exercise e.g. walking. It is not an indication of 
tissue damage, rather it is a brief period of pain which patients experience daily and resolves 
immediately without after effects. In this study we plan to briefly induce and investigate 
ischaemia in the calf.  
 
There are two main aims of my study. The first is to compare the description of any pain 
resulting from ischaemia induced in healthy volunteers with that experienced by patients 
with PAD. The second aim is to investigate the effect of a commonly used physiotherapy 
treatment called Transcutaneous Electrical Nerve Stimulation (TENS) on any pain 
temporarily produced in the leg; along with treadmill walking performance in patients with 
PAD.  
 
The findings of the project will improve the understanding of ischaemic pain and how it 
affects exercise and performance. TENS results will be considered as a possible cost-
effective treatment for these patients, potentially improving their walking, exercise 




I am looking for volunteers to participate in the project. Anyone can volunteer. However, 
there are strict inclusion and exclusion criteria that will be checked prior to testing. These 
are followed to ensure the safety and suitability of every subject participating in the project. 
Anyone with a history of DVT or clotting abnormalities will be excluded from participating. 
Screening of DVT risk factors will be completed prior to testing and cardiovascular markers 
will be monitored closely throughout testing. Also, prior to participating in the study, your 
heart rate and blood pressure will be measured. If these are found to be outwith normal 
limits, you will be informed of this result and will not be included in the study. I will also 
provide you with a letter of any abnormal findings to take to your general practitioner, who 
will advise you of the medical aspects and implications of this finding. If you do not have a 
general practitioner, I will instruct you on the steps to register with a practice via NHS 24 or 
provide information about contacting the university nurse.  
 
If you are suitable to participate and you agree to take part in the study, you will be asked to 
attend for one testing session that will last for approximately 1 ½ hours. The procedure will 
involve completing a few short questionnaires and performing 20 gentle heel-raising 
exercises with a blood pressure cuff inflated around your thigh. You will be asked to do this 
twice with a rest period of 20 minutes between trials.  
 
You are likely to experience pain during testing. If you do develop pain, it is expected to 
develop slowly and you will be in full control of when it stops. Your Heart Rate and Blood 
Pressure will be monitored throughout the procedure to monitor any changes.  
 
You are free to withdraw from the study at any stage and you do not have to give a reason. 
All data will be anonymised as much as possible. Your name will be replaced with a 
participant number, and it will not be possible for you to be identified in any reporting of 
the data gathered. The results may be published in a peer-reviewed journal or presented at 
a conference.  
 
If you would like to contact an independent person, who knows about this project but is not 
involved in it, you are welcome to contact Mr Chee-Wee Tan (Independent Advisor). Their 
contact details are given below. 
 
If you have read and understood this information sheet, any questions you had have been 
answered, and you would like to be a participant in the study, please now see the exclusion 





 Contact Details of the 
Researcher 
Contact Details of the Independent 
Advisor  
Name: Chris Seenan Chee-Wee Tan 
Address: PhD Student, Physiotherapy,  
School of Health Sciences 
Queen Margaret University  
Queen Margaret University Drive  
Musselburgh  
East Lothian  
EH21 6UU 
Physiotherapy Staff,  
School of Health Sciences  
Queen Margaret University  
Queen Margaret University Drive 
Musselburgh  
East Lothian  
EH21 6UU 
Email cseenan@qmu.ac.uk  ctan@qmu.ac.uk   
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EXCLUSION CRITERIA QUESTIONNAIRE 
 
Laboratory and clinical investigation into lower limb ischaemic pain, and the 
effect of Transcutaneous Electrical Nerve Stimulation (TENS) on measures of 
pain and exercise performance  
 
It is important that you do not have any contraindications to the techniques that will be 
used within this study.   
Do you have any of the following?  
□ Any previous history of Deep Vein Thrombosis (DVT) or clotting abnormalities  
□ Diabetes         
□ Vascular pathologies of the upper or lower limb (e.g. Raynauds Disease, peripheral 
vascular abnormalities) 
□ Other circulatory problems 
□ A history of altered blood pressure (e.g. hypertension or hypotension) 
□ Other cardiovascular conditions 
□ Current pain anywhere in your body 
□ Previous chronic pain (constant pain lasting more than 2 weeks)  
□ Current or previous sensation abnormalities in your upper or lower limbs 
□ Recent trauma to your lower limbs 
□ Previous serious trauma to your lower limbs 
□ Peripheral neuropathies, e.g. Sensation abnormalities in your legs or feet 
□ Epilepsy  
□ Cardiac pacemaker  
□ Medical diagnosis including cardiovascular disorder or self-reported psychiatric 
illness 
□ Pregnant or trying to become pregnant  
□ Currently taking pain medication, regular aspirin, statins or the contraceptive pill 
□ Susceptible to skin reactions or have broken / damaged skin on your thigh 
 
Thank you for volunteering but if you answered yes to any of these questions unfortunately 




If you are unsure about any one of these conditions or feel you have one of these conditions 
but not yet diagnosed please inform the researcher and seek medical assistance before 
continuing with the study.  
 
Information regarding seeking medical advice or assistance is available from the researcher. 
In addition, the contact details for NHS 24 where you can find information about registering 
with a gp or seek general medical advice are as follows:  
Tel: 08454 24 24 24      Website: www.nhs24.com  
______________________________________________________________ 
 
(To be completed by the researcher) 
 
Subject Number:  _____ 
Age (18+)   _____ 
Height     _____  
Weight    _____ 
Blood Pressure:  _____ /______ 
Heart Rate:    _____ 
Thigh Circumference:   _____  
Registered with GP?      YES/NO   
Happy and able to seek medical advice if needed? YES/NO 
 










Laboratory and clinical investigation into lower limb ischaemic pain, and the 
effect of Transcutaneous Electrical Nerve Stimulation (TENS) on measures of 
pain and exercise performance 
 
I, ____________________________ agree to take part in the above study.  The purpose of 
the study has been explained to me and I understand that I may experience a level of pain 
during testing.  
 
I have read and understand the information sheet provided and have completed the 
Exclusion Criteria Questionnaire. I am confident that none of the exclusion criteria applies to 
me and if I want to seek medical advice at any point, I am willing and able to do so in 
confidence.  
 
I understand that I am under no obligation to take part in this study. 
 
If I participate in this study, I understand that if at any stage I decide I no longer wish to take 
part, I can withdraw at any time giving no reason. 
 
If I have any further questions regarding this study, I understand that I can contact Mr Chee-
Wee Tan (Independent Advisor). 
 





Signature of participant:  _____________________________________ 
 
Signature of researcher:  _____________________________________ 
 




 Contact Details of the 
Researcher 
Contact Details of the Independent 
Advisor  
Name: Chris Seenan Chee-Wee Tan 
Address: PhD Student, Physiotherapy,  
School of Health Sciences 
Queen Margaret University  
Queen Margaret University Drive  
Musselburgh  
East Lothian  
EH21 6UU 
Physiotherapy Staff,  
School of Health Sciences  
Queen Margaret University  
Queen Margaret University Drive 
Musselburgh  
East Lothian  
EH21 6UU 
Email cseenan@qmu.ac.uk  ctan@qmu.ac.uk   
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Block Randomisation:  
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Participant Information Sheet 
 
A pilot study into patients’ experiences of pain and mobilising with 
Peripheral Arterial Disease (PAD) and the effects of Transcutaneous Electrical 




My name is Chris Seenan and I am a PhD Student at Queen Margaret University, Edinburgh. 
I am required to undertake a project as part of my course and invite you to take part in the 
following study. However, before you decide to do so, I need you to understand firstly why I 
am doing it, and secondly what it would involve if you agreed. I am therefore providing you 
with the following information. Please read it carefully and be sure to ask any questions you 
might have and, if you want, discuss it with others including your friends and family. I will do 
my best to explain the project to you and provide you with any further information you may 
ask for now or later.  
 
We would like to invite you to participate in a research project. We believe it to be of 
potential importance. Before you decide whether or not to take part it is important for you 
to understand why the research is being done and what it will involve if you decide to take 
part.  Please take time to read the following information carefully and be sure to ask any 
questions that you have and if you want, discuss it with family, friends or your GP. We will 
do our best to explain and to provide any further information you may ask now or later. You 
do not have to make an immediate decision.   
 
  
This study has been reviewed by a NHS Research Ethics Committee, which has 
responsibility for scrutinising proposals for medical research on humans.  In this 
case, the reviewing Committee was the Tayside Research Ethics Committee who 
have raised no objections from the point of view of medical ethics.’ 
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What is the purpose of the study?  
You have been invited to take part in this project as you have been diagnosed with 
Peripheral Arterial Disease (PAD). Your consultant has recommended that you might be 
suitable to participate as you experience pain in your leg(s) while walking.  
 
One of the main aims of this study is to examine the pain you experience which is called 
‘Intermittent Claudication’ (IC). We aim to record a detailed account of this pain from a 
patient’s perspective. We would also like to examine the effects of a commonly used, non-
pharmaceutical treatment called Transcutaneous Electrical Nerve Stimulation (TENS). TENS 
is widely used but has yet to be tested for IC pain. We will measure your walking distance on 
the treadmill and test different dosages of TENS. Your treatment dosage will be randomly 
selected to avoid biasing the result.  
 
The findings of the project will hopefully improve the understanding of the pain you 
experience and its effect on walking performance. It may also provide an indication of the 
usefulness of TENS.  
 
Why have I been chosen?  
Your doctor has suggested that you may be suitable to participate in this study if you wish to 
do so. Your name has been suggested because you have PAD and experience pain in your 
leg when walking. The pain is called Intermittent Claudication (IC). We are planning to study 
other people with the same medical condition as you.  
 
What will I have to do if I take part?  
No new drugs will be given as part of this study.  
If you agree to take part in the study, you will be asked to attend on two occasions. When 
you attend for the first visit, you will be asked to complete five, one page, tick-box 
questionnaires; rest for 15 minutes, walk on a treadmill and complete another 
questionnaire. The second visit will be shorter as you will be asked to walk on the treadmill 
and complete one questionnaire.  
 
During each treadmill test you will be asked to report when you feel the claudication pain. 
We will ask you to walk on until you reach the point where you cannot walk any further due 
to the pain in your leg(s). Despite the severity of this pain, it is transient and will resolve 
with rest. While you rest and the pain reduces, we will ask you to describe in detail, the pain 
you experienced using a simple questionnaire, administered by the researcher. During the 
treadmill walking the TENS device will be attached to one of your legs and set to a specific 
dosage.   
 
At the end of each testing session, you will be asked to complete a short questionnaire. This 
will include questions about your experience during the testing procedure and your opinion 




Apart from this, you do not have to do anything different from your normal lifestyle and the 
trial does not affect your current treatment. You will also be reimbursed for any travel 
expenses you incur.  
 
Where will the research be conducted? 
The research will be conducted in The Vascular and Inflammatory Diseases Research Unit, in 
the Institute of Cardiovascular Research, Ninewells Hospital and Medical School, Dundee. 
 
What are the benefits of taking part in this study? 
There are no immediate benefits to you as an individual. 
 
What are the risks of the test involved? 
There are no foreseeable risks in participating in this research. You will experience pain 
during the treadmill walking. When you develop pain, it is expected to develop slowly and 
once you stop, the pain will resolve. You will be connected to a heart rate monitor 
throughout the test.  
 
What are my rights? 
We will inform you of the results of the study and which treatment you received.  With your 
permission, we will contact your GP to let him/her know about your participation in the 
study. Participation in this study is entirely voluntary and you are free to refuse to take part 
or to withdraw from the study at any time without having to give a reason and without this 
affecting your future medical care or your relationship with medical staff looking after you. 
 
Will the research influence the treatment I receive? 
The research does not alter the treatment you receive. Your consultant and GP will start and 
stop treatments as determined by your clinical condition. 
 
Should I let my health insurance company know? 
Some insurance companies consider that participation in medical research such as this is a 
“material fact” which should be mentioned in any proposal for health-related insurance, or 
which could influence their judgment in consideration of claims made under existing 
insurance policies. You should check that participation in this research does not affect any 
policy you might be thinking about taking. 
 
Will my taking part in the study be kept confidential? 
The information collected about you in this study will be anonymised i.e. linked to a special 
code that is stored separately on a password-protected computer file. All information that is 
collected about you during the course of the research will be kept strictly confidential.   
 
No one outside the research team will have any access to any identifying information. All 
identifiable information will be kept securely and will be retained for a period of 3 months 
after the study ends.  
 
Who is organizing and coordinating the study? 
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This study is being coordinated by Queen Margaret University, Edinburgh and The Institute 
of Cardiovascular Research, University of Dundee.  
 
The Tayside Research Ethics Committee B, that has responsibility for scrutinizing proposals 
for medical research on humans in Tayside, has examined the proposal and has raised no 
objections from the point of view of medical ethics. It is a requirement that your records in 
this research, together with any relevant medical records, be made available for scrutiny by 
monitors from NHS Tayside. 
If you would like any further information regarding this study you can contact the 
researcher or the medical staff involved in the study (Contact details below).  
 
Even after you agree to take part, you are still free to withdraw at any time and without 
giving a reason.  A decision to withdraw at any time, or a decision not to take part, will not 
affect the standard of care you receive. 
 
Thank you for taking the time to read this Information Sheet and considering taking part in 






Contact Details of the Researchers  
Name: Chris Seenan Steve McSwiggan  
Address: PhD Research Student, 
Physiotherapy,  
School of Health Sciences 
Queen Margaret University  
Edinburgh 
EH21 6UU 
Senior Research Nurse, 
Study Coordinator, 
Vascular  & Inflammatory Diseases 
Research Unit  
The Institute of Cardiovascular 
Research Ninewells Hospital & Medical 
School, Dundee 
DD1 9SY 
Email cseenan@qmu.ac.uk  s.j.mcswiggan@dundee.ac.uk  
Telephone: 0131 474 0000 
Ext 4795 
01382 660111  
Ext 34147, Bleep 4258 
 
 
Contact Details of the Independent Advisor  
Name: Dr John Dick  
Address: Consultant Vascular Physician  
Wards 3 & 4  









   
Participant Reply Slip  
 
A pilot study into patients’ experiences of pain and mobilising with Peripheral Arterial 
Disease (PAD) and the effects of Transcutaneous Electrical Nerve Stimulation (TENS) on 










Availability to meet at Ninewells: 
 Mon Tues Wed Thurs Fri Sat Sun 
am        














Participant Consent Form 
 
A pilot study into patients’ experiences of pain and mobilising with 
Peripheral Arterial Disease (PAD) and the effects of Transcutaneous Electrical 
Nerve Stimulation (TENS) on pain and treadmill walking  
 
Name of Researcher: Christopher Seenan 
         Please initial box 
1. I confirm that I have read and understand the information sheet dated April 
2009 (Version 2) for the above study and have had the opportunity to 
consider the information, ask questions and have had these answered 
satisfactorily.  
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care 
or legal rights being affected. 
 
3. I understand that relevant sections of my medical notes and data collected 
during the study may be looked at by individuals from Queen Margaret 
University, from regulatory authorities or from NHS Tayside, where it is 
relevant to my taking part in this research. I give permission for these 
individuals to have access to my records.  
 
4. I agree to my GP being informed of my participation in the study 
  
5. I agree to take part in the above study.  
 
_________________________ _______________ ______________ 
Name of Participant  Date Signature 
_________________________ __________ ______________ 
Name of Person taking consent Date Signature 
(If different from researcher) 
_________________________ __________ ______________ 












14.10: APPENDIX 10: TREADMILL STUDY QUESTIONNAIRES 
 
Instructions for completing the questionnaires: 
 
Please could you read carefully and answer the following four, short questionnaires 
(provided on separate sheets):  
 
1. Walking Impairment Questionnaire (WIQ)  
2. Pain Self Efficacy Questionnaire (PSEQ)  
3. Pain Catastrophising Scale (PCS)  
4. Tampa Scale of Kinesiophobia (TSK)  
 
For the first three questionnaires, there are instructions on the top to explain what you 
need to do. If you are unsure about any of them or would like some clarification, please ask 
the researcher.  
 
When you reach the fourth questionnaire (the Tampa Scale of Kinesiophobia) let the 
researcher know and they will explain it to you.  
 
If you have any questions or are unsure about any of the questionnaires, at any point, 







Walking Impairment Questionnaire 
 
 
1. Please place a √ in the box that best describes how much difficulty you have had due to 
pain, aches or cramps during the last week. The response options range from ‘No Difficulty’ 
to ‘Great Difficulty’.  
 
During the last 
week, how much 
difficulty have you 











a. Pain, aching, or 
cramps in your 
calves?  
     
b. Pain, aching, or 
cramps in your 
buttocks?  
     
 
 
For the following questions, the response options range from ‘No Difficulty’ to ‘Unable to 
Do’. If you cannot physically perform a specified activity, for example walk 600 feet (100 
metres) without stopping to rest because of symptoms such as leg pain or discomfort, 
please place a √ in the box labelled ‘Unable to Do’.  
 
However, if you do not perform an activity for reasons unrelated to your circulation 
problems, such as climbing a flight of stairs because your home is on one level or you flat 





2. Please place a √ in the box that best describes how hard it was for you to walk on level 
ground without stopping to rest for each of the following distances during the last week:  
 
 
During the last 
week, how 
difficult was it 














a. Walk indoors, 
such as around 
your home? 
      
b. Walk 50 feet 
(~15 metres)? 
      
c. Walk 150 feet 
(~45 metres)? 
      
d. Walk 300 feet 
(~90 metres)? 
      
e. Walk 600 feet 
(~180 metres)? 
      
f. Walk 900 feet 
(~270 metres)? 
      
g. Walk 1500 
feet (~450 
metres)? 





3. Please place a √ in the box that best describes how hard it was for you to walk 300 feet 
(roughly 90 metres) on level ground at each of these speeds without stopping to rest during 
the last week. 
 
During the last 
week, how 
difficult was it 














a. Walk 300 feet 
slowly?  
      
b. Walk 300 feet 
at an average 
speed?  
      
c. Walk 300 feet 
quickly?  
      
d. Run or jog 
300 feet?  
      
 
 
4. Please place a √ in the box that best describes how hard it was for you to climb stairs 
without stopping to rest during the last week. Please note 1 flight of stairs is roughly equal to 
14 steps.  
 
During the last 
week, how 
difficult was it 















a. Climb 1 flight 
of stairs?  
      
b. Climb 2 
flights of stairs?  
      
c. Climb 3 
flights of stairs?  















 Please answer the following questions in relation to 
























 Please answer the following questions in relation to 
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TITLE: How to measure Initial Claudication Distance (ICD) and Absolute 




COMPILED BY Signed   
 Date  
   
APPROVED BY   Signed  
 Date  
   




1.     PURPOSE 
The purpose of this Standard Operating Procedure is to describe the procedure used for the 
measurements of Initial Claudication Distance (ICD) and Absolute Claudication Distance 
(ACD) on exercise treadmill. 
 
2.     SCOPE 
This SOP is intended for use by personnel who have been trained in this procedure.   
 
3.     RESPONSIBILITY 
All Members of Clinical staff performing this procedure will be responsible for complying 
with the details of this procedure 
 
4.     PROCEDURE 
4.1 Treadmill Test Definitions 
Absolute Claudication Distance (ACD) is defined as the maximum distance in metres and 
centimetres walked by a patient on a treadmill under standardized conditions.  The patient 
should continue the test until walking can no longer be tolerated because of claudication 
symptoms.  It is critical that the patient not stop walking when they normally would do so.  
The patient should be asked to continue to walk until they feel they must stop due to 
claudication symptoms. 
 
Initial Claudication Distance (ICD) is defined as the distance in metres and centimetres 
walked by a patient on a treadmill under standardized conditions before the onset of 
claudication symptoms, regardless of whether this is manifested or characterized as muscle 
pain, ache, cramp, numbness or fatigue.  This does not include joint pain or other pain not 
associated with claudication. 
 
4.2 Treadmill Set Up 
The treadmill must be programmed with the attached Gardner protocol (see Table 1) 
The treadmill’s function must be assessed routinely by the designated staff. 
 
The treadmill room should be free of distractions that might interfere with the treadmill 
test. Ideally, there should be a bed next to the treadmill to accommodate pre-exercise and 
post-exercise ABI testing.  The treadmill should be situated such that the staff are able to 
assist the patient if they have difficulty while on the treadmill. 
 
Treadmill Familiarization 
A short familiarization session on the treadmill must precede the official treadmill test in 
screening phases of studies. The treadmill familiarization should begin at a slow treadmill 
speed of 1.0 mph and 0% grade.  Familiarization should also include walking bouts at 1.5 
mph and 2.0 mph.  Each bout of walking should only last between 10 to 15 seconds, but may 
be repeated as necessary.  The treadmill belt should be stopped between each bout of 
walking so the patient can get comfortable transitioning from straddling the belt to walking 




1. Prior to the patient performing the treadmill test, they should be advised to 
immediately notify the staff performing the treadmill test if they experience any 
physical difficulty such as chest pain / discomfort, shortness of breath (SOB), or 
lightheadedness.  If this occurs, the treadmill should be stopped immediately and 
appropriate medical intervention should be administered. 
2. Have the patient straddle the treadmill belt and step on it once it is fully up to speed 
at 1.0, 1.5 and 2.0 mph for a minimum of 3 separate bouts of walking.  A maximum 
of 10secs walking on the treadmill at each speed. Additional bouts of walking may be 
repeated as necessary. 
3. During familiarization the patient should be instructed to walk on a treadmill in as 
normal a manner as possible.  Make sure they are using a normal stride and not 
doing a shortened stutter step or shuffle step.  They should be instructed to walk 
with their back straight and looking forward instead of looking down at the belt as 
this may make them dizzy. 
4. Also, make sure the patient walks on the treadmill with their hands resting lightly on 
the rail, for balance only.  Discourage the patient from using the rail for support. 
5. This treadmill familiarization should be repeated as often as necessary during the 
course of the trial. 
 
Before the Treadmill Test 
The treadmill controller timer should be used to measure ICD and ACD.  In some cases a 
stopwatch or other suitable timing device may be used.  Time should be recorded in _min 
_sec format. 
 
Continuous ECG testing is strongly recommended during treadmill testing.  
 
It is strongly recommended that the treadmill test be performed at a consistent time of day.  
1. The patient must rest for at least 10 minutes prior to the test.  
2. Patients should refrain from consuming any alcoholic beverage prior to the test 
(i.e., on the day of the test).  Smoking is not permitted within 2 hours of the test. 
3. The room should be maintained at a comfortable temperature. 
4. The patient must wear a pair of comfortable shoes. 
5. The patient must not wear a watch and must be positioned where he/she cannot 
see a clock or timer during the test. 
6. Carefully explain ACD to the patient prior to the treadmill test (i.e. “We want you 
to walk as far as you possibly can”). 
7. Explain the Claudication Symptom Rating Scale (see Appendix 1) to the patient 
prior to treadmill testing.  Ensure this scale is posted directly in front of the 
treadmill where the patient can easily refer to it. 
8. Stress to the patient that they must let the staff know the moment they begin to 
experience claudication symptoms during the treadmill test.  This corresponds to 
“2-Onset” of the Claudication Symptom Rating Scale. 
9. Assess what words the patient uses to describe their claudication symptoms.  Be 
certain to use the same words when questioning the subject about their 
claudication symptoms during the treadmill. 
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10. Instruct the subject to let you know if they experience SOB, chest pain or 
dizziness during the treadmill. 
11. At the screening visit, patients who are forced to discontinue walking for reasons 
other than ischemic leg pain (e.g., angina pectoris, dyspnoea, dizziness, etc.) 
must be excluded from the study. 
 
Starting the Treadmill Test 
1. When starting the actual treadmill test, ensure the treadmill belt is moving at 2.0 
mph before the patient steps on and before starting the Gardner protocol. 
2. Be sure to start the Gardner protocol and timing for both the ACD and ICD when the 
subject’s second heel makes contact with the treadmill belt. 
3. Ask the patient to rate their claudication symptoms using the Claudication Symptom 
Rating Scale frequently throughout the treadmill testing.  Remind them to let you 
know the moment their symptoms start which equals the number 2 – onset on the 
scale. 
4. Give the same feedback/encouragement to each patient. 
5. Document the ICD when the patient first begins to experience claudication 
symptoms. 
6. Ensure that the patient is walking with a comfortable gait. 
7. Ensure that the patient is using the bar on the treadmill for balance only. 
 
 
Ending the Treadmill Test 
1. Remember that number 5 – Severe on the Claudication Rating Scale does not mean 
that the patient should stop walking.  Many patients can continue walking even 
though their symptoms are severe. 
2. Encourage the patient to continue walking until they can no longer tolerate walking 
due to claudication symptoms. 
3. When the patient states that they must stop and ACD is achieved, stop the treadmill 
belt and the timer at the same time. 
4. Transfer the patient to a chair or exam table to rest after the treadmill testing is 
completed. 
5. Verify the reason that the patient stopped the treadmill test and document both the 
reason stopped and the ACD. 
6. If the patient experiences SOB, chest pain, dizziness, significant ECG changes or any 
other significant sign or symptom that makes the site staff concerned for the 
patient’s safety, STOP the treadmill test IMMEDIATELY and take appropriate 
medical intervention. 
 
Gardner Treadmill Protocol for Peripheral Arterial Disease Patients with Intermittent 
Claudication  










Rest/Recovery* 2.0 0 - 
1 2.0 0 2 minutes 
2 2.0 2 2 minutes 
3 2.0 4 2 minutes 
4 2.0 6 2 minutes 
5 2.0 8 2 minutes 
6 2.0 10 2 minutes 
7 2.0 12 2 minutes 
8 2.0 14 2 minutes 
9 2.0 16 2 minutes 
10 2.0 18 2 minutes 
11 2.0 18 At least 20 minutes 
 
* On some treadmills this stage may be called Sitting, Supine and / or Standing.  Other 
treadmills may not have this stage.  The purpose of this stage is to get the belt up to 2 
mph prior to the patient stepping on the belt.  The patient should not straddle the belt 
for longer than necessary. 
 
 
5.        HISTORY OF REVISION 
 




Appendix 1 Claudication Symptom Rising Scale 
 
 
1 - None 
2 - Onset 
3 - Mild 
4 - Moderate 
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  Chris Seenan 
School of Health 
Glasgow Caledonian University 
Cowcaddens Road  
Glasgow  
G4 0BA  
 0141 331 8151 
 chris.seenan@gcu.ac.uk  
 
 
A pilot study into patients’ experiences of pain and mobilising with Peripheral Arterial 
Disease (PAD) and the effects of Transcutaneous Electrical Nerve Stimulation (TENS) on 





Thank you for participating in the above study. Your participation was extremely valuable 
and informative.  
 
I am contacting you to make you aware of the results from the study for your information. 
We found that the TENS device under investigation increased the distance walked on a 
treadmill, compared to non-functioning TENS. The device however, does not appear to have 
any effect on the pain experienced during walking.  
 
These are very interesting results. Despite this, and as I mentioned before, this was merely a 
pilot study and further investigation is required to confirm the findings.  
 
Therefore, we are now looking to progress the research and the next step is to investigate 
the experience of using a TENS device at home for patients with your condition.  
 
To do this, we are planning to conduct a study where we provide TENS devices and training 
to a number of people with your condition and ask them to use it in their daily life for one 
month. At the end of this month we will ask these people to attend a focus group where 




If you are interested in participating in this study, please read the attached information 
sheet thoroughly, discuss it with your family and friends and use the reply slip and pre-paid 
envelope provided. If, for whatever reason, you are not interested, please disregard all of 





Chris Seenan  




14.13: APPENDIX 13: TENS DAILY USE STUDY INFORMATION SHEET  
 
 
Participant Information Sheet 
 
A pilot investigation into patients' experiences of using Transcutaneous 
Electrical Nerve Stimulation (TENS) for daily life with Peripheral Arterial 
Disease (PAD) and Intermittent Claudication (IC)  
 
We would like to invite you to participate in a research project. We believe it to be of 
potential importance. Before you decide whether or not to take part it is important for you 
to understand why the research is being done and what it will involve if you decide to take 
part.  Please take time to read the following information carefully and be sure to ask any 
questions that you have and if you want, discuss it with family, friends or your GP. We will 
do our best to explain and to provide any further information you may ask now or later. You 
do not have to make an immediate decision.   
 
What is the purpose of the study?  
You have been invited to take part in this project as you have been diagnosed with 
Peripheral Arterial Disease (PAD). Your consultant has recommended that you might be 
suitable to participate as you experience pain in your leg(s) while walking.  
 
One of the main aims of this study is to examine the pain you experience which is called 
‘Intermittent Claudication’ (IC). We would like to investigate the experience of patients with 
PAD and IC using a non-pharmaceutical treatment called Transcutaneous Electrical Nerve 
Stimulation (TENS) at home for normal daily activities.  
 
The findings of the project will hopefully improve the understanding of the pain you 
experience and its effect on walking performance. It may also provide an indication of the 
usefulness of TENS for your condition.  
 
Why have I been chosen?  
Your consultant has suggested that you may be suitable to participate in this study if you 
wish to do so. Your name has been suggested because you have PAD and experience pain in 
your leg when walking. The pain is called Intermittent Claudication (IC). We are planning to 




What will I have to do if I take part?  
No new drugs will be given as part of this study.  
If you agree to take part in the study, the researcher will arrange a time for you to visit 
Ninewells Hospital to provide you with a TENS device and training. During this visit you will 
have an opportunity to ask any questions and then you will be asked to take the TENS 
machine home and use it daily. You will be given training in how to use the TENS device 
correctly and safely and asked to complete two, short, tick-box questionnaires. At the end of 
one month you will be asked to attend Ninewells Hospital in Dundee to take part in a focus 
group and complete three, short, tick-box questionnaires. 
 
Apart from this, you do not have to do anything different from your normal lifestyle and the 
trial does not affect your current treatment. You will also be reimbursed for any travel 
expenses you incur.  
 
Where will the research be conducted? 
The research will be conducted in The Vascular and Inflammatory Diseases Research Unit, in 
the Institute of Cardiovascular Research, Ninewells Hospital and Medical School, Dundee. 
 
What are the benefits of taking part in this study? 
If the TENS machine is effective, you may experience a reduction in pain when using the 
device.  
 
What are the risks involved? 
There is a risk of allergy and skin reaction to the pads used with the TENS device. If this 
occurs you will be advised to stop using the device immediately. Full safety training and 
instructions for using the TENS device will be provided.  
 
What are my rights? 
We will inform you of the results of the study. With your permission, we will contact your 
GP to let him/her know about your participation in the study. Participation in this study is 
entirely voluntary and you are free to refuse to take part or to withdraw from the study at 
any time without having to give a reason and without this affecting your future medical care 
or your relationship with medical staff looking after you. If you do withdraw from the study 
after providing written consent, you will not be contacted from that point forward however, 
any data gathered up to that point will still be used in the study.  
 
Will the research influence the treatment I receive? 
The research does not alter the treatment you receive. Your consultant and GP will start and 
stop treatments as determined by your clinical condition. 
 
Should I let my health insurance company know? 
Some insurance companies consider that participation in medical research such as this is a 
“material fact” which should be mentioned in any proposal for health-related insurance, or 
which could influence their judgment in consideration of claims made under existing 
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insurance policies. You should check that participation in this research does not affect any 
policy you might be thinking about taking. 
 
Will my taking part in the study be kept confidential? 
The information collected about you in this study will be anonymised i.e. linked to a special 
code that is stored separately on a password-protected computer file. All information that is 
collected about you during the course of the research will be kept strictly confidential.   
 
No one outside the research team will have any access to any identifying information. All 
identifiable information will be kept securely and will be retained for a period of 3 months 
after the study ends.  
 
Who is organizing and coordinating the study? 
This study is being coordinated by Queen Margaret University, Edinburgh and The Institute 
of Cardiovascular Research, University of Dundee.  
 
The Tayside Committee on medical Research Ethics B, which has responsibility for 
scrutinizing all proposals for medical research on humans in Fife, Forth Valley and Tayside, 
has examined the proposal and has raised no objections from the point of view of medical 
ethics. It is a requirement that your records in this research be made available for scrutiny 
by monitors from Queen Margaret University and NHS Tayside whose role is to check that 
research is properly conducted and the interests of those taking part are adequately 
protected.  
 
If you would like any further information regarding this study you can contact the 
researcher or the medical staff involved in the study (contact details below).  
 
Even after you agree to take part, you are still free to withdraw at any time and without 
giving a reason.  A decision to withdraw at any time, or a decision not to take part, will not 
affect the standard of care you receive. 
  
Thank you for taking the time to read this Information Sheet and considering taking part in 
the study.  
 
If you wish to take part in the study, please complete the attached reply slip and post it to 
us in the pre-paid envelope provided (you do not need to attach a stamp) or, if you prefer, 
please email either of the researchers to indicate your interest in taking part and we will 
get back to you: cseenan@qmu.ac.uk or s.j.mcswiggan@dundee.ac.uk  (This information 




Contact Details of the Researchers  
Name: Chris Seenan Steve McSwiggan  
Address: Lecturer in Physiotherapy  
School of Health  
Glasgow Caledonian 
University  
Cowcaddens Road  
Glasgow  
G4 0BA 
Senior Research Nurse, 
Study Coordinator, 
Vascular  & Inflammatory Diseases 
Research Unit  
The Institute of Cardiovascular 
Research Ninewells Hospital & Medical 
School, Dundee 
DD1 9SY 
Email chris.seenan@gcu.ac.uk  s.j.mcswiggan@dundee.ac.uk  
Telephone: 0141 331 8151 
07515 645 895 
01382 660111  
Ext 34147, Bleep 4258 
 
Contact Details of the Independent Advisor  
Name: Dr John Dick  
Address: Consultant Vascular Physician  
Wards 3 & 4  
Ninewells Hospital and Medical School 
Dundee  
DD1 9SY 
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Participant Consent Form 
A pilot investigation into patients' experiences of using Transcutaneous Electrical Nerve 
Stimulation (TENS) for daily life with Peripheral Arterial Disease (PAD) and Intermittent 
Claudication (IC) 
Name of Researcher: Christopher Seenan 
Please tick box 
1. I confirm that I have read and understand the information sheet dated 
20110329 (Version 5) for the above study and have had the opportunity to 
consider the information, ask questions and have had these answered 
satisfactorily.  
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care 
or legal rights being affected.  
3. I understand that relevant sections of my medical notes and data collected 
during the study may be looked at by individuals from Queen Margaret 
University or from NHS Tayside, where it is relevant to my taking part in this 
research. I give permission for these individuals to have access to my 
records.  
4. I agree to my GP being informed of my participation in the study 
 
5. I agree that any data collected can be used in the study even if I withdraw  
 
6. I agree to the use of audio recordings in the focus group and anonymised 
quotes in written work where applicable  
 
7. I understand that the focus groups are private and confidentiality must be 
adhered to regarding anything discussed  
 
8. I agree to take part in the above study  
 
Name of Participant   Date  Signature 
     
Name of Person taking consent  
(If different from researcher) 
 Date  Signature 
     




















14.15: APPENDIX 15: TENS DAILY USE STUDY PARTICIPANT REPLY SHEET 
 
   
Participant Reply Slip  
 
An investigation into patients' experiences of using Transcutaneous Electrical Nerve 
Stimulation (TENS) for daily life with Peripheral Arterial Disease (PAD) and Intermittent 









Please can you indicate the general times that you might be available to meet at 
Ninewells Hospital to receive your TENS device and training: 
 Mon Tues Wed Thurs Fri Sat Sun 
am        









14.16: APPENDIX 16: TENS DAILY USE STUDY TENS INSTRUCTIONS 
Instructions for Using your PhysioMed™ TENS Device 
 
Preparing and switching it on.  
1. Take the TENS device, the leads and the electrodes out of the case.  
2. Lift the protective cover on the TENS device and attach the leads to the output 
channels (holes in the top of the device, you can use either 1 or both))  
3. Connect the leads to the electrodes (2 or 4)  
4. Clean the skin where you will place the electrodes.  
5. Remove the electrodes from their plastic cover and attach them to the skin. If they 
do not stick properly, clean the skin again and use new electrodes.  
6. Electrodes should be placed over the site of your pain. The electrodes must not 
touch each other.  
7. Switch on the TENS device by slowly turning the on/off dial(s) clockwise until you 
feel a ‘click’, one at a time  
8. Continue to turn the on/off dial until you feel a ‘tingling’ sensation  
9. Once you feel the ‘tingling’ sensation, keep turning the on/off dial until you reach a 
sensation that you would describe as ‘strong, but comfortable’  
10. Clip the TENS device to your clothes in a safe place and make sure there are no 
trailing wires  
 
The TENS machine should be now working correctly.  
During use:  
11. Keep adjusting the on/off dial so that you maintain a ‘strong, but comfortable’ 
sensation  
12. Turn the device on and off using the dial as frequently as required.  
a. When you are sitting or resting it is advised that you turn it off.  
b. When you are walking or active on your feet, it is advised that you turn it on 
(see step 11).  
 
Once you have finished using the device for the day: 
13. Turn it off using the on/off dial. Ensure that you feel a ‘click’ to completely turn it off.  
14. Once turned off, remove the electrodes from the skin and place them back on the 
plastic cover.  





14.17: APPENDIX 17: FOCUS GROUP STATEMENTS  
 
“Going for a walk is not a problem for me”  
 
 “There is nothing that I can do to about my 
disease”  
 
 “The worst part of the disease is the pain”  
 
“TENS is the perfect treatment for walking”   
 
 “TENS is easy to use for people with my 
disease”  
 
 “TENS is not for me”  
 
 “TENS reduces the pain experience of my 
disease”  
 
Do you have any other thoughts about TENS 
and/or walking activity that we may not have 










A pilot study into patients’ experiences of pain and mobilising with 
Peripheral Arterial Disease (PAD) and the effects of Transcutaneous Electrical 
Nerve Stimulation (TENS) on pain and treadmill walking  
 
 
 Please take your time to complete these questionnaires  
 You can complete them all together or separately  
 Please return them in the envelope provided  
 If you have any questions or queries please contact the 







PhD Research Student, Physiotherapy,  
School of Health Sciences 




Tel: 0131 474 0000 (Ext 4795) 






















 Please answer the following questions in relation to 
the past week  
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INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE 
 
We are interested in finding out about the kinds of physical activities that people do as part 
of their everyday lives. The questions will ask you about the time you spent being physically 
active in the last 7 days. Please answer each question even if you do not consider yourself 
to be an active person. Please think about the activities you do at work, as part of your 
house and yard work, to get from place to place, and in your spare time for recreation, 
exercise or sport. 
 
Think about all the vigorous and moderate activities that you did in the last 7 days. 
Vigorous physical activities refer to activities that take hard physical effort and make you 
breathe much harder than normal. Moderate activities refer to activities that take moderate 
physical effort and make you breathe somewhat harder than normal. 
 
PART 1: JOB-RELATED PHYSICAL ACTIVITY 
 
The first section is about your work. This includes paid jobs, farming, volunteer work, course 
work, and any other unpaid work that you did outside your home. Do not include unpaid 
work you might do around your home, like housework, yard work, general maintenance, 
and caring for your family. These are asked in Part 3. 
 
1. Do you currently have a job or do any unpaid work outside your home? 
 
  Yes 
 
 No Skip to PART 2: TRANSPORTATION 
 
The next questions are about all the physical activity you did in the last 7 days as part of 
your paid or unpaid work. This does not include travelling to and from work. 
 
 
2.  During the last 7 days, on how many days did you do vigorous physical activities like 
heavy lifting, digging, heavy construction, or climbing up stairs as part of your work? 
Think about only those physical activities that you did for at least 10 minutes at a 
time. 
 
_____ days per week 
 
 No vigorous job-related physical activity Skip to question 4 
 
3. How much time did you usually spend on one of those days doing vigorous physical 
activities as part of your work? 
 
_____ hours per day 







4. Again, think about only those physical activities that you did for at least 10 minutes 
at a time. During the last 7 days, on how many days did you do moderate physical activities 
like carrying light loads as part of your work? Please do not include walking. 
 
_____ days per week 
 
 No moderate job-related physical activity Skip to question 6 
 
5. How much time did you usually spend on one of those days doing moderate physical 
activities as part of your work? 
 
_____ hours per day 
_____ minutes per day 
 
6. During the last 7 days, on how many days did you walk for at least 10 minutes at a 
time as part of your work? Please do not count any walking you did to travel to or from 
work. 
 
_____ days per week 
 
 No job-related walking Skip to PART 2: TRANSPORTATION 
 
7. How much time did you usually spend on one of those days walking as part of your 
work? 
 
_____ hours per day 
_____ minutes per day 
 
 
PART 2: TRANSPORTATION PHYSICAL ACTIVITY 
 
These questions are about how you travelled from place to place, including to places like 
work, stores, movies, and so on. 
 
8. During the last 7 days, on how many days did you travel in a motor vehicle like a 
train, bus, car, or tram? 
 
_____ days per week 
 
 No travelling in a motor vehicle Skip to question 10 
 
9. How much time did you usually spend on one of those days travelling in a train, bus, 







_____ hours per day 
_____ minutes per day 
 
Now think only about the bicycling and walking you might have done to travel to and from 
work, to do errands, or to go from place to place. 
 
10. During the last 7 days, on how many days did you bicycle for at least 10 minutes at a 
time to go from place to place? 
 
_____ days per week 
 
 No bicycling from place to place Skip to question 12 
 
11. How much time did you usually spend on one of those days to bicycle from place to 
place? 
 
_____ hours per day 
_____ minutes per day 
 
12. During the last 7 days, on how many days did you walk for at least 10 minutes at a 
time to go from place to place? 
 
_____ days per week 
 
 No walking from place to place Skip to PART 3: HOUSEWORK, 
HOUSE MAINTENANCE, AND 
CARING FOR FAMILY 
 
13. How much time did you usually spend on one of those days walking from place to 
place? 
 
_____ hours per day 








PART 3: HOUSEWORK, HOUSE MAINTENANCE, AND CARING FOR FAMILY 
 
This section is about some of the physical activities you might have done in the last 7 days in 
and around your home, like housework, gardening, yard work, general maintenance work, 
and caring for your family. 
 
14. Think about only those physical activities that you did for at least 10 minutes at a 
time. During the last 7 days, on how many days did you do vigorous physical activities like 
heavy lifting, chopping wood, shovelling snow, or digging in the garden or yard? 
 
_____ days per week 
 
 No vigorous activity in garden or yard Skip to question 16 
 
 
15. How much time did you usually spend on one of those days doing vigorous physical 
activities in the garden or yard? 
 
_____ hours per day 
_____ minutes per day 
 
16. Again, think about only those physical activities that you did for at least 10 minutes 
at a time. During the last 7 days, on how many days did you do moderate activities like 
carrying light loads, sweeping, washing windows, and raking in the garden or yard? 
 
_____ days per week 
 
 No moderate activity in garden or yard Skip to question 18 
 
17. How much time did you usually spend on one of those days doing moderate physical 
activities in the garden or yard? 
 
_____ hours per day 
_____ minutes per day 
 
18. Once again, think about only those physical activities that you did for at least 10 
minutes at a time. During the last 7 days, on how many days did you do moderate activities 
like carrying light loads, washing windows, scrubbing floors and sweeping inside your 
home? 
 
_____ days per week 
 
 No moderate activity inside home Skip to PART 4: RECREATION, 








19. How much time did you usually spend on one of those days doing moderate physical 
activities inside your home? 
 
_____ hours per day 
_____ minutes per day 
 
 
PART 4: RECREATION, SPORT, AND LEISURE-TIME PHYSICAL ACTIVITY 
 
This section is about all the physical activities that you did in the last 7 days solely for 
recreation, sport, exercise or leisure. Please do not include any activities you have already 
mentioned. 
 
20. Not counting any walking you have already mentioned, during the last 7 days, on 
how many days did you walk for at least 10 minutes at a time in your leisure time? 
 
_____ days per week 
 
 No walking in leisure time Skip to question 22 
 
21. How much time did you usually spend on one of those days walking in your leisure 
time? 
 
_____ hours per day 
_____ minutes per day 
 
22. Think about only those physical activities that you did for at least 10 minutes at a 
time. During the last 7 days, on how many days did you do vigorous physical activities like 
aerobics, running, fast bicycling, or fast swimming in your leisure time? 
 
_____ days per week 
 
 No vigorous activity in leisure time Skip to question 24 
 
23. How much time did you usually spend on one of those days doing vigorous physical 
activities in your leisure time? 
 
_____ hours per day   _____ minutes per day 
24. Again, think about only those physical activities that you did for at least 10 minutes 
at a time. During the last 7 days, on how many days did you do moderate physical activities 
like bicycling at a regular pace, swimming at a regular pace, and doubles tennis in your 
leisure time? 
 






 No moderate activity in leisure time Skip to PART 5: TIME SPENT 
SITTING 
 
25. How much time did you usually spend on one of those days doing moderate physical 
activities in your leisure time? 
_____ hours per day 
_____ minutes per day 
 
PART 5: TIME SPENT SITTING 
 
The last questions are about the time you spend sitting while at work, at home, while doing 
course work and during leisure time. This may include time spent sitting at a desk, visiting 
friends, reading or sitting or lying down to watch television. Do not include any time spent 
sitting in a motor vehicle that you have already told me about. 
 
26. During the last 7 days, how much time did you usually spend sitting on a weekday? 
 
_____ hours per day 
_____ minutes per day 
 
27. During the last 7 days, how much time did you usually spend sitting on a weekend 
day? 
 
_____ hours per day 


























 Please answer the following questions in relation to 






The following questions are about how you have been affected by the poor circulation in 
your legs in the past two weeks. You will be asked about the symptoms you have had, the 
way that your activities have been affected, and how you have been feeling. 
 
For each question please read all of the answers and then check the one that applies best 
to you. For example: 
 
19. In the last two weeks, problems caused by poor circulation in my legs have made me 
feel frustrated.… 
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
 
So if you had felt frustrated “hardly any of the time” your answer would be: 
 All of the time 
 Most of the time 
 A good bit of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
 
If you are not sure about how to answer a question then please give the best answer you 





1. During the past two weeks, I have had pain in my leg (or foot) when walking.... 
 All of the time 
 Most of the time 
 Much of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
 
2. During the past two weeks, I have been worried that I might injure my leg.... 
 All of the time 
 Most of the time 
 Much of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
 
3. During the past two weeks, cold feet have given me.... 
 A very great deal of discomfort or distress 
 A great deal of discomfort or distress 
 A good deal of discomfort or distress 
 A moderate amount of discomfort or distress 
 Some discomfort or distress 
 Very little discomfort or distress 
 No discomfort or distress 
 
4. During the past two weeks, because of the poor circulation to my legs, my ability to 
exercise or to play sports has been.... 
 Totally limited, couldn’t exercise at all 
 Extremely limited 
 Very limited 
 Moderately limited 
 A little limited 
 Only very slightly limited 
 Not at all limited 
 
5. During the past two weeks, my legs felt tired or weak.... 
 All of the time 
 Most of the time 
 Much of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
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 None of the time 
 
6. During the past two weeks, because of the poor circulation in my legs I have been 
restricted in spending time with my friends or relatives.... 
 All of the time 
 Most of the time 
 Much of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
 
7. During the past two weeks, I have had pain in the foot (or leg) after going to bed at night 
 All of the time 
 Most of the time 
 Much of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
 
8. During the past two weeks, pins and needles or numbness in my leg (or foot) have 
caused me.... 
 A very great deal of discomfort or distress 
 A great deal of discomfort or distress 
 A good deal of discomfort or distress 
 A moderate amount of discomfort or distress 
 Some discomfort or distress 
 Very little discomfort or distress 
 No discomfort or distress 
 
9. During the past two weeks, the distance I can walk has improved.... 
 Not at all—check this if the distance is unchanged or has decreased 
  A little 
  Somewhat 
  Moderately 
  A good deal 
  A great deal 





10. During the past two weeks, because of the poor circulation in my legs, my ability to walk 
has been.... 
 Totally limited, couldn’t walk at all 
 Extremely limited 
 Very limited 
 Moderately limited 
 A little limited 
 Only very slightly limited 
 Not at all limited 
 
11. During the past two weeks, being (or becoming) housebound has concerned me.... 
 A very great deal 
 A great deal 
 A good deal 
 Moderately 
 Somewhat 
 A little 
 Not at all 
 
12. During the past two weeks, I have been concerned about having poor circulation in my 
legs.... 
 All of the time 
 Most of the time 
 Much of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
 
13. During the past two weeks, I have had pain in the foot (or leg) when I am resting 
 All of the time 
 Most of the time 
 Much of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 





14. During the past two weeks, because of the poor circulation in my legs, my ability to 
climb stairs has been.... 
 Totally limited, couldn’t climb stairs at all 
 Extremely limited 
 Very limited 
 Moderately limited 
 A little limited 
 Only very slightly limited 
 Not at all limited 
 
15. During the past two weeks, because of the poor circulation in my legs, my ability to 
participate in social activities has been.... 
 Totally limited, couldn’t socialize at all 
 Extremely limited 
 Very limited 
 Moderately limited 
 A little limited 
 Only very slightly limited 
 Not at all limited 
 
16. During the past two weeks, because of the poor circulation in my legs my ability to do 
routine household work has been.... 
 Totally limited, couldn’t perform housework at all 
 Extremely limited 
 Very limited 
 Moderately limited 
 A little limited 
 Only very slightly limited 
 Not at all limited 
 
17. During the past two weeks, ulcers or sores on my leg (or foot) have caused me pain or 
distress.... 
 All of the time 
 Most of the time 
 Much of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 





18. Because of the poor circulation in my legs, the range of activities that I would have 
liked to do in the past two weeks has been.... 
 Severely limited—most activities not done 
 Very limited 
 Moderately limited—several activities not done 
 Slightly limited 
 Very slightly limited—very few activities not done 
 Hardly limited at all 
 Not limited at all—have done all the activities that I wanted to 
 
19. During the past two weeks, problems caused by poor circulation in my legs has made 
me feel frustrated.... 
 All of the time 
 Most of the time 
 Much of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
 
20. During the past two weeks, when I have had pain in the leg (or foot) it has given me.... 
 A very great deal of discomfort or distress 
 A great deal of discomfort or distress 
 A good deal of discomfort or distress 
 A moderate amount of discomfort or distress 
 Some discomfort or distress 
 Very little discomfort or distress 
 No discomfort or distress 
 
21. During the past two weeks, I have felt guilty about relying on friends or relatives 
 All of the time 
 Most of the time 
 Much of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 





22. During the past two weeks, because of the poor circulation to my legs, my ability to go 
shopping or carry bags has been.... 
 Totally limited, couldn’t go shopping at all 
 Extremely limited 
 Very limited 
 Moderately limited 
 A little limited 
 Only very slightly limited 
 Not at all limited 
 
23. During the past two weeks, I have worried I might be in danger of losing a part of my 
leg or foot.... 
 All of the time 
 Most of the time 
 Much of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
 
24. During the past two weeks, the distance I can walk became less 
 A very great deal 
 A great deal 
 A good deal 
 Moderately 
 Somewhat 
 A little 
 Not at all—check this if the distance is unchanged or has increased 
 
25. During the past two weeks, I have been depressed about the poor circulation in my 
legs.... 
 All of the time 
 Most of the time 
 Much of the time 
 Some of the time 
 A little of the time 
 Hardly any of the time 
 None of the time 
  
 




















 Please complete the following questionnaire relating 





Short-Form McGill Pain Questionnaire-2 (SF-MPQ-2) 
This questionnaire provides you with a list of words that describe some of the different 
qualities of pain and related symptoms. Please put an X through the numbers that best 
describe the intensity of each of the pain and related symptoms you felt during the past week. 
Use 0 if the word does not describe your pain or related symptoms. (SF-MPQ-2 © R. Melzack and the 
Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT), 2009. All Rights Reserved.)  
1. Throbbing pain none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
              
2. Shooting pain none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
              
3. Stabbing pain none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
              
4. Sharp pain none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
              
5. Cramping pain none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
              
6. Gnawing pain none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
              
7. Hot-burning pain none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
              
8. Aching pain none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
              
9. Heavy pain none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
              
10. Tender none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
              
11. Splitting pain none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
              
12. Tiring-exhausting none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
              
13. Sickening none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
              
14. Fearful none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
              
15. Punishing-cruel none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
              
16. Electric-shock pain none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
              
17. Cold-freezing pain none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
              
18. Piercing none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
              
19. Pain caused by 
light touch 
none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
              
20. Itching none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
              
21. Tingling or ‘pins 
and needles’ 
none 0 1 2 3 4 5 6 7 8 9 10 worst possible 
              




















 Please answer the following questions in relation to 
how you feel since starting to use the TENS device   
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Since starting to use TENS, how would you DESCRIBE THE CHANGE (if any) in  
ACTIVITY LIMITATIONS, SYMPTOMS, EMOTIONS and OVERALL QUALITY OF LIFE,  
related to your peripheral arterial disease? (tick ONE box).  
 
 
No change (or condition has got worse)   1 
   
Almost the same, hardly any change at all   2 
   
A little better, but no noticeable change   3 
   
Somewhat better, but the change has not made any real difference   4 
   
Moderately better, and a slight but noticeable change   5 
   
Better, and a definite improvement that has made a real and worthwhile change   6 
   




In a similar way, please circle the number below that matches your degree of change since 





    No 
Change  
    Much 
Worse  









14.19: APPENDIX 19: FOCUS GROUP ANALYSIS  
PAD and IC          
Meaning units  What is it about?  What does it mean?  Sub-themes Themes  
P5 you just have to put up with it 
because you will get it, you will get the 
pain every day so you just have to get 
used to it, put up with it  
There is no other option for them other 
than enduring the pain because there is 
no cure  
Acknowledgement but not necessary 
acceptance of the chronic nature of the 
disease- they have to ‘put up with it’ – 
negative connotations rather than ‘get on 




control of the 
pain and disease 
P3 that’s you tablet is it? That’s your 
simple cure- just stop walking and there 
is no pain  
Stopping walking is easy to do and takes 
the pain away  
There is a simple cure for their pain and they 
can employ it whenever they want. If the pain 
goes away so easily when you stop walking 




control of the 
pain and disease 
P5 you have got to stop, ….. your mind 
is saying to you, ‘stop and it will go 
away if you stop’ …..  that’s right, it does 
go away yeah so you say to yourself, 
what’s the point  
They describe the reasoning in their 
mind while walking: if they stop, the 
pain will go away, if they keep going, it 
will continue. The mind always resorts 
to stopping as this is common sense 
therefore the find it hard to push their 
walking further.  
When they weigh up the benefits of walking 
in pain in their mind, the choice to stop 
always wins as they don’t see the point of 
continuing or they just want the pain to go 




control of the 
pain and disease 
P2 but even before it is sore I think if 
you are walking you are very conscious 
of knowing, now I can get a seat just 
along there or there or I have seen me 
go into a shoe shop because they have 
the bits you can sit to try on shoes, I'm 
no trying on shoes, I just need a seat  
The planning and thinking about when 
they will next get a seat dominates their 
mind when walking and they are 
constantly trying to find opportunities 
to stop and make it look normal  
Constantly thinking about the pain and how 
they are going to manage an ambulatory 
situation. They try to do this in as ‘normal’ a 
way as possible i.e. shoe shop, because they 
are embarrassed by having to stop and want 




control of the 
pain and disease 
P5 I've not changed, you jut get on with 
it and that’s it. You get used to it ken  
They have not changed their lifestyle, 
rather they are just coping with it  
Their limitations are not severe enough to 
warrant a change in lifestyle. They feel strong 




control of the 
pain and disease 
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P1 one of them said to me, ‘I don’t 
know how you can play golf’ but you 
have just got to, if you want to get on 
with your life you just have to do these 
things 
They have managed to accept the 
changes to their life and can therefore 
get on with it. They have noticed that 
others have not yet reached this point.  
With appropriate advice and education 
patients are able to accept and adapt to this 




control of the 
pain and disease 
P2 when I am doing the ironing and 
things like that when you are standing 
you know for a while, and you have got 
to, you know the washing and ironing is 
done in small lots so you are not faced 
with a huge pile and standing for ages 
and I certainly cant do any gardening, 
I've had a gardener for quite some time 
but I couldn’t do it  
They have to alter the way they tackle 
tasks so hat they can manage them- 
pacing  
Independently altering ADLs so that they can 
manage to complete the same tasks.  




control of the 
pain and disease 
P2 I couldn’t even contemplate having a 
dog now because I wouldn’t be able to 
walk it  
Unable to maintain previous lifestyle 
due to pain and decreased walking 
ability  
Self-selecting to opt out of activities. QoL 






control of the 
pain and disease 
P1 well em, not particularly. I can walk 
on golf courses if it is nice and flat and it 
is soft, going for a walk on hard roads is 
a problem for me and climbing up hills  
Environment but surface and gradient 
especially affects the distance they are 
able to walk  
Different environments mean more or less 
walking ability. When encouraging walking, 
need to take environment into consideration  
Walking ability  
Acceptance, 
adaptation and 
control of the 
pain and disease 
P1 I don’t think there is very much I can 
do about it …. well, what they told me 
was my problem is inoperable and em, 
the best thing I can do is walk as much 
as possible  
Lack of treatment options. Walking 
might help the disease  
Lack of control. Walking as a coping 




control of the 
pain and disease 
P3 if what you are doing is going to help 
in the future. I can’t see you getting a 
pill that will cure it, obviously it is going 
to be something surgical I would 
imagine  
Someone will find a cure for their 
disease / pain and it will be passive 
(surgical).  
Unrealistic hope / understanding of the 




control of the 
pain and disease 
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P4 You look back and the things I have 
got to take I think I am taking these 
because the doctor says to take them 
but is it making any difference? Say if I 
was to stop them, would it make it 
worse?  
They are unsure if the medications they 
are taking are making much difference  
They do not know completely the reasons for 
taking the medications and their effects and 
thus are not sure about complying with them. 
However, they have accepted that the doctor 





control of the 
pain and disease 
P5 only comment is that you just have 
to put up with it because you will get it, 
you will get the pain every day so you 
just have to get used to it, put up with it  
There is no other option for them other 
than enduring the pain because there is 
no cure  
Acknowledgement but not necessary 
acceptance of the chronic nature of the 
disease- they have to ‘put up with it’ – 
negative connotations rather than ‘get on 
with life’?   They are indicating that they 
know there is nothing that can be done about 
their pain. They express it in a negative 




control of the 
pain and disease 
P5 because I don’t want to sit in that 
house, ken what I mean? ………. no way, 
so you just have to put up with it.   P4 
yep, the worlds always saying to me 
‘grin and bear it’….    P2 ‘grin and bear 
it’.   P5 exactly.    P4 and that’s been 
happening for 6 years, ‘grin and bear it’  
They don’t want to accept the lifestyle 
limitations so they continue on and ‘put 
up, with the pain  
They are motivated to keep mobilizing and 
continue with as many ADLs as possible, 




control of the 
pain and disease 
P2 no Paracetamol is what they say …… I 
might as well have a couple of sweeties 
…… I cant have anything stronger than 
paracetamol because of the other 
things I am on but I might as well have a 
sweetie for all the good it does, it 
doesn’t make any difference  
Current treatment or advice for 
treatment of pain is insufficient and 
does not work  
They feel their pain is not understood and 
under-treated. They feel the treatment 
options for their pain are limited by the other 
medications they are on. They feel that 




control of the 
pain and disease 
P5 I've not changed, you jut get on with 
it and that’s it. You get used to it ken  
They have not changed their lifestyle, 
rather they are just coping with it  
Their limitations are not severe enough to 
warrant a change in lifestyle. They feel strong 




control of the 
pain and disease 
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P4 it is, they keep saying ‘grin and bear 
it’ and that’s all I have been doing for 
years and years now. P5 yeah, me too, 
the very same. I'm just like, it will be 5 
year, maybe 6 years I have had it and 
you just have to put up with it.  
The lack of advice or treatment options 
for the pain / disease and the fact that 
they are just told to get on with it.  
They are expressing frustration at the lack of 





control of the 
pain and disease 
P4 as soon as they say you could lose 
your leg that’s me, forget about it, grin 
and bear it  
They will not accept the risks of surgery 
to gain a reduction in pain- not severe 
enough.  
They can cope with the level of pain they are 





control of the 
pain and disease 
P4 you know you think what the hell is 
the matter because one you stop as you 
said, once you stop the pain is gone ….. 
that’s what puzzling me all these years 
and it has been going on almost 10 
years now and I keep saying to the 
surgeon and all that and they said we 
could tell you what the problem is and 
we could fix it but we don’t know what 
the problem is so all this is probably 
helping. But it is frustrating the problem 
you know is just in here (points to head) 
you just have to grin and bear it  
They don’t know what the problem is 
and why the pain goes away when you 
stop walking. They don’t believe the 
surgeon knows what is happening 
either and there are no treatment 
options. They feel treatment is just 
general things that all ‘might’ be helping 
in some way. They feel the problem is 
psychological to some degree.  
They feel as though no one understands what 
is wrong with them and therefore there are 
no treatment options, only ‘general’ things to 





control of the 
pain and disease 
P5 when it goes away you are like, well 
fine but when you go away again back it 
comes again so you stop again. That is, 
it is more frustrating than anything  
Pain is not too severe, just frustrating as 
it keeps coming back.  
The intensity of the pain is not too bad; they 
are more affected by the recurrent nature. In 
some ways it would be better if the pain was 
worse?  
Transient pain  Frustration 
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P4 that’s the worst part of this bloody 
pain, it’s the frustration of the pain ….. 
it’s not going to kill you but it is really 
debilitating ……… the thing is its sore but 
once you stop, its gone ……….. that’s 
what puzzles me all the time ………. you 
think, oh god and you sit down and all 
of a sudden, bang and its not there  
The fact that the pain is not that severe 
but it is there every time they walk 
however, when they stop, it goes away. 
They are confused as to the 
mechanisms involved  
The lack of knowledge about the disease and 
the mechanisms of the pain result in 
frustration.   The pain is of a manageable type 
when present i.e. they do not walk until it is 
so severe that they cannot tolerate it 
however, the worst part of the pain is that it 
always comes back  
Transient pain  Frustration 
P4 But as I say they say ‘grin and bear it‘ 
but this has been going on for years and 
years for me, its like having a leg off- 
grin and bear it so you just, what can 
you do?  
They have just been told that they need 
to get on with it and there is nothing 
that can be done for them however, 
they feel that experiencing the pain in 
the leg is like having a leg off 
They are frustrated at the lack of treatment 
options and find it hard to endure the pain  
Grin and bear it  Frustration 
P5 there is only one thing that takes the 
pain away and that is when you sit 
down ……. that takes the pain away …… 
and the frustrating thing is you only 
have to sit for half a minute if at that 
and it is away. Then you walk again an it 
comes back  
When they sit down the pain goes 
away, that is the only method of 
effective pain relief they have found.  
However, it is frustrating when they 
walk again, the pain comes back  
They know that resting relieves the pain 
however, the fact that it comes back after the 
promise of relief might even be worse than if 
it hadn’t gone away in the first place?  
Transient pain  Frustration 
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P5: the same as when you are walking 
to the football with them we have got a 
good bit, maybe, hmm I don’t know, 20 
minute walk from the ground to the bus 
well, I’m like, miles behind them cause I 
cannae keep up with them ken what I 
mean. And even a lot of them are a lot 
older than me and they can ……… and 
you say to yourself ‘how?’ it’s the most 
annoying thing but once I stop like, I just 
need a minute and away I go again and 
its fine for maybe another couple of 
minutes then I have to stop again. 
That’s the most frustrating thing about 
it- you have got to stop.  
Expressing annoyance at lack of walking 
ability and resultant social limitations. 
Expressing frustration about having to 
stop walking all the time and 
embarrassment of falling behind friends  
Frustrated at reduction in mobility.  
Frustration at it being such an overt issue I.e. 





P4 you are a nuisance to them …. cause 
you are taking so long …….. it is, that’s 
the worst part about this pain, it’s the 
frustration  
They feel their disease is affecting other 
people and this is embarrassing and 
frustrating. It is the lack of walking 
ability that is causing this.  
Decreased walking ability leads to feelings of 
frustration as they feel this is affecting others 
as well as themselves. They feel frustrated 




P4 and it is that bloody frustration and 
then you think you will not bother 
coming the next time, I am just stuck 
indoors now and I can’t even go out in 
the garden to help the missus and she’s 
like get yourself indoors, it’s that 
frustrating, its not the pain. Its just up 
here (points to head) it’s not the pain  
They experience frustration at their 
lifestyle limitations rather than because 
of the pain- it is the pain causing the 
issues but it is the social limitations that 
they focus on  
Frustration due to reduced ability to continue 
with daily life is their main issue rather than 






P4 its like when you say, you’re walking 
and when you stop and you sit down for 
2 minutes and it gone and you think, 
that’s fine, and you get up again and it 
starts again. That’s what nobody has 
ever said to me, this is what’s 
happening with this disease, because it 
is a disease. Well you say it is there one 
minute and it is gone the next, you get 
up again and its come again, so but they 
have never explained to me what it is  
Pain is present when walking but goes 
away when you stop. When you start 
walking again it comes back and nobody 
has explained why this happens or what 
is happening in the legs. It is being 
treated as a ‘condition’ not a disease  
They feel that their symptoms are not fully 
understood because it has not been 
explained properly to them. They don’t fully 
understand what is happening when they feel 
pain. This may enhance or contribute to pain-




P4 the thing is you bleeding, you just 
think you can go on a bit more, a bit 
more and then you say no I can’t and 
you stop and the pain is gone ………. Its 
funny, you know you can’t explain it to 
people what it is like unless they have 
had it you know like you  
The fact that when they stop walking 
the pain goes away and it is this that 
others do not understand  
They feel that their disease is not fully 
understood by those around them and this is 





P5 the pain is telling you to stop  
They are sharing their pain beliefs that 
it is a signal to stop walking  
This indicates a lack of understanding of the 






P3 its not permanent damage, you are 
not doing it permanent damage 
because eventually you will stop but if 
you pushed how far, you have done the 
treadmill you stop there because you 
are frightened to go a bit further 
because you don’t know what you are 
doing to yourself  
This participant has slightly more 
understanding of the pain mechanisms 
and has developed an understanding 
that the pain cant be indicating 
permanent damage as they have had it 
for so long and not much has changed.   
However, the still accept that you are 
frightened to push it further just in case. 
This demonstrates the confusion and conflict 
of education, attitudes and beliefs these 
patients face. They have reasoned well that 
the pain cannot be causing permanent 
damage however they are still frightened to 
push it 1. Because it is pain and 2. Because no 
one has told them that this is ok/ described 








P1 if I'm told by my doctors anyway 
without the TENS machine that the 
more I walk, the better chance I have of 
my pain maybe dissipating a bit 
Walking more might reduce pain  
Walking is a way of controlling the pain and 





P3 if it is going to stop it getting worse, 
that’s what I am doing, I will keep doing 
it. Obviously, you would like a cure for it 
but its not going to happen overnight is 
it? 
Walking is a treatment but not a cure 
for the pain / disease  
Walking might help control pain but wont 
cure it. Willing to try interventions that might 




P4 there is nothing you can do to 
change it.   P5 yeah, well that’s what I 
think, that’s my theory as well  
They think there is nothing they can do 
about the pain they experience  
They feel that they have no control over the 
pain and disease progression.  They are 




P4 yeah, well the pills they give you the 
day are not going to cure you but it is 
going to help to lessen the pain ….. you 
know it helps towards the, but it is not 
going to cure it  
They think the medication is helping 
lessen the pain so they continue taking 
them. They say they would do 
something just to stop it getting worse 
but then talk in terms of improvement  
They realise they may not be cured (passive 
attitude) however; they think that the pain 
may lessen if they continue to take the pills. 
This shows hope and maybe poor 
understanding or bad advice? Rather than 
thinking that they might improve, they need 
to be counselled to expect just to not get 




P4 if they could explain to you what is 
causing the pain and if they say look, we 
cant give you anything, well they cant 
give you anything to get rid of the pain, 
maybe it helps ease the pain but you 
cant get rid of it. If they could explain to 
you what’s happening and you could say 
oh, fair enough then  
Healthcare staff not knowing or being 
able to explain what is happening  
They feel that nobody understands what is 
happening to them or if the medical staff 







P5 and its alright for the doctor to say 
‘loose weight, that will help’ but I’m not 
a big eater anyway so my biggest 
problem is cheese but I’m no gonna 
want to stop a things that I love just 
because the pain because how should I? 
I like to go for a pint at the weekend 
with the boys, I’m no gonna stop it …… 
because I don’t want to sit in that 
house, ken what I mean?  
Not changing lifestyle because of the 
pain. They don’t feel that loosing weight 
will make much difference to pain / 
disease. Not willing to make changes to 
eating habits as they don’t see that it 
will help them very much.  
They don’t see the link between weight 
control, eating and their disease. They see it 
only as a pain that should be able to be cured 
and they can continue with their lives. Need 
information and education about the disease 
and how risk factor modification can help and 
what changes to expect and really why they 
need to do it. Not just about the pain- what 




P1 because the chances are the more 
you walk the blood vessels sometimes 
kick into play  …… that’s what I have 
been told. And I think that my playing 
golf bears that out because there are 
some days when I feel a bit of pain and 
it doesn’t last maybe more than a few 
minutes and you keep walking and it 
goes away. It comes back again but it 
does seem to come and go   
This participant understands the 
reasons to walk and how walking can 
make the disease / pain better and 
therefore walks for exercise / 
treatment.  
With correct education and information 
patients will comply with the advice given 
and be motivated to walk.  When they know 
what it is doing, walking can be employed as 
a coping strategy/ treatment and method to 




P3 I have only got it in one leg but I 
presume if I hadn’t taken the 
medication it would have spread to the 
other leg?    P3 it is my right leg that 
bothers me too. If I hadn’t have stopped 
the smoking, would it have got worse?  
They have an idea that their condition 
might have been worse if they hadn’t 
been taking medications / stopped 
smoking  
They do have an appreciation of the 
progressive, chronic nature f their condition 






P5 that’s what he said to me, the only 
option is surgical, well that was like 2 
years ago and I don’t know if anything 
has changed now but that was the only 
thing he said to me would help was that 
thing like you said ….. the stent or taking 
another bit out of my leg and putting it 
in but he said that is the last option  
The options they have for treatment of 
the pain/ disease- they have been told 
that the only option s to have surgery.  
Firstly, they have the perception that their 
condition is treatable / acute rather than a 
chronic, progressive condition for which 
there is no cure.  Secondly, they are left with 
the perception that they have no control over 
their disease and the only person who can do 




P3 I have to take one too but it’s a 
preventative measure  
This patient understands the true 
purpose of the medications and is 
therefore more positive about them  
With correct expectations of outcomes come 





P4 the thing is you bleeding, you just 
think you can go on a bit more, a bit 
more and then you say no I can’t and 
you stop and the pain is gone ………. Its 
funny, you know you can’t explain it to 
people what it is like unless they have 
had it you know like you  
The fact that when they stop walking 
the pain goes away and it is this that 
others do not understand  
They feel that their disease is not fully 
understood by those around them and this is 





P5 that’s what I’m saying, other people 
dinnae understand what the pain that 
you go through, ken what I mean?  
Other people don’t understand the pain 
they endure  
They feel that other cannot understand the 
pain they experience as it is unlike any other 







P3 and they have tried that treadmill 
with putting all the things on you and 
that and the lad explained at the time, 
its not going to cure you, we are 
researching it now to see what it is, and 
until you find out what is causing it but 
they already told me its he narrowing of 
the arteries that’s causing it and 
basically the smoking is causing that. So 
there is not really a cure for it is there? 
Unless they take an artery out and 
replace it and I don’t see that 
happening. I mean and you get to our 
age, well not P5 but myself like, is it 
worth the while? Just put up with the 
pain I certainly wouldn’t rush along for 
it (surgery).    P5 no way, you just put up 
with it 
Firstly they perceive that the previous 
research study was to find out what was 
happening with them. They understand 
what is causing their pain and that there 
is not a cure for it at present unless the 
do bypass surgery. They then go on to 
say that surgery is not worthwhile due 
to the risks involved for minimal benefit 
at their age.  
This participant is aware of the physiological 
mechanisms of the disease and the prognosis. 
They are in agreement that they wouldn’t risk 
surgery for the ‘minimal’ pain they 
experience at present. They do not feel the 
disease has such an effect on their lives that 





P4 You look back and the things I have 
got to take I think I am taking these 
because the doctor says to take them 
but is it making any difference? Say if I 
was to stop them, would it make it 
worse?  
They are unsure if the medications they 
are taking are making much difference  
They do not know completely the reasons for 
taking the medications and their effects and 
thus are not sure about complying with them. 
However, they have accepted that the doctor 





P5 see the likes of when you have to 
carry on you try to keep up with them 
(football crowd) ……. you start walking 
like all kind of funny like you have done 
the toilet in your pants, but you do 
because my brother has said to me 
many times.  
Their walking pattern changes when in 
pain and this is embarrassing for them 
in social situations. Also, this is when it 
normally happens as they are trying to 
keep up  
The pain experience is characterized by 
embarrassment and frustration in a social 
setting 






P2 this is what makes it frustrating you 
see if you are going to go out with 
somebody. You know they want to take 
you here, there or wherever but I mean 
you know that you are gonna have them 
stop every wee bit and they don’t need 
to stop  
The fact that the pain limits their ability 
to participate in social activities due to 
them having to stop all the time. They 
feel frustrated / embarrassed about 
having to stop when their friends don’t 
have to  
The disease / pain causes them 
embarrassment when participating in social 
activities. Fear of embarrassing themselves/ 
being a burden on their friends and family  




P2 to come and do something, the first 
thing you think of is how much walking 
is involved …… and will I just be a 
damned nuisance if I go because I will 
be trailing back and behind the others 
…. you know? And you just don’t go  
When there is an opportunity to 
participate in a social activity they have 
to think about how much walking they 
will need to do as if it too much they 
will not go. This is because they feel 
they are a nuisance. They decide not to 
participate themselves as they are 
worried that their friends will become 
frustrated with their decreased walking 
ability  
Their pain limits their participation in social 
activities and it is directly related to walking 
ability, not degree of pain  






P4 it’s the same on the golf course, I’ve 
had to give up golf because you cannae, 
you cannae get, you pay to play 18 
holes and you cannae get round, you 
get round about 8 and that’s it, and 
your mates are saying ‘come on’ and 
you say I wish I could come on but that’s 
it and so I’ve stopped playing the golf 
and I’ve taken the bowling up and that’s 
helped me a hell of a lot, the bowling, 
and that 3 days a week for about 2 
hours and I really look forward to that 
and funny enough when you are on 
there bowling from the car to the 
bowling green your pain is there but 
once you get on the bowling green it is 
gone   
This patient is describing how their 
decrease in walking ability has limited 
their participation in hobbies- they have 
had to give up golf but they can still play 
bowls.  
This shows an ability to adapt to their 
limitations and motivation to make the most 
of the abilities they have.  




P3 you know it is going to get worse …… 
it would be interesting to try to go 
further just to see what damage you 
would do but then it is too late by then  
They think that if they walk past the 
point they normally stop and 
experience more pain it will cause them 
damage  
They are displaying fear of pain behaviours 
and beliefs relating to their pain so telling 
them to walk further into their pain without 
any more education and information would 
not necessarily be efficacious  
Fear  Pain 
CS so say for now, I want you to just 
think about your health in general, what 
first jumps into your mind, what’s the 
first thing you think about?   P2 the pain 
in my leg. P5 the leg, exactly.   P2 it 
stops you doing everything really.    P5 
that’s the only thing really, thing that 
bothers me, is the legs.  (General 
agreement) 
The pain is the main focus of the health 
self-image.  When they think of their 
disease, they think of their pain  
Pain is the defining factor of the disease 
rather than the general systemic arterial 
disease.  They are focusing on the 
impairment and maybe this is related to 






P3 Paracetamol is what they say 
(General laughter) P3 I might as well 
have a couple of sweeties …… I cant 
have anything stronger than 
paracetamol because of the other 
things I am on but I might as well have a 
sweetie for all the good it does, it 
doesn’t make any difference  
Pharmaceutical pain relief is no good 
because they cant take any strong 
painkillers due to the possible 
interactions with their other 
medications / possible kidney/liver 
damage and the basic painkillers have 
no effect  
Developing further pharmaceutical 
interventions is limited due to the possible 
interactions etc. They feel they need strong 
painkillers but these are not necessarily 





P2 the pain in my leg ….. it stops you 
doing everything really  
Their perception of lifestyle limitations 
due to the pain is large- everything  
This patient feels that the pain is stopping 
them from participating in everything 









TENS         
Meaning units  What is it about?  What does it mean?  Sub-themes Themes  
P1 I certainly found that, I will tell you how 
much I found how good, I have already been 
out and ordered, not that I have used them 
but I have ordered myself some new pads 
They found TENS to be so effective that they 
are going to continue to use it independently 
and have already spent their own money on 
getting more equipment 
They have a lot of confidence in TENS 
and they feel it has helped them 
enough to want to continue using it. 
Along with this, they are so confident 
that they are willing to purchase their 
own equipment  
Benefit  Control 
P5 I would say it is easy to use but I don’t 
think it is any good for the disease, well that’s 
just my personal opinion, it didn’t do me any 
good, well the pain was still there when I was 
using it  
The device was easy to use however, it didn’t 
take the pain away completely therefore was 
assessed to be ineffective  
TENS was simple to use and reduced 
the pain experienced. However, due 
to the participant’s expectations since 
it would take the pain away 
completely, they felt it was not 
effective and therefore would not use 
it.  
Benefits   Expectations 
P5 I still definitely got the pain with it when I 
did use it, did you P3?    P3 oh aye. Aye. I still 
had it but it was a different form of pain    P5 
right   P3 it was sort of numbing, not so sore 
but it was still there   P2 I didn’t feel that this 
sort of alleviated the pain at all, I was aware 
of the pulsing as you are saying but to me it 
wasn’t making things any better  
Mixed feelings and experiences of the 
participants from using TENS. One felt that it 
changed the nature of the pain in a positive 
way. Another was unsure as hadn’t used it 
much and expressed interest in how it 
worked for the other participants. The last 
participant didn’t feel that it helped at all- 
they felt the pulsing but did not feel it 
reduced the pain experienced  
Different participants had different 
experiences of using TENS and its 
effectiveness at reducing pain. This 
could be due to their expectations, 
the severity of their disease, their use 
of the device, peripheral neuropathies 
or other psychological and/or 




P3 my friend, she bought one, they told her it 
was a frozen shoulder, she bought one out of 
the chemist and was using it for about three 
weeks and she said, perfect, it worked perfect 
for her. She saw that one likes and the one 
she got was a lot smaller and she used it for 
15 minutes in the morning and 15 minutes at 
night, shoulder is gone. She has had these 
This participants friend used a TENS machine 
for their frozen shoulder with good results. 
They thought the one they had was a lot 
smaller and they bought it from the 
pharmacy and use it for 2 x 15mins per day  
If they have heard of someone else 
using TENS and getting benefit they 
are more willing to try and likely to 
get positive results as they believe in 
the treatment.  
Beliefs   Expectations 
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injections and that and they didn’t do 
anything for her, so I mean, it must be good 
isn’t it?  
P1 I met a friend, a girl on the golf course and 
she, somebody had told me she had a TENS 
machine and I spoke to her and she has got 
some Japanese, I cant remember what it is 
called but she found it on the internet and she 
must be the same sort of thing as the 
Japanese one, probably a wee bit more 
sophisticated than the TENS machine because 
I think she said she paid £70 for it but it has 
obviously got pads and she uses it for her 
back and she has found it good  
This participant’s friend uses a similar device 
for their back with good results. The 
participant thinks it might be something more 
complicated as it costs £70 and is from Japan.  
Something exotic and expensive has 
been found to be effective by one of 
their friends and thus their 
expectations of TENS are raised and 
they are possibly more willing to give 
it a try and be ready to experience 
positive effects.   
Beliefs  Expectations 
P3 I still had it (the pain) but it was a different 
form of pain ….. it was sort of numbing, not so 
sore but it was still there  
They still felt the pain however, the TENS had 
changed it’s quality and intensity  
TENS was effective in changing the 
pain experience. The participant 
reported a change in quality of pain as 
well as intensity. It however, was not 
completely effective again and thus 
not reported as favourable due to 
differing expectations 
Sensation  Pain 
P3 yeah, it sort of numbed the pain, more 
concentrated, you know instead. The tingling 
takes it away right away, the initial pain. It 
was definitely as I say if, it has got potential; it 
is working on the right lines, its not taking the 
pain away, just covering it  
They felt that the TENS numbed the pain and 
the stimulation takes the pain away 
immediately at the pain threshold level. This 
however, didn’t last and they experienced 
pain and tolerance eventually but they feel it 
is working  
This participant reports that it 
'numbed' their pain and thus was 
effective but not quite enough- they 
feels that it is a good intervention and 







P1 a golf course that is quite difficult to walk 
and I used it and I did have some pain but 
certainly nothing like what I would have 
expected to experience.   
 TENS reduced the amount of pain 
experienced when performing a hobby and 
thus they were able to perform the said 
hobby- something they would not be able to 
do before 
The TENS machine is effective at 
reducing the pain experienced for this 
patient and allowed them to complete 




P3 it numbed the pain, you maybe walked a 
wee bit further. I did notice a couple of times 
my foot went numb when I had the machine 
on. Well that has happened before without 
the machine but it seemed to come on a bit 
earlier  
The TENS machine numbed the pain and 
allowed them to walk a bit further than 
normal.  
TENS is effective in reducing the pain 
experienced apparently through 
gating mechanisms? This helped to 
prolong time to pain tolerance.  
Walking ability  Pain 
P2 yes, I put it on in the morning and had it on 
all day    P4 I used it three times a week for 3 
hours up and down between the bowling 
green     P5 no for me, I used it once a week 
because that’s the only time I go walking 
They all used the device in different ways 
depending on their normal ADLs.  
Patients may just use it to help make 
their normal activities easier rather 
than increasing their level of activity?  




P1 I find I could get round when I am using it 
now this is a golf course that is quite difficult 
to walk and I used it and I did have some pain 
but certainly nothing like what I would have 
expected to experience. So to answer your 
question I would say that the TENS machine 
definitely lessens the pain whether I could, I 
can’t definitively say that it totally takes the 
pain away. 
TENS allowed this participant to play this 
particular golf course that they would have 
normally struggled with significantly less pain 
TENS reduces the pain experienced, 
helps to improve walking ability and 
this allows them to participate in 







P1 if I didn’t have the TENS and this particular 
course I'm thinking, I could never get round 
that course without stopping and having to 
shake my leg and wait a minute which 
becomes quite embarrassing when you are 
playing with someone and you are holding 
them up  
TENS helps them complete an activity which 
in turn means they suffer less embarrassment  
The TENS machine is effective in 
reducing pain and increasing 
performance. This results in and 
reduction in the embarrassment of 
needing to stop/ disease limiting 
function 






P1 it means I could walk further if I wanted to.  
TENS allowed them to walk further if they 
needed to  




P3 every day, maybe not so much at the 
weekends but during the week and I didn’t 
put it on today because I was coming here. I 
would put it on in the morning and take it off 
at night and when I needed it I switched it on  
They put the TENS machine on in the morning 
and wore it all day during the week when at 
work etc. they didn’t wear it as much at the 
weekends- doing less activity?  
Participants use the TENS device all 
day and as instructed and found this 
to be ok. They maybe wear it less 
when doing less activity  
TENS use  Usability 
P1 I don’t think there is any way that I could 
think to be improved just the fact that if it is 
on your legs, you have got to put the wires up 
through your trousers and then gets onto 
your belt so  
There is no way that they can think to 
improve the TENS unit except possibly making 
it wireless 
TENS is relatively easy to use and 
unobtrusive however, it would be 
better if there were no wires/ nothing 




P3 even adults were querying what it was. I 
am willing to try anything    P2 that’s true, I’d 
try anything as well whatever might work  
People would notice the device on their belt 
and think it was strange/ they were 
embarrassed that people noticed it. Despite 
this, they were not too bothered as they are 
desperate to find a solution for their pain and 
don’t mind some embarrassment  
Need to refine the design and possibly 
use wireless TENS to avoid patients 
not using it due to embarrassment. 
They will work hard and sacrifice 
some embarrassment to find a 
solution for their pain.  
TENS use  Usability  
P5 the thing about it for me was the tingling in 
my legs with it. I can’t bear it   P4 oh I didn’t 
mind that, I enjoyed that, the tingling in your 
legs, aye it helped  
One participant disliked the tingling sensation 
of TENS, another enjoyed it  
TENS is not suitable for everyone 
based on personal preference. This 
may have affected usage in the 
current study as well  
Sensations  Usability  
P1 it means I could walk further if I wanted to. 
The times I have used it....... I use it now only 
if I am going t be playing 18 holes of golf, I 
wouldn’t put it on if I had to walk down the 
street to pick something up at the shop it is 
quite difficult with me it is on a slight hill 
when I am walking home I feel a slight pain 
but I wouldn’t put the TENS machine on to do 
that  
TENS helps this participant walk further if he 
wanted to however, he didn’t always use it 
for short journeys he felt it wasn’t required- 
just put up with the pain. When he was doing 
anything more, he would use the TENS  
When TENS is effective in this 
participant who uses it selectively and 
only when he was walking for a 
prolonged period of time.  
TENS use  Usability  
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P1 is it easy to use? I would say for the 
majority of people, yes but I am one of these 
technophobe when it comes to any I find 
anything like that difficult but that is not to 
say it, that is only because of me, I think most 
folk would find it quite simple 
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